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Abstract 
  
In the last decade, the pharmaceutical industry has been experiencing a period of drastic change 
in the way new products and processes are being conceived, due to the introduction of the 
Quality by design (QbD) initiative put forth by the pharmaceutical regulatory agencies (such as 
the Food and Drug Adminstration (FDA) and the European Medicines Agency (EMA)). 
One of the most important aspects introduced in the QbD framework is that of design space 
(DS) of a pharmaceutical product, defined as “the multidimensional combination and 
interaction of input variables (e.g. material attributes) and process parameters that have been 
demonstrated to provide assurance of quality”. The identification of the DS represents a key 
advantage for pharmaceutical companies, since once the DS has been approved by the 
regulatory agency, movements within the DS do not constitute a manufacturing change and 
therefore do not require any further regulatory post-approval. This translates into an enhanced 
flexibility during process operation, with significant advantages in terms of productivity and 
process economics. 
Mathematical modeling, both first-principles and data-driven, has proven to be a valuable tool 
to assist a DS identification exercise. The development of advanced mathematical techniques 
for the determination and maintenance of a design space, as well as the quantification of the 
uncertainty associated with its identification, is a research area that has gained increasing 
attention during the last years. 
The objective of this Dissertation is to develop novel methodologies to assist the (i) 
determination of the design space of a new pharmaceutical product, (ii) quantify the assurance 
of quality for a new pharmaceutical product as advocated by the regulatory agencies, (iii) adapt 
and maintain a design space during plant operation, and (iv) design optimal experiments for the 
calibration of first-principles mathematical models to be used for design space identification. 
 
With respect to the issue of design space determination, a methodology is proposed that 
combines surrogate-based feasibility analysis and latent-variable modeling for the identification 
of the design space of a new pharmaceutical product. Projection onto latent structures (PLS) is 
exploited to obtain a latent representation of the space identified by the model inputs (i.e. raw 
material properties and process parameters) and surrogate-based feasibility is then used to 
reconstruct the boundary of the DS on this latent representation, with significant reduction of 
the overall computational burden. The final result is a compact representation of the DS that 
can be easily expressed in terms of the original physically-relevant input variables (process 
 
 
viii Abstract 
 
________________________________________________________ 
© 2018 Gabriele Bano, University of Padova (Italy) 
 
parameters and raw material properties) and can then be easily interpreted by industrial 
practitioners. 
 
As regards the quantification of “assurance” of quality, two novel methodologies are 
proposed to account for the two most common sources of model uncertainty (structural and 
parametric) in the model-based identification of the DS of a new pharmaceutical product. 
The first methodology is specifically suited for the quantification of assurance of quality when 
a PLS model is to be used for DS identification. Two frequentist analytical models are proposed 
to back-propagate the uncertainty from the quality attributes of the final product to the space 
identified by the set of raw material properties and process parameters of the manufacturing 
process. It is shown how these models can be used to identify a subset of input combinations 
(i.e., raw material properties and process parameters) within which the DS is expected to lie 
with a given degree of confidence. It is also shown how this reduced space of input 
combinations (called experiment space) can be used to tailor an experimental campaign for the 
final assessment of the DS, with a significant reduction of the experimental effort required with 
respect to a non-tailored experimental campaign. The validity of the proposed methodology is 
tested on granulation and roll compaction processes, involving both simulated and experimental 
data.  
The second methodology proposes a joint Bayesian/latent-variable approach, and the assurance 
of quality is quantified in terms of the probability that the final product will meet its 
specifications. In this context, the DS is defined in a probabilistic framework as the set of input 
combinations that guarantee that the probability that the product will meet its quality 
specifications is greater than a predefined threshold value. Bayesian multivariate linear 
regression is coupled with latent-variable modeling in order to obtain a computationally 
friendly implementation of this probabilistic DS. Specifically, PLS is exploited to reduce the 
computational burden for the discretization of the input domain and to give a compact 
representation of the DS. On the other hand, Bayesian multivariate linear regression is used to 
compute the probability that the product will meet the desired quality for each of the 
discretization points of the input domain. The ability of the methodology to give a scientifically-
driven representation of the probabilistic DS is proved with three case studies involving 
literature experimental data of pharmaceutical unit operations. 
 
With respect to the issue of the maintenance of a design space, a methodology is proposed to 
adapt in real time a model-based representation of a design space during plant operation in the 
presence of process-model mismatch. 
Based on the availability of a first-principles model (FPM) or semi-empirical model for the 
manufacturing process, together with measurements from plant sensors, the methodology 
jointly exploits (i) a dynamic state estimator and (ii) feasibility analysis to perform a risk-based 
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online maintenance of the DS. The state estimator is deployed to obtain an up-to-date FPM by 
adjusting in real-time a small subset of the model parameters. Feasibility analysis and surrogate-
based feasibility analysis are used to update the DS in real-time by exploiting the up-to-date 
FPM returned by the state estimator. The effectiveness of the methodology is shown with two 
simulated case studies, namely the roll compaction of microcrystalline cellulose and the 
penicillin fermentation in a pilot scale bioreactor. 
 
As regards the design of optimal experiments for the calibration of mathematical models for 
DS identification, a model-based design of experiments (MBDoE) approach is presented for an 
industrial freeze-drying process. A preliminary analysis is performed to choose the most 
suitable process model between different model alternatives and to test the structural 
consistency of the chosen model. A new experiment is then designed based on this model using 
MBDoE techniques, in order to increase the precision of the estimates of the most influential 
model parameters. The results of the MBDoE activity are then tested both in silico and on the 
real equipment.
 ________________________________________________________ 
© 2018 Gabriele Bano, University of Padova (Italy) 
 
 
Riassunto 
 
Negli ultimi anni, le modalità con le quali le aziende farmaceutiche sviluppano e 
successivamente producono nuovi prodotti sta subendo un cambiamento radicale, a causa 
dell’introduzione dell’iniziativa Quality by Design (QbD) da parte delle agenzie di 
regolamentazione, come l’americana Food and Drug Administration (FDA) o l’agenzia europea 
del farmaco (European Medicines Agency; EMA). 
Lo scopo dell’iniziativa è quello di promuovere l’adozione di un approccio scientifico e 
sistematico nelle fasi di (i) sviluppo di prodotto e di processo, (ii) trasferimento di processo da 
scala laboratorio a scala industriale e (iii) monitoraggio e controllo di processo. Il fine ultimo 
dell’iniziativa è quello di stimolare l’utilizzo di tecniche scientifiche rigorose all’interno di un 
contesto industriale, come quello farmaceutico, tipicamente orientato all’empirismo e poco 
propenso al cambiamento (in larga parte a causa degli stringenti vincoli regolatori imposti in 
passato). 
Uno dei concetti più importanti introdotti nell’ambito dell’iniziativa QbD è quello di spazio di 
progetto (design space; DS) di un nuovo prodotto farmaceutico. Lo spazio di progetto è definito 
come l’insieme delle combinazioni delle proprietà delle materie prime (ad esempio, la 
composizione del principio attivo) e dei parametri di processo (portate, temperature, etc…) per 
le quali la qualità finale del prodotto risulta essere garantita. Le aziende interessate possono (in 
forma volontaria) identificare lo spazio di progetto di un nuovo prodotto e sottoporlo 
all’approvazione delle agenzie regolatorie: se il DS viene approvato, il processo può essere 
esercito, senza dover richiedere una nuova approvazione all’ente regolatore, anche cambiando 
le condizioni operative e/o le proprietà delle materie prime, purché la loro combinazione 
rimanga all’interno dello spazio di progetto. Ciò comporta un notevole vantaggio in termini di 
flessibilità nell’esercizio del processo produttivo, consentendo alle aziende di ottimizzare la 
marcia dell’impianto con conseguente notevole riduzione dei costi di esercizio. 
Al fine di ottenere l’approvazione del DS, le agenzie regolatorie richiedono che vengano 
rispettati due concetti chiave, ovvero che l’azienda: (i) dimostri con un metodo scientifico 
rigoroso la procedura utilizzata per l’identificazione dello spazio di progetto; (ii) quantifichi il 
grado di certezza (e quindi, la probabilità) che la qualità del prodotto venga garantita qualora il 
processo venga esercito all’interno dello spazio di progetto.  
Da un punto di vista ingegneristico, entrambe le richieste possono essere affrontate attraverso 
l’utilizzo congiunto di modellazione matematica e osservazioni sperimentali. Le tecniche 
modellistiche possono essere basate esclusivamente su dati storici di laboratorio o di impianto 
(modelli cosiddetti data-driven), su una conoscenza approfondita dei fenomeni fisici e chimici 
che avvengono nel processo (modelli a principi primi o knowledge-driven) o su una 
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combinazione di entrambi (modelli semi-empirici). In tutti i suddetti casi, vi è la necessità di 
sviluppare metodologie sistematiche che, basandosi sulla tipologia di modello prescelta, 
consentano di soddisfare entrambe le richieste degli enti regolatori. 
Nonostante il numero di contributi scientifici in questo ambito sia aumentato in modo 
significativo negli ultimi anni, permane la necessità di sviluppare e integrare le tecniche 
esistenti per sviluppare metodologie che consentano di risolvere quattro aspetti ancora irrisolti, 
e cioè: 
1. identificare con il minor carico computazionale possibile lo spazio di progetto, e 
ottenerne una rappresentazione immediata che possa essere interpretata anche dal 
personale non esperto in modellazione matematica; 
2. fornire una metrica dell’incertezza associata alla predizione, mediante modello, dello 
spazio di progetto; 
3. adattare la predizione dello spazio di progetto durante la marcia dell’impianto, per far 
fronte a mancanze strutturali del modello e/o deviazioni parametriche dello stesso; 
4. progettare esperimenti ottimali per l’identificazione di modelli a principi primi al fine 
di individuare rapidamente lo spazio di progetto di nuovi prodotti. 
L’obiettivo di questa Dissertazione è proporre tecniche di modellazione avanzata per affrontare 
le quattro problematiche sopra descritte. L’approccio scientifico adottato si basa sia sullo 
sviluppo di nuove procedure metodologiche, sia sull’integrazione e combinazione di tecniche 
note. 
 
La problematica riguardante la quantificazione dell’incertezza associata alla predizione del 
DS di un nuovo prodotto farmaceutico viene affrontata nei Capitoli 3 e 4. 
In particolare, nel Capitolo 3 viene presentata una metodologia per quantificare l’incertezza 
associata ad una predizione del DS qualora un modello di proiezione su strutture latenti (PLS: 
projection onto latent structures) venga utilizzato a tal scopo. La metodologia si basa sullo 
sviluppo di due nuovi modelli di propagazione dell’incertezza dallo spazio della qualità di 
prodotto (cioè dallo spazio delle uscite del modello) allo spazio delle proprietà delle materie 
prime e parametri di processo (cioè lo spazio degli ingressi del modello). I due modelli vengono 
derivati in modo analitico sfruttando nozioni di statistica frequentista, e successivamente 
integrati in un contesto di inversione di modelli a variabili latenti. La procedura consente di 
individuare un sottospazio del dominio degli ingressi, chiamato spazio degli esperimenti (ES; 
experiment space) nel quale è possibile garantire, con un livello di fiducia preassegnato, che lo 
spazio di progetto risieda. Da un punto di vista pratico, l’individuazione dello spazio degli 
esperimenti può essere sfruttata per condurre una campagna sperimentale mirata in una zona 
ristretta del dominio degli ingressi, al fine di ottenere più rapidamente l’identificazione 
definitiva del DS del nuovo prodotto. Ciò comporta un vantaggio in termini di riduzione dei 
tempi e dei costi della campagna sperimentale, con conseguente guadagno in termini di 
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competitività da parte dell’azienda che ne voglia trarre beneficio. L’efficacia della metodologia 
proposta viene verificata su diversi casi studio riguardanti alcune operazioni unitarie tipiche 
dell’industria farmaceutica (ad esempio, granulazione a secco/a umido), utilizzando sia dati 
simulati al calcolatore che dati sperimentali di letteratura. 
Nel Capitolo 4 viene presentata una metodologia che, attraverso la combinazione di tecniche di 
statistica Bayesiana e di regressione multivariata, consente di ottenere una metrica (ossia una 
valutazione quantitativa) dell’incertezza associata alla predizione di uno spazio di progetto. 
Tale metrica viene definita come la probabilità (intesa in termini Bayesiani) che il prodotto 
soddisfi le specifiche di qualità suddette. In quest’ottica, lo spazio di progetto viene identificato 
come l’insieme di combinazioni di caratteristiche delle materie prime e parametri di processo 
per i quali la probabilità che il prodotto sia in specifica supera un certo valore di soglia definito 
dall’utente e consistente con le richieste dell’ente regolatorio.  
La metodologia proposta si basa sue due idee chiave: (i) l’utilizzo di un modello PLS per la 
riduzione delle dimensione dello spazio degli ingressi, con conseguente riduzione del carico 
computazionale e ottenimento di una rappresentazione compatta di tale spazio; (ii) l’utilizzo di 
metodi Monte Carlo basati su catene di Markov per la ricostruzione delle funzioni di densità di 
probabilità (PDF: probability density function) delle uscite del modello per diversi valori degli 
ingressi. Il risultato finale è una rappresentazione compatta (in molte situazioni, 
bidimensionale) dello spazio di progetto probabilistico, garantendo un pieno adempimento alle 
richieste degli enti regolatori. L’efficacia della metodologia viene verificata anche in questo 
caso su diversi casi di studio relativi ad operazioni unitarie tipiche dell’industria farmaceutica, 
coinvolgenti sia dati simulati al calcolatore che dati sperimentali di letteratura. 
 
Per quanto riguarda la problematica dell’identificazione dello spazio di progetto di un nuovo 
prodotto farmaceutico, nel Capitolo 5 viene presentata una metodologia che combina un 
modello PLS e una tecnica denominata analisi di fattibilità basata su surrogati (surrogate-based 
feasibility analysis) per identificare il DS. Il modello PLS viene utilizzato per ridurre la 
dimensione dello spazio degli ingressi mediante l’introduzione di un numero ridotto di variabili 
latenti, cioè combinazioni lineari degli ingressi reali. L’analisi di fattibilità basata su una 
funzione base di tipo radiale (radial-basis function; RBF) viene successivamente utilizzata per 
identificare lo spazio di progetto all’interno dello spazio latente. La riduzione della dimensione 
dello spazio degli ingressi viene utilizzata per rendere l’analisi di fattibilità possibile da un 
punto di vista computazionale, con un significativo vantaggio sia in termini di durata totale 
della simulazione, sia in termini di precisione ottenibile per l’identificazione del DS. L’efficacia 
della metodologia proposta viene dimostrata sia su una linea di produzione continua 
(coinvolgente sei operazioni unitarie) di compresse, sia su esempi relativi a dati simulati al 
calcolatore. 
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Con riferimento alla problematica dell’adattamento in linea della predizione dello spazio di 
progetto, nel Capitolo 6 viene proposta una metodologia che consente di correggere in linea la 
predizione del DS sulla base delle misure raccolte durante la marcia dell’impianto. La 
metodologia sfrutta in maniera congiunta uno stimatore dinamico di stato e l’analisi di fattibilità 
descritta al Capitolo 5 per adattare in tempo reale la predizione del DS in presenza di un 
disallineamento fra le predizioni di modello e il comportamento dell’impianto (process/model 
mismatch). Basandosi sulle misure in linea disponibili, lo stimatore dinamico viene utilizzato 
per correggere in tempo reale alcuni dei parametri critici del modello e per ottenere una stima 
accurata dello stato del sistema. L’analisi di fattibilità (basata o meno su modelli surrogati) 
viene successivamente utilizzata per predire lo spazio di progetto sulla base della correzione 
apportata al modello da parte dello stimatore. Il DS adattativo può quindi essere utilizzato per 
ottimizzare in tempo reale il processo produttivo, supportare in tempo reale il processo 
decisionale (ad esempio, la chiusura o apertura manuale di determinate valvole da parte degli 
operatori), o fungere da base per la definizione dei set-point del sistema di controllo 
implementato nell’impianto. La procedura proposta è stata verificata in silico su un processo 
continuo di granulazione di un formulato e su un processo di produzione di penicillina in un 
bioreattore. Entrambi i casi studio analizzati dimostrano l’affidabilità della metodologia. 
 
Per quanto concerne la progettazione di esperimenti ottimali per l’identificazione di modelli 
a principi primi, da usarsi successivamente per identificare il DS di un nuovo prodotto, nel 
Capitolo 7 viene presentata un’applicazione relativa ad un processo industriale di 
liofilizzazione. Dopo una fase preliminare di identificazione del modello a principi primi da 
utilizzare per la descrizione del processo, viene eseguita una verifica della consistenza 
strutturale di tale modello e vengono identificati i parametri che maggiormente influiscono sulle 
sue predizioni. Sulla base di tale analisi preliminare, viene progettato un nuovo esperimento 
attraverso l’utilizzo di tecniche di progettazione ottimale degli esperimenti basata su modello 
(model-based design of experiments; MBDoE). L’esperimento viene progettato in modo tale da 
massimizzare l’informazione che può essere estratta dai dati sperimentali ai fini della 
calibrazione di modello. L’esperimento progettato è stato condotto nell’impianto industriale, e 
i dati ottenuti hanno consentito di migliorare significativamente la precisione e l’accuratezza 
della stima dei parametri del modello.
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Chapter 1 
Motivation and state of the art* 
 
 
The objective of this Chapter is to provide an overview of the background and motivations of 
this Dissertation. First, facts and figures on the current state and future trends of the 
pharmaceutical industry are presented. Then, the Quality by design (QbD) initiative that has 
been introduced in the pharmaceutical context is analyzed from a regulatory perspective, with 
particular focus on the concept of design space (DS) of a new drug. The main challenges that, 
from a process systems engineering perspective, need to be addressed for the identification and 
maintenance of a design space are then pinpointed. Finally, the state-of-the art on the ways 
these challenges have, up to now, being addressed in the scientific literature is presented and 
critically discussed. 
1.1 Pharmaceutical industry: facts and figures 
This section provides facts and figures on the state of the pharmaceutical industry, with 
particular focus on four different thematic areas: i) economic evolution; ii) pharmaceutical 
research and development; iii) pharmaceutical manufacturing; iv) role of the regulatory 
agencies. 
1.1.1 Economic outlook 
Whilst the economic outlook is characterized by positive expectations on the healthcare market 
growth and global medicine expenditure, the pharmaceutical industry is facing unprecedented 
challenges due to a large number of patent expirations, lower market growth in the so-called 
pharmerging countries1 and increased pricing and market pressures. A recent market report 
proposed by the QuantileIMS Institute (QuantileIMS Institute, 2016) forecasts that the total 
expenditure for drugs will reach $1.5 trillion by 2021, with an increase of 33% with respect to 
                                                          
* Bano, G., Facco, P., Bezzo, F., Barolo, M. (2018) Design space description in pharmaceutical development and 
manufacturing: a review. In preparation. 
1 The countries are: China, Brazil, India, Russia, Mexico, Turkey, Poland, Saudi Arabia, Indonesia, Egypt, Philippines, 
Pakistan, Vietnam, Bangladesh, Argentina, Algeria, Colombia, South Africa, Chile, Nigeria, Kazakhstan. 
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the global medicine expenditure of 2016, but with a moderate decrease on the compound annual 
growth rate2 (CAGR), that is expected to range between 4% and 7 % with respect to the nearly 
9% annual growth rate of the years 2014 and 2015. A more conservative market report that has 
been recently proposed by EvaluatePharma® (EvaluatePharma, 2018) suggests that the above 
figures should be revised to $ 1.2 trillion by 2024, with an average annual growth rate of 6.4%, 
as a consequence of the sales losses due to the increased genericization of drugs and due to a 
slower performance of the market of biosimilars. Similar figures are reported in the economic 
analysis suggested by Deloitte (Deloitte, 2018). As reported in Table 1.1, the US market is 
expected to remain the world’s largest pharmaceutical market, but the annual growth rate is 
forecast to decrease significantly from the 12% reached in 2015 to 6-7% in the next five years. 
On the other hand, China is expected to continue playing a key role as the second largest market, 
with a robust average annual growth rate of 12%. As for Europe, the situation is expected to be 
less thriving than in the rest of the highly industrialized countries, with a forecast annual growth 
rate of 1-4 %, mainly due to the weak economic growth in the region. Finally, the growth of the 
pharmaceutical market is expected to proceed at a slower pace in the pharmerging countries 
(excluding China), from an average of 7% in the year 2012-2016 to an average of 4% for the 
years 2016-2021. 
Table 1.1 Top 20 countries ranking forecast by 2021 based on the 
pharmaceutical market size (100 = U.S. market size). Adapted from 
QuantileIMS Institute, 2016. 
Rank # Country 
Market size index (100 = 
U.S.) in constant USD 
1 U.S. 100 
2 China 25 
3 Japan 14 
4 Germany 8 
5 Brazil 6 
6 U.K. 6 
7 Italy 5 
8 France 5 
9 India 5 
10 Spain 4 
11 Canada 4 
12 South Korea 2 
13 Russia 2 
14 Turkey 2 
15 Australia 2 
16 Mexico 2 
17 Saudi Arabia 1 
18 Poland 1 
19 Argentina 1 
20 Egypt 1 
  
                                                          
2 CAGR is the rate of return of an investment that would be obtained by investing the profits at the end of each year. 
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The general consensus on the significant increase of the global medicine expenditure for the 
next years is supported by the fact that the global population is expected to increase by an 
average 1.24% by 2030, with an increase of people aged 65-80 from 22% in 2000 to 28% in 
2030 (QuantileIMS Institute, 2016). This aspect, together with an easier availability of drugs to 
more people due to the increasing urbanization and growing of the middle class (Rauschnabel, 
2018), represents a key driver for the expansion of the healthcare market in the next years.  
The top 20 pharmaceutical companies are expected to keep their leading position during the 
next years, but a reduction from 63.2% (in 2017) to 51.9% (in 2024) of the total market share 
of these companies is expected to happen in favor of the other market players. Table 1.2 gives 
an overview of the top 20 pharma companies and their forecast prescription drug sales for the 
period 2017-2024 (EvaluatePharma, 2018). The same table suggests that the next years will be 
characterized by an increased competition between the different pharma players, and therefore 
innovation and differentiation will play a key role for the maintenance of the market shares.  
Table 1.2 Worldwide (WW) prescription drug sales and market share for the 
top 20 pharma companies for the period 2017-2024. Adapted from 
EvaluatePharma, 2018. 
Rank # Company                      Prescription sales ($ bn) 
Market share 
(%) 
Rank 
change (+/–) 
  2017 2024 2017 2024  
       
1 Novartis 41.9 53.2 5.3 4.4 +1 
2 Pfizer 45.4 51.2 5.8 4.3 –1 
3 Roche 41.7 50.6 5.3 4.2 +0 
4 Johnson & Johnson 34.4 47.4 4.4 3.9 +1 
5 Sanofi 34.1 44.2 4.3 3.7 +1 
6 GlaxoSmithKline 28.7 38.4 3.6 3.2 +1 
7 Merck & co. 35.4 38.0 4.5 3.2 –3 
8 AbbVie 27.7 37.2 3.5 3.1 +0 
9 AstraZeneca 19.8 31.7 2.5 2.6 +2 
10 Bristol-Myers Squibb 19.3 28.7 2.4 2.4 +2 
11 Amgen 21.8 24.8 2.8 2.1 –1 
12 Novo Nordisk 17.0 24.6 2.2 2.0 +4 
13 Celgene 12.9 23.7 1.6 2.0 +8 
14 Eli Lilly 18.5 22.2 2.3 1.8 –1 
15 Bayer 17.7 19.7 2.2 1.6 +0 
16 Gilead Sciences 25.7 19.0 3.3 1.6 –7 
17 Boehringer Ingelheim 14.3 18.3 1.8 1.5 +2 
18 Shire 14.4 17.7 1.8 1.5 +0 
19 Takeda 13.3 17.0 1.7 1.4 +1 
20 Allergan 14.9 16.8 1.9 1.4 –3 
       
 Total top 20 498.8 624.7 63.2 51.9  
 Other 290.0 578.8 36.8 48.1  
 Total 788.8 1203.5 100.0 100.0  
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In terms of employment, the pharmaceutical industry is expected to maintain a leading role in 
the manufacturing sector, thanks to a steady employment growth both in high- and low-income 
countries. A recent review from the International Federation of Pharmaceutical Manufacturers 
& Associations (IFPMA, 2017) reports that the pharmaceutical industry employed around 5.1 
million people worldwide in 2014, with an increase of 1.5 million with respect to the 2006 and 
with steady expectations on the annual growth for the period 2014–2021. Moreover, due to its 
peculiar feature of employing high-skilled workers with high qualifications, the pharmaceutical 
sector induces the creation of many other indirect jobs within the manufacturing sector. The 
qualified training and the direct exposure to innovative processes and new technologies that 
pharmaceutical employees experience also represents an asset for the entire workforce. In fact, 
it has been proven (WifOR, 2016) that many pharmaceutical workers decide to exploit the 
knowledge gained during their working experience to start new companies or to transfer their 
skills to other manufacturing sectors, thus fostering economic development.  
Different positions and solutions have been proposed to boost the economic performance of the 
pharmaceutical industry with respect to the forecast figures described above. However, the most 
important analysts (QuantileIMS Institute, 2016; Deloitte, 2018; EvaluatePharma, 2018; 
KPMG, 2018; McKinsey, 2018; PwC, 2018;) seem to agree on the following key actions that 
pharmaceutical companies should implement to increase their competitiveness: 
1. Increase R&D productivity in terms of discovery and launch of new molecular entities 
(NMEs) and biologicals; 
2. Increase the automation of the manufacturing processes, in line with the Industry 4.0 
paradigm (Kagermann et al., 2011) that has been recently gained attention in the 
manufacturing sector; 
3. Exploit big data methodologies to extract information on the patient profiles, and 
therefore design new drugs that are perfectly suited to the patient needs; 
4. Optimize the supply chain and consider strategic clinical, regulatory and scientific 
partnerships. 
In view of the above, it is clear that the introduction of innovative solutions and technologies 
to assist all the different stages of pharmaceutical production (i.e. drug discovery, product and 
process development, product manufacturing) will represent a competitive advantage for 
companies in an era of patent expiration and strict governments’ budget constraints.  
1.1.2 Pharmaceutical R&D: past, present & future 
The discovery, test and approval of new drugs represents the milestone upon which 
pharmaceutical companies can diversify and strengthen their assets. Research and development 
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(R&D) is the activity that is deemed to support the discovery, launch and approval of NMEs 
and new biological entities (commonly referred to as biologicals)3 in the market.  
The process that leads to the launch of a new drug on the market is typically very long and is 
comprised by several steps, as schematically shown in Fig. 1.1. 
 
 
 
Figure 1.1 Pre-launch stages for a new pharmaceutical drug and qualitative profile of R&D costs during the 
pre-launch stage. 
 
Research deals with the first two steps of the process, which are: 
1) Drug discovery. Chemical or biological compounds that exhibit the potential to treat 
new or existing conditions are initially screened. A promising compound is, on average, 
found every 5,000-10,000 candidates (IFPMA, 2017). This step may take up to 6 years 
and the chance of success are, as explained above, less than 0.01% (EFPIA, 2017; 
IFPMA, 2017).  
2) Pre-clinical trials. At this stage, the safety and efficacy of the compound is tested before 
testing its performance on humans. Different types of pre-clinical tests exist: these 
include, but are not limited to, pharmacodynamics and pharmacokinetic tests, toxicity 
tests, ADME (adsorption, distribution, metabolism and excretion) tests, and are 
typically performed both in silico and in vivo. It is estimated that a top-20 
pharmaceutical company has, on average, around 250 compounds under pre-clinical 
tests per year (IFPMA, 2017; EvaluatePharma, 2018) and the completion of this step 
may take up to 2 years. 
                                                          
3 New molecular entities are drugs that contain an active moiety that has not been previously approved by the regulatory agency.   
They are typically new chemical entities. Biologicals represent biologic compounds or vaccines that have not been previously 
approved by the regulatory agency.  
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The budget required to perform the two research tasks described above is typically very large, 
and the return on investment is very low, due to the low chance of success. It is estimated 
(EFPIA, 2017, Deloitte, 2017) that around 21% of the overall budget for the launch of a new 
drug is used in these two stages (Fig. 1.2). 
Development refers to the activities that are performed after the new drug successfully passes 
the pre-clinical trials and is characterized by a series of clinical trials (i.e. on humans). These 
clinical trials are divided into three different phases, which need to subsequently obtain positive 
results (i.e., the drug needs to pass Phase I in order to enter Phase II, and so on). The phases 
are: 
3) Phase I.  This phase is intended as the first stage for the assessment of the efficacy and 
safety of the new drug on humans. It involves a small number of healthy volunteers 
(typically in the range 20-100) and the rate of success is, on average, around 65% 
(IFPMA, 2017). The main target of this step is to assess a suitable dose (or range of 
doses) for the new drug to be effective. 
4) Phase II. This phase is intended to assess if the drug has any biological activities or side 
effects on humans. The number of volunteers involved is larger (100-500) and the rate 
of success for this phase drastically decreases to around 40% (IFPMA, 2017). Most of 
the new drugs fail during this phase, where it is typically discovered that the drug does 
not work as planned or may exhibit toxicity effects (Deloitte, 2017). 
5) Phase III. This phase involves a much larger number of volunteers (1000-5000) and is 
aimed at assessing the real effectiveness of the drug with respect to the current 
treatments. Due to the large number of people involved, this phase represents a costly 
and time-consuming step, but the rate of success are typically higher than for phase II 
(an average success rate is around 50%). 
 
 
Figure 1.2 R&D costs division in the pharmaceutical industry (IFPMA, 2017). 
 
The overall development process requires 6 to 8 years (IFPMA, 2017, Deloitte, 2017, 
EvaluatePharma, 2018) and up to 65% of the overall budget for the launch of the new drug (Fig. 
1.2).  Therefore, the overall research and development process is deemed to absorb more than 
85% of the total budget for the development and launch of a new molecular entity.  
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If the new drug successfully passes all the phases of the clinical trials, the following step is the 
submission for approval to the regulatory agency (green text in Fig. 1.1).  
This step may take up to 2 years and absorbs around 2% of the total budget. If successful, the 
drug is ready for its launch on the market. However, periodic clinical trials are required after 
the launch in order to review the safety and efficacy of the drug. This step is typically referred 
to as Phase IV clinical trials, and may absorb up to 12% of the total budget (Deloitte, 2017). A 
qualitative trend of the R&D costs (thus excluding the approval and Phase IV costs) during the 
development of a new drug is shown in Fig. 1.1 (red dashed line).  
From the above considerations, it can be concluded that R&D costs represent a significant 
portion of the overall costs that pharmaceutical companies are forced to face (∼ 20%; Deloitte, 
2017) and are characterized by low chances of success and continuously decreasing returns on 
investments (Deloitte, 2017; IFPMA, 2017; McKinsey, 2017; EvaluatePharma, 2018). Deloitte 
(2017) estimates that the overall cost for the development of a new drug (from discovery to 
launch) has reached, on average, the all-time peak of 165 billion dollars in 2017, and is expected 
to increase during the next years. EvaluatePharma® (EvaluatePharma, 2018) estimates an 
average growth rate for the worldwide R&D costs in the pharmaceutical industry of 3.2% for 
the period 2018-2024. The past and the expected trend for the worldwide R&D spend is reported 
in Table 1.3. 
Table 1.3.  Worldwide pharma R&D spend and growth rate with respect to 
the previous year in the period 2010-2024. Adapted from EvaluatePharma, 
2018. 
Year 
R&D spend [$bn] R&D spend growth 
with respect to the previous year [%] 
2010 129 (-) 
2011 137 +6.2 
2012 136 –0.4 
2013 138 +1.7 
2014 144 +4.4 
2015 149 +3.5 
2016 159 +6.3 
2017 165 +3.9 
2018 172 +4.1 
2019 177(*) +3.1 
2020 183(*) +3.0 
2021 188(*) +3.1 
2022 194(*) +3.0 
2023 199(*) +2.5 
2024 204(*) +2.6 
                                         (*) = forecast 
 
If, from one side, the global R&D spend is expected to increase nonstop during the next years, 
the expectations on the number of NMEs and biologicals that can potentially be approved by 
the regulatory agencies seem promising. In fact, after a very poor performance in 2016, the 
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number of approved NMEs and biologicals has significantly increased in 2017, and historically 
high levels are expected to be reached in the next six years. Table 1.4 shows the number of 
NMEs and biologicals that have been approved by the Food and Drug Administration (FDA) 
in the period 2002-2017. The number of drugs that are expected to be launched in the market 
for the next six years is forecast to be, on average, 45 per year (QuantileIMS, 2016; 
EvaluatePharma, 2018) with a peak of 63 new approved drugs forecast for 2024. It is worth 
noticing that these forecasts are subject to a high degree of uncertainty, since regulatory 
requirements are expected to become stricter year after year, and the pre-launch stage is 
characterized by unpredictable events that may lead to a regulatory rejection. 
Table 1.4. FDA new drug approvals (NMEs + biologicals). Adapted from 
EvaluatePharma, 2018. 
Year # of NMEs approved # of biologicals approved Total NMEs+biologicals approved 
2002 17 9 26 
2003 21 14 35 
2004 31 7 38 
2005 18 10 28 
2006 18 11 29 
2007 16 9 25 
2008 21 10 31 
2009 20 15 35 
2010 15 11 26 
2011 24 11 35 
2012 34 10 44 
2013 25 10 35 
2014 30 21 51 
2015 33 23 56 
2016 15 12 27 
2017 36 19 55 
 
In summary, pharmaceutical R&D is inherently a high-risk, high-reward endeavor. However, 
the steep increase of the costs for drug development that is expected to continue during the next 
years is building up a remarkable pressure on R&D productivity. Pharmaceutical companies 
are forced to deal with an increasing competition on the global market, and new technologies 
that can speed-up the R&D process are becoming essential tools to cope with this problem. 
Although it is impossible to find a common agreement between the different analysts on the 
tools that should be used to increase R&D productivity, some recognized solutions (Deloitte, 
2017; McKinsey, 2018; PwC, 2018) that can be proposed are: 
 the use of artificial intelligence (AI) techniques to assist and speed-up the drug 
discovery stage. AI algorithms can be used to analyze large amount of data from 
different sources, such as pre-clinical or clinical-trials of already existing compounds, 
in order to get new insights that may help researchers to identify new patients’ needs 
and therefore new drug discoveries. Moreover, AI algorithms can be used to identify 
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potential candidates for clinical trials through targeted advertising (thanks to huge 
amount of data available, for example, from social media) and to assist a better 
understanding of the patients’ needs.   
 Use of real world evidence (RWE)4 to obtain a better understanding of rare diseases, to 
identify new potential diseases, to assist clinical trials or to expedite the enrolment of 
volunteers.  
 Use of in silico tools (i.e., model-based tools) to assist: i) the product development stage; 
ii) the process (or “recipe”) development stage, i.e. the way the new drug is designed to 
be manufactured. In more detail, modeling tools are expected to predict clinical 
outcomes, inform clinical trials design and support evidence of safety and efficacy of 
the new drug during the product development stage. On the other hands, in silico 
simulations are expected to assist the conceptual development, the design and the 
optimization of the manufacturing process for the production of the new drug. 
 Use of robotic and cognitive automation to automatize certain aspects of the R&D 
process, such as the design and monitoring of the clinical trials, or organize and speed-
up the large amount of documentation that needs to be filled in during the drug 
development process and in the submission for approval by the regulatory agency. 
Most of the techniques described above have long been known and used within the process 
systems engineering (PSE) community, which therefore can give a key contribution to boost 
pharma R&D productivity.  
 
1.1.3. Pharmaceutical manufacturing: past, present & future 
As described in the previous section, pharmaceutical R&D (which not only includes product 
development, but also process development) is worldwide recognized as a time-consuming, 
highly specialized cutting-edge activity, due to the strict requirements that new products need 
to fulfill before being launched to the market. However, on the other side, pharmaceutical 
manufacturing has been traditionally characterized by strict and experience-based procedures, 
that led to the adoption of several process malpractices and high percentages of rejected 
products during the production campaigns. The main reason for this lack of innovation is to be 
found in the strict regulatory environment within which companies were forced to operate. The 
regulatory agencies, in fact, by addressing all the focus towards the achievement of the desired 
drug safety and efficacy, were unintentionally stimulating companies to invest their money on 
obtaining new patents, rather than on innovating and revamping their manufacturing processes. 
The final result was that, in terms of manufacturing procedures and facilities, the 
                                                          
4 RWE is the evidence obtained from observational data that are not obtained during clinical trials and that are typically 
stored in electronic health records, billing activities databases, registries, mobile devices and so on.  
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pharmaceutical industry was (and still is) lagging behind several other industries, despite its 
cutting-edge R&D activity and its role for the society.  
A turning point in the relationship between pharmaceutical companies and regulatory agencies 
was first introduced in 2004 (FDA, 2004a; FDA, 2004b) by the American FDA. FDA was the 
first agency to acknowledge that the rigid regulatory environment was the main restraint for 
companies to not invest on innovation and on the adoption of cutting-edge technologies in 
product manufacturing. Several initiatives (FDA, 2004a; FDA, 2004b; FDA, 2004c; FDA, 
2006) culminated in the introduction of the Quality by Design (QbD) framework (as opposed 
to Quality by Testing), whose objective is to favor a flexible and efficient environment within 
which high quality products can be manufactured without extensive regulatory oversight. QbD 
promotes the adoption of systematic and science-based (as opposed to experience-based) tools 
to assist: i) product and process design (i.e., product and process development); ii) technology 
transfer; iii) product manufacturing. A detailed description of all these aspects is given in § 1.2.  
Regarding product manufacturing, the introduction of QbD represented (and is still 
representing) the main driving force for the modernization of the practices and technologies 
that are adopted in pharmaceutical manufacturing. In terms of product manufacturing, the early 
stage of QbD (2009-2011) was mainly focused on the implementation of some of the new ideas 
introduced within this new framework (adoption of process analytical technologies (PAT); 
exploitation of real-time release testing and in/on-line quality testing to pre-existing and well-
established manufacturing processes and procedures (Reklaitis, 2017). These processes are 
traditionally operated batchwise and involve multiple units and stages that are typically 
followed in sequence according to strict procedures. In the following years (2012-2015), as a 
result of the adoption of new paradigms to assist the product and process development stage 
(culminating in the definition of the design space of the product to be manufactured), particular 
effort was put towards the development of efficient control strategies and monitoring tools to 
guarantee process operation within the boundary of the design space. The focus was, again, 
mainly towards traditional technologies operated batchwise, and still represents the most 
important target that pharmaceutical companies are addressing to improve their process 
operation5 (Reklaitis et al., 2017). 
Continuous manufacturing (CM) of pharmaceuticals has gained attention from the scientific 
community, the industrial practitioners and the regulators (Lee et al., 2015; Fisher et al., 2016; 
Kopcha, 2017; Nasr, 2017; Yu and Kopcha, 2017). It is worth noticing that the possibility of 
adopting continuous operation for some of the units involved during drug manufacturing was 
first proposed in the 90s (Paul, 1990) and kept being proposed throughout the years 
(Dienenmann, 2000). Potentially, CM could enable a much faster and more efficient (in terms 
                                                          
5 It is estimated that more than 95% of the unit operations involved in the pharmaceutical industry are operate batchwise or 
semi-batchwise, and, despite the increasing attention towards continuous manufacturing, this percentage is expected to 
remain stable for the next 5-8 years (Troup and Georgakis, 2013; Reklaitis et al., 2017). 
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of reduction of products that need to discarded due to off-specifications) operation with respect 
to batch manufacturing, as a result of the tighter handling of product specifications that can be 
obtained with this technology. Moreover, it would enable a substantial reduction of the energy 
needs of the manufacturing line and would involve a sensible reduction of the risk of human 
error due to its high degree of automation. However, some challenges still need to be faced for 
a practical implementation of CM, e.g., high equipment and installation costs, the costs of 
developing and implementing the advanced process control strategies that are needed to 
guarantee product specifications, and the strategies to be adopted in the presence of a product 
recall. These drawbacks, together with the strict regulatory environment within which 
companies were forced to operate, represented the main reasons that kept CM as a potential, 
but not applicable alternative to the traditional batch approach in the early 2000s. The recent 
launch of the QbD initiative has revived the interest towards this technology, even though the 
lack of a regulatory framework on this topic is still limiting a systematic approach to its 
implementation. To have an idea of the gap that currently exists between the scientific literature 
(where the number of publications on CM has exponentially grown in the past 5 years) and the 
practical implementation of CM (Collins, 2018), it is worth considering that the only marketed 
products that have been obtained through CM are the two reported by the FDA (Kopcha, 2017) 
and a new drug that has been recently approved (Collins, 2018). 
Interestingly, the opinion of industrial practitioners on the real benefits of CM is not always as 
optimistic as the one of many regulators and academics (Reklaitis, 2017). For example, Collins 
(2018) highlights the fact that the costs for implementing CM are comparable with the costs 
required to upgrade (i.e., to adopt the technologies encouraged within the QbD framework) the 
existing batch operations. However, while CM is characterized by a total lack of experience 
and a scarce (or inexistent) regulatory framework, batch manufacturing is well-established and 
is characterized by a wide and detailed regulation. Therefore, it is worth questioning the real 
advantage of investing in CM with respect to investing in the upgrade of the existing batch 
operations. 
Despite the different views on the benefits that CM may bring to the pharmaceutical industry, 
it is commonly accepted that batch manufacturing will still be the preferred route towards drug 
production, while CM will keep gaining increasing attention especially for the production of 
the new drugs that will be launched in the market (Reklaitis, 2017; Collins, 2018). 
Independently of the type of operation adopted, the next years are expected to bring an increased 
level of digitalization within the manufacturing processes, in line with the Industry 4.0 
revolution (Kagermann et al., 2011) that has recently involved other manufacturing sectors. 
The digitalization of drug manufacturing is expected to involve an extensive use of process 
simulators, advance process control and monitoring techniques, supply chain automation and 
big data technologies to extract information from the huge amount of data that are collected 
throughout the product lifecycle (Herwig et al., 2017; Ding, 2018; Rauschnabel, 2018). A 
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futuristic overview of the challenges that must be faced towards the implementation of the 
Industry 4.0 paradigm in pharma is given by Herwig et al. (2017). As for R&D (i.e., product 
and process development), process systems engineering tools are expected to give a key 
contribution to the solution of these challenges (Reklaitis, 2017). 
1.1.4 Regulatory aspects: past, present & future 
As briefly mentioned in the previous section, the role of the regulatory agencies is of paramount 
importance for protecting and improving human health, as well as for influencing the decisions 
and strategies that pharmaceutical companies adopt to keep their competitiveness in the global 
market. These agencies include the already cited FDA, the European Medicines Agency (EMA) 
and many other regulatory bodies that are spread all over the world (a full list can be found in 
Global Regulatory Authority Websites, 2018). Some of the activities carried out by these 
agencies are (Collins, 2018): i) the review of information for new drug submissions from 
pharmaceutical companies; ii) the review of updated process information throughout the 
lifecycle of medicines; iii) the regular inspection of manufacturing sites around the world and 
iv) the continuous assurance of compliance of quality. Some of these agencies share alignment 
on the most important regulations and quality expectations for the medicines that are introduced 
in the market through the International Council on Harmonization (ICH)6, while others have 
specific expectations that are not always shared by the other regulatory bodies. Despite this 
complex regulatory framework, several common ideas can be found between the different 
regulatory entities, and the discussion proposed in this Dissertation will mainly focus on the 
ideas and guidelines enforced within the context of ICH.   
The need to establish common regulations for good practices in pharmaceutical development 
and manufacturing was largely driven by toxicological safety-related disasters such as the elixir 
of sulfanilamide incident in 1932 (Immel, 2001) or the sulfathiazole disaster in 1941 (Swann, 
1999). In the former case, diethylene glycol was used within the elixir, without testing its 
toxicity (which is now well-known) to humans. The latter incident, instead, refers to the 
commercialization by the Winthrop Chemical Company of New York of sulfathiazole tablets 
contaminated with phenobarbital, which caused hundreds of deaths and thousands of injuries, 
and that was proven to be due to a manufacturing control failure and serious firm’s 
irregularities. These two disasters pushed FDA to conceive (and finalize in 1987) the current 
Good Manufacturing Practices (cGMP), that were intended to guarantee the safety and efficacy 
of drugs through the use of methods, facilities and controls for the manufacturing, processing, 
packing or holding of these products (Immel, 2001; Woodcock, 2013; Collins, 2018). 
Based on the context in which these cGMPs were first conceived (i.e. as a reaction to the 
incidents described above), it is easy to understand why the main focus of these documents was 
                                                          
6 ICH is composed by the regulatory authorities of Europe, U.S. and Japan, together with industrial experts. 
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addressed towards ensuring the toxicological safety of the drug, rather than promoting the 
adoption of innovative methodologies and technologies for drug development and 
manufacturing. Indeed, interpretations of these cGMPs varied amongst companies (Collins, 
2018), and the two main strategies adopted by the regulatory bodies to ensure compliance with 
the cGMPs were: i) the manufacturing site inspection approach (Junod, 2004), and ii) the 
preparation of guidance documents, which contain nonbinding recommendations and invite the 
companies to engage in a proactive discussion with the regulatory agency. These guidance 
documents were not intended to substitute the cGMPs (whose adherence is mandatory), but 
rather as a series of suggestions that, if followed, would have helped the company to comply 
with them.  
The guidance documents’ approach immediately received an incredibly positive feedback from 
companies. Since these documents contain the current regulatory agency’s thinking on the 
topic, many manufacturers started to interpret their recommendations as compulsory (Collins, 
2018), and they are nowadays recognized as the fastest and most efficient way to understand 
the position of the regulatory agencies on a given topic. Given the success of this formula, and 
based on the increased awareness of the regulatory agencies to foster innovation within the 
pharmaceutical context (§ 1.1.3), a series of important initiatives was put forth by the American 
FDA in the early 2000s. First, in 2004, the “Pharmaceutical cGMPs for the 21st century – A 
risk-based approach” was introduced (FDA, 2004b). The targets of this new set of cGMPs 
were, among others, to foster the adoption of new technological advances in pharmaceutical 
manufacturing, introduce quality system and risk management approaches for product 
development and manufacturing and, in a nutshell, promote the adoption of science-based 
approaches and state-of-the-art technologies within the existing pharmaceutical framework. 
Many other initiatives followed this original document (FDA, 2004c; FDA, 2006) and the 
formalization of this new approach for pharmaceutical development and manufacturing was 
finalized through a series of ICH guidelines (ICH 2006, 2009a, 2009b, 2011, 2012) that 
represent the foundation of the broad framework which is now known as Quality by Design 
(QbD). The introduction of the QbD initiative aimed at replacing the traditional procedural and 
inspection-based approach to assure compliance (i.e., product quality) with a new scientific and 
risk-based approach, characterized by a greater understanding of the product and process 
considered, as well as the sources of variability that can potentially affect product quality. The 
fundamental idea behind Qbd is that product quality should be “built” into the product since its 
conception and design, rather than verified after its manufacturing. This requires a mechanistic 
understanding of the relationship between product quality and all the sources of variability that 
may have an impact on it. 
The launch of QbD represented a turning point for the pharmaceutical community, and the 
practical implementation of this paradigm still remains the core of the current pharmaceutical 
innovation (that not only involves the R&D process, but also the manufacturing stage, as 
  
14 Chapter 1 
________________________________________________________ 
© 2018 Gabriele Bano, University of Padova (Italy) 
 
explained in § 1.1.3). From their side, the regulatory agencies regularly release documents 
(which are, mainly, guidelines or drafts of guidelines, in view of the considerations described 
above) aimed at describing their current thinking on specific topics. A brief record of the main 
ICH guidelines that have been proposed throughout the years and that contain the main ideas 
of the QbD paradigm are reported in Table 1.5. As can be noticed, the release of these guidelines 
is still an ongoing process (two final guidelines and one draft have been released in 2018), and 
represent a reference for the practical implementation of the QbD paradigm. Moreover, in order 
to centralize the regulatory activities in terms of review, policy, research and science activities, 
the FDA has recently created the Office for Pharmaceutical Quality (OPQ) (Yu and Woodstock, 
2015), whose aim is to uniform and ease any communications between the regulatory bodies 
and the manufacturers. A detailed description of the activities carried out by this “central” 
regulatory body is reported by Yu and Woodstock (2015). 
1.1.4 Regulatory aspects: past, present & future 
As briefly mentioned in the previous section, the role of the regulatory agencies is of paramount 
importance for protecting and improving human health, as well as for influencing the decisions 
and strategies that pharmaceutical companies adopt to keep their competitiveness in the global 
market. These agencies include the already cited FDA, the European Medicines Agency (EMA) 
and many other regulatory bodies that are spread all over the world (a full list can be found in 
Global Regulatory Authority Websites, 2018). Some of the activities carried out by these 
agencies are (Collins, 2018): i) the review of information for new drug submissions from 
pharmaceutical companies; ii) the review of updated process information throughout the 
lifecycle of medicines; iii) the regular inspection of manufacturing sites around the world and 
iv) the continuous assurance of compliance of quality. Some of these agencies share alignment 
on the most important regulations and quality expectations for the medicines that are introduced 
in the market through the International Council on Harmonization (ICH)7, while others have 
specific expectations that are not always shared by the other regulatory bodies. Despite this 
complex regulatory framework, several common ideas can be found between the different 
regulatory entities, and the discussion proposed in this Dissertation will mainly focus on the 
ideas and guidelines enforced within the context of ICH.   
The need to establish common regulations for good practices in pharmaceutical development 
and manufacturing was largely driven by toxicological safety-related disasters such as the elixir 
of sulfanilamide incident in 1932 (Immel, 2001) or the sulfathiazole disaster in 1941 (Swann, 
1999). In the former case, diethylene glycol was used within the elixir, without testing its 
toxicity (that is now well-known) to humans. 
 
                                                          
7 ICH is composed by the regulatory authorities of Europe, U.S. and Japan, together with industrial experts. 
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Table 1.5.  Main ICH guidelines describing the key ideas of the QbD paradigm 
(adapted and updated from Tomba, 2013). 
Date Document Reference Title Type 
06/01/2006 ICH Q9 ICH (2006) Q9- Quality risk management 
(QRM) system. 
Final guidance 
     
04/07/2009 ICH Q10 ICH(2009a) Q10 – Pharmaceutical quality 
system  
Final guidance 
     
11/20/2009 ICH Q8(R2) ICH(2009b) Q8(R2)- Pharmaceutical 
development 
Final guidance 
     
11/01/2011 ICH Q&A ICH (2011) Q8, Q9, Q10 Questions and 
Answers 
Final guidance 
     
07/25/2012 ICH Q&A 
from training 
sessions 
ICH (2012a) Q8, Q9, Q10 points to consider Final guidance 
     
11/09/2012 ICH Q11 ICH (2012b) Q11- Development and 
manufacture of drug substances 
Final guidance 
     
09/30/2016 ICH Q7 ICH (2016) Q7- Good manufacturing practice 
guidance for active 
pharmaceutical ingredients. 
Guidance for industry 
Final guidance 
     
02/23/2018 ICH Q11 
Q&A 
ICH (2018a) Q11- Development of 
manufacture of drug substances – 
Questions and answers 
Final guidance 
     
     
04/19/2018 ICH Q7 
Q&A 
ICH(2018b) Q7- Good manufacturing practice 
guidance for active 
pharmaceutical industry. 
Guidance for industry- Questions 
and answers 
Final guidance 
     
05/30/2018 ICH Q12 ICH(2018c) Q12- Technical and regulatory 
considerations for pharmaceutical 
product lifecycle management. 
Core guideline for industry 
Draft guidance 
 
 The latter incident, instead, refers to the commercialization by the Winthrop Chemical 
Company of New York of sulfathiazole tablets contaminated with phenobarbital, which caused 
hundreds of deaths and thousands of injuries, and that was proven to be due to a manufacturing 
control failure and serious firm’s irregularities. These two disasters pushed FDA to conceive, 
and after few years (specifically, in 1987) finalize the current Good Manufacturing Practices 
(cGMP), that were intended to guarantee the safety and efficacy of drugs through the use of 
methods, facilities and controls for the manufacturing, processing, packing or holding of these 
products (Immel, 2001; Woodcock, 2013; Collins, 2018). Based on the context in which these 
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cGMPs were first conceived (i.e. as a reaction to the incidents described above), it is easy to 
understand why the main focus of these documents was addressed towards ensuring the 
toxicological safety of the drug, rather than promoting the adoption of innovative 
methodologies and technologies for drug development and manufacturing. Indeed, 
interpretations of these cGMPs varied amongst companies (Collins, 2018), and the two main 
strategies adopted by the regulatory bodies to ensure compliance with the cGMPs were: i) the 
manufacturing site inspection approach (Junod, 2004) and ii) the preparation of guidance 
documents, which contain nonbinding recommendations and invite the companies to engage in 
a proactive discussion with the regulatory agency. These guidance documents were not intended 
to substitute the cGMPs (whose adherence is mandatory), but rather as a series of suggestions 
that, if followed, would have helped the company to comply with them.  
The guidance documents’ approach immediately received an incredibly positive feedback from 
companies. Since these documents contain the current regulatory agency’s thinking on the 
topic, many manufacturers started to interpret their recommendations as compulsory (Collins, 
2018), and they are nowadays recognized as the fastest and most efficient way to understand 
the position of the regulatory agencies on a given topic. Given the success of this formula, and 
based on the increased awareness of the regulatory agencies to foster innovation within the 
pharmaceutical context (§ 1.1.3), a series of important initiatives was put forth by the American 
FDA in the early 2000s. First, in 2004, the “Pharmaceutical cGMPs for the 21st century – A 
risk-based approach” was introduced (FDA, 2004b). The targets of this new set of cGMPs 
were, among others, to foster the adoption of new technological advances in pharmaceutical 
manufacturing, introduce quality system and risk management approaches for product 
development and manufacturing and, in a nutshell, promote the adoption of science-based 
approaches and state-of-the-art technologies within the existing pharmaceutical framework. 
Many other initiatives followed this original document (FDA, 2004c; FDA, 2006) and the 
formalization of this new approach for pharmaceutical development and manufacturing was 
finalized through a series of ICH guidelines (ICH 2006, 2009a, 2009b, 2011, 2012) which 
represent the foundation of the broad framework which is now known as Quality by Design 
(QbD). The introduction of the QbD initiative aimed at replacing the traditional procedural and 
inspection-based approach to assure compliance (i.e. product quality) with a new scientific and 
risk-based approach, characterized by a greater understanding of the product and process 
considered, as well as the sources of variability that can potentially affect product quality. The 
fundamental idea behind Qbd is that product quality should be “built” into the product since its 
conception and design, rather than verified after its manufacturing. This requires a mechanistic 
understanding of the relationship between product quality and all the sources of variability that 
may have an impact on it. 
The launch of QbD represented a turning point for the pharmaceutical community, and the 
practical implementation of this paradigm still remains the core of the current pharmaceutical 
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innovation (that not only involves the R&D process, but also the manufacturing stage, as 
explained in § 1.1.3). From their side, the regulatory agencies regularly release documents 
(which are, mainly, guidelines or drafts of guidelines, in view of the considerations described 
above) aimed at describing their current thinking on specific topics. A brief record of the main 
ICH guidelines that have been proposed throughout the years and that contain the main ideas 
of the QbD paradigm are reported in Table 1.5. As can be noticed, the release of these guidelines 
is still an ongoing process (two final guidelines and one draft have been released in 2018) and 
represent a reference for the practical implementation of the QbD paradigm. Moreover, in order 
to centralize the regulatory activities in terms of review, policy, research and science activities, 
FDA has recently created few years ago the Office for Pharmaceutical Quality (OPQ) (Yu and 
Woodstock, 2015), whose aim is to uniform and ease any communications between the 
regulatory bodies and the manufacturers. A detailed description of the activities carried out by 
this “central” regulatory body is reported in Yu and Woodstock, 2015. 
1.2 Quality by design paradigms: regulatory overview 
The concepts embedded within the Quality by Design initiative can be understood through a 
rigorous interpretation of the guidelines that have been issued, and are still being issued, by the 
regulatory agencies. From a general perspective, the interpretation of QbD proposed by the 
regulators can be schematically summarized as a sequence of 5 activities (Yu et al., 2014; Yu 
et al., 2015):  
1) identification of a quality target product profile (QTPP), from which the critical quality 
attributes (CQAs) of the drug under development can be assessed; 
2) product design and understanding, including the identification of the raw material 
properties that are critical for product quality (often defined as critical material 
attributes; CMA); 
3) process design and understanding, including the identification of critical process 
parameters (CPPs) and the derivation of a mechanistic relationship between the raw 
material properties and CPPs with the product CQAs; 
4) definition of a control strategy, in terms of identifying the specifications for the API, 
excipient and the final drug, and in terms of developing a strategy to control each step 
of the manufacturing process; 
5) exploitation of process capability and adoption of a continual process improvement 
strategy. 
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Table 1.5.  Brief record of the main ICH guidelines that describe the key ideas 
of the QbD paradigm. Adapted and updated from Tomba, 2013. 
Date Document Reference Title Type 
06/01/2006 ICH Q9 ICH (2006) Q9- Quality risk management 
(QRM) system. 
Final guidance 
     
04/07/2009 ICH Q10 ICH(2009a) Q10 – Pharmaceutical quality 
system  
Final guidance 
     
11/20/2009 ICH Q8(R2) ICH(2009b) Q8(R2)- Pharmaceutical 
development 
Final guidance 
     
11/01/2011 ICH Q&A ICH (2011) Q8, Q9, Q10 Questions and 
Answers 
Final guidance 
     
07/25/2012 ICH Q&A 
from training 
sessions 
ICH (2012a) Q8, Q9, Q10 points to consider Final guidance 
     
11/09/2012 ICH Q11 ICH (2012b) Q11- Development and 
manufacture of drug substances 
Final guidance 
     
09/30/2016 ICH Q7 ICH (2016) Q7- Good manufacturing practice 
guidance for active 
pharmaceutical ingredients. 
Guidance for industry 
Final guidance 
     
02/23/2018 ICH Q11 
Q&A 
ICH (2018a) Q11- Development of 
manufacture of drug substances – 
Questions and answers 
Final guidance 
     
     
04/19/2018 ICH Q7 
Q&A 
ICH(2018b) Q7- Good manufacturing practice 
guidance for active 
pharmaceutical industry. 
Guidance for industry- Questions 
and answers 
Final guidance 
     
05/30/2018 ICH Q12 ICH(2018c) Q12- Technical and regulatory 
considerations for pharmaceutical 
product lifecycle management. 
Core guideline for industry 
Draft guidance 
 
Based on the definition proposed in § 1.1.2 and § 1.1.3, steps 1-4 are typical R&D activities, 
while steps 5 is related to the manufacturing stage8. This concept has been eventually 
formalized in the ICH-Q10 guideline (ICH, 2009a), where the activities that characterize the 
lifecycle of a pharmaceutical product are classified as follows: 
a) Pharmaceutical development, that collects steps 1-3 of the previous classification; 
                                                          
8 Note that the definition of the control strategy, even if practically tested and implemented during the manufacturing stage, 
may be conceived during the process development stage (i.e., step 3). 
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b) Technology transfer, whose goal is to transfer product and process knowledge from 
development to manufacturing (scale-up) or from different manufacturing sites (scale-
out); 
c) Commercial manufacturing (or product manufacturing), which collects steps 4 and 5 of 
the previous classification. 
Moreover, a new step (called product discontinuation) has been added to the previous 
classification. The goal of this step is to develop strategies for an effective management of the 
terminal stage of the product lifecycle (e.g. product recall from the market). The key activities 
and the key terminology that is adopted in the three steps (a,b,c) described above is briefly 
reviewed in the following sections. 
1.2.1 Pharmaceutical development 
The definition of pharmaceutical development and the steps that should be implemented during 
this activity according the QbD framework are thoroughly described in the regulatory guideline 
ICH Q8(R2) (ICH, 2009b). ICH defines pharmaceutical development as the activity “whose 
aim is to design a quality product and its manufacturing process to consistently deliver the 
intended performance of the product” (ICH, 2009b). The elements that, according to the QbD 
framework, pharmaceutical development should include are schematically shown in Fig. 1.3. 
 
 
Figure 1.3 Elements that should be considered in pharmaceutical development according to ICH (ICH, 2009b). 
 
Steps (a), (b), (c), (e) are considered minimum requirements, while step (d) represents the core 
step to implement an enhanced QbD approach. 
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1.2.1.1 Step (a): identification of the Quality Target Product Profile (QTPP) 
Before going through the different steps of pharmaceutical development, the definition of 
quality for a pharmaceutical drug must be given. According to the ICH Q6A guideline, quality 
is defined as the suitability of either a drug substance or drug product for its intended use (ICH, 
1999). A revised definition of quality is proposed in the ICH Q9 guideline, where quality is 
defined as the degree to which a set of inherent properties of a product fulfills requirements 
(ICH, 2006). A prospective summary of the quality characteristics of the product that ideally 
should be achieved to ensure the desired safety and efficacy is defined as the Quality Target 
Product Profile (QTPP). The identification of the QTPP is a key step of pharmaceutical 
development and directly influences the success of all the remaining activities. Raw and 
coworkers (Raw et al., 2011) analyzed the impact that a wrong identification of the QTPP can 
have on the subsequent development stages, emphasizing that this step is often underestimated 
by companies. Following the regulatory guidelines (ICH, 2009b), the definition of the QTPP 
should include the following aspects: 
 intended use in clinical setting, route of administration, dosage form, delivery systems; 
 dosage strength(s); 
 container closure system; 
 therapeutic moiety release or delivery and attributes affecting pharmacokinetic 
characteristics (e.g. dissolution, aerodynamic performance) appropriate to the drug 
product dosage form being developed; 
 drug product quality criteria (e.g. sterility, purity, stability and drug release) appropriate 
for the intended marketed product. 
Once identified, the QTPP forms the basis for the identification of the critical quality attributes 
(CQAs) of the product. 
1.2.1.2 Step (b): identification of the product Critical Quality Attributes (CQAs) 
A critical quality attribute (CQA) is defined by ICH (ICH, 2009b) as a physical, chemical, 
biological or microbiological property or characteristic of an output material, including a 
finished drug product, that should be within an appropriate limit, range, distribution to ensure 
the desired product quality. According to this definition, the CQAs may not only be related to 
the drug product, but also to the intermediates (i.e., in-process materials). CQAs should be 
derived from the QTPP identified at the previous step, and criticality should be primarily based 
upon the severity of harm to the patient should the product fall outside the acceptable range for 
that attribute (Yu et al., 2014). Examples of CQAs could include all those aspects affecting 
product purity, dug release and stability, or specific properties such as aerodynamic properties 
for inhaled products, sterility for parenterals and so on. The CQAs of intermediates could 
include specific properties (e.g. particle size distribution, bulk density etc…) that may 
potentially affect product CQAs. It is worth noticing that, in several situations, the CQAs of the 
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intermediates are improperly referred to as “product” CQAs. For the sake of simplicity, in this 
Dissertation, this terminology will be adopted. 
1.2.1.3 Step (c): product and process design and understanding 
Steps (c) and (d) of the methodology presented in (§ 1.2) can be classified according to two 
different and sequential activities: i) product design and understanding and ii) process design 
and understanding.  
Product design is concerned with the assessment of the ability of the product to meet the desired 
QTPP and maintain the desired QTPP over the product shelf life. Product understanding is 
related to the identification of the raw material properties that can potentially affect the product 
CQAs, and on the ability to link these material properties to the product CQAs (ICH, 2012b; 
Yu et al., 2014). Process understanding is related to the identification of the critical process 
parameters (CPPs) that can potentially affect the product CQAs, and on the development of a 
link between the CPPs and the CQAs. Finally, process design is concerned with the design of 
a manufacturing process that can consistently guarantee to produce the desired product and to 
maintain the desired product CQAs throughout the entire production campaign. 
With respect to product design, the key elements that should be taken into account at this stage 
are (ICH, 2012b; Yu et al., 2014): 
 physical, chemical and biological characterization of the API; 
 identification and selection of the excipient type and grade, and understanding of its 
potential variability; 
 understanding of the interaction between drug and excipients. 
Examples of physical properties of the API that may be considered are solubility, dissolution 
rate, stability and many others. Chemical properties may include, for example, chemical 
stability in solid state; examples of biological properties are bioavailability and membrane 
permeability. The final target of this step is to design, through an open-ended activity of 
formulation optimization, a product that meet the desired QTPP and that can guarantee to 
preserve this QTPP throughout its entire lifecycle. 
With respect to product understanding, the identification of the raw material properties (critical 
material attributes; CMAs) that affect the product CQAs is the first step that must be followed. 
Following the regulatory parlance, a CMA is a physical, chemical, biological or microbiological 
property or characteristic of an input material that should be within an appropriate limit, range 
or distribution to assure product quality (ICH, 2009b). It is worth noticing the similarity of this 
definition with that of CQA (§ 1.2.1.2), but the difference is that, while CQAs are related to 
output materials (such as intermediates and the drug product), CMAs are related to input 
materials (such as the drug substance and the excipients). Moreover, the CQA of an 
intermediate may become a CMA of that same intermediate for a downstream manufacturing 
step (Yu et al., 2014). Given that investigating all the material attributes that may potentially 
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affect the product CQAs is not practically feasible (due to the large number of attributes to be 
investigated), it is recommended (ICH, 2009b; Yu et al., 2014) to follow a risk-based approach 
based on prior knowledge and scientific understanding to identify the CMAs and relate them to 
the product CQAs. This activity can include the following steps (Yu et al., 2014: Yu et al., 
2017): 
 qualitative determination of all possible known input material attributes that may affect 
the product CQAs; 
 identification of potentially high-risk attributes through risk assessment methodologies 
and scientific knowledge; 
 design and execution of experiments (eventually designed with design of experiments; 
DoE) based on predefined levels or ranges for the attributes identified at the previous 
step; 
 analysis of the experimental data with data-driven or (whenever possible) mechanistic 
modeling to assess the criticality of each attribute. 
With respect to the process design activity, the process that should be used to manufacture the 
drug product must be conceived at this stage. The target of process design is to identify all the 
unit operations and manufacturing stages (along with their operating mode, i.e. batch or 
continuous) that should be adopted for the manufacturing of the drug product. The design of 
the manufacturing process should not only guarantee to obtain the desired product 
characteristics, but also that these characteristics can be achieved throughout the entire 
production campaign. The regulatory guidelines (ICH, 2009b) explicitly require a detailed 
description of the unit operations and equipment involved in the manufacturing process when 
applying for a new drug approval, emphasizing that every choice should be justified 
scientifically, and not based only on experience (e.g., from previous products). Moreover, 
scientific proof of the appropriateness of the equipment and unit configurations chosen should 
be given. 
With respect to process understanding, the key elements that should be followed are 
intrinsically similar to those of product understanding (Yu et al., 2014): 
 qualitative determination of all possible known process parameters that may impact on 
the product CQAs; 
 identification of potentially high-risk process parameters through risk assessment 
methodologies and scientific knowledge; 
 design and execution of experiments (eventually designed) based on predefined levels 
or ranges for the parameters identified at the previous step; 
 analysis of the experimental data with data-driven or mechanistic modeling to assess if 
a given process parameter is critical. 
The main target of this stage is the identification of the critical process parameters (CPPs) that 
have an impact on the product CQAs during manufacturing and the identification of a link 
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between the CPPs and the CQAs. These can be obtained with a combination of experimentation 
and modeling (data-driven or mechanistic), as will be discussed in § 1.3. In many situations, 
the models that link the CMAs with the CQAs obtain during product understanding are 
integrated with the models that link the CPPs and CQAs obtained at this stage, thus obtaining 
an “integrated” model that related the CMAs and CPPs with the product CQAs. Once this “link” 
is obtained, the next step is the identification of the design space of the drug product considered. 
1.2.1.4 Step (d): design space (DS) description 
The concept of design space (DS) of a pharmaceutical process represents one of the 
fundamental paradigms of the QbD initiative. According to the regulatory documents (ICH, 
2009b), the DS is defined as “the multidimensional combination and interaction of input 
variables (e.g. material attributes) and process parameters that have been demonstrated to 
provide assurance of quality”.  Based on the definitions given in § 1.2.1.3, the definition of DS 
can also be reformulated as the multivariate space identified by the CMAs and CPPs that 
guarantee to obtain the desired product CQAs.  
The establishment of the design space is to be considered as the ultimate result of the product 
and process understanding activities, and it represents the most important evidence of the 
change in the relationship between the regulatory bodies and pharmaceutical companies 
introduced within the QbD initiative. In fact, if the design space is approved by the regulatory 
agency, the process can be run anywhere within the design space without requiring any 
regulatory post-approval endorsement. This translates into an enhanced process flexibility, in 
contrast with the traditional approach where every change in the process had to be 
communicated to the regulatory body for assessment and approval. The DS therefore represents 
a “window” of operating conditions within which the company can optimize the manufacturing 
process, which can increase process profitability. 
Five remarks are worth being discussed with respect to the regulatory definition of DS and its 
implications. Additional (technical) comments will be provided in § 1.3. 
 Remark #1: the identification of the design space, even if strongly encouraged by the 
regulatory bodies, is a non-binding activity that can be performed on a volunteer basis. 
The regulatory guidelines, in fact, explicitly state that the design space “can be proposed 
by the applicant and is subject to regulatory assessment and approval” (ICH, 2009b). 
 Remark #2: in the definition given by the regulatory agencies, the multivariate nature 
of the design space is explicitly emphasized. In mathematical terms, this means that the 
design space is given by the manifold spanned by the vector field of each relevant input 
parameter (CPPs and CMAs) and that the correlation between these inputs should be 
taken into account when defining the DS. Accordingly, univariate experiments (i.e., 
experiments performed by changing one input factor at a time) cannot constitute the 
basis for the definition of a DS. The definition of the DS as a combination of proven 
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acceptable ranges9 is therefore not permitted (ICH, 2009b), since it lacks of 
understanding of the possible interactions between the input parameters. Interestingly, 
it should be noted that the regulatory documents are not entirely consistent in this 
respect. In fact, while stating that the DS cannot be expressed in terms of PARs, they 
also state that “a design space can be expressed in terms of ranges of material attributes 
and process parameters, or through more complex mathematical relationships” (ICH, 
2009b). Clearly, the first part of this statement is not consistent with the previous one 
or, provided that those attributes are obtained as a result of a multivariate analysis (i.e., 
accounting for input correlation), is to be considered at least misleading. 
 Remark #3: the regulatory documents leave the freedom to establish independent design 
spaces for each single unit operation of the manufacturing line, or a single design space 
that spans multiple operations (ICH, 2009b). From the one side, the establishment of 
independent design spaces for single unit operations is typically simpler to develop; 
however, on the other side, the definition of a single design space for the overall 
manufacturing line can provide an enhanced operational flexibility (ICH, 2009b). In 
practical terms, this poses two technical problems: i) how to derive the design space of 
an entire manufacturing line given the independent design spaces of the single unit 
operations of that line (if the first option is adopted); ii) how to deal with the complexity 
and high dimensionality of a single DS for a whole manufacturing process (if the second 
option is adopted).  
 Remark #4: when a design space is to be established, the scale at which the DS has been 
developed should be stated and the relevance of the proposed design space with respect 
to the plant manufacturing process should be described. In this respect, the regulatory 
guidelines provide qualitative recommendations without giving substantial details. The 
regulatory documents leave the freedom to develop the DS at any scale the manufacturer 
may consider relevant (ICH, 2009b). However, if the DS developed at a small scale 
(e.g., laboratory scale) is claimed to be applicable to the manufacturing process, the 
rationale behind the scale-up of the DS that has been adopted should be described (ICH, 
2009b). In this regard, the regulatory guidelines suggest to describe the design space in 
terms of relevant scale-independent parameters, and to give a thorough description of 
the models adopted for scaling (ICH, 2009b). 
 Remark #5: from a general perspective, it should be emphasized that the regulatory 
guidelines only provide general indications on how to establish the design space, but no 
specific technical recommendations are given. This leaves the freedom to the 
manufacturer to develop and propose the rationale adopted for the description of the 
DS. If, from one side, this represents a clear advantage for the applicants, since it 
                                                          
9 A proven acceptable range (PAR) is defined as a “characterised range of a process parameter for which operation within this 
range, while keeping the others parameters constant, will result in producing a material meeting relevant quality criteria”. 
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provides greater flexibility on the choice of the experimental/modeling strategy to be 
adopted, from the other side it paves the way for different interpretations of the 
regulatory documents, thus compromising the development of a common 
implementation framework. This problem has been recently highlighted by industrial 
practitioners (Watson et al., 2018) and will be discussed in more detail in § 1.4.4.. 
1.2.1.5 Step (e): definition of a control strategy 
The definition of control strategy given by the regulatory documents is “a planned set of 
controls, derived from current product and process understanding that ensures process 
performance and product quality” (ICH, 2009b). This definition is not the same definition that 
is typically adopted in common engineering understanding, where the term control is 
specifically related to the concept of process control. In fact, the definition of control strategy 
proposed by the regulatory agencies involves three different levels of controls (Yu et al., 2014), 
namely: 
 Level 1. This type of control coincides with the engineering definition of process 
control, i.e., it is related to the monitoring of CMAs and automatic adjustment of CPPs 
to consistently obtain the desired product CQAs. In other terms, Level 1 control is 
related to the exploitation of (feedback/feedforward/advanced) process control 
strategies to guarantee that desired product quality characteristics (set-points) can be 
obtained by appropriate manipulation of the process parameters (i.e., CPPs), even in the 
presence of disturbances (i.e., raw material properties fluctuations). 
 Level 2. This type of control is related to the implementation of non-automatic decisions 
(i.e., decisions implemented manually by operators) within the boundaries of the design 
space, with the aim of reducing end-product testing. 
 Level 3. This type of control is the one that has been traditionally implemented in the 
pharmaceutical industry. It relies on extensive end-product testing and tight handling of 
process parameters. In practical terms, this type of control is equivalent to an a 
posteriori product quality verification (quality by testing), and has nothing to do with 
the engineering definition of control. 
To give a simple engineering interpretation of three different levels of control proposed by the 
regulatory bodies, a rough classification is that Level 1 control coincides with the concept of 
closed-loop process control (i.e., feedback, feedforward, or other advanced process control 
techniques), Level 2 with the concept of open-loop process control (i.e., manual control), while 
Level 3 is equivalent to not having process control at all. The regulatory documents encourage 
the use of a combination of Level 1 and Level 2 controls for a correct implementation of the 
QbD framework (ICH, 2009b; Yu et al., 2014). It should be noted that regulatory documents 
are not entirely clear on the relationship existing between control strategy and design space. In 
fact, while in one point of the body of the ICH Q8(R2) guideline the identification of the design 
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space and the definition of a control strategy are presented as two sequential activities (ICH, 
2009b), in other sections of the same guideline it is stated that “(…) an appropriate control 
strategy can, for example, include a proposal for a design space(s) and/or real-time release 
testing”. It is not entirely clear, therefore, if the control strategy should guarantee that the 
process can be operated within the boundary of the DS previously established, or if the 
identification of the DS can be interpreted as part of the control strategy itself. 
1.2.2 Technology transfer 
Technology transfer includes all the activities required to transfer the manufacturing process 
from the laboratory scale to the commercial scale (possibly through a pilot plant). These 
activities include not only the transfer of equipment and process operating conditions, but also 
all the subsidiary technologies tested and implemented at the laboratory scale (e.g., sensors, 
analyzers, control instrumentation etc…). Within these activities, the scale-up of the design 
space and control strategy discussed in § 1.2 represent key steps to guarantee that the desired 
product quality can be obtained also in the commercial scale plant. According to the regulatory 
recommendations, technology transfer is an activity that should be performed using a risk-based 
approach (ICH, 2006) and should pose the basis for a continual process improvement strategy. 
Despite simple general recommendations on how technology transfer should be implemented, 
it is worth noticing that the regulatory documents do not provide technical recommendations 
on how this step should be implemented. Therefore, manufacturers are left with the freedom to 
prove the effectiveness of the scale-up procedures adopted (Yu et al., 2014). This has the 
advantage of giving great flexibility on how to face this problem, but at the same time leaves 
companies with several different options and interpretations (Watson et al., 2018).  
1.2.3 Commercial manufacturing & continual process improvement 
Commercial manufacturing is the culmination of the product/process design and technology 
transfer activities, and is meant to obtain a mass production of the desired drug. As briefly 
discussed in §1.1.3, pharmaceutical processes typically involve several operating units that may 
be operated batchwise or continuously. Despite very few entire manufacturing lines are 
operated continuously, the presence of single units operated continuously has long been 
considered as a standard practice in pharmaceutical manufacturing (Garcia-Munoz et al., 2018).  
The regulatory documents explicitly mention two elements that should be considered when 
mass production of the drug has been reached: process capability and continual process 
improvement (ICH, 2006; ICH, 2009b, Yu et al., 2014). 
Process capability is defined as “a measure of the inherent variability of a stable process that is 
in a state of statistical control in relation to the established acceptance criteria” (ICH, 2006; Yu 
et al., 2014). In practical terms, the definition of process capability given by the regulators is 
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equivalent to the concept of process monitoring, to be intended as the early identification of 
potential sources of common-cause variation within the process. Once these common sources 
of variation have been identified, mitigation actions should be taken via the control strategy to 
guarantee that the process will give the desire product quality (i.e., process control). 
The regulatory concept of continual process improvement refers to a set of activities that the 
company can carry out to enhance the ability of the process to maintain product quality (ICH, 
2006; Yu et al., 2014). These activities may include, but are not limited to (Yu et al., 2014): 
 measuring key aspects of the current process and collect relevant data; 
 analyzing the data to investigate and verify cause and effect relationships; 
 improving or optimizing the current process based upon data analysis ; 
 continuously monitoring the process and implementing control systems such as 
statistical process control. 
The regulatory agencies encourage manufacturers to exploit the additional process knowledge 
that can be obtained during manufacturing (e.g., through sensors, analyzers etc…) to improve 
their processes (ICH, 2009a; ICH, 2009b). In this respect, a specific mention is given to the 
periodic maintenance of design spaces obtained using mathematical models. The ICH Q8(R2) 
document, in fact, explicitly states that “(…) for certain design spaces using mathematical 
models, periodic maintenance could be useful to ensure the model’s performance…” and that 
“expansion, reduction of redefinition of the design space could be desired upon gaining 
additional process knowledge” (ICH, 2009b). Interestingly, while specific mention to the 
possibility of updating the design space during the product lifecycle is given, no indication on 
how this should be done and communicated to the regulatory bodies are given. 
Solicited by manufacturers (Herwig et al., 2017; Watson et al., 2018), ICH has recently released 
a draft for a new guidance, the Q12 guidance on Technical and regulatory considerations for 
pharmaceutical product lifecycle management, that aims at removing the “(…) technical and 
regulatory gaps that limit the full realization of more flexible regulatory approaches to post-
approval changes as describe in ICH Q8(R2) and Q10 Annex 1…” (ICH, 2018). This document 
is still a draft guidance and is currently under public evaluation for final approval. Once 
finalized, the guidance will represent the regulatory reference for a common implementation of 
product lifecycle approaches, including design space updates and control strategy updates. 
1.2.4 Technical and economic benefits of QbD: a critical review 
Since the launch of the QbD initiative, several surveys and reviews have been published to 
understand the reaction of the pharmaceutical companies to this new paradigm, both in technical 
and economic terms.  
IBM (IBM, 2005) was the first one to forecast the impact of QbD from an economic point of 
view. As an example, for a drug with US$ 1billion peak annual sales, it was estimated that 
practical implementation of the QbD paradigm could have generated an extra US$ 1.6 billion 
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over the entire drug lifecycle (IBM, 2005). Despite this rather optimistic forecast, the opinion 
of market observers started becoming more prudent when the QbD implementation process 
started taking place within industry. In 2009 a private survey of the FDA, which was then made 
publicly available by McKinsey (McKinsey,2009), revealed that, despite the potential of QbD 
to promote innovative technological advancements, many industrial companies were still 
skeptics on its real economic benefits (in terms of return on investment). FDA identified four 
different challenges occurring within companies and six internal challenges occurring within 
the regulatory bodies. The four challenges involving companies were briefly summarized as 
follows (McKinsey, 2009): 
 disconnection between cross functional areas of the same company, e.g. R&D and 
manufacturing; 
 lack of belief in business case, i.e., many companies proved to be skeptic about the 
timing and the investments required to practically implement QbD; 
 lack of suitable technological equipment for a correct implementation of QbD; 
 alignment with third parties (e.g., suppliers) on QbD implementation. 
As per the regulatory bodies, the following criticalities were emphasized: 
 presence of a small portion of people within FDA not supportive towards the real 
efficacy of QbD; 
 lack of technical and specific guidance on how to implement in practice the principles 
of QbD; 
 misalignment between international regulatory bodies; 
 lack of preparation on the topic of some regulators that could be deduced during on-site 
inspections; 
 scarce collaboration between companies and regulators; 
 scarce ability of the regulatory to inspire confidence on the actual benefits of QbD 
implementation. 
The regulatory agencies promoted different initiatives to face both the internal challenges and 
the challenges that were directly investing pharmaceutical companies. Positive results were 
obtained and the QbD paradigms started to spread at a very fast pace within the community. 
The increasing interest of companies towards a systematic implementation of the QbD approach 
was first confirmed by an industrial survey10 conducted by Kourti and coworkers (Kourti and 
Davis, 2012), where the benefits of QbD in terms of improved product and process 
understanding and improved robustness in manufacturing were extensively acknowledged. A 
later survey (Cook et al., 2014) conducted by the American Association of Pharmaceutical 
Scientists (AAPS), involving 149 pharmaceutical scientists11, reported that the majority of 
                                                          
10 The survey involved 12 different pharma companies, including bio-tech companies. 
11 The composition of the scientists was as follows: 88% from industry, 7% from academia, 4% from regulatory bodies, 1% 
others. 
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respondents (54 to 76%) acknowledged an extensive use of QbD tools and elements for product 
and process development. Moreover, respondents acknowledged the positive benefits of QbD 
in terms of the impact it can have on the patient’s health (78%), as well as on internal processes 
such as knowledge management (85%), decision-making (79%) and lean manufacture (71%) 
(Cook et al., 2014). However, scientists seemed to be more skeptics (more than 50%) on the 
economic benefits (in terms of return on investments) of the QbD implementation. Very recent 
surveys on this topic (Chatfield, 2017; Lundsberg-Nielsen and Bruce, 2017) confirm that QbD 
has now reached a mature and generalized level of implementation between companies, and the 
economic benefits that can be obtained are starting getting acknowledged. However, critical 
gaps still exist between the regulatory bodies and pharmaceutical companies on the technical 
details for a correct implementation between the QbD (Herwig et al., 2017; Watson et al., 2018; 
Collins, 2018). Process systems engineering tools are expected to play a key role to reduce this 
gap (Herwig et al., 2017; Reklaitis, 2017) and to enhance the profitability of a correct QbD 
implementation. 
1.3 Mathematical modelling 
1.3 Mathematical modelling for QbD implementation 
As extensively discussed in the previous sections, the most important target of the QbD 
paradigm is to promote the adoption of rigorous scientific tools to assist the different stages 
(pharmaceutical development, technology transfer, commercial manufacturing) of the lifecycle 
of a new pharmaceutical drug. One of the most important tools that can be used to achieve this 
purpose is mathematical modelling (García-Muñoz and Oksanen, 2010). 
The importance of mathematical modelling for a correct implementation of the QbD paradigm 
is extensively emphasized in the regulatory documents (FDA, 2004c; ICH, 2009a; ICH, 
2009b,ICH, 2012a). Since the final scope of every development/manufacturing activity is the 
achievement of the desired product quality, models are classified by regulators according to 
their impact (low/medium/high) in assuring this target (ICH, 2012a). Following the regulatory 
parlance (ICH, 2012a), low-impact models are defined as models that are typically used in 
product/process development (e.g., for formulation optimization). Medium-impact models are 
models that can be useful in assuring quality of the product but are not the sole indicators of 
product quality (e.g., most design space models). High-impact models are models whose 
predictions are significant indicators of product quality (e.g., a chemometric model for product 
assay or a surrogate model for dissolution). 
From a PSE perspective, a much more useful classification of the models that can be exploited 
in pharmaceutical development/manufacturing is based on the following two criteria (Bonvin 
et al., 2017): 
 model type, i.e., knowledge-driven, hybrid or data-driven; 
  
30 Chapter 1 
________________________________________________________ 
© 2018 Gabriele Bano, University of Padova (Italy) 
 
 model scope, i.e. based on the final purpose of implementation (e.g., models for design 
space determination). 
From a general perspective, a model is characterized by three elements: equations, variables 
and parameters. The model type describes the amount of knowledge embedded within the 
model. In this regard, models can be classified as knowledge-driven (also known as first-
principles or mechanistic or deterministic), hybrid (also known as semi-empirical or gray-box) 
and data-driven (also known as data-based or empirical or black-box). 
Knowledge-driven models are based on fundamental knowledge of the underlying physical 
phenomena that govern the system under investigation. For these models, the equations 
describe in mathematical terms the physical laws (e.g., mass and energy balances, heat/mass 
transfer mechanisms) representing the system; the variables represent the system states; 
parameters inform on how the mathematical description given by the equations should be tuned 
to match the actual system behavior. Data-driven models do not embed any knowledge on the 
physical mechanisms involved in the system. For these models, the equations simply represent 
a convenient representation of the dataset(s) collected for the system under investigation; 
variables collect the inputs and outputs of the dataset; parameters inform on how equations 
should be tuned to match the available data. Semi-empirical models represent an intermediate 
situation between knowledge-driven and data-driven models, i.e. they combine fundamental 
knowledge on the system to describe certain phenomena with empirical reasoning to describe 
others phenomena. 
The model scope describes the purpose of implementation (i.e., the application) of the model. 
Models can be exploited to assist the three stages of the drug lifecycle (pharmaceutical 
development, technology transfer, commercial manufacturing and continual process 
improvement). In pharmaceutical development, models can be used to assist all the sequential 
activities discussed in § 1.2.1 (QTTP and CQAs identification; product and process 
understanding; product and process design, including design space identification and definition 
of a control strategy) with the purpose of accelerating the launch of new products in the market. 
With respect to technology transfer, models can be used to assist both the scale-up and scale-
out of the manufacturing process (including its design space and its control strategy), with the 
purpose of facilitating its transfer between different scales or between different sites. Finally, 
with respect to commercial manufacturing and continual process improvement, models can be 
used to assist product quality monitoring and control, as well as to enhance process productivity 
(i.e., via process optimization) and to assist process intensification. 
The increasing interest of the pharmaceutical community towards mathematical modelling has 
been thoroughly reviewed by Troup and Georgakis (2013), Rogers and Ierapetritou (2015) and, 
very recently, by Reklaitis et al. (2017).  
In 2013, Troup and Georgakis (2013) presented the results of a survey involving 21 
professionals from worldwide top-pharma companies on the use of mathematical modelling for 
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process analytics, process monitoring, plant-wide information system, unit operation modeling, 
quality control and process optimization. The results showed that, with respect to process 
analytics and monitoring, the use of multivariate chemometric models and multivariate 
statistical process control represented common practices in the industrial context (according to 
67% of the respondents), as well as the use of statistical multivariate tool to analyze historical 
process data. With respect to process modelling and optimization, more than one third of the 
respondents revealed that data-driven approaches were adopted to model between 80-100% of 
the unit operations of the manufacturing lines, while the other two thirds revealed that data-
driven approaches were exploited to model at least 60% of the unit operations. However, the 
use of first principles models were acknowledged for at least 10% of the unit operations, mainly 
involving secondary manufacturing activities. Moreover, the advantages (possibility to perform 
extrapolation, wider applicability range, possibility to include product physical properties) and 
disadvantages (costs and complexity of model development, computational burden) of first-
principles models with respect to data-driven models were stressed out by the respondents.  
In 2015, a review by Rogers and Ierapetritou (2015) revealed the increasing interest of the 
pharmaceutical community towards the use of hybrid as well as first-principles models. This 
interest was partially driven by the increasing attention towards continuous manufacturing in 
the pharmaceutical community (§ 1.1.3). Very recently, Reklaitis et al. (2017) revealed that 
data-driven, hybrid and first-principles models are nowadays jointly exploited by 
pharmaceutical companies to tackle different problems of the drug lifecycle. Specifically, while 
data-driven approaches still represent the most adopted tools for process analytics, process 
monitoring and process control, hybrid as well as first-principles models are starting being 
exploited much more frequently to assist the different phases of pharmaceutical development. 
Moreover, due to the recent advancements in computational power and technology, it is 
expected that online applications of these model will play a key role in the next years (Reklaitis 
et al., 2017). 
Within the different scopes of mathematical modeling in the pharmaceutical context, the 
identification of the design space of a new pharmaceutical product probably represents the most 
important one (García-Muñoz and Oksanen, 2010). For example, almost 70% of the 
respondents of the survey of Troup and Georgakis (2013) reported the use of multivariate 
approaches for DS identification, while Reklaitis et al. (2017) suggested that this activity is 
nowadays common routine in pharmaceutical R&D. Since the launch of the QbD initiative, 
different modelling strategies have been proposed to tackle this issue. The aim of the next 
sections is to propose a critical review of the most important contributions on this topic, from 
both industry and academia. 
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1.4 Design space applications throughout drug lifecycle 
Considering the three different activities (pharmaceutical development, technology transfer, 
commercial manufacturing and continual process improvement) of a drug lifecycle, different 
applications related to the concept of design space can be identified. These possible problems 
are briefly summarized in Fig. 1.3. 
 
 
Figure 1.4 Different problems involved in a design space description during pharmaceutical development, 
technology transfer, and commercial manufacturing and continual process improvement. 
 
With respect to pharmaceutical development, typical issues to be tackled are: 
 design space description and uncertainty quantification; 
 design space propagation from individual units to the entire process. 
Design space description concerns the identification of the subset of raw material properties 
and CPPs that allows obtaining the desired quality characteristics for a new drug under 
development. This activity should be complemented with analysis of the uncertainty associate 
to the proposed description of the DS.  
Design space propagation refers to the problem of defining the DS of the overall manufacturing 
line, based on the design spaces of the individual units arranged in the line. As discussed in 
§1.2.1.4, DSs are typically determined for single unit operations , but the determination of a 
single DS for the entire manufacturing process is always desirable to increase process 
flexibility. 
With respect to technology transfer activities, issues related to the DS are: 
 design space scale-up; 
 design space scale-out. 
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Design space scale-up refers to the transfer of the DS obtained at the laboratory scale during 
product/process development to the commercial manufacturing scale by preserving its 
validity12. On the other side, design space scale-out refers to the transfer of the design space 
between different sites producing the same product but implementing different process 
configurations. 
With respect to commercial manufacturing and continual process improvement, the main issue 
related to the concept of DS is that of design space maintenance. Design space maintenance is 
the continuous verification and, possibly, update of the design space of the manufacturing 
process during plant operation, in order to preserve its validity throughout the entire production 
campaign. 
Several contributions on the use of mathematical modeling to assist each of the activities 
described above have been presented in the literature. A short review of these contributions is 
presented in the following sections. 
1.4.1 Design space description and uncertainty quantification 
Exploitation of mathematical modelling for DS description is very frequent (Reklaitis, 2017). 
From a general perspective, DS description, as well as quantification of uncertainty in the 
description, require two elements:  
a) a model to relate the raw material properties and CPPs to the product CQAs; 
b) a methodology that, given the desired quality specifications and the model of point (a), 
returns the model-based prediction of the DS, including the uncertainty associated with 
this prediction. 
With respect to the first point, several modelling strategies have been proposed in the literaute  
to relate the CMAs and CPPs with the product CQAs for a new drug. A thorough review on 
this topic can be found in the work of Tomba (2012) and Reklaitis (2017). With respect to the 
second point, a summary of  the different approaches (related to knowledge-driven, data-driven 
and hybrid models respectively) is shown in Fig.1.5. 
1.4.1.1 Design space description strategies for data-driven models 
Once a model to relate the CMAs and CPPs to the product CQAs has been selected and 
validated against experimental evidence, the next step is to determine the DS with a given 
mathematical technique and appropriate uncertainty metrics. As summarized in Fig.1.5, 
alternative approaches have been proposed to perform this task for knowledge-driven models, 
data-driven models and hybrid models.  
 
                                                          
12 This means that the subset of CPPs and raw material properties that are derived from the laboratory-scale DS must guarantee 
the desired product quality on the commercial manufacturing scale. 
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Figure 1.5 Available mathematical techniques to assist DS description. 
 
In the context of data-driven models, multivariate data analysis based on DoE data is one of the 
oldest strategies that have been adopted to assist DS description. Once one selected multivariate 
model (e.g., multivariate linear regression) is built upon DoE-based data, this analysis simply 
consists of describing the DS in mathematical terms (via mathematical inversion of the original 
model) or, in most situations, in graphical terms (typically with contour surface plots that span 
the entire input domain). A detailed review of the different contributions on this topic has been 
presented by Lepore and Spavins (2008) and has been recently updated by Reklaitis et al. 
(2017). 
Response surface methodology (RSM; Box and Wilson, 1951) represents a class of statistical 
methods that consist of three iterative steps:  
1. selection of a model to relate CMAs and CPPs to product CQAs within the ones 
described above (typically, a polynomial regression model); 
2. design (using standard DoE techniques) and execution of experiments in order to 
tune the parameters of the model until the model representativeness is satisfactory 
(if no satisfactory prediction fidelity is obtained by tuning the model parameters, the 
model structure can be changed); 
3. exploitation of optimization methods to find the values of the independent variables 
(i.e., CMAs and CPPs) that produce the desired values of the responses (i.e., product 
CQAs). This step is equivalent to identify the boundary of the design space within 
the region of the input domain within which the model is deemed to be 
representative (also known as knowledge space). 
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Therefore, with respect to simple DoE-based multivariate analysis, RSMs have the peculiarity 
to require an iterative process that includes an optimization strategy. RSM has for long 
represented one of the most used techniques for DS determination in an industrial context 
(Lepore and Spavins, 2008; Garcia-Munoz et al., 2015). However, due to the increasing 
attention towards hybrid and knowledge-driven models, its use has seen a slight decrease during 
the last years (Garcia- Munoz et al., 2015). Nonetheless, several applications of RSM for DS 
determination have been reported. Examples include the use of RSM for the determination of 
the design space of fluid bed granulators (Zacour et al., 2012), continuous mixers (Boukouvala 
et al., 2010), wet granulators (Huang et al., 2009), direct compression (Charoo et al., 2012) or 
entire manufacturing lines (am Ende et al., 2007). Several other applications have been recently 
reviewed by Reklaitis et al. (2017). The main advantage of these techniques is that they are 
very easy to use thanks to the use of specific commercial software; on the other hand, they are 
not able to handle model parameter uncertainty in a rigorous manner (Peterson, 2004). 
Latent variable model inversion is related to the inversion of the LVMs  in order to identify the 
subset of input combinations (CPPs and CMAs) that allows obtaining the desired product 
CQAs. The advantage of this approach is that the DS can be determined and represented on the 
latent space, which has usually a much smaller dimension than the original input space, thus 
obtaining a compact representation of the DS. The theoretical framework for LVM inversion 
has been originally proposed by Kourti (2006), and then implemented in practice by Garcia-
Munoz et al. (2010) and eventually refined by Tomba et al., (2012). Examples on the use of 
LVM inversion for DS description of tablet manufacturing lines (Liu et al., 2011; Yacoub and 
MacGregor, 2011), granulation and roll compaction (Tomba et al., 2013; Facco et al., 2015) 
have been reported. A detailed description of these methods will be given in Chapter 2. 
Monte Carlo methodologies perform a random sampling of the input domain (using one 
selected sampling strategy) and compute the values of the model outputs for each of the 
sampling points selected. The single values of the model outputs obtained for each sampling 
point are then used to obtain approximate distributions of the model outputs, where 
“distribution” is to be intended according to its frequentist meaning, not the Bayesian one. 
These distributions are then used to build appropriate confidence intervals (or regions, if the 
number of product CQAs is greater than one). The subset of input combinations that guarantee 
to obtain the product CQAs within these confidence regions is then identified as the DS of the 
product considered. 
Applications of this approach with standard multivariate linear regression (Gujra et al., 2007), 
stepwise multivariate linear regression (Debrus et al., 2011) and polynomial regression models 
(Kauffman and Geoffroy, 2008) have been reported. Additional applications have been 
reviewed by Reklaitis et al. (2017). 
Bayesian methodologies combine fundamentals of Bayesian statistics with one of the 
aforementioned data-driven models (in most situations, multivariate linear regression models) 
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to return a probabilistic representation of the DS of a new pharmaceutical product. The most 
important difference of these methods with respect, for example, to standard Monte Carlo 
methods is that model inputs and outputs (as well as model parameters) are not treated as 
deterministic variables (i.e., described by single numerical values), but as random variables 
(i.e., described by probability distributions). The probabilistic DS is obtained with these 
approaches by first building the posterior predictive distribution of the product CQAs , and then 
by identifying the subset of the input domain that guarantee to obtain the desired product quality 
characteristics with a probability greater than a predefined threshold value. The pioneer on the 
use of Bayesian techniques for DS determination is Peterson (2004; 2008), and some 
applications of these techniques for DS determination have been reported (Stockdale et al., 
2009; Peterson, 2009; Peterson, 2010). The main disadvantage of these methodologies is that 
they require expensive Markov Chain Monte Carlo (MCMC) simulations, which can become 
prohibitive when the number of input factors is large.  
1.4.1.2 Design space description strategies for knowledge-driven models 
In the context of knowledge-driven models, the mathematical techniques that have been 
proposed to assist a DS determination are: 
 Global sensitivity analysis (GSA); 
 feasibility analysis; 
 operability analysis. 
Due to the limited diffusion of knowledge-driven models for the description of pharmaceutical 
unit operations, the contributions that can be found in the open literature are fewer than for data-
driven models. However, increasing attention has been directed towards these methodologies 
recently. 
Global sensitivity analysis (GSA; Saltelli et al., 2008) collects a series of simulation tools whose 
aim is to evaluate how the variability on the model outputs can be apportioned to the different 
model inputs. In pharmaceutical development, this can be used to: 
a) determine the CPPs and CMAs that are most influential with respect to the product 
CQAs; 
b) determine the probability distributions of the model outputs by spanning the entire range 
of variability of the model inputs; 
c) determine the subset of the input domain that allows satisfying the desired specifications 
on the product CQAs with a given confidence (i.e. the DS). 
The three activities (a)-(b)-(c) can be performed separately or (more often) in a sequential 
manner. Different categories of GSA methods have been proposed, namely: i) screening 
methods; ii) regression-based methods; iii) variance-based methods; iv) metamodel-based 
methods. A thorough review on these techniques can be found in the study of Iooss and 
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Lemaître (2015). In the context of DS determination, the two approaches that are mostly 
adopted are screening methods and variance-based methods. 
Screening methods (Saltelli et al., 2008) consider wide ranges of variation for the model inputs 
and compute a global sensitivity metric for a given output as an average of local measures. The 
most important method belonging to this category is the Morris method (Morris, 1991). A recent 
application of this method for the determination of the most influential CPPs of a continuous 
pharmaceutical manufacturing line and subsequent DS determination has been proposed by 
Wang et al. (2017).  
Variance-based methods (Helton et al., 2003) decompose the variance of each single model 
output into several components, including the contributions of the single input factors as well 
as their interaction. The most famous methods belonging to this category are the so called 
Sobol’s methods (Sobol, 1993; Sobol, 2001), which exploit a Monte-Carlo approach to compute 
the variance of each output and to decompose it according to the contributions of the different 
input factors. The use of these methods in pharmaceutical manufacturing has been strongly 
supported by their recent implementation in advanced process modelling environment such as 
gPROMS® (Process Systems Enterprise, 2014). Recent applications of Sobol’s methods in 
pharmaceutical manufacturing have been proposed by Wang et al. (2017) and Garcia-Munoz 
et al. (2018), where their ability to return to rapidly screen the entire input domain and identify 
the boundary of the DS for a large number of input factors has been proven.  
While GSA solves the DS determination problem as a “forward” problem, (i.e., by building the 
posterior distributions of the product CQAs through extensive sampling within the input 
domain and performing one simulation for each input sample), a technique that solves the DS 
determination problem as an “inverse” problem is feasibility analysis. 
Feasibility analysis was first proposed for the design of general chemical processes (Halemane 
and Grossman, 1983) and that only recently has been applied for the determination of the DS 
of pharmaceutical processes. Differently from GSA, feasibility analysis solves the DS 
determination problem as an “inverse” problem: assigned the specifications (constraints) for 
the product CQAs, the portion of the input domain that allows satisfying those constraints (i.e., 
the DS) is obtained by solving a bi-level nonlinear programming optimization problem. The 
solution of the bi-level optimization problem requires the definition of a function, called 
feasibility function, that collects the maximum value of all the quality constraints imposed on 
product. Mathematical details on this technique, together with recent advances in this area, can 
be found in the recent work of Bhosekar and Ierapetritou (2017). Feasibility analysis has been 
proposed to assist DS description for single unit operations such as roller compaction (Banjeree 
et al., 2010) granulation (Rogers and Ierapetritou, 2015; Wang and Ierapetritou, 2017) as well 
as for the determination of the DS of an entire continuous manufacturing line (Wang et al., 
2017b). The main advantage of this technique is that multivariate constraints on the product 
CQAs can be handled in straightforward fashion; the main disadvantage is that all the sources 
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of uncertainty (e.g., on model parameters) as well as external disturbances that may affect the 
DS prediction must be determined and modeled a priori. Additionally, this technique suffers 
from the curse of dimensionality, i.e., obtaining a solution within a reasonable amount of time 
can become prohibitive when the number of input factors is large. 
Operability analysis (Vinson and Georgakis, 2000) is a mathematical technique that aims at 
understanding whether all the points in the desirable output ranges (i.e., product quality) are 
operable in the presence of expected disturbances and with the available ranges of the inputs 
(i.e., CPPs and CMAs). In the pharmaceutical context, the definition of DS is equivalent to the 
definition of “operable space” used by this technique. Description of the DS with operability 
analysis, although conceptually very similar to feasibility analysis, presents the substantial 
difference of not requiring the solution of a nonlinear optimization problem. Examples of 
applications for pharmaceutical unit operations have been proposed by Uztürk and Georgakis 
(2002) and by Georgakis (2017). The use of this technique for DS determination, however, is 
still very limited and mainly focused on bio-pharmaceutical operations. 
1.4.1.3 Design space description strategies for hybrid models 
In the context of hybrid models, mention should be given to surrogate-based feasibility analysis 
(Banjeree et al., 2010; Rogers and Ierapetritou, 2015), which is a particular type of feasibility 
analysis that is applied with computationally expensive models characterized by black-box 
constraints on the product CQAs (i.e., hybrid models). The idea behind this technique is to build 
a computationally cheap approximation of the original hybrid model, which is called a 
surrogate, and to compute the DS of the original model based on this surrogate. Different types 
of surrogate can be used (Banjeree et al., 2010), including kriging surrogates, radial basis 
functions (RBFs) and simple polynomial interpolants (Rogers et al., 2015). Applications of 
surrogate-based feasibility analysis for DS determination have been proposed recently (Wang 
and Ierapetritou, 2017a; Wang et al., 2017). A detailed description of this approach will be 
provided in § 5.2. 
1.4.2 Design space propagation from individual units to an entire process 
A pharmaceutical manufacturing process is typically composed by several processing units. As 
described in the regulatory documents (ICH, 2009), during a DS description it would always 
be desirable obtaining the DS for the entire manufacturing process rather than for the individual 
units only. Some attempts of defining the DS for entire manufacturing lines have been proposed 
recentlyature (Wang and Ierapetritou, 2017b). However, in many practical situations, the 
determination of the DS is performed for each individual unit of the manufacturing line, due to 
the complexity (both in terms of model building effort and computational power required) of 
dealing with integrated flowsheet models. Strategies to describe the DS of the entire process 
based on the DSs of the individual unit operations would therefore be useful to fit the regulatory 
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guidelines. However, the contributions that can be found in the literature on this topic are very 
limited. From a modelling perspective, the determination of the DS of an entire process based 
on the DSs of the individual processing units can be interpreted as a problem of how input 
variability propagates across the entire manufacturing line (the output of the first unit becomes 
the input of the second one, and so on) till the final product. Attempts of studying this variability 
propagation have been proposed by Rogers and Ierapetritou (2015) and Wang and Ierapetritou 
(2017a) in the context of feasibility analysis, and by Metta et al. (2018) in the context of a 
DEM- PBMs.  
1.4.3 Design space scale-up and scale-out 
The design space of a new pharmaceutical product is typically determined and validated at 
laboratory scale during the drug development stage. However, its final use is intended for the 
commercial manufacturing scale. The activity that is deemed to transfer the DS obtained at the 
laboratory scale to the commercial scale is defined as DS scale-up. From an industrial 
perspective, the advantage of developing a DS at laboratory scale and scaling it up to the 
commercial manufacturing scale is that the costs for the experimental assessment of the DS are 
much lower at the laboratory scale. Therefore, the main target of the DS scale-up activity is to 
reduce to a minimum the number of experimental runs that must be performed on the 
commercial-scale plant for the final assessment of the DS. In this regard, model-based 
approaches play a key role to assist a DS scale-up exercise. 
Despite several contributions on the scale-up of pharmaceutical unit operations/processes have 
been published, the number of studies on DS scale-up is very limited. In the context of data-
driven approaches, the available contributions are limited to the exploitation of historical plant 
data of products similar to the one under development to perform the DS scale-up activity. 
Latent variable models are exploited to this purpose; in particular, Garcia-Munoz et al. (2004, 
2005) proposed a new PLS-based technique, called joint-Y PLS (JY-PLS), specifically 
designed to relate two datasets of the same process at two different scales, in order to identify 
the relationships between variables at multiple scales and identify similarities that can be 
exploited for DS scale-up. Liu et al. (2011b) exploited this technique to assist the DS scale-up 
for a roller compaction process, while Garcia-Munoz et al., (2009) used JY-PLS to understand 
the effect of raw material properties on product CQAs on different scales in order to guide a 
DS scale-up exercise. 
In the context of knowledge-driven models, a larger number of contributions can be found, and 
this is mostly related to the fact that knowledge-driven models require fewer plant data. These 
studies can be classified according to two categories: 
a) contributions based on the derivation of scale-up relationships from CFD or DEM 
simulations; 
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b) contributions based on the derivation of scale-independent formulations for the DS. 
In the first category, scale-up relationships are derived from complex CFD/DEM simulations 
and used to scale up the DS from the laboratory scale to the production scale. Examples of this 
approach include applications to fluid bed drying (Parker et al., 2013; Chen et al., 2018), freeze 
drying (Zhu et al, 2018), mixing (Lindenberg and Mazzotti, 2009), film and pan coating 
(Pandey et al., 2013; Chen et al., 2017) and blending (Horibe et al., 2018). As an example, 
Pandey et al. (2013) developed a DEM simulation to study the effect of changing operating 
conditions and equipment scale on the particle motion during pan coating, and based on the 
DEM results developed a simple scale-up relationship for the DS of the pan coater. Zhu et al. 
(2018) followed a similar procedure for the scale-up of a freeze drying cycle, but they exploited 
intensive CFD simulations. Horibe et al. (2018) used DEM simulations to derive scale-up 
relationships for pharmaceutical blenders. 
In the second category, a mechanistic model is typically used to determine the DS at the 
laboratory scale (i.e., the DS prediction is validated against experimental data obtained at the 
laboratory scale). Then, the model is re-formulated using scale-independent parameters 
(typically, dimensionless numbers) that allow transferring the DS to the larger scale. It is worth 
noticing that this approach is also advocated by the regulatory agencies (§ 1.1.2.). Reported 
applications of this approach are very limited and mostly refer to the scale-up of the DS for 
pharmaceutical freeze-drying processes. For example, Fissore and Barresi (2011b) and Pisano 
et al. (2013) derived a scale-independent formulation for a simple mechanistic model of the 
primary drying stage of a freeze-drying process, and used this formulation to derive the DS of 
the process at commercial scale. A very recent work of Yoshino et al. (2018) use a similar 
approach to assist the scale-up of a film coating process, while Garcia-Munoz et al. (2015) 
exploit this methodology to scale-up the DS for the adsorption of a drug substance in a packed-
bed reactor. 
Scale-up is not the only technology transfer activity that involves a DS description. In fact, 
when the product is already being manufactured in the commercial plant, there may be the need 
to: 
 transfer the manufacturing of the given product to a different site, with a different 
process configuration; 
 use the same process to produce a different product. 
Both activities are referred to as scale-out activities (Reklaitis, 2017). However, whereas the 
problem of product transfer has been addressed by several authors (Jaeckle and MacGregor, 
2000; Garcia Munoz et al., 2005; Tomba et al., 2013), the problem of assisting the scale-out of 
a DS has not been addressed so far in the open literature, even if its importance has been 
emphasized (Reklaitis, 2017). 
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1.4.4 Design space maintenance 
If the DS for a given product is known, the input materials properties and process operating 
conditions lie within the DS. However, if the DS was described using a model of the process, 
an issue arises on whether the model originally used to simulate the process (hence, to describe 
the DS) is still valid under the current process state. Process/model mismatch may arise from 
uncertainty in the evaluation of some model parameters (e.g., a heat exchange coefficient may 
change due to fouling), or insufficient/inappropriate description of the underlying physical 
phenomena driving the process (e.g., environmental factors not accounted for). The fact that, 
during the plant lifecycle, the model may not be able to accurately reproduce the actual plant 
behavior, questions the appropriateness of the operating conditions selected by using the DS 
defined using that model. 
When a model is used to assist DS description in a lab-scale plant, the different sources of 
uncertainty (e.g., parametric uncertainty) and structural mismatch (e.g., environmental factors) 
that can potentially affect the prediction fidelity of the model at the plant scale should be 
included and accounted for in the DS description. This requires knowing a priori all the 
uncertainties and disturbances that may affect plant operation. However, in practical situations, 
modelling all these possible sources of uncertainty and disturbances is never possible. Different 
phenomena may occur during plant operation (e.g., parameters drifts or unmodeled phenomena 
that could not be observed at the laboratory scale, such as the effect of upstream and 
downstream units) that can impact on the prediction fidelity of the model, hence on the model-
based DS representation. In some cases, some of these phenomena can be observed and 
accounted for during the DS scale-up activity. However, there is no guarantee that plant 
operation will remain stable over long periods, hence that the initial model-based DS 
description will preserve its validity throughout the entire production campaign. 
Following the regulatory parlance, the activity that is deemed to keep constantly updated the 
DS of a pharmaceutical product throughout its entire lifecycle is named DS maintenance (ICH, 
2009). even though no indications are given by the regulators on how to perform this activity. 
From a modelling perspective, despite the importance of performing a regular model 
maintenance during pharmaceutical manufacturing is not new (Wise and Roginski, 2015; 
Flaten, 2018), applications are limited to the maintenance of multivariate data-driven models 
(e.g., PCA or PLS models) for process monitoring purposes. Contributions on how to perform 
a DS maintenance (with either data-driven or knowledge-driven models) are lacking. The 
relevance  of developing such contributions within the framework of the Industry 4.0 initiative 
has been emphasized by Herwig et al. (2017), and the recent launch of the Q12 regulatory 
document (ICH, 2018) is expected to push the scientific community to tackle this topic in the 
near future (Herwig et al., 2017). 
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1.5 Objectives of the research 
Despite the increasing attention towards mathematical modelling for DS description, several 
issues still need to be addressed to obtain a general modelling framework for practical 
implementation of the regulatory guidelines. These issues can be briefly summarized into four 
points. 
1. A key requirement advocated by the regulatory agencies for a correct description of the 
design space is the quantification of the assurance of quality for the final product. From 
a modeling perspective, this translates into a rigorous quantification of the uncertainty 
associated with the model-based prediction of the DS. However, the majority of the 
contributions presented in the literature focus on the adoption of deterministic 
approaches for DS identification rather than probabilistic ones: whereas the former do 
not consider model uncertainty, the latter do. 
2. The few probabilistic approaches presented in the literature mainly focus on situations 
where the product quality can be described in terms of univariate quality specifications, 
while in most practical situations the quality of the product is expressed in terms of 
multivariate specifications. 
3. In the context of first-principles and semi-empirical modeling, advanced techniques are 
required in order to handle several inputs (process parameters and raw material 
properties) in a computationally efficient way. Most of the proposed techniques still 
rely on computationally expensive simulations which, in some cases, are not even able 
to return a DS description with the desired level of accuracy. Moreover, providing a 
compact and easy-to-interpret representation the DS when a large number of inputs are 
involved is typically impossible, thus preventing easy interpretation of the results by 
regulators and non-practitioners. There is therefore the need to develop 
computationally efficient methodologies that allow obtaining user-friendly and ready-
to-use representations of the design space.  
4. While several modeling strategies have been proposed for the identification of the DS 
at the product and process development stage, very few studies address how to regularly 
assess and possibly adjust its model-based representation during product 
manufacturing. In fact, the prediction fidelity of the model adopted at the 
product/process development stage may deteriorate during plant operation, thus 
affecting the validity of the prediction of the DS obtained at the beginning of the 
product lifecycle. In other terms, several phenomena may arise during plant operation 
(e.g. parameter drifts, un-modeled physical phenomena such as environmental effects, 
effect of upstream and downstream units, etc…) that may partially or totally invalidate 
the prediction of the DS obtained at the product and process development stage. The 
importance of exploiting the additional process knowledge that can be gained during 
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plant operation for reduction, expansion or redefinition of the design space is clearly 
stated in the regulatory documents (ICH, 2009) and is part of a continual process 
improvement strategy that pharmaceutical companies should adopt for a correct 
implementation of the QbD framework. The scientific contributions on this topic are 
still very limited and tailored to very specific applications, while the development of 
general methodologies is still an open research area. 
5. The identification of the DS by means of first-principles or semi-empirical models 
require accurate and precise estimation of the model parameters, in order to obtain a 
high prediction fidelity and therefore a reliable estimation of the DS. The parameter 
estimation activity is performed by challenging the model predictions against the 
experimental observations that can be collected during an experimental campaign on 
the real equipment. When the number of parameters is large or the parameters are 
strongly correlated with each other, obtaining an accurate and precise parameter can be 
difficult and require a large number of experiments. It is therefore desirable to design 
new experiments in order to maximize the information that can be extracted from these 
experiments for a precise estimation of the model parameters. A class of techniques 
that can be exploited to this purpose are model-based design of experiments (MBDoE) 
techniques. While MBDoE techniques have recently gained increasing attention in 
many process engineering applications, their use in pharmaceutical product and process 
development contexts is still very limited. The introduction of MBDoE to assist 
pharmaceutical product and process development is therefore still an open research 
area. 
 
In view of the above, the objective of this Dissertation is to propose novel and systematic 
methodologies to tackle the research issues previously discussed. Specifically, the innovative 
contributions that can be found in this Dissertation are the following. 
 
 Quantification of the “assurance” of quality for a new pharmaceutical product as 
advocated by the regulatory agencies, with particular focus on data-driven modeling 
strategies such as latent variable modeling (LVM) and multivariate linear regression. 
Two situations are addressed, namely: i) the situation where a projection onto latent 
structures (PLS) model is to be used for design space identification; ii) the situation 
where a general multivariate linear regression model is to be used for DS identification. 
With respect to the former case, the inversion of latent-variable models, such as PLS 
models, has proved to be an effective tool to assist the determination of the DS of a new 
pharmaceutical product. A challenging issue in PLS model inversion is to describe how 
the uncertainty on the model outputs (product quality) relates to the uncertainty on the 
model inputs (raw material properties and process parameters). This in turn translates 
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into a quantitative inclusion of the concept of assurance of quality for the final product 
in the model-based representation of the design space. The objective of the first part of 
this Dissertation is to develop a methodology to relate the uncertainty on the output of 
a PLS model to the uncertainty on the model inputs. The expected result is the 
identification of a portion of the original input domain within which the DS of the 
product under development is expected to lie with a confidence equal to or greater than 
an assigned threshold. This narrow region of the input domain is expected to be used to 
assist a targeted experimental campaign for the final assessment of the DS, with 
significant reduction of the time and costs of the experimentation. 
With respect to the second aspect, the objective is to exploit elements of Bayesian 
statistics in order to quantify the probability that a pharmaceutical product will meet its 
quality specifications during manufacturing. The focus is restricted on situations where 
a multivariate linear regression model is used to relate the process parameters and raw 
material properties with the product quality attributes. The final target is to obtain a 
quantitative metric, i.e. the Bayesian probability of the product to meet its quality 
specifications, that completely addresses the concept of assurance of quality advocated 
by the regulatory agencies. The DS that can be obtained within this Bayesian framework 
can therefore be defined as a probabilistic DS, and it can be claimed that its derivation 
is entirely consistent with the regulatory guidelines.  
 
 Design space description using semi-empirical or first-principles models, with 
particular focus on the reduction of the overall computational burden and the 
development of low-dimensional and easy to interpret representations of the design 
space. The research effort will be targeted on a mathematical technique that has been 
recently proven to be potentially very effective for DS determination with complex 
mathematical models. This technique is surrogate-based feasibility analysis and, 
although being very efficient in handling complex multivariate quality specifications 
and complex process models, it suffers from one important drawback, i.e. the curse of 
dimensionality. In other terms, when the number of input factors is large, this technique 
shows severe limitations in obtaining an accurate prediction of the design space within 
a reasonable computational time. A methodology will be developed in this Dissertation 
to solve this issue and an application to a continuous manufacturing line of a 
pharmaceutical tablet will be presented. 
 
 Maintenance of a model-based design space during plant operation, based on the 
concept of continual process improvement and lifecycle management advocated by the 
regulatory agencies. The target in this respect is to develop an automatic methodology 
to obtain an accurate real-time representation of the design space as process operation 
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progresses, by exploiting the additional process knowledge that can be captured during 
product manufacturing. The methodology presented in this Dissertation will use 
concepts of model adaptation and state estimation to reach this target, and concepts of 
feasibility analysis and surrogate-based feasibility analysis to assist the real time DS 
identification. 
 
 Design of optimal experiments for model calibration and design space description, 
with specific focus on industrial freeze-drying processes. The main objective is to show 
how the exploitation of model-based design of experiments (MBDoE) can be used to 
assist the design of informative experiments for the identification of complex 
mechanistic models of freeze-drying processes, and how these models can be used to 
assist DS description. The final target is to reduce the number and cost of the 
experiments to be performed for model identification, thus speeding up the process 
development stage and boosting its profitability. 
 
Simulated, experimental and industrial case studies will be presented throughout the 
Dissertation to prove the effectiveness of the proposed methodologies. A schematic roadmap 
for the interpretation of the Dissertation is presented in the next section. 
1.6  Dissertation roadmap 
The Dissertation is organized following the four research objectives presented in the previous 
section. A schematic roadmap of the Dissertation is shown in Fig. 1.5. After a brief review of 
the mathematical tools exploited throughout the Dissertation (Chapter 2), the central chapters 
(Chapters 3,4,5,6) collect four innovative methodologies to tackle the first three research 
objectives presented above. The nature of these chapters is purely methodological, and the 
effectiveness of the innovative modeling strategies proposed are tested with industrially-
relevant case studies.  The final chapter (Chapter 7) is focused on an industrial application of a 
well-established methodology (model-based design of experiments; MBDoE): its main 
innovation is therefore related to the area of application of the methodology, rather than the 
methodology itself. 
With respect to the issue of quantification of assurance of quality, in Chapter 3 a methodology 
is proposed to handle the back-propagation of uncertainty from the outputs (i.e. product quality) 
to the inputs (i.e. raw material properties and process paraemters) of a PLS model. The 
methodology is exploited to identify a small portion (defined as the experiment space; ES) of 
the input domain within which the design space of a new pharmaceutical product is expected 
to lie with a given degree of confidence. It will be shown with both simulated and experimental 
case studies that the identification of such experiment space allows the product developer to 
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tailor his/her experimental campaign on a smaller domain of input combinations, with 
significant reduction of the time and cost of the experiments for DS assessment. 
In Chapter 4, a methodology is proposed to quantify the probability that a new drug will meet 
its quality specifications by combining latent variable modelling (specifically, a PLS model) 
with a Bayesian multivariate linear regression model. The set of input combinations for which 
this probability (to be intended in its Bayesian interpretation) is greater than an assigned 
threshold is identified as the probabilistic (or Bayesian) design space of the new product. The 
Bayesian probability can therefore be considered as a scientific and unambiguous metric to 
implement the concept of assurance of quality advocated by the regulatory agencies, and the 
probabilistic design space can be considered as fully compliant with the regulatory guidelines. 
It will be shown how PLS modelling can be coupled with Bayesian model calibration to reduce 
the dimensionality of the input domain, thus allowing :i) a significant reduction of the 
computational burden of the simulations (which require extensive Markov chain Monte-Carlo 
computations); ii) a compact representation of the design space that can be easily interpreted 
by regulators or non-practitioners.    The effectiveness of the proposed approach will be shown 
with both simulated and experimental case studies of pharmaceutical unit operations. 
In Chapter 5, a methodology to overcome the curse of dimensionality of surrogate-based 
feasibility analysis for design space description of a new pharmaceutical product with semi-
empirical or first-principles models is presented. The ability of PLS to reduce the input space 
dimensionality is exploited to obtain a low-dimensional representation (i.e., a latent 
representation) of the input domain. An adaptive sampling feasibility analysis based on a radial-
basis function (RBF) surrogate is then used to identify the boundary of the design space on the 
latent space. It will be shown how the proposed approach can be exploited to give an accurate 
and robust description of the design space by simultaneously reducing the computational 
burden for the feasibility analysis problem. The effectiveness of the methodology will be 
challenged with a complex integrated flowsheet model of a continuous manufacturing line of a 
pharmaceutical tablet. 
Chapter 6 presents a methodology to obtain a real-time representation of the design space of a 
pharmaceutical process while plant operation progresses. Given a first-principles model of the 
process and measurements from plant sensors, the proposed approach exploits a dynamic state 
estimator and feasibility analysis to obtain the real-time representation of the design space. The 
state estimator is deployed to adapt online the model predictions with the available plant 
observations, while feasibility analysis and surrogate-based feasibility analysis are exploited to 
obtain the boundary of the design space with the up-to-date model returned by the state 
estimator. The ability of the methodology to timely track changes in the DS representation will 
be shown with two simulated case studies, the former involving an enforced parametric 
mismatch, the latter a structural mismatch.  
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Finally, Chapter 7 discusses an industrial application of MBDoE techniques for the 
identification of a mechanistic model of a pharmaceutical freeze dryer. Particular focus is given 
to the primary drying stage of the process, which has a strong impact on the overall process 
efficiency due to its duration (∼60-80% of the overall freeze-drying cycle). Optimal 
experiments are designed in order to extract the maximum information from the data for the 
estimation of two critical model parameters. A good improvement of the model identifiability 
will be shown be performing the designed experiments both in silico and in the real equipment. 
                                                                            ________________________________________________________ 
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   Chapter 2 
 
Methods 
 
This chapter provides a concise overview of the mathematical techniques that are exploited in 
this Dissertation. The chapter is organized in four sections.  In Section A, a review of projection 
on latent structures (PLS) for dimensionality reduction is presented. In Section B, the key 
concepts of Bayesian statistics and Bayesian multivariate regression are summarized. In Section 
C, the mathematical formulation of feasibility analysis and surrogate-based feasibility analysis 
is discussed. Lastly, in Section D state estimation techniques for online model adaptation and 
recalibration are presented. 
 
SECTION A: DIMENSIONALITY REDUCTION TECHNIQUES 
 
Latent variable models (LVMs) are a class of statistical models that are used for three main 
purposes: (i) data interpretation, (ii) dimensionality reduction and (iii) regression analysis. 
Let 𝐗 [𝑁 × 𝑉] be a historical dataset of 𝑁 observations of 𝑉 observable variables. The aim of 
LVMs is to explain the correlation structure of 𝐗 by means of 𝐴 unobservable variables, called 
latent variables (LVs), that explain the maximum multidimensional variance of the original 
dataset. In the presence of a strong collinearity in the original dataset, LVMs are able to capture 
the information retained in the matrix 𝐗 with a much smaller number of LVs, i.e. 𝐴 ≪ 𝑉. One 
of the most important LVM that can be used to interpret and reduce the dimensionality of a 
highly correlated dataset is principal component analysis (PCA; Jackson, 1991). 
In many other applications, the historical dataset is split into a matrix of 𝑉 input variables 
𝐗 [𝑁 × 𝑉] and a matrix of 𝑀 response variables 𝐘 [𝑁 × 𝑀]. In this context, LVMs are used to 
explain the joint correlation structure of 𝐗 and 𝐘, i.e. the LVs are selected in order to explain 
the maximum multidimensional variance of the input space that is mostly correlated with the 
output space. The identification of this correlation structure can then be used to predict a new 
response given a new set of model regressors (i.e. for regression analysis). One of the most 
common techniques in this area is projection on latent structures (PLS; Wold et al., 1983). In 
the following, a brief theoretical overview of PLS and on the available methodologies to 
estimate prediction uncertainty in PLS modeling is presented. 
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2.1 Projection on latent structures (PLS)  
Projection on latent structures (PLS; Wold et al., 1983; Höskuldsson, 1988) is a LVM that aims 
at (i) explaining the joint correlation structure of the input matrix 𝐗 and the response matrix 𝐘 
and (ii) predicting a new response  ?̂?𝑝 [1 × 𝑀] given a set of new regressors 𝐱𝑝. 
PLS can be used to perform the first task or both the two tasks described above. In the former 
case, PLS is used as a dimensionality reduction technique. In the latter case, PLS is used as a 
multivariate linear regression technique. In both scenarios, PLS identifies a small set of 𝐴 LVs 
that explain as much as possible of the joint covariance of 𝐗 and 𝐘. This decomposition proves 
to be particularly useful when a set of response variables has to be correlated with a large set of 
highly collinear input variables. 
The structure of a PLS model can be summarized by the set of equations: 
 
𝐗 = 𝐓𝐏T + 𝐄X  (2.1) 
 
𝐘 = 𝐓𝐐T + 𝐄Y (2.2) 
 
𝐓 = 𝐗𝐖∗ (2.3) 
 
where 𝐓 [𝑁 × 𝐴] is the score matrix, 𝐏 [𝑉 × 𝐴] and 𝐐 [𝑀 × 𝐴] are the 𝐗 and 𝐘 loading matrices, 
𝐄X and 𝐄Y the residuals; 𝐖
∗[𝑉 × 𝐴] is the weight matrix, through which the data in 𝐗 are 
projected onto the latent space to give 𝐓 according to Eq. (2.3).  
The weight vector 𝐰1 [𝑉 × 1] related to the first LV can be computed by solving the 
eigenvector decomposition problem for the matrix 𝐗T𝐘𝐘T𝐗: 
 
𝐗T𝐘𝐘T𝐗𝐰1 = 𝜆1𝐰1 (2.4) 
 
where 𝜆1 is the eigenvalue associated with the first LV. Eq. (2.4) is equivalent to solving the 
optimization problem: 
 
max
𝐰1
(𝐰1
T𝐗T𝐘𝐘T𝐗𝐰1) 
 
(2.5) 
s.t      𝐰1
T𝐰1 = 1. (2.6) 
 
Given 𝐰1, the score vector 𝐭1[𝑁 × 1] related to the first LV can be computed according to the 
following expression: 
 
𝐭1 = 𝐗𝐰1. (2.7) 
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The weights related to the subsequent LVs can be computed according to the optimization 
problem (2.5), but using the deflated input and output matrices 𝐗𝑎+1 and 𝐘𝑎+1 respectively. 
These matrices are defined for 𝑎 = 1, 2, … , 𝐴 − 1 as: 
 
𝐗𝑎+1 = (𝐈𝑁 −
𝐭𝑎𝐭𝑎
T
𝐭𝑎T𝐭𝑎
)𝐗𝑖  
 
 
(2.8) 
𝐘𝑎+1 = (𝐈𝑁 −
𝐭𝑎𝐭𝑎
T
𝐭𝑎T𝐭𝑎
)𝐘𝑖 (2.9) 
 
where 𝐈𝑁 is the 𝑁 ×𝑁 identity matrix. The corresponding loading vectors for the 𝑎-th LV 
related to 𝑋 and 𝑌 respectively are given by: 
 
𝐩𝑎
𝑇 =
𝐭𝑎
T𝐗𝑎
𝐭𝑎T𝐭𝑎
  
 
(2.10) 
𝐪𝑎
𝑇 =
𝐭𝑎
T𝐘𝑎
𝐭𝑎T𝐭𝑎
. (2.11) 
 
The weight matrix 𝐖∗ that appears in Eq. (2.3) is related to the matrix 𝐖 that collects the 
weight vectors 𝐰𝑖, 𝑖 = 1, … , 𝑉 according to the following relationship: 
 
 𝐖∗ = 𝐖(𝐏T𝐖)−1 . (2.12) 
 
It is worth noticing that the 𝐗-score matrix of Eq. (2.2) is sometimes substituted by the 𝐘- 
loading matrix 𝐔 [𝑁 × 𝐴]. The two score matrices are related to each other by a linear 
relationship (called inner relation; Geladi and Kowalski, 1986), thus making the two 
formulations mathematically equivalent. 
The solution of the eigenvector problem (2.4) is not straightforward from an algebraic point of 
view (e.g. via singular value decomposition (SVD) techniques) and is particularly cumbersome 
when dealing with missing data in the original dataset. Therefore, several iterative algorithms 
have been proposed in the literature for a computationally efficient implementation of PLS. The 
two most famous algorithms are the NIPALS algorithm (Wold et al., 1983) and the SIMPLS 
algorithm (de Jong, 1993). A thorough description of these algorithms can be found in the cited 
references. 
2.1.1 Pre- and post- PLS modeling activities 
When a PLS model is used to describe a historical dataset [𝐗; 𝐘], three activities must be 
performed at different stages of the modeling procedure, namely: 
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1. data pretreatment (before building the PLS model); 
2. selection of the optimal number of LVs (to finalize the PLS model structure); 
3. PLS model diagnostics (to validate the performance of the PLS model). 
A point-to-point description of these activities is described in the following sections. 
2.1.1.1 Data pretreatment 
Data pretreatment is a preliminary step that is performed in order to avoid misleading results 
from the PLS model. This activity needs to be done to account for the different physical nature 
and dimensions of the variables of the original dataset. 
Different data pretreatment techniques exist (Eriksson et al., 2006), including mean-centering, 
auto-scaling, filtering and denoising. When the variables of the historical dataset are physically 
different, as it is often the case with process variables, the most suitable data pretreatment 
technique is auto-scaling.  
Auto-scaling consists of subtracting to each column of the original dataset [𝐗; 𝐘] the mean value 
of that column and then dividing each element for the standard deviation of the column. In other 
terms, each column is mean-centered and then normalized with its standard deviation. This 
allows obtaining unbiased directions of maximum variability from the PLS model that are not 
affected by the mean values of the original variables.  Moreover, the scaling operation (i.e. 
normalization with the standard deviation) has the advantage of partially linearizing the original 
dataset.  
All the studies presented in this Dissertation assume that the historical data have been auto-
scaled according to the procedure described above. 
2.1.1.2 Selection of the optimal number of LVs 
A key step of the PLS model building activity is the selection of the number of LVs (i.e. the 
dimensionality of the latent space). From a general perspective, the selection of the number of 
LVs depends on several factors and should be suited to the final application of the PLS model. 
In most situations, it may be desirable to select a number of LVs that explain a big portion of 
the variability of both the input and output datasets. However, there may be situations where 
only one of the two aforementioned requirements needs to be fulfilled. 
Different methods have been proposed in the literature to select the appropriate number of LVs. 
The most famous are: 
 the scree test (Jackson et al., 1991); 
 the eigenvalue-greater-than-one rule (Mardia et al., 1979); 
 cross-validation (Wold, 1978). 
The scree test is a graphical procedure that monitors a metric (the explained variance 𝑅2 of the 
input and output calibration datasets) and assumes that the optimal number of LVs is the one 
that yields to a “stabilization” to the metric profile. The underlying assumption behind this 
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approach is that the amount of explained variability of the original dataset reaches a “steady-
state” after a certain number of LVs.  
The eigenvalue-greater-than-one rule is a method that discards all the latent variables whose 
associate eigenvalue is smaller than one. In fact, if data are auto-scaled, the eigenvalue 
associated with the 𝑎-th LV roughly describes the number of original variables that are captured 
by the given LV. Therefore, all the latent variables that describe less than one original variable 
are discarded and not considered in the PLS model.  
Cross-validation is a technique that selects the optimal number of LVs by minimizing the error 
of the PLS model in reconstructing new samples. Different cross-validation procedures are 
presented in the literature: the most common is the one proposed by Wold (Wold, 1978). 
Mathematical details can be found in the cited reference. 
2.1.1.3 PLS model diagnostics 
Once a PLS model has been calibrated,  it is necessary to assess its performance by means of 
some diagnostic procedures. Three different areas can be identified: model diagnostics, sample 
diagnostics and variable diagnostics. All these procedures can be performed on one or both the 
input and output matrices. 
As regard model diagnostics, the most important metric that is typically used is the amount of 
variability of the original data captured by the model, i.e. the coefficient of determination 𝑅2: 
  
 𝑅2 = 1 −
∑ ∑ (𝑥𝑛,𝑣 − ?̂?𝑛,𝑣)
2𝑉
𝑣=1  
𝑁
𝑛=1
∑ ∑ (𝑥𝑛,𝑣)
2𝑉
𝑣=1
𝑁
𝑛=1
. 
(2.13) 
 
The value ?̂?𝑛,𝑣 is the PLS reconstruction of the 𝑥𝑛,𝑣 element of the original input matrix. The 
same definition (2.13) can be applied to the output matrix. To distinguish between the amount 
of 𝐗- and 𝐲- variability explained by the PLS model, the coefficient of determinations will be 
denoted as  𝑅𝑋
2 and 𝑅𝑦
2 respectively.  
As regard sample diagnostics, it is possible to identify potential outliers or samples of the 
original dataset that have a strong influence on the PLS model with two metrics, namely the 
Hotelling’s 𝑇2 and the squared prediction error 𝑆𝑃𝐸.  
The Hotellintg’s 𝑇2 (Hotelling, 1933) is a metric that quantifies the Mahalanobis distance from 
the projection of a sample on the latent space to the origin of the latent space itself. It is mainly 
used to assess the deviation of a given sample with respect to the average conditions of the 
historical dataset. The higher this metric for a given sample, the lower the adherence of the 
sample with respect to the calibration dataset, the higher its leverage with respect to the model 
(i.e. the higher its influence on model calibration). The Hotellintg’s 𝑇2 for the 𝑛-th sample is 
computed according to the equation (Mardia et al., 1979): 
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 𝑇𝑛
2 = 𝐭𝑛
T𝚲 𝐭𝑛. =  ∑
𝑡𝑎,𝑛
2
𝜆𝑎
𝐴
𝑎=1
 
(2.14) 
 
where 𝐭𝑛 is the score vector of the 𝑛-th observation, 𝜆𝑎 is the 𝑎-th eigenvalue and 𝚲 is the [𝐴 ×
𝐴] matrix collecting the 𝐴 eigenvalues on its diagonal.  
The squared prediction error (SPE) is a metric that describes the mismatch between the value 
of a sample 𝐱𝑛 and its model representation ?̂?𝑛. Geometrically, it represents the squared 
orthogonal (Euclidean) distance between the projection of the 𝑛-th observation and the latent 
space, and it is computed as: 
 
𝑆𝑃𝐸𝑛 = (𝐱𝑛 − ?̂?𝑛)
T(𝐱𝑛 − ?̂?𝑛) = 𝐞𝑛
T𝐞𝑛  (2.15) 
 
where 𝐞𝑛 is the residual vector for the 𝑛-th observation. Samples with high values of 𝑆𝑃𝐸𝑛 
have a different correlation structure with respect to the one captured by the PLS model, and 
therefore are not described properly by the model.  
As regard variable diagnostics, it is often desirable to understand which regressor variables are 
most influential with respect to the model responses and therefore mainly affect the PLS model. 
This can be quantified with a metric called  VIP index (variable importance in the projection; 
Chong and Jun, 2005), that is given by: 
 
𝑉𝐼𝑃𝑣 = √𝑉
∑ 𝑅𝑦,𝑎2 (𝑤𝑣,𝑎)
2𝐴
𝑎=1
∑ 𝑅𝑦,𝑎2
𝐴
𝑎=1
  
(2.16) 
 
where 𝑅𝑦,𝑎
2  is the amount of 𝐲-variance explained by the 𝑎-th LV and 𝑤𝑣,𝑎 is the weight of the 
𝑣-th input variable on the 𝑎-th LV. The higher the value of  𝑉𝐼𝑃𝑣, the higher the influence of 
the 𝑣-th input variable on the PLS model. Typically, variables with values of 𝑉𝐼𝑃𝑣 greater than 
one are considered as valuable predictor for the model responses (Eriksson et al., 2001). 
2.2 Prediction uncertainty in PLS modeling 
As stated in the previous section, once a PLS model has been calibrated according to Eq. (2.1)-
(2.3), a new response ?̂?𝑝 can be predicted given a set of regressors 𝐱𝑝 (i.e. the PLS model can 
be used for regression analysis). The model prediction ?̂?𝑝 can be obtained according to: 
 
?̂?𝑝 = 𝐭𝑝𝐐
T   
 
(2.17) 
where  𝐭𝑝 is the score vector related to the new set of regressors 𝐱𝑝: 
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 𝐭𝑝 =
𝐱𝑝𝐖
𝐏T𝐖
 . (2.18) 
 
When using a PLS model to predict a new response, prediction uncertainty must be quantified 
in order to assess the predictive ability of the model.  Different approaches have been proposed 
in the literature (a thorough review can be found in the work of Zhang and Garcia-Munoz, 
2012). All these methods assume that a single univariate response must be predicted (i.e. ?̂?𝑝 =
?̂?𝑝) an rely on the interpretation of the PLS model as a standard linear regression model (details 
on the derivation of this formulation can be found in Wold et al., 1983): 
 
𝑦𝑝 = 𝐱𝑝
T𝛃 + 𝜖𝑝 .   
 
(2.19) 
The general procedure to estimate prediction uncertainty is composed by the following two 
steps: 
1. Step #1: an estimation of the standard deviation of the prediction error 𝑠 is obtained and 
the degrees of freedom 𝑑𝑓 of the model are computed. 
2. Step #2: A confidence interval for the model prediction ?̂?𝑝 is established assuming a 𝑡-
statistics distribution with (𝑁 − 𝑑𝑓) degrees of freedom and significance level 𝛼 for the 
prediction error: 
 
               𝐶𝐼 = ?̂?𝑝 ± 𝑡𝛼
2
,(𝑁−𝑑𝑓) 𝑠 .   
 
(2.20) 
 
The sources of uncertainty that can affect the model prediction can be classified into three 
categories: 
1. Measurement errors in both the input and output calibration dataset; 
2. uncertainty in the model parameters ; 
3. structural uncertainty due to the un-modeled part of  ?̂?𝑝 (e.g. due to nonlinearities of the 
original dataset that cannot be captured with the linear PLS model). 
The available approaches typically consider only the second and third sources of uncertainty, 
i.e. they describe how the uncertainty on the model parameters propagates to the model response 
and accounts for structural uncertainty by assuming an error distribution for the model residuals. 
These uncertainty propagation models can be classified in four categories: Ordinary-Least-
Squares (OLS)-type methods, linearization-based methods, resampling-based methods and the 
Unscrambler method.  A brief review of each of these approaches is presented in the following. 
2.2.1 OLS-type methods 
The starting point of OLS-type methods is the OLS expression for the vector of model 
parameters: 
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 ?̂?𝑂𝐿𝑆 = (𝐗
T𝐗)−1𝐗T𝐲   
 
(2.21) 
where 𝐲 is the univariate output calibration dataset.  By taking the covariance of both sides of 
Eq. (2.19), it follows: 
 
cov( ?̂?𝑂𝐿𝑆) = (𝐗
T𝐗)−1𝐗Tcov(𝐮) 𝐗(𝐗T𝐗)−1 = (𝐗T𝐗)−1𝜎2   
 
(2.22) 
where cov(𝐮) = σ2𝐈𝑁 ,  with 𝜎
2 variance of the model residuals. The combination of  (2.19) 
and (2.22) leads to: 
  
var(?̂?𝑝) = var( 𝐱𝑝
T?̂?𝑂𝐿𝑆) + var(𝜖𝑝) = 𝐱𝑝
Tcov( ?̂?𝑂𝐿𝑆)𝐱𝑝 + 𝜎
2 = 𝜎2(ℎ𝑝 + 1)   
 
(2.23) 
where ℎ𝑝 is defined as the leverage of the 𝑝 observation and is given by: 
 
ℎ𝑝 = 𝐱𝑝
T (𝐗T𝐗)−1𝐱𝑝. 
 
(2.24) 
The geometrical meaning of ℎ𝑝 corresponds to the distance of the new observation with respect 
to the calibration center (i.e. to the origin of the axis of the PLS model). The standard deviation 
of the prediction error 𝑠 can thus be obtained from Eq. (2.25): 
 
𝑠 = 𝜎√1 + ℎ𝑝. 
 
(2.25) 
Eq. (2.25), even though derived for an OLS estimate of the model parameters for a standard 
linear regression model, can be transposed to a PLS model in a straightforward manner. 
Mathematical details can be found in the work of Zhang and Garcia-Munoz (2009). The same 
formulation of Eq. (2.17) can be used to obtain the standard deviation of the prediction error, 
where the leverage ℎ𝑝 can be derived from the score vector 𝐭𝑝  of the new observation as in the 
following: 
 
ℎ𝑝 = 𝐭𝑝
T𝐭𝑝. 
 
(2.26) 
Eq. (2.17) can be used to build to build the confidence interval for the new prediction of the 
PLS model, according to step#2 of the methodology described above. 
Faber and Kowalski (1997) proposed an extension to Eq. (2.25) that accounts for the 
measurement errors in both the input and response matrices. The main limitation of this 
approach is that it requires an estimate of the error variance of the input and output calibration 
datasets from replicated experiments, thus limiting its practical implementation. A through 
mathematical description of this approach can be found in the cited reference.  
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2.2.2 Linearization-based methods 
The derivation of prediction uncertainty with these methods is obtained by first-order 
linearization of the nonlinear dependency of the model parameters ?̂? with respect to the model 
response 𝑦. The dependency of ?̂? on the model response 𝑦 is obtained by Taylor series 
expansion truncated after the first term: 
 
 ?̂?(𝑦) =  ?̂?(𝑦𝑝) + 𝐉𝑝(𝑦 − 𝑦𝑝). 
 
(2.27) 
where 𝐉𝑝 is the Jacobian matrix of the derivatives of each element of ?̂? with respect to 𝑦 
computed at 𝑦 = 𝑦𝑝. By taking the covariance of both sides of Eq. (2.27), an estimate of the 
uncertainty on the model parameters can be obtained: 
 
cov(?̂?) ≃ 𝐉𝑝𝐉𝑝
T𝜎2. 
 
(2.28) 
By plugging Eq. (2.28) into Eq. (2.23), an estimate of the prediction uncertainty can be obtained 
according to: 
 
var(?̂?𝑝) = 𝜎
2(1 + 𝐱𝑝
T𝐉𝑝𝐉𝑝
T𝐱𝑝). 
 
(2.29) 
Prediction uncertainty (2.29) can be computed once an appropriate estimate of the covariance  
𝐉𝑝 is obtained. Different methods have been proposed, based on differential calculus (Phatak et 
al., 1993) or inductive estimation algorithms (Denham, 1997 ; Seernels et al., 2004). A recent 
work on this topic has been presented by Zhang and Fearn (2015).  
2.2.3 Re-sampling based methods 
The underlying idea behind these methods is to build synthetic datasets from the original 
calibration dataset by introducing artificial perturbations and  to estimate the covariance of the 
model parameters  based on these datasets. The two most important methods are jack-knife and 
bootstrap (Zhang and Garcia-Munoz, 2012). 
Jack-knife consists of generating 𝐾 datasets (𝐗𝑘, 𝑦𝑘), 𝑘 = 1,2, … , 𝐾 by deleting one calibration 
sample at a time from the original dataset and estimating the regression coefficient  ?̂?𝑘 for each 
reduced dataset. A set of “pseudo” regression coefficients ?̂?𝑝𝑠,𝑘 are then obtained according to 
the following equation: 
 
?̂?𝑝𝑠,𝑘 = 𝑁?̂? − (𝑁 − 1)?̂?𝑘;      𝑘 = 1,…𝐾  
 
(2.30) 
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where  ?̂? is the vector of the model parameters obtained with the entire calibration dataset. From 
Eq. (2.30) and after small algebraic manipulations, the covariance of ?̂?  can be obtained 
according to: 
 
cov(?̂?) =
1
𝑁(𝑁 − 1)
∑(?̂?𝑝𝑠,𝑘 − ?̅?𝑝𝑠)
𝐾
𝑖=1
(?̂?𝑝𝑠,𝑘 − ?̅?𝑝𝑠)
T   
 
(2.31) 
where ?̅?𝑝𝑠 is the vector collecting the average values of the pseudo parameters. The 
combination of Eq. (2.31) with Eq. (2.23) yields the estimation of prediction uncertainty using 
a jack-knife approach: 
 
var(?̂?𝑝) = 𝐱𝑝
T 1
𝑁(𝑁−1)
∑ (?̂?𝑝𝑠,𝑘 − ?̅?𝑝𝑠)
𝐾
𝑖=1 (?̂?𝑝𝑠,𝑘 − ?̅?𝑝𝑠)
T 𝐱𝑝 + 𝜎
2 . 
 
(2.32) 
As regard bootstrap techniques, two main approaches to estimate prediction uncertainty can be 
found in the literature, namely bootstrap by residuals and bootstrap by objects.  
In the former approach, new residual vectors are randomly generated by drawing the original 
residuals with replacements and new datasets are obtained by adding these new residuals to the 
fitted response ?̂?𝑝. The variance of the regression coefficients vector can then be derived under 
the assumption of independent and identically distributed re-sampled datasets. The procedure 
is as follows. 
First, the real residuals are computed according to : 
 
𝜖𝑛 =
𝑦𝑐𝑎𝑙,𝑛 − ?̂?𝑐𝑎𝑙,𝑛
(1 −
𝑑𝑓
𝑁 )
1
2
 ; 𝑛 = 1,2, … , 𝑁 
 
(2.33) 
where ?̂?𝑐𝑎𝑙,𝑛 is the 𝑛-th PLS fitted response for the 𝑛-th calibration sample. The new residual 
vectors and the corresponding new response datasets are then computed according to the set of 
equations: 
 
𝜓𝑛
𝑏 = round [𝑈(0,1) ⋅ 𝑁] + 1 ;    𝑛 = 1,2, … ,𝑁; 𝑏 = 1,2, … , 𝐵  
 
(2.34) 
𝑦𝑛
𝑏 = ?̂?𝑐𝑎𝑙,𝑛 + 𝜖𝜓𝑛𝑏 ;                           𝑛 = 1,2, … , 𝑁; 𝑏 = 1,2, … , 𝐵 (2.35) 
 
where round [⋅] represents the rounding to the nearest integer number towards zero and 𝑈(0,1) 
is a random number drawn from a uniform distribution between 0 and 1. The bootstrap 
procedure is repeated 𝐵 times, thus generating 𝐵 re-sampled datasets. The value of 𝐵 should be 
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chosen large enough to obtain accurate estimate of the covariance of the model parameters: 
typical values are in the range 𝐵 = [100 ÷ 10000].  
The set of 𝐵 re-sampled datasets can therefore be mathematically summarized as: 
 
(𝐱𝑛
𝑏 , 𝐲𝑛
𝑏) = (𝐱cal,𝑛, 𝐲𝑛
𝑏), 𝑛 = 1,2, …𝑁;    𝑏 = 1,2, … , 𝐵 (2.36) 
𝐗𝑏 = (𝐱1
𝑏, … , 𝐱𝑁
𝑏 )
T
                 𝑏 = 1,2, … , 𝐵 (2.37) 
𝐲𝑏 = (𝐲1
𝑏 , … , 𝐲𝑁
𝑏)
T
                  𝑏 = 1,2, … , 𝐵                  (2.38) 
 
with 𝐱cal,𝑛 input vector for the 𝑛-th calibration sample. For each resampled dataset [𝐗𝑏; 𝐲𝑏], the 
corresponding vector of model parameters ?̂?𝑏 can be obtained by fitting the model responses 
of the given dataset. Once iterated for all the 𝐵 datasets, the bootstrap estimated of the 
covariance of the vector of model parameters ?̂? can be obtained according to: 
 
cov(?̂?) =
1
𝐵 − 1
 ∑(?̂?𝑏 − ?̅?)(?̂?𝑏 − ?̅?)
T
𝐵
𝑏=1
  
 
(2.39) 
where  ?̅? is the average of the 𝐵 regression vectors ?̂?𝑏. By plugging in Eq. (2.39) into Eq. (2.23) 
the estimation of prediction uncertainty can be obtained: 
 
var(?̂?𝑝) = 𝐱𝑝
T 1
𝐵−1
 ∑ (?̂?𝑏 − ?̅?)(?̂?𝑏 − ?̅?)
T𝐵
𝑏=1 𝐱𝑝 + 𝜎
2.   
 
(2.40) 
Eq. (2.40) is the mathematical formulation of the variance of a new PLS response obtained 
with a bootstrap of residuals method. 
In the bootstrap by objects approach, the procedure is the same as in the bootstrap by residuals, 
with the difference that the 𝐵 re-sampled datasets are generated by randomly drawing sample 
(and not residuals) with replacements. The covariance of the model parameters vector is 
obtained as in Eq. (2.39), and prediction uncertainty has the exact same formulation as in Eq. 
(2.40). 
2.2.4 The Unscrambler method 
The Unscrambler formula (De Vries and Ter Braak, 1995) for the estimation of prediction 
uncertainty in PLS modeling is an empirical formula that is implemented in the chemometrics 
commercial software Unscrambler™.  Its derivation has been thoroughly reviewed  in the 
literature (De Vries and Ter Braak, 1995; Høy et al., 1998). Given the formulation of the PLS 
prediction model (2.17), the underlying idea behind this approach is to derive two expressions 
for prediction uncertainty assuming first that the PLS scores are not affected by uncertainty, 
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and then that the model loadings are not affected by uncertainty. An average of the two 
expressions is then obtained leading the following estimate of prediction uncertainty: 
 
var(?̂?𝑝) = 𝑉𝑦𝑣𝑎𝑙 (1 −
𝐴+1
𝑁
) (ℎ𝑝 +
𝑉𝑥𝑝
𝑉𝐱𝑡𝑜𝑡,𝑣𝑎𝑙
) .   (2.41) 
 
where 𝑉𝑦𝑣𝑎𝑙is the 𝑦- residual variance in the validation dataset, 𝑉𝐗𝑡𝑜𝑡,𝑣𝑎𝑙  is the average 𝐱-residual 
variance in the validation dataset and 𝑉𝑥𝑝is the 𝐱-residual variance in the new regression vector 
𝐱𝑝. Details on the mathematical derivation of Eq. (2.41) are reported in the cited references. 
2.2.5 Estimation of 𝜎2 and degrees of freedom 
The estimation of prediction uncertainty according to OLS-type methods (2.23), linearization-
based methods (2.29), jack-knife approach (2.32) and bootstrap methods (2.40) requires an 
estimation of the standard deviation of the model residuals 𝜎.  
An unbiased estimator of 𝜎 that is typically used in the chemometrics literature is the root means 
squared error of calibration 𝑅𝑀𝑆𝐸𝐶:  
 
𝑅𝑀𝑆𝐸𝐶 = (
∑ (𝑦𝑐𝑎𝑙,𝑛 − ?̂?𝑐𝑎𝑙,𝑛)
2𝑁
𝑛=1
𝑁 − 𝑑𝑓
) (2.42) 
 
where ?̂?𝑐𝑎𝑙,𝑛 is the PLS prediction of the 𝑛-th calibration object. 𝑅𝑀𝑆𝐸𝐶 is used in place of 𝜎 
to estimate prediction uncertainty according to the methods described in the previous sections. 
However, the use of 𝑅𝑀𝑆𝐸𝐶 according to Eq. (2.42) poses the problem of obtaining an accurate 
estimation of the degrees of freedom of the model13. Three approaches have been proposed to 
estimate 𝑑𝑓 (Zhang and Garcia-Munoz, 2009): 
1. Naïve approach: each PLS factor (i.e. LV) is assumed to consume one degree of 
freedom; 
2. Pseudo degrees of freedom (PDF) approach: it computes 𝑑𝑓 based on the ratio of a 
model fit error and a predictive performance error (derivation can be found in the work 
of Zhang and Garcia-Munoz, 2009); 
3. Generalized degrees of freedom (GDF) approach: it computes 𝑑𝑓 based on the sum of 
the sensitivity of each fitted response to perturbations in the corresponding observed 
response. 
In this study, the only approach that has been used to estimate 𝑑𝑓 is the Naïve approach. 
Additional details are provided in Chapter 3.  
                                                          
13 Note that the estimation of the degrees of freedom is also intrinsically required in order to estimate prediction uncertainty 
in the bootstrap by objects/residuals approach. Moreover, the estimate of 𝑑𝑓 is required in order to build the confidence 
interval for the model prediction (Step #2). 
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2.2.5.1 Summary 
A schematic review of all the methods to estimate prediction uncertainty in PLS modeling 
described above is reported in Table 2.1. In the same table, the different types of model 
uncertainty that are taken into account by each method are also reported. 
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Table 2.1. Summary of the different methods to estimate prediction uncertainty in PLS modeling. 
Method Std. of prediction uncertainty 𝑠 = √var(?̂?𝑝) 
Measurement uncertainty 
on 𝐗 and y? 
Uncertainty on model 
parameters? 
Structural 
uncertainty? 
OLS-type 𝑠 = 𝑅𝑀𝑆𝐸𝐶√1 + ℎ𝑝 ✘ ✔ ✔ 
Linearization 
 
s = 𝑅𝑀𝑆𝐸𝐶√(1 + 𝐱𝑝T𝐉𝑝𝐉𝑝T𝐱𝑝) 
 
✘ ✔ ✔ 
Jack-knife 
 
s = √𝐱𝑝T
1
𝑁(𝑁 − 1)
∑(?̂?𝑝𝑠,𝑘 − ?̅?𝑝𝑠)
𝐾
𝑖=1
(?̂?𝑝𝑠,𝑘 − ?̅?𝑝𝑠)T 𝐱𝑝 + 𝑅𝑀𝑆𝐸𝐶2 
 
✘ ✔ ✔ 
Bootstrap 
residuals 
 
s = √𝐱𝑝T
1
𝐵 − 1
 ∑(?̂?𝑏 − ?̅?)(?̂?𝑏 − ?̅?)
T
𝐵
𝑏=1
𝐱𝑝 + 𝑅𝑀𝑆𝐸𝐶2 
 
✘ ✔ ✔ 
Bootstrap 
objects s =
√𝐱𝑝T
1
𝐵 − 1
 ∑(?̂?𝑏 − ?̅?)(?̂?𝑏 − ?̅?)
T
𝐵
𝑏=1
𝐱𝑝 + 𝑅𝑀𝑆𝐸𝐶2 ✘ ✔ ✔ 
Unscrambler  s = √𝑉𝑦𝑣𝑎𝑙 (1 −
𝐴+1
𝑁
) (ℎ𝑝 +
𝑉𝑥𝑝
𝑉𝐱𝑡𝑜𝑡,𝑣𝑎𝑙
) . ✘ ✔ ✔ 
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SECTION B: BAYESIAN MODELING 
 
Since the introduction of Bayes’ theorem (Bayes, 1763), Bayesian statistical modeling has been 
considered as an alternative school of thought as opposed to classical frequentist statistical 
modeling. The two approaches rely on a completely different interpretation of the concept of 
probability: in frequentist statistics, probability is defined as the frequency that an event will 
occur over a large number of trials. On the other hand, in Bayesian statistics, probability is 
considered as the degree of plausibility for the occurrence of a given event.  
In the process systems engineering community, Bayesian modeling has gained particular 
attention in the last few decades, thanks to the rapid increase of computational power for 
intensive numerical calculations. The ability to perform in a very short time Markov-chain 
Monte Carlo (MCMC) simulations, such as the ones required in Bayesian modeling, played a 
key role for the application of Bayesian methodologies in chemical engineering- related 
problems. 
In this section, a brief mathematical background on Bayesian statistics is presented. A particular 
focus is given to Bayesian multivariate linear regression, since its practical application to 
problems related to the pharmaceutical industry will be presented in Chapter 4.  A rigorous 
mathematical description of Bayesian modelling for chemical engineers can be found in the 
work of Lenk and DeSarbo (2000). 
2.3 Key concepts of Bayesian statistics 
The key assumption of Bayesian statistics is that the variables of interest are random variables 
described by probability density functions (PDFs). Let 𝐘 = (𝐲1, 𝐲2, … , 𝐲𝑀) be a set of 𝑁 
observations of the multivariate responses 𝐲𝑚[𝑁 × 1],𝑚 = 1,2, … ,𝑀. In the Bayesian 
framework, 𝐲𝑚, 𝑚 = 1,2, … ,𝑀 are a set of random variables described by their respective 
probability distributions. The vector 𝐲 = (𝑦1, 𝑦2, … , 𝑦𝑀) that collects all the 𝑀 response 
variables is therefore assumed to be a multivariate random variable with a given PDF. It is 
assumed that 𝐲 depends upon a set of parameters 𝛉 according to a given pre-defined model (i.e. 
regression model, mechanistic model etc…). The PDF of 𝐲, given the parameters 𝛉 and any 
other pertinent information about the system 𝐼, is expressed as 𝑝(𝐲|𝛉, 𝐼). 𝐼 includes, for 
example, any relevant assumption that is made on the type and shape of the PDF of 𝐲. The 
vector of parameters 𝛉 is considered as a multivariate random variable with PDF  𝑝(𝛉|𝐲, 𝐼). 
Any information known a priori on the values and uncertainty of the model parameters 𝛉  is 
described by the PDF 𝑝(𝛉|𝐼). For sake of simplicity, 𝐼 will be omitted in the following notation. 
Bayes’ theorem can be formulated according to the following expression: 
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𝑝(𝛉|𝐲) =
𝑝(𝐲|𝛉)𝑝(𝛉)
∫ 𝑝(𝐲|𝛉)𝑝(𝛉)d𝛉𝜃
 (2.43) 
 
where 𝑝(𝛉) is called the prior (distribution) of 𝛉, 𝑝(𝛉|𝐲) the posterior of 𝛉 and 𝑝(𝐲|𝛉) is called 
the likelihood function and it is often written as ℒ(𝛉|𝐲). The prior of 𝛉 contains all the 
information available a priori on 𝛉; the likelihood function describes the plausibility of 𝛉 given 
𝐲, while 𝑝(𝛉|𝐲) describes how 𝛉 is distributed given the observed response data. The 
denominator of Eq. (2.43) is a constant normalizing factor that depends only on the data 
available. For this reason, Eq. (2.43) is often expressed as: 
 
𝑝(𝛉|𝐲) ∼ ℒ(𝛉|𝐲) 𝑝(𝛉) . (2.44) 
 
Eq. (2.44) clarifies that the posterior distribution of the parameters 𝛉, given the observed data, 
is obtained from the prior knowledge about 𝛉, updated according to the likelihood function 
ℒ(𝛉|𝐲). The correct interpretation and application of Eq. (2.44) requires few comments, 
namely: 
1. How the prior distribution 𝑝(𝛉) should be assigned; 
2. how the final posterior 𝑝(𝛉|𝐲) can be computed from a practical viewpoint; 
3. how the uncertainty on the prediction of a new response ?̂?𝑝 can be obtained in a Bayesian 
framework. 
2.3.1 Prior distribution 𝑝(𝜽) 
The incorporation of the prior distribution 𝑝(𝛉) in the computation of the posterior of the model 
parameters is one of the key difference between Bayesian and frequentist parameter estimation. 
Every Bayesian computation requires an appropriate choice of the prior of 𝛉: this is often 
considered as a strong argument against Bayesian modeling, since there is no general rule on 
the choice of 𝑝(𝛉). However, in many model-based engineering-related problems, the 
possibility of incorporating available knowledge on the system can be extremely beneficial to 
improve the accuracy of model predictions. In this sense, the above argument can be easily 
reverted and the incorporation of 𝑝(𝛉) in the analysis can be seen as one of the strengths of the 
Bayesian framework. 
Although there is no general rule for the choice of 𝑝(𝛉), there are two different types of priors 
that can be used when performing a Bayesian simulation: 
1. Non-informative prior distributions 
2. Informative prior distributions. 
Non-informative priors are used when very limited or no knowledge is available for the model 
parameters 𝛉. In this case, the posterior 𝑝(𝛉|𝐲) is affected only by the likelihood ℒ(𝛉|𝐲). The 
typical choice of non-informative prior that can be made is a flat prior distribution for 𝛉 over 
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its entire domain. However, it is worth noticing that there are other type of priors that, even 
though they can be classified as informative from a structural point of view, can be considered 
as non-informative when the values of some or all of their moments is not informative. A typical 
example is a Gaussian prior distribution (thus informative from a structural point of view) with 
a very large standard deviation and a random guess of its mean value. This type of prior 
distribution has to be considered non-informative, even though formally informative from a 
structural point of view. The reason why the choice of non-informative priors with informative 
structure can be useful in certain applications will be discussed in more detail in Chapter 4.  
Informative priors can be used when general knowledge is available on 𝛉, e.g. from previous 
experiments or from previous studies for the system under analysis. In this case, suitable PDF 
structures and values for their moments can be assigned for the prior 𝑝(𝛉). The definition of 
informative priors typically becomes more challenging when the dimensionality of 𝛉 increases 
(Coleman and Block, 2006). The problem can be typically solved by performing a sensitivity 
analysis of the posterior with respect to the conditional priors of the single parameters, and then 
obtaining a suitable joint prior for 𝛉 based on the results of this analysis. 
2.3.2 Posterior distribution 𝑝(𝜽|𝒚) 
Once the prior distribution for the model parameters has been set, the posterior  𝑝(𝛉|𝐲) can be 
computed according to Bayes’ theorem (2.44).  The solution of (2.44) can be analytical or 
numerical. Obtaining an analytical expression for 𝑝(𝛉|𝐲) is possible in very rare situations and 
under very strict simplifications (low dimensionality, linearity, simple priors etc…). In many 
engineering-related problems, the solution of (2.44) can only be obtained with numerical 
sampling methodologies such as Markov Chain Monte Carlo (MCMC) techniques. Different 
sampling algorithms have been proposed that are able to follow any joint posterior distribution 
of the model parameters. The most famous MCMC sampling algorithms are the Metropolis 
algorithm and the Metropolis-Hastings algorithm (Hastings, 1970), the modified Metropolis-
Hastings algorithm and the Gibbs sampler (Geman, S. and Geman, D., 1993). The description 
of these algorithms is out of the scope of this Dissertation. A thorough description can be found 
in the cited references.  
The application of these sampling strategies to obtain a discrete representation of  𝑝(𝛉|𝐲) 
requires intensive computer simulations due to the (possibly) slow convergence of the Markov 
chains (MCs). The assessment of the convergence of the MCs and the computational 
requirements are thoroughly discussed in Chapter 4. 
2.3.3 Posterior predictive distribution of a new response ?̂?𝑝 
Once the parameters of the model have been calibrated in a Bayesian framework (i.e. their 
posterior distribution has been obtained), it is very often desirable to use that model to predict 
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a new response ?̂?p and to compute the uncertainty associated with that prediction. The strength 
of Bayesian modeling is that the value of a new prediction and its uncertainty are derived in a 
unified framework. In fact, as discussed in section 2.3, the model prediction ?̂?p is treated as 
random variable and it is therefore described by a PDF 𝑝(?̂?𝑝|𝐲). The distribution 𝑝(?̂?𝑝|𝐲) is 
called the posterior predictive distribution (PPD) of ?̂?𝑝. The PPD of ?̂?p can be formally 
computed as: 
 
𝑝(?̂?𝑝|𝐲) = ∫ 𝑝 (?̂?𝑝, 𝛉|𝐲)d𝛉 = ∫ 𝑝 (?̂?𝑝|𝐲, 𝛉)𝑝(𝛉|𝐲)d𝛉
𝛉𝛉
 . (2.45) 
 
Under the assumption that, for a given 𝛉, ?̂?𝑝 and 𝐲 are conditionally independent, Eq. (2.45) can be 
simplified to: 
 
𝑝(?̂?𝑝|𝐲) = ∫ 𝑝 (?̂?𝑝|𝛉)𝑝(𝛉|𝐲)d𝛉
𝛉
 . (2.46) 
 
According to Eq. (2.45), the computation of the PPD of  ?̂?𝑝 requires the posterior distribution 
𝑝(𝛉|𝐲) of the model parameters, obtained according to Eq. (2.44), and the PDF  𝑝(?̂?𝑝|𝛉), which 
can be obtained from the original model for the given values of 𝛉. If analytical expressions for 
𝑝(𝛉|𝐲) and 𝑝(?̂?𝑝|𝛉) were available, Eq. (2.46) could be used to obtain an analytical expression 
for 𝑝(?̂?𝑝|𝐲) by direct integration.  However, as previously explained, the analytical expression 
of 𝑝(𝛉|𝐲) is almost never available and this PDF is usually obtained via MCMC sampling. For 
this reason, the PPD of  ?̂?𝑝 can only be obtained by propagating the posterior PDF of the model 
parameters to the model responses, i.e. samples from the PPD can  be obtained following the 
procedure: 
1. Draw a sample 𝛉(𝑙) from the posterior distribution of the model parameters  𝑝(𝛉|𝐲); 
2. Draw the respective model response ?̂?𝑝
(𝑙)
  from the model 𝑝(?̂?𝑝|𝛉); 
3. Repeat for 𝑙 = 1,2, … , 𝐿 times, with 𝐿 number of samples (user-defined). 
The application of the above procedure allows obtaining the PPD for a new response, with the 
notable drawback of increasing the total computational time (sampling from the PPDS sums up 
to the sampling from the posterior of the model parameters). 
2.3.4 Credible region Vs Confidence region 
The PPD of a new response that can be obtained from a Bayesian simulation carries information 
on both the predicted value of the new response vector ?̂?𝑝 and its uncertainty. In this regards, it 
can be said that prediction uncertainty is incorporated in a straightforward fashion in the 
Bayesian framework. 
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In many situations, it is desirable to express the uncertainty on the model predictions in terms 
of confidence intervals/regions around the expected value of ?̂?𝑝, similarly to what is done in 
classical frequentist modeling.  
From a Bayesian perspective, the concepts of confidence interval and confidence region of 
frequentist statistics are replaced by the concepts of credible interval and credible region. 
Although the two definitions (confidence region/ credible region) may look similar at a first 
sight, they are completely different from both a methodological and significance point of view. 
In frequentist statistics, the predicted response ?̂?𝑝 is considered as a fixed value and the 
boundary of the 𝑀- dimensional confidence region as a random variable. On the other side, in 
Bayesian statistics, the predicted response ?̂?𝑝 is considered as a random variable and the 
boundary of the 𝑀- dimensional credible region as a random variable. In other terms, a 
frequentist (1 − 𝛼)% confidence region means that if a large number of repeated samples from 
the original population is drawn, (1-𝛼)% of these samples would fall within the calculated 
confidence region, with 𝛼 = user-defined significance level. On the other hand, a 𝛿 (%) credible 
interval for the random variable ?̂?𝑝 means that the probability that ?̂?𝑝 lies within the credible 
region is equal to 𝛿.  
From a mathematical point of view, a 𝛿 (%) credible region 𝐶𝛿 for the random variable ?̂?𝑝 can 
be defined as: 
 
𝐶𝛿 :  ∫ 𝑝 (?̂?𝑝|𝐲)d?̂?𝑝
Cδ
 = 𝛿 (2.47) 
 
The definition of credible region (2.47) gives a measure of prediction uncertainty that can be 
obtained in a straightforward way for both univariate and multivariate responses. This last 
situation is of particular interest in engineering-related problems and gives a great advantage 
with respect to classical frequentist statistics, where the definition of multidimensional 
confidence regions for multivariate response vectors is often very complicated or obtained 
under strong and limiting assumptions. 
2.4 Bayesian multivariate linear regression 
As observed in section 2.1, many applications involve the availability of a historical dataset of 
model responses 𝐘 [𝑁 × 𝑀], that has to be correlated with a historical dataset of model inputs 
(ore regressors) 𝐗 [𝑁 × 𝑉]. The simplest model that can be used to correlated the input dataset 
with the output dasate is a linear multivariate regression model: 
 
  𝐘 = 𝐗𝐁 + 𝐄 (2.48) 
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where 𝐁 [𝑉 × 𝑀] is the matrix of model parameters, and 𝐄 [𝑁 × 𝑀] is the matrix of model 
residuals. The model residuals are assumed to have 𝟎- mean and characterized by a semi-
definite positive covariance matrix 𝚺 [N ×M], equal for every model residual 𝐞𝑚, 𝑚 =
1,2, … ,𝑀. 
The Bayesian calibration of the regression model (2.48) can be obtained by sampling from the 
joint multivariate posterior PDF of 𝐁 according to Eq. (2.44). The calibrated regression model 
can then be used to predict a new response ?̂?𝑝 and characterize prediction uncertainty according 
to Eq. (2.46). The simple model structure of Eq. (2.48) allows obtaining a deeper insight on the 
likelihood function and posterior distribution of 𝐁. The main characteristics are briefly 
described in the following sections. 
2.4.1 Likelihood function in multivariate linear regression 
The linear regression model (2.48) allows obtaining a simple analytical expression for the 
likelihood function ℒ(𝐁, 𝚺|𝐲) under the assumption that the model residual are independent 
identically normal distributed with mean 𝟎 and covariance 𝚺. From the properties of normal 
distributions, it follows that each response vector 𝐲𝑚, 𝑚 = 1,2, …𝑀 is assumed to follow a 
multivariate normal distribution according to: 
 
  𝐲𝑛 ∼ 𝑁𝑚(𝐱𝑖𝐁, 𝚺),       𝑛 = 1, .2, … ,𝑁. (2.49) 
 
Under this assumption, the likelihood function ℒ(𝐁, 𝚺|𝐲) can be analytically expressed as: 
 
  ℒ(𝐁, 𝚺|𝐲) = (2𝜋)−
𝑀𝑁
2 det(𝚺)−
𝑁
2 exp(−
1
2
𝛴𝑛=1
𝑁  [(𝐲𝑛 − 𝐱𝑛𝐁)𝚺
−1(𝐲𝑛 − 𝐱𝑛𝐁)
T])   (2.50) 
 
or more conveniently as: 
 
  ℒ(𝐁, 𝚺|𝐲) ∼ det(𝚺)−
𝑁
2 exp (−
1
2
 𝑡𝑟 [𝚺−1(𝐘 − 𝐗𝐁)T(𝐘 − 𝐗𝐁)])   (2.51) 
 
Expression (2.51), combined with any choice of the prior distributions of the model parameters 
and the covariance of the residuals, allows obtaining the joint posterior of the model parameters 
and the covariance of the residuals. A possible set of prior distributions that can be assigned is 
discussed in the next section. 
2.4.2 Prior distributions 
Depending on the choice of the joint prior distribution for the model parameters and the 
residuals covariance (informative/non-informative, as discussed in section 2.3.1), the joint 
posterior can be obtained by updating the given prior through the likelihood function (2.51). 
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As regard non-informative prior distributions, different choices have been proposed in the 
literature(see e.g. Geisser and Cornfield (1963)). A typical choice is that of assuming 𝐵 and Σ 
completely independent to each other and assigning a flat distribution for 𝐁 (i.e. a non-
informative prior) and an inverse Wishart distribution for 𝚺 (Wishart, 1958). 
A common choice that is adopted is to use a structural informative prior distribution for 𝐁, and 
assigning informative or non-informative values to the moments of this distribution according 
to the previous knowledge available on the model parameters. Typically, a (𝑉 ×𝑀) matrix-
variate normal distribution is assigned to the conditional distribution of 𝐁 with respect to 𝚺, and 
a inverse Wishart distribution is assigned as the prior of 𝚺. To understand the reasoning behind 
this choice, it is worth noticing that the joint prior distribution of 𝐁 and 𝚺 (𝑝(𝑩, 𝚺)) can be 
decomposed as: 
 
  𝑝(𝐁, 𝚺) = 𝑝(𝐁|𝚺)𝑝(𝚺)   (2.52) 
 
where 𝑝(𝐁|𝚺) is the conditional distribution of 𝐁 with respect to 𝚺, and 𝑝(𝚺) is the prior 
distribution of  𝚺. Based on Eq. (2.52), the choice of a matrix-variate normal distribution for 
𝑝(𝐁|𝚺) and an inverse Wishart distribution for 𝑝(𝚺) is related to the fact that they both represent 
conjugate prior distributions (i.e. a joint Normal-Wishart prior distribution for (𝐁, 𝚺−1) will 
generate a Normal-Wishart posterior distribution for 𝑝(𝐁, 𝚺−1)). Therefore, 𝑝(𝐁|𝚺) can be 
expressed as: 
 
  𝑝(𝐁|𝚺) ∼ 𝑁𝑉×𝑀(𝐁0, 𝚺, 𝚺0)  (2.53) 
 
where 𝐁0 and 𝚺0 are the initial guesses for the model parameters and residuals covariance 
respectively (i.e. the values that the user can set in order to make more or less informative the 
prior distribution). On the other hand, an inverse Wishart distribution is assigned to 𝑝(𝚺): 
 
  𝑝(𝚺) ∼ 𝑊−1(𝛀, 𝜈0)  (2.54) 
 
where 𝛀 is called the a priori response scale matrix and can be interpreted as a sum of squared 
errors, and 𝜈0 (user-defined) is the number of degrees of freedom of the prior distribution. The 
lower 𝜈0, the lower the subjectivity of the prior distribution. The analytical expression of the 
inverse Wishart distribution can be found in the work of Wishart (1958). 
Eq (2.54) and (2.53) leads to the joint prior distribution according to Eq. (2.52). The above 
priors have been set in all the work presented in this Dissertation and additional details on this 
topic will be given in Chapter 4.  
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2.4.3 Posterior distribution 
By combining Eq. (2.54) with (2.53) through Eq. (2.52), and combining them with Eq. (2.51), 
the joint posterior distribution of 𝐁 and 𝚺 can be obtained from Eq. (2.44) according to the 
following expression: 
 
𝑝(𝐁, 𝚺|𝐗, 𝐘) ∼  ℒ(𝐁, 𝚺|𝐲) 𝑝(𝐁|𝚺)𝑝(𝚺) ∼ 
∼  det(𝚺)−
𝑁
2 exp (−
1
2
𝑡𝑟[𝚺−1(𝐘 − 𝐗𝐁)T(𝐘 − 𝐗𝐁)]) ⋅ 
⋅ det(𝚺)−
𝑉
2 exp (−
1
2
𝑡𝑟[𝚺−1(𝐁 − 𝐁0)
𝑇𝚺0
−1(𝐁 − 𝐁0)]) det(𝚺)
−𝜈0−2𝑀
2 exp (−
1
2
𝑡𝑟(𝛀𝚺−1))  
(2.55) 
 
Sampling from the above distribution can be obtained with one of the MCMC sampling 
strategies discussed in section 2.3.2. The obtained PDF can then be obtained to build the PPD 
of a new response according to the procedure described in the next section. 
2.4.4 Posterior predictive distribution of a new response 
The PPD for a new response can be obtained by re-writing Eq. (2.45) adapted to the multivariate 
linear regression scenario, i.e.: 
 
  𝑝(?̂?𝑝|𝐗, 𝐘, 𝐱𝑝) =  ∫ ∫𝑝(?̂?𝑝|𝐁, 𝚺)𝑝(𝐁, 𝚺)d𝐁d𝚺
𝚺𝐁
 (2.56) 
 
Depending to the type of priors chosen (non-informative or informative), it may be possible to 
give an analytical expression to Eq. (2.56). For example, if the structurally informative priors 
described in section 2.4.2 are used, the corresponding PPD can be obtained by plugging in Eq. 
(2.55) into Eq. (2.56) and Eq. (2.49) adapted to the new response vector ?̂?𝑝.  In any case, the 
PPD is typically obtained with the sampling procedure described in section 2.3.2. 
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SECTION C: FEASIBILITY ANALYSIS  
 
The concept of feasibility and flexibility analysis applied to chemical engineering problems 
was first introduced in the ‘80s by the joint studies of Morari (Lenhoff and Morari, 1982) and 
Grossmann (Halemane and Grossman, 1983). Although the definitions of feasibility and 
flexibility analysis are different from each other, they are often interchanged with a slight 
misuse of terminology. 
Feasibility analysis describes the ability of a process to satisfy all the relevant constraints 
(quality constraints, production constraints, environmental constraints) in the presence of 
uncertainty on (i) model parameters, (ii) raw material properties (external variability) and (iii) 
critical process parameters (external variability). These three sources of uncertainty are 
typically identified as uncertain parameters, and the combination of these parameters that 
satisfy all the relevant constraints is defined as feasible region. The identification of the feasible 
region can be obtained by solving a feasibility test problem. Mathematically, the variables that 
appear in a feasibility test problem formulation can be classified as: 
1. design variables 𝐝 [1 × 𝐷 ]: variables related to the structure and equipment size; 
2. control variables 𝐮 [1 × 𝑈]: manipulated variables of the system; 
3. uncertain parameters 𝛘 [1 × 𝐶], as defined above. 
If the process is at steady-state, the set of 𝐽 relevant constraints imposed on the process under 
investigation can be mathematically written in forms of inequalities of the type: 
 
   𝑓𝑗(𝐝, 𝛘, 𝐮) ≤ 0,   𝑗 = 1,2, … , 𝐽.  (2.57) 
  
If it is assumed that there are no control variables in the system, the maximum values of all 
these constraints defines the so-called feasibility function Ψ(𝐝, 𝛘): 
 
   Ψ(𝐝, 𝛘) = max
𝐽
𝑓𝑗(𝐝, 𝛘)  (2.58) 
 
s.t.  𝛘 ∈ [𝝌𝑚𝑖𝑛 ;  𝝌𝑚𝑎𝑥]. 
 
 
If the process design is fixed, the feasibility function has an immediate interpretation: if 
Ψ(𝐝, 𝛘) < 0, the process can be feasibly operated for the given uncertain parameters 𝛘; if 
Ψ(𝐝, 𝛘) > 0, the process is infeasible. It follows that the feasible region can be defined as the 
combinations of uncertain parameters that satisfy Ψ(𝐝, 𝛘) < 0; in particular, the combinations 
of uncertain parameters that satisfy the condition Ψ(𝐝, 𝛘) = 0 represent the boundary of the 
feasible region. 
The solution of the feasibility problem (2.58) can be obtained by solving the equivalent 
optimization problem: 
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   Ψ(𝐝, 𝛘) = min
𝑝
𝑝  (2.59) 
s. t.   𝑓𝑗(𝐝, 𝛘) ≤ 𝑝, 𝑗 = 1,2, … , 𝐽. 
 
The solution of the optimization problem (2.59) is straightforward if the process constraints are 
differential closed-form constraints and their evaluation is computationally tractable. However, 
many applications involve black-box constraints and the evaluation of the original process 
model can be extremely demanding from a computational point of view. For this reason, 
different surrogate-based approaches have been developed to overcome these limitations 
(Bhosekar and Ierapetritou, 2017). These methods build a surrogate as a cheap and reliable 
approximation of the original process model, and compute the feasible region based on this 
surrogate rather than the original process model. The main concepts of surrogate-based 
feasibility analysis are briefly summarized below. An extension of feasibility analysis applied 
to dynamical systems is reported in Chapter 6.  
2.5 Surrogate-based feasibility analysis 
The key idea of surrogate-based feasibility analysis is to build a surrogate as an approximation 
of the original process model, and use this surrogate to solve the feasibility problem in order to 
identify the feasible region of the process. Clearly, the approximation error that is introduced 
with the surrogate must be kept to a minimum, in order to avoid a wrong representation of the 
feasible region with respect to the one that can be obtained with the original process model. 
Surrogate-based feasibility analysis consists of different steps, namely: 
1. initial sampling of the input domain (i.e. uncertain parameters domain); 
2. evaluation of the feasibility function for each of the initial samples obtained at step 1;  
3. determination of a response surface for the feasibility function; 
4. continuous update of the surrogate model with adaptive sampling strategies until the 
surrogate accuracy is deemed to be sufficient; 
5. prediction of the feasible region boundary using the surrogate obtained after the 
adaptive sampling strategy. 
Different choices can be used when applying this methodology, including the choice of the 
surrogate model, the type of adaptive sampling strategy adopted and the stopping criterion for 
the surrogate accuracy. A brief of each of these aspects is reported below. 
2.5.1 Surrogate models 
Different surrogate models have been proposed in the literature in order to perform a feasibility 
analysis exercise, including high-dimensional model representations (Banerjee and 
Ierapetritou, 2002; Banerjee et al., 2010), Kriging surrogates (Boukouvala and Ierapetritou, 
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2012; Boukouvala and Ierapetritou, 2013) and Radial-Basis function (RBF) surrogates (Wang 
and Ierapetritou, 2017). Kriging surrogates and RBF surrogates have been proven to be more 
efficient than high-dimensional surrogates, while maintaining the computational burden 
relatively low. 
2.5.1.1 Kriging surrogate 
Kriging (Krige, 1951) is a well-established interpolation method that has proven to work 
efficiently as an approximation of many nonlinear dynamic models. The basic idea of Kriging 
is that the function value for an unexplored sampling point can be obtained as a weighted sum 
of the function values at known sampling locations. Given 𝑆 design sites, the function value at 
the unknown sampling point 𝐱∗ can be obtained from the function values at the known design 
sites 𝐱𝑠, 𝑠 = 1,2, … 𝑆 according to: 
  
  𝑓(𝐱∗) =∑𝑤𝑠 𝑓(𝐱𝑠)
𝑆
𝑠=1
+ 𝜖∗  (2.60) 
 
where 𝜖∗ is the variance of the Kriging predictor at the sampling point 𝐱∗. Eq. (2.60) can be 
decomposed into a regression model and a correlation model, according to the structure: 
 
  𝑓(𝐱∗) = 𝐟(𝐱𝑠)
T𝛾 + 𝐫(𝐱𝑠)
T𝛿  (2.61) 
 
where 𝐟(𝐱𝑠)
T is the vector collecting the function values at the 𝑆 design sites and 𝐫(𝐱𝑠)
T is a 
vector collecting the correlations between the function values at the 𝑆 design sites.  
Different types of regression models and correlation models can be used in Eq. (2.61), thus 
leading to different types of Kriging estimators. The regression models are typically 
polynomial, e.g. zero-th order, first-order, second-order polynomials and so on. The correlation 
models can be of different types, including linear, exponential and Gaussian correlation models. 
A thorough discussion on the different correlation models of the Kriging estimator can be found 
in the work of Kleijnen (Kleijnen, 2009). 
2.5.1.2 Radial-basis function (RBF) surrogate 
RBF surrogates for feasibility analysis have recently gained attention, since it has been proven 
that they can outperform Kriging surrogates in many relevant situations (Wang and Ierapetritou, 
2017). Let 𝐱1, 𝐱2, … , 𝐱𝑆 be the usual known set of sampling points and 𝑓(𝐱1), 𝑓(𝐱2),… , 𝑓(𝐱𝑆) 
the respective function values as for the Kriging surrogate. Mathematically, a RBF surrogate 
can be expressed with the formulation: 
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  𝑠𝑠(𝐱) =  ∑𝜆𝑠𝜙||𝐱 − 𝐱𝑠||2 + 𝐛
T𝐱 + 𝑎
S
s=1
  (2.62) 
 
where || ⋅ ||2 is the Euclidean distance, 𝛌 = [𝜆1, 𝜆2, … , 𝜆𝑆], 𝐛 and 𝑎 are model coefficients that 
can be obtained by solving the system of equations: 
 
   (
𝚽 𝐒
𝐒T 𝟎
) (
𝛌
𝐜
) = (
𝐅
𝟎
) 
  
(2.63) 
with: 
 
   𝐒 = (
𝐱1
𝑇
𝐱2
𝑇
⋮
𝐱𝑆
𝑇
 1
 1
 1
 1
) ; 𝝀 = (
𝜆1
𝜆2
⋮
𝜆𝑆
) ; 𝐜 =
(
 
 
b1
b2
⋮
b𝑄
𝑎 )
 
 
 ;  𝐅 = (
𝑓(𝐱1)
𝑓(𝐱2)
⋮
𝑓(𝐱𝑆)
) .  
  
(2.64) 
The basis function 𝜙 can be chosen depending on the problem considered: common choices are 
linear, cubic and Gaussian basis functions. Additional details on this aspect can be found in the 
work of Forrester and Keane (2009). 
2.5.2 Adaptive sampling 
As explained in Section 2.5, the surrogate can be continuously updated using an adaptive 
sampling strategy until its accuracy reached a pre-defined threshold value. Adaptive sampling 
allows increasing the surrogate accuracy in contrast with the standard space-filling sampling 
algorithms. The basic idea of adaptive sampling for the identification of the feasible region is 
as follows. The new sampling points are chosen based on two criteria: 
1. New points should be chosen near the boundary of the feasible region (local search); 
2. New points should be chosen in unexplored portions of the uncertain parameters 
domain, i.e. where prediction uncertainty is higher (global search). 
The balance of these local and global search criteria should allow a thorough exploration of the 
entire input domain and an accurate identification of the boundary of the feasible region. 
Mathematically, this can be obtained by maximizing at each iteration a modified expected 
improvement (EI) function (Wang and Ierapetritou, 2017): 
 
  max
𝐱
𝐸𝐼𝑓𝑒𝑎𝑠(𝐱) = 𝑠 × 𝜙 (
−?̂?
𝑠
) = 𝑠 × (
1
 √2𝜋
)  𝑒
−0.5(
?̂?2  
𝑠2
)
  
 
(2.65) 
where ?̂? is the surrogate model prediction at 𝐱 and 𝑠 is the standard error of prediction. If a 
Kriging surrogate is used, 𝑠 is simply the square root of the estimated prediction variance. With 
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RBF surrogates, 𝑠 can be estimated through an “error indicator” 1/𝜇 first proposed by Gutmann 
(2001) or with the modified error indicator ” 1/𝜇𝑛 proposed by Wang and Ierapetritou (2017). 
Details on the mathematical formulation of these error indicators can be found in the cited 
references. 
2.5.3 Surrogate accuracy 
Defining the accuracy of the results of a surrogate-based feasibility analysis exercise depend 
on the main purpose of the analysis and there are no general metrics that can be used for any 
situation. If the main purpose of surrogate-based feasibility analysis is that of determining with 
high accuracy the boundary of the feasible region of the system under investigation, there are 
three key requirements that can be used to assess surrogate accuracy: 
1. The portion of feasible region that has been correctly identified by the surrogate is 
sufficiently high; 
2. The portion of infeasible region that has been correctly identified by the surrogate is 
sufficiently high; 
3. The surrogate does not considerably overestimate the actual feasible region of the 
system. 
The third requirement is particularly useful when applied to pharmaceutical processes, as 
discussed in Chapter 5.  
Several metrics have been proposed to assess the surrogate accuracy based on the following 
considerations (Rogers and Ierapetritou, 2015; Adi et al., 2016). However, all these metrics lack 
of meeting at least one of the above criteria. A new set of metrics that allows fulfilling all of 
the above requirements have been recently proposed by Wang and Ierapetritou (2017). A 
detailed discussion and extension of these metrics is reported in Chapter 5. 
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SECTION D: STATE ESTIMATION TECHNIQUES FOR ONLINE MODEL 
CALIBRATION 
 
The main application of state estimators (or state observers) in the process industry is for 
process control, i.e. state estimators are used to continuously update the model-prediction of 
the current state of the system, given the availability of a limited number of online 
measurements from plant sensors. The up-to-date system state is then used to inform pre-
defined control strategies (e.g. model predictive control) on the most suitable control action to  
be implemented at the given point in time. 
Formally, the role of a state estimator can be briefly described as follows. 
Let ℵ be the system under analysis (e.g. single unit/entire manufacturing line of a pilot/full-
scale plant). Let 𝐟(𝐱, 𝐮) be a mathematical model (data-driven and/or semi-empirical and/or 
mechanistic) that is used to describe the behavior of ℵ. The vector 𝐱[1 × 𝑄] collects all the state 
variables of the system, while 𝐮 [1 × 𝑈] collects all the control variables. It is assumed that 
online measurements 𝐳 [1 × 𝑍] are available from plant sensors. These measurements can be 
considered continuous in time 𝐳(𝑡) or, in most practical situations, to be obtained at discrete 
points in time 𝐳𝑘, 𝑘 = 1,2, … , 𝐾. In this Dissertation, the only scenario that will be considered 
is the one with discrete measurements. The following formulation is based on this underlying 
assumption. 
A state estimator can be defined as an observer that allows updating the model-based estimate 
of the system state ?̂?𝑘
− at time 𝑡𝑘, by accounting for the available measurements at the same 
time 𝐲𝑘. The updated system state ?̂?𝑘
+ is expected to give a more accurate representation of the 
system at time 𝑡𝑘 with respect to the original model prediction. 
In the classical formulation, it is assumed that the system behavior can be described by a set of 
ordinary differential equations (ODEs) that can be expressed in a discrete-time form as: 
 
  𝒙𝑘 = 𝑓(𝐱𝑘−1, 𝐮𝑘) + 𝐰𝑘  (2.66) 
 
where 𝐰𝑘 is the process error (sometimes called, in a misleading way, process noise) at time 
𝑡𝑘. The measurements 𝐳𝑘 are related to the system state through a measurement (or observation) 
equation 𝐡(𝐱𝑘), i.e.: 
 
  𝒛𝑘 = 𝐡(𝐱𝑘) + 𝐯𝑘   (2.67) 
 
where 𝐯𝑘 is the measurement noise. Eq. (2.66) and (2.67) represent the starting point for any 
state estimation algorithm. However, it must be noticed that many chemical engineering-related 
systems are typically described by set of high-order algebraic and differential equations (i.e. 
high-index DAEs) whose reduction to pure ODE systems is not always possible. Therefore, the 
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classical formulation (2.66) does not hold true for these systems and, consequently, the 
available state estimation algorithms cannot be applied in a straightforward fashion. An 
extension of state estimation techniques to DAE systems is thoroughly described in Chapter 6. 
In the following, it is assumed that the system state can be described by the discrete-time ODE 
formulation (2.66). The three estimation algorithms that will be briefly discussed are the 
Extended Kalman Filter (EKF), the Unscented Kalman Filter (UKF) and the Ensemble Kalman 
Filter (EnKF). A discussion on other more sophisticated state estimators (e.g. particle filters 
(PFs), Moving Horizon Estimation (MHE) algorithms) can be found in the work of Rao et al., 
2001. 
2.6 State estimation algorithms 
The Kalman filter (Kalman, 1960) has been the precursor of most of the available state 
estimation algorithms and has been widely used in the process industry throughout these last 
decades. Although its original formulation can be applied to systems described by a linear state 
space model in Eq.(2.66), several extensions to nonlinear state space models have been 
proposed in the literature. The most famous extension is the Extended Kalman Filter (EKF), 
that has proved to be successful in several chemical engineering applications (Haseltine and 
Rawlings, 2005). In the last few years, due to the poor performance of the classical EKF 
formulation with highly nonlinear systems, other more sophisticated state estimation algorithms 
have been proposed. Among these, the Unscented  Kalman Filter (UKF) and the Particle Filter 
(PF) have gained particular attention in the last years. Other formulations (EnKF, MHE) are out 
of the scope of this Dissertation. 
2.6.1 Extended Kalman Filter (EKF) 
Based on the discrete-time state space model (2.66) and observation model (2.67), the EKF can 
be formulated at each time step according to a two-step procedure (Jazwinski, 1960): 
1. State prediction from time step 𝑡𝑘−1 to time step 𝑡𝑘; 
2. Measurement update at time step 𝑡𝑘. 
The relevant equations involved in each step can be summarized as follows. 
2.6.1.1 Prediction step 
The process error and the measurement noise are assumed to be white Gaussian noises with 
mean 𝟎 and covariance 𝐐 and 𝐑 respectively, i.e.: 
0. 
  𝐰𝑘 ∼ 𝑵(𝟎,𝐐𝑘); 𝐯𝑘 ∼ 𝑁(𝟎, 𝐑𝑘).  (2.68) 
Moreover, the initial state of the system 𝐱0 is assumed to be normally distributed with initial 
state estimate ?̂?0 and error covariance for the state estimate 𝐏0. In all the following state 
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estimation algorithms, it is implicitly assumed that 𝐐𝑘 and 𝐑𝑘 are tuning parameters to be set 
according to the case study considered. Additional details on the choice of  𝐐𝑘 and 𝐑𝑘 on 
practical application will be thoroughly discussed in Chapter 6. 
The state prediction 𝐱𝑘
− from time 𝑡𝑘−1  to time 𝑡𝑘 is obtained through the set of model equations 
𝐟 according to: 
 
  𝐱𝑘
− = 𝒇(𝐱𝑘−1, 𝐮𝑘)  (2.69) 
 
The error covariance the state prediction at time 𝑡𝑘 𝐏𝑘
− is obtained through the expression: 
 
  𝐏𝑘
− = 𝐅𝑘−1𝐏𝑘−1
+ 𝐅𝑘−1
𝑇 + 𝐐𝑘−1 (2.70) 
 
where 𝐏𝑘−1
+  is the updated error covariance at the previous time 𝑡𝑘−1, and 𝐅𝑘−1 is the following 
Jacobian matrix: 
 
𝐅𝑘−1 = (
𝜕𝐟
𝜕𝐱
)
𝐱= 𝐱𝑘−1
+
.       (2.71) 
 
Eq. (2.70) is in the same form of the famous Riccati equation (Riccati, 1724) for linear systems, 
and it is obtained by a first order linearization of the error estimate on the systems state. It is 
worth noticing that this last aspect is one of the main drawbacks of the EKF, since the error 
covariance is propagated from one time step to another with a linearized propagation equation, 
thus posing a serious limitation when the behavior of the system is highly nonlinear. 
2.6.1.2 Measurement update step 
Given the measurement 𝐲𝑘 at time 𝑡𝑘, the system state prediction 𝐱𝑘
− and error covariance 
prediction 𝐏𝑘
−  are updated accordingly to their new values 𝐱𝑘
+ and 𝐏𝑘
+ according to the 
following filter equations: 
 
𝐱𝑘
+ = 𝐱𝑘
− + 𝐊𝑘[𝐳𝑘 − 𝐡(𝐱𝑘
−)] ;       (2.72) 
  
𝐏𝑘
+ = (𝐈𝑄×𝑄 − 𝐊𝑘)𝐏𝑘
− (2.73) 
 
where 𝐊𝑘 is the Kalman gain and is defined as: 
 
   𝐊𝑘 = 𝐏𝑘
−𝐇𝑘
𝑇(𝐇𝑘𝐏𝑘
−𝐇𝑘
𝑇 + 𝐑𝑘)
−1 , (2.74) 
 
while 𝐈𝑄×𝑄 is the identity matrix, and 𝐇𝑘 is the Jacobian matrix: 
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𝐇𝑘 = (
𝜕𝐡
𝜕𝐱
)
𝐱= 𝐱𝑘
−
.       (2.75) 
 
Eq. (2.72) suggests that the correction to the model-predicted state 𝐱𝑘
− is proportional to the 
measurement residual (𝐲𝑘 − 𝐡(𝐱𝑘
−)), with the proportionality factor given by the Kalman gain 
of Eq. (2.74). 
The combination of Eqs. (2.69)-(2.74) represents the EKF algorithm. From these equations, it 
is possible to notice that one big disadvantage of the EKF is that it requires the computation of 
(possibly) large dimensional Jacobians matrices. The numerical computation of these Jacobians 
can be sometimes very difficult or very expensive, thus limiting the robustness of this filter. 
2.6.2 Unscented Kalman Filter (UKF) 
The underlying assumption behind the EKF formulation is that, if the system state is considered 
as random variable, this variable is assumed to be distributed with a Gaussian PDF. The mean 
of this PDF is propagated from one point in time to another according to Eq. (2.69), while the  
covariance of this PDF is propagated according to the linearized analytical expression (2.70). 
As discussed in section 2.6.1.2, this approach has the notable disadvantage of introducing a 
linearization error and requiring the computation of expensive Jacobians. 
The two key ideas behind the Unscented Kalman filter (UKF) algorithm that aims at 
overcoming the limitations of the EKF are: 
1. It is easier to perform a nonlinear transformation on a single point rather than an 
entire PDF; 
2. it is easy to find a set of deterministic points (called sigma points) whose sample 
PDF approximates the true PDF of the state vector. 
Consistently with these statements, the UKF approximates the true PDF of the state vector with 
a set of deterministic (i.e. pre-allocated) sampling points, and propagates this PDF by 
propagating each of these sampling points through the nonlinear transformation 𝐟(𝐱, 𝐮). This 
procedure has the notable advantage of avoiding linearization errors and the computation of 
Jacobians. Mathematically, the algorithm can be decomposed in the same prediction and update 
step as for the EKF. The relevant equations are discussed below. 
2.6.2.1 Prediction step 
The key problem of the UKF is the choice of the sigma points whose sample PDF is assumed 
to be an approximation of the true PDF of the state vector. The criterion that is adopted is as 
follows.  
Let 𝜂 be the updated PDF of the state vector at time 𝑡𝑘−1, whose mean value and covariance 
are given by 𝐱𝑘−1
+  and 𝐏𝑘−1
+  respectively. In the UKF algorithm, 𝜂 is approximated with the 
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sampling PDF of 2𝐿 (𝐿 is user-defined) sampling points chosen according to the following 
criterion: 
 
  𝐱𝑘−1
− (𝑙)
= 𝒙𝑘−1
+ + (√𝐿𝐏𝑘−1
+ )
(𝑙)
         𝑙 = 1,2, … , 𝐿 (2.76) 
 
  𝐱𝑘−1
− (𝑙)
= 𝒙𝑘−1
+ − (√𝐿𝐏𝑘−1
+ )
(𝑙)
         𝑙 = 𝐿 + 1,… , 2𝐿. (2.77) 
 
The 2𝐿 sigma points are then propagated to time 𝑡𝑘 using the model equations 𝐟(𝐱, 𝐮): 
 
  𝐱𝑘
−(𝑙)
= 𝒇(𝐱𝑘−1
−(𝑙)
, 𝐮𝑘)  (2.78) 
 
and the predicted estimate and covariance of the state vector are computed as: 
 
  𝐱𝑘
− =∑𝑊𝑠
(𝑙)
 𝐱𝑘
−(𝑙)
2𝐿
𝑙=1
 ;  (2.79) 
 
  𝐏𝑘
− =∑ 𝑊𝑐
(𝑙)
 (𝐱𝑘
−(𝑙) − 𝐱𝑘
−)(𝐱𝑘
−(𝑙) − 𝐱𝑘
−)
T
2𝐿
𝑙=1
+ 𝐐𝑘−1 . (2.80) 
 
where the weighting factors are given by: 
 
  𝑊𝒔
(0)
=
𝜆
𝐿 + 𝜆
   (2.81) 
 
  𝑊𝒄
(0)
=
𝜆
𝐿 + 𝜆
+ (1 − 𝛼2 + 𝛽)  (2.82) 
 
  𝑊𝑠
(𝑙)
= 𝑊𝑐
(𝑙)
=
1
2(𝐿 + 𝜆)
 (2.83) 
 
  𝜆 =  𝛼2(𝐿 + 𝜅) − 𝐿. (2.84) 
 
The two parameters 𝛼 and 𝜅 are related to the spread of the sigma points of the sample PDF, 
while 𝛽 is related to the PDF of the state vector. Although these parameters can be considered 
as tuning parameters (Wan et al., 2000), their recommended values are typically 𝛼 = 10−3,
𝜅 = 0, 𝛽 = 2. 
Eq. (2.79) and (2.80) represent the prediction equations for the UKF. 
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2.6.2.2 Measurement update step 
In the update step, 2𝐿 sigma points are chosen using the same approach of the prediction step 
but considering that best state and error estimates are now 𝐱𝑘
− and 𝐏𝑘
−. Eqs (2.76) thorugh (2.84) 
are therefore used to select the new sampling points according to these two best estimates. It is 
worth noticing that the covariance 𝐏𝑘
− is augmented with the model error 𝐐𝑘 as in Eq. (2.80). 
The obtained sampling points 𝐱𝑘
+(𝑙)
 , 𝑙 = 1,2, … , 𝐿 are projected through the measurement 
function 𝐡(𝐱) to generate 2𝐿 “predicted” measurements 𝐲𝑘
(𝑙)
 according to: 
 
  𝐳𝑘
+(𝑙)
= 𝒉(𝐱𝑘
+(𝑙)), 𝑙 = 1,2, . . 2𝐿. (2.85) 
 
The predicted measurements (2.85) are then combined in order to obtain the predicted 
measurement error 𝐳𝑘
+ and the predicted measurement covariance 𝐏𝑧 according to: 
 
  𝐳𝑘
+ =∑𝑊𝑠
(𝑙)
𝐳𝑘
+(𝑙)
2𝐿
𝑙=1
 ; (2.86) 
 
  𝐏𝑧 =∑𝑊𝑐
(𝑙)
(𝐳𝑘
+(𝑙)
− 𝒛𝑘) (𝒛𝑘
+(𝑙) − 𝒛𝑘)
T
2𝐿
𝑙=1
 . (2.87) 
 
The cross state-measurement covariance 𝐏𝑥𝑧 is then computed: 
 
  𝐏𝑥𝑧 =∑𝑊𝑐
(𝑙)
 (𝐱𝑘
+(𝑙) − 𝐱𝑘
−)(𝒛𝑘
+(𝑙) − 𝒛𝑘)
T
2𝐿
𝑙=1
  (2.88) 
 
And its value is used to compute the “Kalman” gain: 
 
  𝐊𝑘 = 𝐏𝑥𝑧 𝐏𝑧
−1. (2.89) 
 
The update equations for the state vector and the error covariance can therefore be written in 
the standard form: 
 
𝐱𝑘
+ = 𝐱𝑘
− + 𝐊𝑘[𝐳𝑘 − 𝐡(𝐱𝑘
−)] ;       (2.90) 
  
𝐏𝑘
+ = 𝐏𝑘
− − 𝐊𝑘𝐏𝑧𝐊𝑘
T. (2.91) 
 
Eqs (2.90) and (2.91) are the final update equations for the UKF. 
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2.6.3 Ensemble Kalman Filter (EnKF) 
The EnKF can be considered as a Bayesian MCMC implementation of the EKF and relies on 
similar concepts with respect to the ones of the UKF, i.e: 
1. It is easier to propagate points rather than distributions through nonlinear operators; 
2. it is easy to approximate the state vector PDF with a sample PDF. 
However, the most important difference between the UnKF and the EnKF is that the sampling 
points are not pre-allocated as in the UKF, but are drawn randomly according to a MCMC 
approach. The EnKF is sometimes erroneously considered as a particular type of particle filter, 
since it relies on the same Bayesian MCMC sampling approach. However, the EnKF is based 
on the assumption that the state vector follows a multivariate Gaussian PDF, while PFs do not 
make any assumption regarding the shape of the PDF of the state vector. For this reason, it is 
more convenient to consider the EnKF as a MCMC implementation of a standard EKF, rather 
than a specific type of particle filter. 
The PDF of the state vector is approximated with 𝑆 randomly-drawn sample points, with 𝑆 (i.e. 
the ensemble size) chosen according to user’s risk adversity (typical values are in the range 
50 ÷ 1000). Therefore, the EnKF is particular suited for systems involving a large number of 
state variables (i.e. 𝑄 ≫ 𝑆), since the computational burden can be significantly reduced. 
The relevant equations for the EnKF can be classified as for the previous filters in a prediction 
and update step. 
2.6.3.1 Prediction step 
A time 𝑡𝑘, the PDF of the state vector is approximated with an ensemble of 𝑆 randomly-drawn 
sampling points : 
   
  𝑋𝑘
− = (𝐱𝑘
−(1), 𝐱𝑘
−(2), … , 𝐱𝑘
−(𝑆)). (2.92) 
 
The ensemble mean ?̅?𝑘
−  is used to approximate the state prediction 𝐱𝑘
− at time 𝑡𝑘 : 
 
  𝐱𝑘
− ∼ ?̅?𝑘
− =
1
𝑆
∑𝐱𝑘
−(𝑠)
𝑆
𝑠=1
. (2.93) 
 
The ensemble error is then computed according to the following expression: 
 
  𝐄𝑘
− = [(𝐱𝑘
−(1) − ?̅?𝑘
−), (𝐱𝑘
−(2) − ?̅?𝑘
−),… , (𝐱𝑘
−(𝑆) − ?̅?𝑘
−)].   (2.94) 
 
The ensemble covariance ?̅?𝑘
− is then computed and used as an approximation of the true 
covariance 𝐏𝑘
− of the state vector: 
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  𝐏𝑘
− ∼ ?̅?𝑘
− =
1
(𝑆 − 1)
 𝐄𝑘
−(𝐄𝑘
−)T. (2.95) 
 
Eqs (2.93) and (2.95) are the prediction step equations for the EnKF. 
2.6.3.2 Measurement update step 
In this step, a set of “perturbed” measurements 𝐳𝑘
𝑠 , 𝑠 = 1,2, … , 𝑆 is first obtained from the 
observed measurements at time 𝑡𝑘, 𝐳𝑘,  according to: 
 
  𝐳𝑘
(𝑠)
= 𝐳𝑘 + 𝐯𝑘
(𝑠)
 ,    𝑠 = 1,2, … 𝑆 (2.96) 
 
where 𝐯𝑘
(𝑠)
 is randomly drawn from the PDF 𝑁(𝟎, 𝐑𝑘).  
Secondly, the measurement ensemble error covariance 𝐄𝑦𝑘
−  is computed according to: 
  
  𝐄𝑦𝑘
− =  [ (𝐳𝑘
−(1) − ?̅?𝑘), (𝐳𝑘
−(2) − ?̅?𝑘), … , (𝐳𝑘
−(𝑆) − ?̅?𝑘)]  (2.97) 
 
where ?̅?𝑘 is the mean of the ensemble (2.96). Given 𝐄𝑦𝑘
− , the “Kalman” gain 𝐊𝑘 can then be 
computed according to: 
 
  𝐊𝑘 =
1
𝑆 − 1
𝐄𝑘
−(𝐄𝑦𝑘
− )
𝑇
 [
1
𝑆 − 1
𝐄𝑦𝑘
− (𝐄𝑦𝑘
− )
𝑇
]
−1
.  (2.98) 
 
Each member of the ensemble (2.92) can therefore be updated according to the standard 
expression: 
 
  𝐱𝑘
+(𝑠)
= 𝐱𝑘
−(𝑠)
+ 𝐊𝑘 (𝐳𝑘
(𝑠) − 𝐡(𝐱𝑘
−(𝑠)))  ,    𝑠 = 1,2, … 𝑆. (2.99) 
 
The updated state vector 𝑥𝑘
+ and the updated covariance 𝑃𝑘
+ can then be computed as the mean 
and the covariance of this updated ensemble (2.99), using the same structural expression of Eq. 
(2.93) and (2.95). 
The updated ensemble is then propagated to the next step in time following the set of model 
equations 𝐟(𝐱, 𝐮). 
2.7 State estimation and online model recalibration 
State estimators are typically deployed in the process industry in order to obtain an accurate 
prediction of the up-to-date state of the system. This information is then typically used as an 
input for the control system implemented in the plant (e.g. MPC). However, state estimators 
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can be used not only to obtain information about the current state of the system, but also to 
perform an online re-calibration of some of the parameters of the original process model (or to 
account for un-modeled disturbances that arise during the actual plant operation). In fact, during 
the normal operation of the plant, the representativeness of the model may change due to slow- 
dynamics physical phenomena that were not considered during the offline model calibration. 
Typical examples are fouling and catalyst deactivation. These phenomena may cause a drift in 
the some of the original model parameters and therefore a process-model mismatch (PMM) on 
the key performance indicators (KPIs) of the system. In order to account for these phenomena, 
state estimators can be deployed to obtain a regular re-calibration of some of the model 
parameters in order to remove the PMM on the KPIs. The choice of which model parameters 
should be re-calibrated online can be done based on previous knowledge or through sensitivity 
analysis on the KPIs. This aspect will be discussed in more detail in Chapter 6. 
Let  ?̃? be the set of model parameters that need to be re-calibrated online. The simplest way to 
perform a re-calibration through a state estimator is to perform a state augmentation procedure 
The state-space model (2.66) is therefore re-written as: 
 
  𝐱𝑘 = 𝑓(𝐱𝑘−1, 𝐮𝑘) + 𝐰𝑘  (2.100) 
 
  ?̃?𝑘 = ?̃?𝑘−1  + 𝐰?̃?  (2.101) 
 
with 𝐰?̃? ∼ 𝑁(𝟎, 𝐑?̃?) “process” error on the model parameters ?̃? (the covariance 𝐑?̃? has to be 
considered as a tuning parameter) and initial conditions: 
 
  𝐱(0) = 𝐱0  (2.102) 
 
  ?̃?(0) = ?̅?  (2.103) 
 
where ?̅? is the vector collecting the nominal values of the parameters. It is worth noticing that 
Eq. (2.101) corresponds to the following set of equations in continuous form: 
 
 
d?̃?
dt
= 𝟎.  (2.104) 
 
The model parameters ?̃? are then used as additional states to be updated based on the 
measurements coming from plant sensors following one of the algorithms described above (or 
other state estimation algorithms that have not been considered in this Dissertation).
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Chapter 3 
 
Uncertainty back-propagation in PLS 
modeling for design space 
determination*
 
 
In this Chapter, a methodology to relate the uncertainty on the output of a PLS model to the 
uncertainty on the model inputs is proposed. Two uncertainty back-propagation models are 
formulated and critically compared and frequentist confidence regions (CRs) for the solution 
of the inversion problem are built. These CRs are used to target an experimental campaign for 
the identification of the design space (DS) of a new pharmaceutical product. 
The proposed methodology is tested on three different case studies, two of which involve 
experimental data taken from the literature, respectively on a roller compactor and on a wet 
granulator. It is shown that both uncertainty back-propagation models are effective in 
bracketing the design space of a new pharmaceutical product, with the second model 
outperforming the first one in terms of shrinkage of the space within which experiments should 
be carried out to identify the DS. 
3.1 Introduction 
The quality-by design (QbD) initiative set forth by the pharmaceutical regulatory agencies 
(such as the U.S. Food and Drug Administration and the European Medicines Agency) 
encourages the adoption of systematic and science-based tools for the development and 
manufacturing of new pharmaceutical products (ICH, 2005). One key aspect of QbD is the 
determination of the design space (DS) of the process that manufactures the product under 
development. The DS is defined as the multidimensional combination and interaction of input 
variables (e.g. material attributes) and process parameters that have been demonstrated to 
                                                          
* Bano G., Facco, P., Meneghetti, N., Bezzo F., Barolo M. (2017) Uncertainty back-propagation in PLS model inversion for 
design space determination in pharmaceutical product development. Comput. Chem. Eng. 101, 110-124. 
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provide assurance of quality (ICH, 2009). Identification of the DS of a new product is important, 
because “working within the DS is not considered as a change” (ICH, 2009), and as such does 
not require any further approval by the regulatory agencies. On the other hand, movements 
outside the DS would normally initiate a regulatory post-approval process. 
Different model-based techniques can be used to assist a DS identification exercise. The use of 
static and dynamic first principles models has been reported (Pantelides et al., 2009; Prpich et 
al., 2010; Close et al., 2014), as well as that of dynamic grey-box state-space models (Kishida 
and Braatz, 2012; Kishida and Braatz, 2014), possibly accounting for the effect of feedback 
control (Harinath et al., 2015), and of data-driven models (MacGregor and Bruwer, 2008; 
Peterson, 2008). Among data-driven models, approaches based on design of experiments 
(Zidan et al., 2007; am Ende et al., 2007; Lepore and Spavins, 2008; Chatzizacharia et al., 
2014) and latent variable models have become particularly popular within the pharmaceutical 
industry community. 
When a new product under development is similar to other products already developed (“old” 
products), historical information on the old products can be very useful for the determination 
of the DS for the new one. Facco et al. (2015) proposed a latent-variable (LV) model inversion 
approach (Jaeckle and MacGregor, 2000) to segment the knowledge space (KS, i.e. the space 
of historical information about the manufacturing of the old products) in such a way as to 
identify a subspace of it (called the experiment space; ES) that brackets the DS of the new 
product. Experiments to identify the DS can be carried out within the ES, with the advantage 
that this space is narrower that the KS, so that product development can be sped up. The model 
inverted by Facco et al. (2015) to determine the ES is a partial least-squares (PLS) regression 
one (Geladi and Kowalski, 1986; Wold et al., 1983). Since this model is subject to prediction 
uncertainty, upon inversion the uncertainty is back-propagated to the input space, hence 
affecting the ES determination as shown by the authors. 
Whereas the methodology proposed by Facco et al. (2015) is effective in segmenting the KS, 
it nevertheless suffers from some limitations. Firstly, the general issue of how the prediction 
uncertainty is allocated between the model inputs and the model parameters is not addressed. 
Secondly, the methodology returns an ES that is defined in the space of latent inputs rather than 
in the space of true inputs. While using the latent space is permitted by the regulatory agencies 
and can be useful to provide a compact graphical representation of a large-dimensional input 
space, this representation may be cumbersome for a practitioner aiming to design a set of 
experiments to be carried out at given values of the true inputs. A third limitation is related to 
the fact that the methodology only refers to products characterized by one equality constraint 
specification. However, in several practical situations, the product quality target may be 
assigned also in terms of inequality constraints. 
In this study, an approach is proposed that can handle the back-propagation of uncertainty from 
the outputs to the inputs of a PLS model, while simultaneously allowing one to overcome the 
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limitations of the methodology proposed by Facco et al. (2015). The proposed approach makes 
it possible to quantify the uncertainty on the PLS inversion solution in terms of both latent 
variables (LVs) and real input variables. Two uncertainty back-propagation models are 
formulated and solved using an optimization framework. Confidence regions (CRs) for the PLS 
inversion solution identifying the ES are built at an assigned significance level for both back-
propagation models. The resulting ES is deemed to include the DS of the product under 
development, thus allowing the developer to tailor his/her experimental campaign on a smaller 
domain of input combinations. The proposed methodology is first tested on a nonlinear 
mathematical example, with quality targets described by equality or inequality constraints. 
Then, five case studies involving experimental data taken from the literature are considered, 
one concerning the roll compaction of an intermediate drug load formulation (Souihi et al., 
2015), and the others concerning different types of granulation processes (Vemavarapu et al. 
,2009; Oka et al., 2015; Facco et al. (2015). 
3.2 Methods 
In the following, the link between the mathematical methods used in this Chapter and their 
application in pharmaceutical development is briefly discussed. 
3.2.1 Projection to latent structures (PLS) for pharmaceutical product 
development 
Let 𝐗 [𝑁 × 𝑉] be a regressor (or input) matrix of 𝑁 training observations and 𝑉 variables, and 
𝐘 [𝑁 × 𝐿] a response (or output) matrix of 𝐿 variables. The regressor matrix collects the 
material attributes and process parameters and settings of the system under investigation, while 
the output matrix collects the product quality attributes of the pharmaceutical product to be 
designed. Data are assumed to be autoscaled, i.e. mean-centered and scaled to unit variance. 
PLS (Geladi and Kowalski, 1986; Wold et al., 1983) is a multivariate regression technique that 
projects the regressor and response variables onto a common latent space (the model space) of 
𝐴 new variables, called LVs, according to the model structure:  
 
𝐗 = 𝐓𝐏T + 𝐄𝐗  (3.1) 
𝐘 = 𝐓𝐐T + 𝐄𝐘  (3.2) 
𝐓 = 𝐗𝐖∗  (3.3) 
where 𝐓 [𝑁 × 𝐴] is the score matrix, 𝐏 [𝑉 × 𝐴] and 𝐐 [𝐿 × 𝐴] are the 𝐗 and 𝐘 loading matrices, 
𝐄𝐗 and 𝐄𝐘 the residuals; 𝐖
∗[𝑉 × 𝐴] is the weight matrix, through which the data in 𝐗 are 
projected onto the latent space to give 𝐓 according to Eq.(3.3).  
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In this study, the algorithm used to build the PLS model is NIPALS (Geladi and Kowalski, 
1986). 
When a new observation 𝐱𝑝[1 × 𝑉] is considered, its projection 𝐭𝑝 on the latent space can be 
obtained according to:  
 
𝐭𝑝 =
𝐱𝑝𝐖
∗
𝐏T𝐖∗
  (3.4) 
and whether or not this new observation conforms to the calibration data set is assessed using 
two indices: 
• the Hotelling’s 𝑇2 statistic (Hotelling, 1931):  
 
𝑇𝑝
2 = ∑
𝑡𝑎,𝑝
2
𝜆𝑎
𝐴
𝑎=1    ,  (3.5) 
where 𝜆𝑎 is the eigenvalue of the matrix 𝐗
T𝐘𝐘T𝐗 related to the 𝑎-th LV. 𝑇𝑝
2 is a measure 
of the Mahalanobis distance of the projection of 𝐱𝑝 from the origin of the latent space, 
and is usually compared to the respective 95% confidence limit:  
 
𝑇𝑙𝑖𝑚
2 =
(𝑁−1)𝐴
𝑁−𝐴
𝐹𝐴,𝑁−𝐴,0.95   ,  (3.6) 
where 𝐹𝐴,𝑁−𝐴,0.95 is the value of the 95% percentile of the 𝐹-distribution with 𝐴 and 
(𝑁 − 𝐴) degrees of freedom; 
 
• the SPE statistic:  
SPE𝑝 = 𝐞𝐱,𝑝
T 𝐞𝐱,𝑝 ,  (3.7) 
which is the Euclidean distance of the projection of 𝐱𝑝 from the latent space. SPE𝑝 is 
usually compared to the 95% confidence limit: 
 
SPE𝑙𝑖𝑚 =
𝜎𝑞
2𝜇
𝜒2𝜇
𝜎𝑞
,0.95
2  , (3.8) 
where 𝜇 and 𝜎𝑞 are the mean and standard deviation of the training set residuals, 
respectively, and 𝜒2𝜇
𝜎𝑞
,0.95
2  is the chi-square distribution with (
2𝜇
𝜎𝑞
) degrees of freedom and 
significance level 0.95. 
 
In the 𝐴-dimensional latent space, 𝑇𝑙𝑖𝑚
2  determines a 95% hyper-ellipsoidal confidence region 
whose semiaxis 𝑠𝑎 alongh the 𝑎-th LV is given by:  
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𝑠𝑎 = √𝜆𝑎𝑇lim   
2    . (3.9) 
This region is called the historical KS, and inference using the PLS model can be made only 
for points that lie inside this region. Therefore, in this study the input combinations, whose 
projections lie outside the KS, are assumed not to be described properly by the model. 
This study deals with univariate responses (𝐿 = 1), so that 𝐘 becomes 𝐲 [𝑁 × 1], 𝐐 becomes 
𝐪 [1 × 𝐴], and 𝐄𝐘 becomes 𝐞𝐲 [𝑁 × 1]. 
Once a PLS model has been calibrated using a training set of regressors and responses according 
to Eqs (3.1)-(3.3), a new response ?̂?𝑝[1 × 𝐿] can be predicted, given a set of input data 
𝐱𝐩[1 × 𝑉]:  
 
𝐲
𝑝
= 𝐭𝐩𝐐
T (3.10) 
 
where 𝐭𝐩 is the score vector of the new observation as given by Eq. (3.4). 
A PLS model can also be used in its inverse form to determine the set 𝐱𝑛𝑒𝑤 of input 
combinations that yields a desired quality target 𝑦𝑑𝑒𝑠 (Jaeckle and MacGregor, 2000). 
From a mathematical point of view, the prediction model (10) is a linear transformation ℒ𝑃𝐿𝑆(𝐭) 
from an A-dimensional space 𝛴𝐓 (the score or latent space) to a 1 dimensional space 𝛴𝑦 (the 
response or y-space), whose kernel can be defined as:  
 
ker(ℒ𝑃𝐿𝑆) = {𝐭 ∈ 𝛴𝐓: ℒPLS(𝐭) = 0}.  (3.11) 
 
 The rank-nullity theorem can be used to determine the dimension of ker(ℒ𝑃𝐿𝑆):  
 
dim(ker(ℒ𝑃𝐿𝑆)) = dim(𝛴𝐓) − dim(Im(ℒ𝑃𝐿𝑆))  (3.12) 
 
from which, since dim(𝛴𝐓) = 𝐴 and (for this study) dim(Im(ℒ𝑃𝐿𝑆)) = 1, it follows that:  
 
dim(ker(ℒ𝑃𝐿𝑆)) = 𝐴 − 1   . (3.13) 
 
If the dimension of the latent space (i.e., 𝐴) is the same as the dimension of the 𝑦-space (i.e., 
1), then dim(ker(ℒ𝑃𝐿𝑆)) = 0 and a unique solution vector 𝐱𝑛𝑒𝑤 for a given target 𝑦𝑑𝑒𝑠 exists:  
 
𝐱𝑛𝑒𝑤 = 𝐭𝑛𝑒𝑤𝐏
T (3.14) 
 
with: 
 
𝐭𝑛𝑒𝑤
T = (𝐐T𝐐)−1𝐐T𝑦𝑑𝑒𝑠
T    . (3.15) 
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Note that 𝐱𝑛𝑒𝑤 (or 𝐭𝑛𝑒𝑤 if working on the score space) can be calculated as in Eq. (3.14) or 
(3.15) for any value of 𝐴. This solution will be denoted as the direct inversion solution to the 
inversion problem. 
On the other hand, if the dimension of the latent space is greater than the dimension of the 𝑦-
space (i.e. 𝐴 > 1), then dim(ker(ℒ𝑃𝐿𝑆)) > 1 and multiple solutions of the model inversion 
problem exist. The set 𝑊of possible solutions on the model space that guarantees the desired 
response 𝑦𝑑𝑒𝑠 can be described as:  
 
𝑊 = {(𝐭𝑛𝑒𝑤 + 𝐭), 𝐭 ∈ ker(ℒ𝑝𝑙𝑠)}  (3.16) 
 
and is called null space (Jaeckle and MacGregor, 1998). The null space can be computed 
analytically by determining the kernel of the 𝑦-loadings matrix 𝐐. 
If the PLS model is not affected by uncertainty and the quality target is described by equality 
constraints only, the null space can be interpreted as the mathematical description of the DS14. 
However, since any model is affected by uncertainty, also the null space determined by model 
inversion is affected by uncertainty. By back-propagating the model prediction uncertainty onto 
the model space, Facco et al. (2015) determined a subspace of it (the ES) that most likely 
brackets the DS.  
3.2.2 Formulation of prediction uncertainty 
Consider the PLS prediction model. Given a new observation 𝐱𝑝, the expected value of the 
response variable 𝑦
𝑝
 can be computed using (3.10). If the PLS model were not affected by 
uncertainty, 𝑦
𝑝
 would be equal to the true value of the response 𝑦𝑝, i.e. to the value of the 
response variable that would be obtained in the real process using the set of inputs defined by 
𝐱𝑝. However, since the model is affected by uncertainty, a mismatch between 𝑦𝑝 and 
𝑦𝑝 is observed. Three different sources of uncertainty
15 can affect the prediction of a new 
observation: 
1. measurement uncertainty in both the regressor matrix (𝐗) and the response matrix (𝐘) used 
to calibrate the PLS model (Reis et al., 2005); 
2. uncertainty in the estimated model regression parameters (Faber and Kowalski, 1997); 
3. uncertainty due to the unmodeled part of 𝑦𝑝. Assuming that the residual 𝑒𝑝 = 𝑦𝑝 − 𝑦𝑝 
belongs to a normal distribution with zero mean and variance 𝜎2, the contribution to the 
overall prediction uncertainty given by this term is 𝜎2. 
                                                          
14 Strictly speaking, when the PLS model is not affected by uncertainty and the quality target is described by one equality 
constraint, the null space represents the projection of the DS onto the PLS model space. 
15 It is assumed that the variance of the residuals and the variance of the measurement errors in the input/output data are 
independent of the sample considered. 
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In this study, the prediction uncertainty is estimated according to the work of Faber and 
Kowalski (1997), which accounts for the second and third contributions mentioned above. 
An estimation of the variance var(𝑦?^?) of the prediction error is calculated using the relationship 
(Faber and Kowalski 1997):  
 
 𝑠2 =  var(𝑦
𝑝
) = 𝜎2(1 + ℎ𝑝)   , (3.17) 
where ℎ𝑝 is the leverage of the new observation:  
 
ℎ𝑝 =
𝐭𝑝 𝚲
−1 𝐭𝑝
T
𝑁−1
   . (3.18) 
The variance 𝜎2 of the residuals is estimated as the square of standard error of calibration (SEC):  
 
𝜎2 ≅ SEC2 =
∑ (𝑦𝑛−?^?𝑛)
2𝑁
𝑛=1
𝑁−𝑑𝑓
   , (3.19) 
where 𝑦𝑛 and 𝑦𝑛 refer to the 𝑛-th calibration sample, and 𝑑𝑓 is the number of degrees of 
freedom of the model. In this study, 𝑑𝑓 has been set equal to 𝐴, although different approaches 
to estimate 𝑑𝑓 exist (Voet, 1999). 
The derivation of Eq. (3.17) involves a zeroth-order local linearization of the PLS estimator, 
and holds true under some assumptions (Vanlaer et al., 2009). Eq. (3.17) is made up of two 
contributions: σ2 is the contribution to the prediction uncertainty due to the unmodeled part of 
𝑦
𝑝
, while 𝜎2ℎ𝑝 accounts for the uncertainty in the model parameters. The 100(1 − 𝛼)% 
confidence interval (CI) on y^
p
 can be expressed as: 
 
CI = 𝑦
𝑛
± 𝑠 𝑡𝛼
2
,𝑁−𝑑𝑓 , (3.20) 
where 𝛼 is the significance level for the confidence interval. 
3.2.3 Back-propagation of uncertainty in PLS model inversion 
When a PLS model is used in its direct form (i.e., to predict a response from a set of inputs) a 
100(1 − 𝛼)% CI can be built for the prediction using the procedure outlined in section 3.2.2. 
The wider the CI at a given significance level, the larger the uncertainty on the output 
prediction. On the other hand, when a PLS model is used in its inverse form (i.e., to predict a 
new set 𝐱𝑛𝑒𝑤 of inputs that yield a desired target 𝑦𝑑𝑒𝑠), the prediction uncertainty is back-
propagated to the calculated inputs. If 𝐴 > 1, a null space exists, and the uncertainty in null-
space determination must be accounted for.  
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A systematic methodology is now developed to back-propagate the 𝑦-space uncertainty to the 
latent space of input variables first, and to the real input space subsequently. 
Consider the prediction model (3.10). By taking the variance/covariance of both sides it 
follows:  
 
cov(𝐲
𝑝
) = cov(𝐭𝑝𝐐
T)   . (3.21) 
If model (3.17) is used to estimate the prediction uncertainty, then it follows that: 
 
SEC2(1 + ℎ𝑝) = cov(𝐭𝑝𝐐
T)   . (3.22) 
The right-hand side of Eq. (3.22) is difficult to estimate, since both the scores and the loadings 
are affected by uncertainty and depend on each other. However, two limiting situations can be 
considered (Høy et al., 1998): 
 
1. the loadings are not affected by error. If this is the case, Eq. (3.22) simplifies to:  
 
SEC2(1 + ℎ𝑝) = 𝐐
Tcov(𝐭𝑝)𝐐   . (3.23) 
In this scenario, only the scores are assumed to contribute to the overall prediction 
uncertainty. In other terms, the overall prediction uncertainty on the 𝑦-space is entirely 
back-propagated to the score space of the inputs; 
 
2. the scores are not affected by error. In this case,  Eq. (3.22) simplifies as follows:  
SEC2(1 + ℎ𝑝) = 𝐭𝑝
Tcov(𝐐T)𝐭𝑝   . (3.24) 
In this scenario, the overall prediction uncertainty on the 𝑦-space is fully back-propagated 
to the loadings of the model, i.e. it is assumed that the null space can be exactly located in 
the latent space when the PLS model is inverted, and the only source of uncertainty is due 
to the calibration step. 
 
Following the idea implemented in the popular chemometrics software The UnscramblerTM 
(Camo ® Inc., Oslo, Norway), the right-hand terms of (3.23) and (3.24) can be averaged using 
the correction factor proposed by De Vries and Ter Braak (1995) to obtain:  
 
𝑆𝐸𝐶2(1 + ℎ𝑝) = (1 −
𝐴+1
𝑁
) [𝐭𝑝
Tcov(𝐐T)𝐭𝑝⏟        

+ 𝐐Tcov(𝐭)𝐐⏟      

]   . (3.25) 
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Eq. (3.25) is empirical and has no theoretical foundation (Faber and Kowalski, 1996), but is 
nevertheless widely used (Andersson et al., 1999; Cahyadi et al., 2010). By using this approach, 
the overall prediction uncertainty is obtained as the average of the contribution due to the 
loadings uncertainty ( in Eq. (3.25)) and the contribution due to the scores uncertainty ( in 
Eq. (3.25)). In other terms, the prediction uncertainty is simultaneously determined by the 
uncertainty on the model “parameters” (i.e, the loadings) and the uncertainty on the location of 
the scores on the score space. It is reasonable to think that, when PLS model inversion is 
performed, only a fraction of the overall prediction uncertainty is back-propagated to the scores 
(i.e., to the location of the null space in the score space), whereas the remaining fraction is 
assigned to the loadings (i.e., to uncertainty on the model parameters). 
Contribution  can be estimated as in De Vries and Ter Braak (1995):  
 
𝐭𝑝
Tcov(𝐐T)𝐭𝑝 = 𝑉𝑦,𝑣𝑎𝑙ℎ𝑝   , (3.26) 
where 𝑉𝑦,𝑣𝑎𝑙 is the residual variance of the response variable in the validation dataset. By 
substituting (3.26) into (3.25), it follows:  
 
𝑆𝐸𝐶2(1 + ℎ𝑝) = (1 −
𝐴+1
𝑁
) [𝑉𝑦,𝑣𝑎𝑙ℎ𝑝⏟    

+ 𝐐Tcov(𝒕𝑝)𝐐⏟        

] .  (3.27) 
Eq. (3.27) shows that the contribution  of the loadings to the overall prediction uncertainty is 
proportional to the leverage of the new observation. This is reasonable, since the uncertainty 
due to the non-representativeness of the model increases when the distance of the validation 
dataset projection from the origin on the score space increases. 
The weighting factor 𝑉𝑦,𝑣𝑎𝑙 in (3.27) is strongly dependent on the validation dataset available 
and significantly affects contribution  to the overall prediction uncertainty. To avoid this 
dependency on the validation dataset available, a modification to Eq. (3.27) is proposed. 
Assume that the right-hand term of (3.26) can be re-written as 𝐶ℎ𝑝, with 𝐶 being a weighting 
factor to be tuned. Following this assumption, we will first investigate how the contribution of 
the scores to the overall prediction uncertainty depends on the leverage of the observation ℎ𝑝. 
Then, we will identify the threshold value of ℎ𝑝 that causes the contribution of the scores to 
vanish. We will finally determine the value of the weighting factor 𝐶 that corresponds to this 
limiting situation. 
By substituting 𝑉𝑦,𝑣𝑎𝑙 with 𝐶 into (3.27) and rearranging, the following equation can be 
obtained:  
 
𝐐Tcov(𝐭𝑝)𝐐 =
SEC2
1−
𝐴+1
𝑁
+ [
SEC2−𝐶(1−
𝐴+1
𝑁
)
1−
𝐴+1
𝑁
] ℎ𝑝   . (3.28) 
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The left-hand term of (3.28) is the contribution to the prediction uncertainty related to the 
scores: if ℎ𝑝 increases, this contribution decreases since the dominant contribution becomes the 
one related to the non-representativeness of the model (i.e., related to the loadings). In 
particular, the contribution of the scores vanishes (i.e, all the uncertainty on the prediction is 
due to the non-representativeness of the model) when:  
 
ℎ𝑝 =
SEC2
𝐶(1−
𝐴+1
𝑁
)−SEC2
= ℎ∗   . (3.29) 
In other words, for those points on the score space that satisfy the condition ℎ𝑝 < ℎ
∗, both the 
scores and the loadings contribute to the overall prediction uncertainty; in this case, the 
contribution of the scores (loadings) is greater (smaller) for low (high) values of ℎ𝑝. When ℎ𝑝 ≥
 ℎ∗, the model is considered as non-representative, and the inversion should not be performed. 
To determine a value for the weighting factor 𝐶, recall that a likely region of the score space 
within which the model is considered representative is the KS (section 2.1). Then, if C is 
selected in such a way that ℎ∗ corresponds to the 95% confidence limit of the Hotelling’s 𝑇2 
(i.e ℎ∗ = ℎ𝑙𝑖𝑚) then the points outside the KS will only be affected by uncertainty due to the 
model non-representativeness. It follows that: 
 
  𝐐Tcov(𝐭) 𝐐 =  
SEC2
1−
𝐴+1
𝑁
+ [
SEC2−𝐶(1−
𝐴+1
𝑁
)
1−
A+1
N
] ℎ𝑝    if   ℎ𝑝 < ℎ𝑙𝑖𝑚 
 
(3.30) 
  𝐐Tcov(𝐭) 𝐐 =  0                                              if   ℎ𝑝 ≥ ℎ𝑙𝑖𝑚 (3.31) 
 
The weighting factor 𝐶 can then be tuned to have ℎ∗ = ℎ𝑙𝑖𝑚:  
 
𝐶 =
SEC2(1 + ℎ𝑙𝑖𝑚)
(1 − 
𝐴+1
𝑁
)ℎ𝑙𝑖𝑚
=
SEC2[1 + (
𝑇𝑙𝑖𝑚
2
𝑁−1
 + 
1
𝑁
)]
(1 − 
𝐴+1
𝑁
)(
𝑇𝑙𝑖𝑚
2
𝑁−1
 + 
1
𝑁
)
    . (3.32) 
The resulting uncertainty back-propagation model is then given by:  
 
SEC2(1 + ℎ𝑝) = (1 −
𝐴+1
𝑁
) [𝐶ℎ𝑝 + 𝐐
Tcov(𝐭𝑝)𝐐]   , (3.33) 
with 𝐶 defined as in (3.32) . 
To summarize, when a PLS model is inverted, the back-propagation of uncertainty can be done: 
• model #1: according to (3.23), if only the contribution of the scores is considered. This is 
a conservative situation, since all the prediction uncertainty is back-propagated to the 
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calculated solution of the inversion problem (i.e., to the location of the null space on the 
score space, as in Facco et al., 2015); 
• model #2: according to (3.33), in the more general situation where the contributions of 
both the scores and the loadings to the overall prediction uncertainty are accounted for. 
Clearly, Eq. (3.33) is an empirical back-propagation formula whose effectiveness must be 
evaluated. 
3.3 Uncertainty back-propagation and experiment space determination 
The problem of developing a new product with a desired quality target 𝑦𝑑𝑒𝑠 is addressed. 
Consider a PLS model built on a historical dataset of input combinations 𝐗 that yield products 
whose quality is summarized by 𝐲. If the model is used for prediction, the response  ?̂?𝑝 that 
corresponds to the desired input specifications 𝐱𝑝 can be computed according to the steps 
bracketed by the dashed black box of Fig. 3.1. On the other hand, when the model is inverted, 
the set of regressors that, according to the model, corresponds to the desired quality target 𝑦𝑑𝑒𝑠 
(that can be expressed in terms of equality or inequality constraints) can be determined. 
If the number of latent variables is greater than one, the set of inputs (on the score space) that 
matches  𝑦𝑑𝑒𝑠 is the vector space 𝑊 of Eq. (3.16). As described in 3.2.3, the prediction of 𝑊 is 
affected by different sources of uncertainty. To quantify this uncertainty, we use the systematic 
methodology centered on the back-propagation formulas (3.23) and (3.32)-(3.33). The rationale 
behind the proposed methodology is shown in Fig. 3.1, blue dashed box. The step-by-step 
procedure is presented in the next section. 
3.3.1 Proposed methodology 
In this section, the methodology will be illustrated in detail only for problems where an equality 
constraint is set on the product quality (𝑦 = 𝑦𝑑𝑒𝑠); the extension to inequality constraints is 
straightforward and will be discussed in section 3.5.2. Given the calibration dataset [𝐗; 𝐲], a 
PLS model with 𝐴 LVs relating 𝐗 to y is built. 𝐴 can be chosen according to the eigenvalue-
greater-than-one rule (Kaiser, 1960), in such a way as to explain a significant fraction of the 
variance of both 𝐲 and 𝐗 (to have good reliability also in model inversion). The projections of 
the calibration samples onto the score plot and the KS boundary (blue ellipse) are shown in Fig. 
3.2a for 𝐴 = 2. 
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Figure 3.1. Schematic of uncertainty characterization in PLS modelling. When a PLS model 
is used for prediction (i.e., to predict the product quality given a set of raw material 
properties and process parameters), the steps are those bracketed by the dashed black box. 
When the model is inverted (i.e., it is used to determine the combinations of raw material 
properties and process parameters that give rise to a desired product quality), the steps are 
those bracketed by the dashed red box. The rationale behind the back-propagation of 
uncertainty in PLS model inversion according to the proposed methodology involves the 
steps bracketed by the dashed blue box. 
1. A model to estimate the variance on the model prediction is chosen. The model considered 
in this study is given by (3.17). 
2. A new product of quality 𝑦𝑑𝑒𝑠 is desired. The direct inversion solution 𝐭𝑛𝑒𝑤 on the score 
space corresponding to the given quality target 𝑦𝑑𝑒𝑠 is calculated according to (3.15). If 
𝐴 > 1, a null space of dimension 𝐴 − 1 exists and can be computed as in section 3.2.2. If 
𝐴 = 2, the graphical representation of the null space in the score plot is a straight line 
passing through 𝐭𝑛𝑒𝑤, as shown in Fig. 3.2b. 
3. The null space is discretized at 𝐿 score points (with 𝐿 sufficiently large). The coordinates 
of the l-th score point along the null space are (𝑡1,𝑙, 𝑡2,𝑙, … , 𝑡𝐴,𝑙). For each of these points, 
the associated covariance matrix: 
cov(𝐭l) =  
(
 
 
 
𝜎𝑡1,𝑙
2   cov(𝑡1,𝑙 , 𝑡2,𝑙) ⋯    cov(𝑡1,𝑙, 𝑡𝐴,𝑙) 
   cov(𝑡2,𝑙, 𝑡1,𝑙)           𝜎𝑡2,𝑙
2  ⋯           ⋮
⋮             ⋮            ⋱           ⋮        
cov(𝑡𝐴,𝑙 , 𝑡1,𝑙)           ⋯   ⋯         𝜎𝑡𝐴,𝑙
2
    )
 
 
 
 (3.34) 
 
is calculated using one of the following two options: 
  
Uncertainty back-propagation in PLS modeling for design space determination 97 
 
________________________________________________________ 
© 2018 Gabriele Bano, University of Padova (Italy) 
 
 model #1: if it is assumed that the prediction uncertainty is back-propagated to the 
scores only, the uncertainty back-propagation formula is given by (3.23). Eq. (3.23) 
is solved as a constrained optimization problem:  
cov(𝐭𝑙) = min
cov(𝐭)
[𝐐Tcov(𝐭)𝐐 − SEC2(1 + ℎ𝑝)][𝐐
Tcov(𝐭)𝐐 − SEC2(1 + ℎ𝑝)]
T
(3.35) 
         s.t  𝜎𝑡𝑖,𝑙
2 > 0 ,                                         𝑖 = 1,… , 𝐴                                             (3.36)  
cov(𝑡𝑖,𝑙, 𝑡𝑗,𝑙) = cov (𝑡𝑗,𝑙, 𝑡𝑖,𝑙) = 0 ,      𝑖, 𝑗 = 1,… , 𝐴                                            (3.37)                                                             
  
Constraint (3.37) reflects the fact the scores are uncorrelated, because the NIPALS 
algorithm produces orthogonal 𝐗-scores.  
 
 Model #2: the uncertainty back-propagation formula is given by (33), meaning that 
the uncertainty on the prediction is propagated on both the loadings and the scores. 
Eq. (33) is solved as a constrained optimization:  
 
cov(𝐭𝑙) = min
cov(𝐭)
{(1 −
𝐴+1
𝑁
) [𝐶ℎ𝑝 + 𝐐
T cov(𝐭)𝐐] − SEC2(1 + ℎ𝑝)} {(1 −
𝐴+1
𝑁
) [𝐶ℎ𝑝 +
𝐐T cov(𝐭)𝐐] − SEC2(1 + ℎ𝑝)}
T
                                                      (3.38) 
  
                    s.t 
                     𝜎𝑡𝑖,𝑙
2 > 0 ,                                                     𝑖 = 1,… , 𝐴  (3.39) 
cov(𝑡𝑖,𝑙 , 𝑡𝑗,𝑙) = cov (𝑡𝑗,𝑙 , 𝑡𝑖,𝑙) = 0 ,            𝑖, 𝑗 = 1,… , 𝐴.                      (3.40) 
4. The set of 𝐿 points 𝐭𝑙 along the null space and their associated covariance matrices 
cov (𝐭𝑙) can be used to completely identify a restricted portion of the KS that is 
expected to bracket the DS projection of the process. To this purpose, for each point 
a (1 − 𝛼)%-confidence hyper-ellipsoid is built by joining the points of coordinates 
𝐭[1 × 𝐴] that satisfy the equation (Tomba et al., 2012):  
 
(𝐭 − 𝐭𝑙)cov(𝐭𝑙)(𝐭 − 𝐭𝑙)
T =
𝐴(𝑁2−1)
𝑁(𝑁−𝐴)
𝐹𝐴,𝑁−𝐴,𝛼   , (3.41) 
where 𝐹𝐴,𝑁−𝐴,𝛼 is the value corresponding to the 𝛼-th% percentile of the 𝐹 
distribution with 𝐴 and (𝑁 − 𝐴) degrees of freedom. An example of projection on 
the score space of the 95% confidence hyper-ellipsoids on the first two LVs is 
shown in Fig. 3.2c (model #1) and Fig. 3.2e (model #2). 
5. The confidence limits of the null space can be built by calculating the envelope of 
the 𝐿 (1 − 𝛼)(%)-confidence hyper-ellipsoids determined in the previous step. The 
region bracketed by this envelope is the experiment space, namely a subspace of the 
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KS within which the DS projection of the process is likely to lie with a confidence 
of at least (1 − 𝛼)(%). A graphical interpretation is shown in Fig. 2d for model #1 
and in Fig. 3.2f for model #1 and model #2 altogether. When the scores are assumed 
not to be affected by uncertainty, the null space can be exactly located on the score 
space (black solid straight line). On the opposite, when the prediction uncertainty is 
entirely back-propagated to the scores, the ES is the one bracketed by the divergent 
red solid lines (model #1). The average situation, according to model #2, is 
represented by the black dashed lines: the uncertainty in the location of the null 
space decreases as far as the leverage of the 𝑙-th point increases, and it becomes zero 
outside the KS (where the model is not representative). 
6. Each point 𝐭𝑙 of the null space is projected onto the multivariate 𝑉-dimensional real 
input space to give 𝐱𝑙 according to: 
  
𝐱𝑙 = 𝐭𝑙𝐏
T   .                                                                                                   (3.42) 
 
The uncertainty related to this 𝑙-th point of the null space, described by its 
covariance cov(𝐭𝑙), is back-propagated to the real input space using the back-
propagation formula: 
 
cov(𝐭𝑙) = 𝐖
∗Tcov(𝐱𝑙)𝐖
∗   .                                                                            (3.43) 
 
Eq. (3.43) is derived from (3.3) by assuming that the model weights are not affected 
by uncertainty. This is a conservative assumption since all the uncertainty related to 
𝐭𝑙 is back-propagated to the multidimensional input space. Eq. (3.43) is solved for 
cov(𝐱𝑙) using an optimization framework and enforcing cov(𝐱𝑙) to be positive 
definite. 
 
7. The multidimensional confidence region for the projected null space is built on the 
real input space following the same procedure as for steps #5 and #6, by substituting 
𝐭𝑙 with 𝐱𝑙 and cov(𝐭𝑙) with cov(𝐱𝑙). This generates a 𝑉-dimensional space of 
combinations of input variables that brackets the real DS with at least (1 − 𝛼)(%) 
confidence. To obtain a graphical interpretation of this multidimensional space, its 
projections onto two-dimensional plots of pairs of input variables can be plotted. It 
is worth remembering that this multidimensional space is completely defined by the 
set of points 𝐱𝑙 and their associated covariance matrices cov(𝐱𝑙). 
 
With respect to the methodology proposed by Facco et al. (2015), the following improvements 
are obtained: 
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 The proposed methodology is completely analytical and allows quantifying the uncertainty 
on  the  inversion solution in terms of point estimates and corresponding covariance 
matrices. 
 As in Facco et al. (2015), the solution of the PLS model inversion problem and the 
estimation of solution uncertainty can be conveniently expressed in terms of LVs instead 
of true input variables, thus obtaining a strong reduction of the problem dimension. 
However, from a practical point of view, the approach by Facco et al. (2015) requires one 
to transform the result of the PLS inversion problem and its uncertainty in terms of real 
input variables. The proposed methodology allows one to project the solution back in the 
real input space together with the analytical quantification of its uncertainty. 
 The proposed methodology is general and can also be used when multivariate quality 
targets are assigned, provided that a reliable model to estimate the uncertainty on the 
prediction of the multivariate response is available. The development of such models is 
still an open research area and this study may direct further investigation on this topic. 
The methodology has been tested on three case studies. All the algorithms were implemented 
in MATLAB v. 2015b using a sequential quadratic programming optimization algorithm. 
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(a)                                                                                  (b) 
 
(c)                                                                                     (d) 
 
                                                                   (e)                                                                                      (f) 
Figure 3.2.  (a) Projection of the calibration samples onto the score space and KS boundary. 
(b) Direct inversion solution (triangle) and null space across it (solid line). (c) and (e): 95% 
confidence ellipses along the null space for model #1 and #2. (d) and (f ): envelope of the 
confidence ellipses obtained with model #1 (red lines) and model #2(dashed lines). 
  
Uncertainty back-propagation in PLS modeling for design space determination 101 
 
________________________________________________________ 
© 2018 Gabriele Bano, University of Padova (Italy) 
 
3.4 Case studies 
3.4.1 Case study #1: mathematical example 
The first illustrative example is the nonlinear mathematical example presented by Facco et al. 
(2015). The calibration dataset is made of 15 observations of five input variables 𝐗 [15 × 5] =
[𝐱1, 𝐱2, 𝐱3, 𝐱4, 𝐱5] and one response variable 𝐲[15 × 1]. Two (𝐱1, 𝐱2) of the five input variables 
are independent and are generated as normal random Gaussian distributions with mean and 
standard deviation as in Tab. 1. The other three (𝐱3, 𝐱4, 𝐱5) dependent input variables are related 
to 𝐱1 and 𝐱2 for any observation 𝑖 according to:  
𝑥𝑖,3 = 𝑥𝑖,1
2   (3.45) 
𝑥𝑖,4 = 𝑥𝑖,2
2   (3.46) 
𝑥𝑖,5 = 𝑥𝑖,1𝑥𝑖,2   . (3.47) 
The response dataset is obtained using the model:  
𝐲 = 𝑘0 + 𝑘1𝐱1 + 𝑘2𝐱2 + 𝑘3𝐱3 + 𝑘4𝐱4 + 𝑘5𝐱5                                                    (3.48) 
with [𝑘0, 𝑘1, 𝑘2, 𝑘3, 𝑘4, 𝑘5] = [−21.0,4.3,0.022,−0.0064,1.1, −0.12]. 
Table 3.1. Case study #1: characterization of the input/output data. 
Variable Mean Standard deviation 
Inputs 
𝐱𝟏 
 
41.73 
 
16.07 
𝐱𝟐 11.13 2.97 
𝐱3 1999.15 1408.07 
𝐱𝟒 132.63 66.93 
𝐱𝟓 464.85 227.38 
Response   
𝐲 235.99 71.35 
3.4.2 Case study #2: roll compaction of an intermediate drug load 
formulation 
This case study concerns a roll compaction of an intermediate drug load formulation with the 
following composition: 15% paracetamol, 55.3% mannitol, 23.7% microcrystalline cellulose, 
4% croscarmellose and 2% sodium stearyl fumarate. Experimental data for this case study have 
been provided by Souihi et al. (2015) and refer to two different equipment configurations 
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(vertically- and horizontally- fed roll compactor). Details on the process and on the formulation 
can be found in the cited reference. 
The historical data set includes 34 observations (11 related to the vertically-fed roll 
configuration, 23 to the horizontally-fed roll configuration) of 4 input variables (roll force, roll 
width, roll diameter, dimensionless ratio of gap to roll diameter 𝐺𝐷) and one quality response 
variable (ribbon porosity)16. A summary of this dataset is reported in Table 3.2. The input 
variables are collected in the calibration regressor matrix 𝐗 [34 × 4], and the observations of 
the ribbon porosity are collected in the response vector 𝐲 [34 × 1]. 
Table 3.2. Case study #2: list of the input and response variables (data from 
Souihi et al., 2015). 
 ID Variable name Units Symbol 
Inputs    
1 Roll force [kN/cm] 𝑝𝑟𝑜𝑙𝑙  
2 Roll width [mm] 𝑠𝑟𝑜𝑙𝑙  
3 Roll diameter [mm] 𝐷𝑟𝑜𝑙𝑙  
4 Ratio of the gap to roll diameter [-] 𝐺𝐷 
Response    
R1 Ribbon porosity [%] 𝑃 
 
Nine external validation samples are used in the work of Souihi et al. (2015) to validate the 
model predictions. These validation samples have been used also in this study to test the 
effectiveness of the proposed methodology. 
3.4.3 Case study #3: high-shear wet granulation of a pharmaceutical 
blend 
Experimental data for this case study are taken from Oka et al. (2015) and are based on a design 
of experiment approach (full factorial, 3 × 3 × 3). The high-shear wet granulation of a two-
component (API + excipient) pharmaceutical blend is considered. The effect of three process 
parameters (impeller speed, liquid to solid ratio (𝐿/𝑆), wet massing time) on the median particle 
size 𝑑50 is considered. Twenty-seven observations of the input process parameters and of the 
corresponding 𝑑50 are available. This historical dataset is split into 20 randomly-chosen 
calibration samples and 7 validation samples. The input calibration matrix 𝐗 [20 × 3] collects 
the 20 calibration observations of the three process inputs, whereas the response calibration 
matrix 𝐲 [20 × 1] collects the respective 20 observations for the median particle size. A list of 
the input and output variables considered in this case study is given in Table 3.3. 
                                                          
16 In the work of Souihi et al. (2015), other 4 input variables (roll gap, roll speed, screw speed, ratio between the screw speed 
and the roll speed) are considered. However, since they have little effect on ribbon porosity (see Fig. 3.7a of the cited 
reference for more detail) they have not been included into the calibration dataset. 
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Table 3.3. Case study #3: list of the input and response variables (data from 
Oka et al, 2015). 
ID Variable name Units Symbol 
Inputs 
1 
 
Liquid to solid ratio 
 
[-] 
 
𝐿/𝑆 
2 Impeller speed [rpm] 𝑣𝑖𝑚𝑝 
3 Wet massing time [min] 𝑡𝑤𝑒𝑡 
Response    
R1 Median particle size [𝜇𝑚] 𝑑50 
 
3.4.4 Case study #4: dry granulation by roller compaction 
Historical data for this case study were generated by Facco et al. (2015) using the modelling 
environment of gSOLIDS® (Process Systems Enterprise Ltd, 201417) based on the model of 
Johanson (1965). Eight input variables (compressibility factor, roller diameter, roller width, 
roller speed, pressure force, friction angle between solid granulate and roller compactor, 
effective friction angle and springback factor) and one response variable (intravoid fraction of 
the solids out of the compactor) are considered. Details on the characterization of the 
input/output data for the calibration data set are reported in the cited reference.  
 
3.4.5 Case study #5: wet granulation  
This case study deals with the design of a powder product by means of high-shear wet 
granulation. The historical data set is taken from the experimental work of Vemavarapu et al. 
(2009) and is composed by 25 observations of seven input material properties (H2O solubility, 
contact angle, H2O holding capacity, Sauter mean diameter, distribution span, surface area, pore 
volume) and one response variable (fraction of granules larger than 1,4 mm). Additional details 
on the historical data set can be found in the cited reference. 
3.5 Results for case study #1 
3.5.1 Quality target described by an equality constraint 
The problem of determining the set of process inputs that yields a product with 𝑦𝑑𝑒𝑠 = 300 is 
addressed. First, a PLS model using the calibration datasets 𝐗 and 𝐲 as described in section 
3.4.1 is built. The diagnostics of such a model is presented in Table 3.4. 
                                                          
17 Free software license provided by Process Systems Enterprise Ltd is gratefully acknowledged.  
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Table 3.4. Case study #1. Diagnostics of the PLS model. 
LV # 𝑅𝑋
2(%) 𝑅𝑋,𝑐𝑢𝑚
2 (%) 𝑅𝑦
2 (%) 𝑅𝑦,𝑐𝑢𝑚
2  (%)  
1 60.59 60.59 96.63 96.63  
2 38.47 99.06 1.48 98.11  
3 0.67 99.73 0.94 99.05  
4 0.19 99.92 0.71 99.77  
5 0.08 100.00 0.23 100.00  
 
Two LVs (𝐴 = 2) are chosen, explaining more than 99% of the total variability of 𝐗 and more 
than 98% of the total variability of 𝐲. Since 𝐴 > dim (𝐲) = 1, a 1-dimensional null space exists. 
The DS corresponding to 𝑦𝑑𝑒𝑠 is calculated from model (3.48) and then projected onto the score 
space (green line in Figs. 3.3a and 3.4a) and on the real input space (green line in Figs. 3.3b 
and 3.4b). Notice that, since the number of independent input variables is 2, also the dimension 
of the true input space is 2. The DS of the process is a curve because model (3.48) is nonlinear. 
The input combinations that project outside the KS (which is bracketed by the blue contours 
both in Figure 3.3 and in Figure 3.4) cannot be represented by the PLS model because outside 
the KS the model cannot be assumed to be fully representative. 
 
(a)                                                                  (b) 
Figure 3.3. Case study #1, uncertainty back-propagation model #1: confidence limits of the 
null space and projection of the DS (a) onto the score space and (b) onto the real input space. 
One issue deserves attention. The DS of the product is defined as the set of input combinations 
that corresponds exactly to a product with quality 𝑦𝑑𝑒𝑠. The green line of Figs. 3.3a and 3.4a is 
actually the projection of the DS onto the score space, i.e., it is the DS as it is “seen” by the PLS 
model. Different PLS models (i.e., different calibration datasets) would result in different DS 
projections. However, for a given 𝑦𝑑𝑒𝑠, the DS is unique by definition. For example, the green 
lines of Figs. 3.3b and 3.4b represent the DS for 𝑦𝑑𝑒𝑠=300. Since in these plots the DS is 
expressed in terms of real input variables, its representation is independent of the PLS model 
used to interpret the historical dataset.  
  
Uncertainty back-propagation in PLS modeling for design space determination 105 
 
________________________________________________________ 
© 2018 Gabriele Bano, University of Padova (Italy) 
 
(a)                                                                       (b) 
Figure 3.4. Case study #1, uncertainty back-propagation model #2: confidence limits of the 
null space and projection of the DS (a) onto the score space and (b) onto the real input 
space.  
The direct inversion solution 𝐱𝑛𝑒𝑤 (black triangles of Figs. 3b and 4b) and its projection 𝐭𝑛𝑒𝑤 
(black triangles of Fig. 3.3a and 3.4a) are then computed. The null space is then plotted in the 
score space (black solid line of Figs. 3.3a and 3.4a). A finite number of 𝐿 points are chosen 
along the null space and their projections onto the real input space are shown as black diamonds 
in Figs. 3.3b and 3.4b. It is worth noticing that not all the input combinations lying along the 
null space may be achievable in practice  because of physical or operational constraints. The 
same thing can be said for the DS. For each of the 𝐿 points along the null space, the 95% 
confidence ellipse is built using the uncertainty back-propagation model #1 (red solid ellipses 
of Fig. 3.3a) and the modified model #2 (black solid ellipses of Fig. 3.4a). The envelope curves 
of this family of co-axial 95% confidence ellipses are then plotted (model #1: red solid lines of 
Fig. 3.3a; model #2: black dashed lines of Fig. 4a). Their projections onto the real input space 
are shown in Figs. 3.3b and 3.4b, respectively. The resulting ESs obtained with model #1 and 
model #2 are shown on the score space in Fig. 3.5a and on the real input space in Fig. 3.5b. 
Notice that part of the ES built using model #1 (blue region) is overlapped with the one built 
using model #2; namely, the red region is the portion of the KS that belongs to the CR obtained 
with model #1, but not with model #2. It can be noticed that the predicted ES for model #1, as 
well as that for model #2, effectively bracket a large fraction of the DS of the process lying 
within the KS. However, due to the system nonlinearity, not all the DS projection that lies inside 
the KS can be bracketed. The colored regions of Fig. 3.5b are the combinations of true 
independent input variables that should be primarily considered in the experimental campaign 
to determine the DS of the new product. They indeed point to a region, much narrower than the 
KS, within which the DS of the process is likely to lie. 
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(a)                                                                     (b) 
 
Figure 3.5. Case study #1: graphical interpretation on (a) the score space and (b) the real 
input space   of the ES built using the uncertainty back-propagation model #1 (red + blue 
area) and model #2 (blue area).  
From a practical viewpoint, when a new product of desired characteristics needs to be 
developed, the DS is not known a priori. The direct validation of the proposed methodology 
would therefore require the experimental validation of the results obtained from the model. In 
this mathematical example, the effectiveness of the proposed methodology has been validated 
using coverage probabilities (CPs) according to the following procedure. A set of 𝑁𝑣𝑎𝑙 = 1000 
validation samples (𝐗∗, 𝐲∗) and 𝑁𝑐𝑎𝑙 calibration samples are generated as described in section 
4.1. A PLS model with 𝐴 = 2 LVs is built with the calibration data set. For each validation 
sample, the null space and its confidence regions at assigned confidence levels are calculated 
using alternatively model #1 and model #2. It is then checked if the projection 𝐭𝑝 of the known 
reference value 𝐱𝑟𝑒𝑎𝑙 falls within the specified confidence region of the null space. The CP is 
calculated as the ratio between the number of validation samples that fall within the predefined 
CR of the null space and the total number of validation samples (CP is expressed as a 
percentage). If a validation sample is found to be outside the KS, it is discarded and not 
considered in the analysis. The CP is expected to be equal to, or greater than, the assigned 
confidence level, which is set to 95%. 
To analyze the effect of the size of the calibration dataset, CPs have been calculated using 
different values for  𝑁𝑐𝑎𝑙, but always maintaining the same 1000 validation samples. Results 
are reported in Table 3.5. 
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Table 3.5. Case study #1: observed CPs for uncertainty back-propagation 
models #1 and #2 with a confidence level of 95%. CPs lower than the 
predefined confidence level are highlighted in bold. 
𝑵𝒄𝒂𝒍 𝐂𝐏 model #1 (%) 𝐂𝐏 model #2 (%) 
5 92.5 86.1 
10 93.6 88.5 
15 94.1 91.6 
20 95.1 93.2 
25 95.8 95.8 
30 99.0 95.4 
50 96.1 95.2 
100 97.8 96.1 
150 98.2 96.8 
200 99.3 97.2 
 
It can be seen that both uncertainty back-propagation models perform properly even when only 
few calibration samples are available. Model #1 seems to perform slightly better than model 
#2: this is reasonable, since in this model all the prediction uncertainty is back-propagated to 
the scores and the CR of model #1 is larger than the one of model #2. However, an additional 
issue that should be considered when assessing the performance of the two uncertainty back-
propagation models is quantifying the extent of the shrinkage (with respect to the original KS) 
of the space within which experiments should be carried out to identify the DS. We therefore 
propose a simple metric to quantify the extent of the shrinking of the experimental region to be 
spanned by experiments. 
Consider the 𝑉-dimensional space obtained as the projection of the KS from the score space to 
the real input space. Let 𝑉𝑘 be the hypervolume of this space. Then consider the projections of 
the ES boundaries located inside the KS (obtained with model #1 or #2) on the 𝑉-dimensional 
input space, and let 𝑉𝑒,𝑖 be the hypervolume of the region bracketed by these boundaries, with 
𝑖 = 1 (model #1) or 𝑖 = 2 (model #2). The ES shrinking (ESS) factor for model 𝑖 can be 
quantified as: 
 
ESS𝑖(%) = [1 − (
𝑉𝑒,𝑖
𝑉𝑘
)] ⋅ 100  (3.49) 
The larger this factor, the more effective the segmentation of the KS obtained with a given 
uncertainty back-propagation model. This metric complements the CP to evaluate the model 
performance. An effective uncertainty back-propagation model should be reliable (i.e., with CP 
equal to, or greater than, the predefined confidence level) and ensure the largest possible 
shrinking of the ES at the same time. 
In the case study under investigation, the real input space is 2-dimensional and (3.49) reduces 
to a ratio of areas. The ratio ESS𝑖 as a function of the size of the calibration data set for model 
#1 and #2 is reported in Table  3.6. 
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Table 3.6. Case study #1: experimental space shrinking using the uncertainty 
back-propagation models #1 and #2.  
𝑵𝒄𝒂𝒍 
𝐄𝐒𝐒𝟏 (%) 
model #1 
𝐄𝐒𝐒𝟐(%)  
model #2 
10 79.0 93.3 
15 86.0 97.2 
20 81.6 96.4 
25 74.3 94.3 
30 77.5 92.7 
50 83.1 97.0 
100 86.5 97.4 
200 88.9 98.0 
500 91.5 98.8 
1000 91.1 97.5 
 
It can be noticed that the shrinkage of the experiment space that can be obtained with model #2 
is significantly larger than the one that can be obtained with model #1. This is due to the fact 
that model #1 is more conservative than model #2. Moreover, ESS1 is much more dependent 
on the size of the calibration data set than ESS2. 
3.5.2 Quality target described by an inequality constraint 
In several practical situations, the quality target for the product to be developed is not specified 
as an equality constraint, but as an acceptance region (i.e., as a set of inequality constraints). In 
the following, we discuss the case where the set of quality constraints is assigned as 𝑦𝑙𝑜 ≤
𝑦𝑑𝑒𝑠 ≤ 𝑦𝑢𝑝, where ylo and yup are the lower and upper bounds for ydes, respectively. 
Consider Fig. 3.6. The bounds for 𝑦𝑑𝑒𝑠 are set to 𝑦𝑙𝑜 = 278 and 𝑦𝑢𝑝 = 378. A PLS model with 
𝐴 = 2 LVs and 𝑁 = 15 calibration samples is built as in section 3.5.1. The green area shown 
in Fig. 3.6a is the projection of the DS falling within the KS. This area is bracketed by the KS 
boundary and by the DS projections as if these projections corresponded to two distinct equality 
constraints, namely 𝑦𝑑𝑒𝑠 = 𝑦𝑙𝑜 and 𝑦𝑑𝑒𝑠 = 𝑦𝑢𝑝. The null spaces corresponding to 𝑦𝑑𝑒𝑠 = 𝑦𝑙𝑜 
and 𝑦𝑑𝑒𝑠 = 𝑦𝑢𝑝 can then be computed. If no uncertainty on the location of these boundary null 
spaces is assumed, the DS projection that would be predicted by the PLS model is the one given 
by the black area of Fig. 3.6b. 
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(a) 
 
(b) 
Figure 3.6. Case study #1, quality target described by 278 ≤ ydes ≤ 378: (a) projection of the 
true DS on the score space (green area); (b) DS projection predicted by the PLS model when 
prediction uncertainty is not accounted for (black area). 
If prediction uncertainty is accounted for, the envelope curves of  the 95% confidence ellipses 
for the boundary null space locations can be built by using the uncertainty back-propagation 
model #1 or model#2 as shown in Figs. 3.7a and 3.7b, respectively. 
 
 
(a)                                                                          (b) 
 
Figure 3.7. Case study #1, quality target described by 278 ≤ ydes ≤ 378: 95% envelope curves 
of the 95% confidence ellipses for the boundary null spaces according to (a) model #1 and 
(b) model #2. 
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Therefore, the DS is expected to lie within the red area of Fig. 3.8a (uncertainty back-
propagation model #1) or within the blue area of  Fig. 3.8b (uncertainty back-propagation model 
#2). 
 
(a)                                                                (b) 
Figure 3.8. Case study #1, quality target described by 278 ≤ ydes ≤ 378:  ES according to 
(a) model #1 and (b) model #2. 
 
Fig. 3.9 provides a comprehensive graphical interpretation of the overall discussion. If the 
segmentation of the KS is done using the PLS inversion solution and model uncertainty is not 
accounted for (Fig. 3.9a), a large portion of the DS projection is not bracketed and therefore 
will go unexplored during an experimental campaign. Note that in this case uncertainty in the 
determination of the DS projection mainly derives from the fact that a linear model (the PLS 
model) is used to predict a strongly nonlinear DS. When uncertainty in the PLS inversion 
solution is accounted for, a larger portion of the DS of the process is bracketed (Fig. 3.9b for 
model #1, Fig. 3.9c for model #2). However, a much smaller subspace of the DS is still not 
bracketed (green areas) by the envelope curves of the inversion solution. In fact, the 
contribution of the variance of the residuals to the overall prediction uncertainty in Eq. (3.17), 
which partially accounts for nonlinearity, is back-propagated to the calculated solution. By 
increasing the confidence level (i.e. by reducing the risk of not bracketing the DS), a broader 
ES would be obtained. In a nutshell, the greater the desired confidence level in bracketing the 
DS of the new product, the wider the operating window that must be investigated by 
experimentation. 
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(a) 
 
(b)                                                                      (c) 
 
Figure 3.9.  Case study #1, quality target described by 278 ≤ ydes ≤ 378. (a) Model-predicted 
DS projection without accounting for uncertainty (black area), and portion of the DS 
projection that is not bracketed by the model predictions (green area). (b) ES (red area) 
according to model #1, and portion of the DS projection that is not bracketed (green area). 
(c) ES (blue area) according to model #2, and portion of the DS projection that is not 
bracketed 
3.6 Results for case study #2 
The same external validation data set as in Souihi et al. (2015) is used. First, a PLS model is 
built using the 34 calibration samples. The model diagnostics is shown in Table 3.9. 
Table 3.9. Case study #2: diagnostics of the PLS model. 
LV # 𝑹𝑿
𝟐(%) 𝑹𝑿,𝒄𝒖𝒎
𝟐 (%) 𝑹𝒚
𝟐 (%) 𝑹𝒚,𝒄𝒖𝒎
𝟐  (%) 
1 57.72 57.72 66.82 66.82 
2 38.87 96.59 20.28 87.10 
3 3.41 100.00 12.33 99.43 
4 0.00 100.00 0.57 100.00 
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Using 𝐴 = 2 LVs, 96.6% of the total variability of 𝐗 and 87.1% of the total variability of 𝐲 are 
explained. The proposed methodology is then tested on the 9 validation samples available. As 
an illustrative example, the results obtained for a product with desired average porosity ydes = 
22.6% (validation sample #7) are shown in Fig. 3.10. 
 
 
Figure 3.10. Case study #2: bracketing the DS projection of an intermediate drug load 
formulation with ydes = 22.6%. The green circle is the projection of the inputs actually giving 
ydes, the black triangle is the direct inversion solution, the black solid line is the null space as 
calculated by the PLS model, the red solid lines are the envelope of the 95% confidence 
ellipses of the null space as calculated by model #1 and the black dashed lines those 
calculated by model #2. 
 
The projection of the process inputs actually required to obtain the desired product quality 
(green circle in Fig. 3.10) lies within the ES both for model #1 and for model #2. It is worth 
noticing that this green circle is only one of the possible real input combinations that can lead 
to the desired product quality. We will refer to this point as  𝐭𝑟𝑒𝑎𝑙. The null space related to the 
direct inversion solution 𝐭𝑛𝑒𝑤 (black solid line in Fig. 3.10) is quite far from 𝐭𝑟𝑒𝑎𝑙. Therefore, 
if the PLS model were used without accounting for prediction uncertainty, a significant error 
on the location of the DS projection would be obtained. The 𝐸𝑆𝑆 indices that can be obtained 
with the two models for this case study are 𝐸𝑆𝑆1 = 77.9% and 𝐸𝑆𝑆2 = 87.7% respectively. 
The proposed methodology has been tested on all the 9 validation samples available. The rate 
of success was 100% both with model#1 and with model #2.  
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3.7 Results for case study #3  
A PLS model is first built using the randomly-chosen 20 calibration samples. 𝐴 = 2  LVs are 
used, accounting for 76.3% of the total variability of 𝐗 and 86.5% of the total variability of 𝐲. 
The seven validation samples are then used to test the effectiveness of the proposed 
methodology. An example is shown in Fig. 3.11 (validation sample #2). The green circle is the 
projection onto the score space of the input combination that actually yields the desired median 
particle size (𝑑50
𝑑𝑒𝑠 = 1101 𝜇𝑚). The direct inversion solution (black triangle) and the null 
space across it (black solid line) are shown in the same figure. It can be noticed that, if 
uncertainty is not accounted for, the model-predicted DS projection would not include the actual 
set of inputs. When considering the back-propagation of uncertainty on the score space, the 
resulting ES effectively brackets the true input combination for the desired quality target. By 
carrying out the experimental campaign across these restricted operating windows, an 
experiment space shrinkage of 𝐸𝑆𝑆1 = 69.3% and 𝐸𝑆𝑆2 = 74.5% can be obtained.  
 
Figure 3.11. Case study #3: bracketing the true input combinations (green dot) yielding a 
desired median particle size granulate (𝑑50
𝑑𝑒𝑠 = 1101 𝜇𝑚) in a high-shear wet granulation 
process. The KS is segmented using model #1 (red convolution lines) and model #2 (black 
dashed convolution lines). 
3.8 Results for case study #4 
Differently from Facco et al. (2015), 30 calibration samples are selected randomly from the 
historical dataset (composed by 80 samples). The problem of designing a process that allows 
one to obtain a granulate with intravoid fraction of the solids out of the roller compactor of 
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𝑦𝑑𝑒𝑠 = 0.6341 m
3/m3 is considered. The results obtained with two uncertainty back-
propagation models are shown in Fig. 3.12. A reduction of the experimental effort of 𝐸𝑆𝑆1 =
69% can be obtained by using model #1, and of 𝐸𝑆𝑆2 = 76% with model #2. 
 
 
Figure 3.12. Case study #4: bracketing the true input combinations (green circle) yielding a 
desired intravoid fraction of solids out of the roller compactor (ydes = 0:6341m3/m3). 
3.9 Results for case study #5 
Fourteen calibration samples are randomly-chosen from the historical dataset, and a PLS model 
accounting for 67.2 % of the total variability of 𝐗 and 79.3 % of the total variability of 𝐲 is built 
based on this calibration data set. The problem of bracketing the knowledge space to provide 
guidance for the experimental campaign of granulate with a percent of oversize granules equal 
to 74% is considered. The results are shown in Fig. 3.13. It can be noticed that, also in this case, 
the segmentation of the knowledge space is effective for both uncertainty back-propagation 
models, being able to bracket the real input combination that yield the desired product. The 
reduction of the experimental effort that can be obtained for this case study are 𝐸𝑆𝑆1 = 56.1% 
and 𝐸𝑆𝑆2 = 66.3%. 
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Figure 3.13. Case study #5: bracketing the true input combinations (green dot) that gives a 
granulate with a percent of oversize granules equal to 74% in a high-shear wet granulation 
process.  
3.10 Conclusions 
In this study, the possibility of using PLS model inversion to assist the determination of the 
design space of a new pharmaceutical product has been discussed. A methodology to back-
propagate the uncertainty on the prediction of the PLS model to the calculated inputs has been 
developed, and the practical outcomes that can be obtained in pharmaceutical product 
development have been discussed. Two uncertainty back-propagation models have been 
formulated, and their performance critically compared. The first model assumes that all the 
prediction uncertainty is back-propagated to the PLS scores, whereas the second one attempts 
to allocate the overall prediction uncertainty on both the scores and the loadings. From a 
mathematical viewpoint, the two models allow one to determine the covariance matrix of a 
point belonging to the solution space of the PLS inversion problem by making some 
assumptions on how uncertainty back-propagates from the 𝑦-space to the latent space first, then 
to the real input space. The final objective of the methodology is to build confidence regions 
for the calculated solution of the inversion problem, thus identifying an operational space (i.e., 
a set of combinations of raw material properties and process parameters) that brackets the real 
DS of the product at the predefined confidence level. From a practitioner’s perspective, the 
proposed methodology can be used to substantially shrink the space within which experiments 
must be carried out to identify the DS, since the experimental campaign can be focused on this 
restricted operating window instead of the entire historical decision space. Moreover, the 
proposed procedure returns an accurate quantification of uncertainty for quality risk 
management. 
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The effectiveness of the proposed methodology has been tested on three different case studies. 
The ability of the two uncertainty back-propagation models to effectively bracket the real DS 
of the new product and to shrink the experiment space have been assessed. The first model is 
more conservative than the second, in the sense that it guarantees a slightly higher performance 
in bracketing the true DS of the product; however, it also results in a less effective shrinkage of 
the experiment space.  
Some areas of further investigation can be pointed out. The proposed procedure can be extended 
to multivariate product specifications, given the availability of a reliable model to estimate the 
prediction covariance matrix in PLS modelling. The development of such a model is still an 
open research area. Moreover, more sophisticated and rigorous relations may be derived to 
relate the uncertainty on the model outputs to the uncertainty on the model inputs. These 
formulas should account for the intrinsic reduced-rank nature of PLS modeling. Additionally, 
uncertainty in the input and output measurements should be accounted for.
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Chapter 4 
 
A Bayesian/latent variable approach for 
design space determination* 
 
In this Chapter, a methodology that combines latent-variable modeling and multivariate 
Bayesian regression is presented in order to identify a subset of input combinations (process 
operating conditions and raw materials properties) within which the design space  (DS) of a 
new pharmaceutical product will lie at a probability equal to, or greater than, an assigned 
threshold. The methodology is tested on three relevant pharmaceutical case studies, two of 
which involving experimental data. The ability of the proposed approach to obtain a 
probabilistic identification of the DS, while simultaneously reducing the computational burden 
for the discretization of the input domain and providing a simple graphical representation of the 
DS, is shown. 
4.1 Introduction 
In the last decade, the pharmaceutical regulatory agencies have strongly encouraged the 
pharmaceutical industries to gain deeper understanding of their manufacturing processes. The 
International Conference on Harmonization (ICH) Q8 guideline (ICH, 2009) emphasized the 
Quality by Design (QbD) approach, according to which quality should be built into the product 
since its conception, and not simply tested after the manufacturing process is completed. This 
requires understanding how input materials properties and process operating conditions can 
affect the product quality. A key concept introduced by this guideline is that of design space 
(DS), defined as the “multidimensional combination and interaction of input variables (e.g. 
material attributes) and process parameters that have been demonstrated to provide assurance 
of quality” (ICH, 2009).  As long as raw material properties and process parameters are changed 
within the approved DS, no regulatory process of post-approval change is required. Product 
quality is expressed in terms of critical quality attributes (CQAs), which must lie within 
                                                          
* Bano, G., Facco, P., Bezzo, F., Barolo, M. (2018) Probabilistic design space determination in pharmaceutical development: 
a Bayesian/latent variable approach. AIChE J. 64, 2438- 2449. 
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acceptance limits defined a priori. “Assurance of quality” implicitly requires quantifying the 
confidence of the manufacturer at providing products with the desired quality.  
In this study, we address the problem of identifying the DS of a new pharmaceutical product. 
From a general perspective, assisting the identification of the DS requires both experimentation 
and mathematical modeling. When models are used to identify the DS, different sources of 
uncertainty can affect the DS identification exercise, e.g. model parameter uncertainty (Faber 
and Kowalski, 1997), measurement uncertainty in the calibration dataset (Reis and Saravia, 
2005), and structural uncertainty due to inadequacy of the model structure. However, as 
observed by Peterson (Peterson, 2008),  most of the available modeling techniques used to assist 
a DS identification exercise do not account for model uncertainty, and some of them do not 
even fully account for the multivariate correlation between model inputs and outputs. For 
example, overlapping mean response surface methodologies (Anderson and Whitcomb, 1998; 
Zidan et al., 2007) fail to account for model parameter uncertainty and for the correlation 
between the CQAs. The multivariate correlation between inputs and outputs is inherently 
considered in latent-variable modeling (LVM; Tomba et al., 2013). However, accounting for 
model uncertainty when using this approach may be complex and at present has been shown 
only for products characterized by a single CQA, i.e. when quality is a univariate property 
(Bano et al., 2017). 
A comprehensive way to account for model parameter uncertainty and correlation between the 
CQAs, as well as to provide a metric for the assurance of quality, is to use a Bayesian posterior 
predictive approach. The idea of Bayesian or probabilistic DS was first introduced by Peterson 
(Peterson, 2004). With this approach, the posterior predictive probability to observe the CQAs 
within their predefined specifications is computed. DoE techniques are used to determine 
appropriate experimental conditions for the design of multivariate linear regression models 
between the input factors and the CQAs (Peterson and Yahyah, 2009; Stockdale and Cheng, 
2009; Debrus et al., 2011). The multivariate regression model is then used to predict the DS in 
a Bayesian framework. The input domain is first discretized using a sampling algorithm. 
Samples from the joint posterior distribution of the CQAs are then drawn using Markov-Chain 
Monte Carlo (MCMC) techniques for each discretization point of the input domain. The 
probability of the CQAs to meet their specifications for the given point is then recorded. The 
DS is finally identified as the subspace of the original input domain within which the probability 
of the CQAs to meet their specifications is higher than a user-defined acceptance level. 
Several studies proved the ability of the above approach to quantify the concept of “assurance 
of quality” defined by ICH (Stockdale and Cheng, 2009; Debrus et al., 2011; Peterson and Lief, 
2010). However, two issues are still unresolved: (i) how to obtain a computationally tractable 
discretization of the multidimensional input domain when several input factors are involved, 
and (ii) how to express the results of the DS identification exercise in an intuitive and compact 
way (e.g., graphically). With respect to the first issue, the typical approach for the discretization 
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of the input domain is to use space-filling algorithms. However, these algorithms suffer from 
the curse of dimensionality (Cioppa and Lucas, 2007),  i.e. the computational burden increases 
very significantly with the number of input factors. With reference to the second issue, the 
results of a multidimensional DS identification exercise are usually expressed in a tabular way, 
or as a matrix of two-dimensional probability maps by considering two inputs at a time and 
fixing the other factors to their nominal values. Both these approaches are difficult to interpret 
and fail in giving an intuitive representation of the multivariate DS. The aim of this study is to 
exploit the advantages of LVM to overcome both issues, while maintaining the Bayesian 
posterior predictive approach for DS identification. 
We assume that a historical dataset of products “similar” (Jaeckle and McGregor, 1998) to the 
one under development is available. The historical dataset is first used to build a partial least-
squares (PLS) regression model. PLS is used to obtain a linear transformation between the 
original multidimensional input domain and a low-dimensional latent space, and the Bayesian 
posterior predictive approach proposed by Peterson (Peterson, 2004) is applied to identify the 
probabilistic DS. The reduction of the input space dimensionality obtained with PLS is 
exploited to obtain a computationally efficient discretization of the input domain and to express 
the DS in an intuitive 2-dimensional graphical way, thus overcoming two of the main 
limitations of the approach proposed by Peterson. The practical outcome of the proposed 
methodology is the identification of the DS in a probabilistic fashion, which can be used to 
demonstrate the confidence the manufacturer has on the product meeting its quality targets 
when the manufacturing process is run within the proposed DS.  
The methodology is tested on three case studies. The first one involves a model-generated 
historical dataset for the dry granulation of a pharmaceutical blend (taken from the work of 
Facco et. al. (2015), based on the model of Johanson (1965)). In the second case study, a high-
shear wet granulation process of a pharmaceutical blend is addressed, using experimental data 
from Oka et. al. (2015). The third case study involves the roller compaction an intermediate 
drug load formulation, with  experimental data taken from Souihi et al. (2015) . 
4.2 Review of Partial least-squares (PLS) regression 
Let [𝐗; 𝐘] be a historical dataset of “old” products similar18 to the one under development. 
Matrix 𝐗 [𝐼 × 𝑄] collects I samples concerned with a set of Q process inputs (raw material 
properties and process parameters) that affect the M quality attributes 𝐘[𝐼 × 𝑀] of the historical 
products. 
Partial least-squares (PLS) regression (Wold et al., 1983; Geladi and Kowalski, 1986) is a 
multivariate regression technique that projects a dataset of input and response variables onto a 
                                                          
18 Product similarity can be assessed using the methodology proposed by Jaeckle  and MacGregor (1998). 
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common latent space of 𝐴 new variables, called latent variables (LVs). This set of new variables 
is determined by finding the multidimensional direction on the 𝐗-space that explains the 
maximum multidimensional variance direction in the 𝐘-space, according to the model structure: 
 
𝐗 = 𝐓𝐏T + 𝐄𝐗  (4.1) 
𝐘 = 𝐓𝐐T + 𝐄𝐘  (4.2) 
𝐓 = 𝐗𝐖∗  (4.3) 
where 𝐓 [𝐼 × 𝐴] is the score matrix, 𝐏 [𝑄 × 𝐴] and 𝐐 [𝑀 × 𝐴] are the 𝐗 and 𝐘 loading matrices, 
𝐄𝐗 and 𝐄𝐘 the residuals; 𝐖
∗[𝑄 × 𝐴] is the weight matrix. 
The number 𝐴 ≪ 𝑄 of LVs can be chosen in such a way as to explain a meaningful fraction of 
the variance of both the input and output data. In the presence of a strong input collinearity, a 
significant reduction of the problem dimensionality can be obtained by applying this data 
compression technique. This property will be exploited as later illustrated in Section 4.4. 
The subspace of the input domain enclosed by the historical dataset is called the knowledge 
space (KS; MacGregor and Bruwer, 2008). Mathematically, the KS can be identified in the 
latent space as the hyper-ellipsoidal confidence region determined by the 95% confidence limit 
for the the Hotelling’s 𝑇2 statistic (Tracy et al., 1992): 
  
𝑇𝑙𝑖𝑚
2 =
𝐴(𝐼2−1)
𝐼(𝐼−𝐴)
𝐹𝐴,(𝐼−𝐴),0.95   ,  (4.4) 
where 𝐹𝐴,(𝐼−𝐴),0.95 is the value of the 95% percentile of the 𝐹-distribution with 𝐴 and (𝐼 − 𝐴) 
degrees of freedom. The hyper-ellipsoid semiaxes are given by: 
 
𝑠𝑎 = √𝜆𝑎𝑇lim   
2                                  𝑎 = 1,… , 𝐴 (4.5) 
where 𝜆𝑎, 𝑎 = 1,… , 𝐴 is the variance of the scores related to the 𝑎-th LV. 
4.3 Bayesian design space: mathematical formulation 
Let 𝐱 = (𝑥1, 𝑥2, … , 𝑥𝑄) be the vector that collects the set of inputs and 𝐲 = (𝑦1, 𝑦2, … , 𝑦𝑀) the 
one that collects all the response variables. Let 𝐡(𝐱) be a model relating the inputs to the 
outputs. From a modeling perspective, the DS of the new product can be interpreted as the 
region of the input domain where the corresponding predicted model response 𝐲 = 𝐡(𝐱) has an 
acceptable probability to satisfy assigned specifications. In this study, only the subspace of the 
DS lying within the projection of the KS onto the latent space is explored. To simplify the 
notation, we will refer to this subspace as to the DS itself. 
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The desired quality characteristics for the product to be developed can be expressed in terms of 
acceptance criteria. The region where all product quality attributes meet their acceptance 
criteria is defined as the acceptance region (AR). 
A risk-based definition of the DS is the one proposed by Peterson (Peterson, 2008): 
 
DS = {𝐱 ∈ KS: Pr(𝐲 ∈ AR|𝐱, 𝐗, 𝐘) ≥ 𝜃𝑡ℎ} (4.6) 
 
where th  is an assigned probability threshold for the product quality to be acceptable. Eq. (4.6) 
clarifies that this study considers the DS as the subspace of the historical KS where the posterior 
probability that the product attributes will all lie within their acceptance criteria is greater than 
an assigned threshold, conditionally on the historical dataset [𝐗; 𝐘]. The DS as defined by (4.6) 
will be denoted as probabilistic or Bayesian DS.  
The definition of DS as in (4.6) allows for a quantification of the concept of “assurance of 
quality” as advocated by ICH. The benefits of this Bayesian approach have been extensively 
discussed (Lebrun et al., 2013).  Eq. (4.6) is general and can be used whenever a model relating 
the product quality 𝐘 to the raw material properties and process parameters 𝐗 is available. In 
this study, the model used to relate the product quality to the input factors is a multivariate 
linear regression model: 
 
𝐘 = 𝐗𝚩 + 𝐄 (4.7) 
 
where 𝚩 [𝑄 ×𝑀] is the matrix of model parameters and 𝐄 [𝐼 × 𝑀] = [𝐞1, … , 𝐞𝐼]
T is the matrix 
of the residuals. The residuals are assumed to be independent and normally distributed with 
mean 𝟎 [𝐼 × 𝑀] and covariance 𝚺 [𝑀 ×𝑀], i.e. 𝐞𝑖 𝑁(𝟎, 𝚺), 𝑖 = 1,… , 𝐼. 
The posterior predictive probability included in (4.6) can be determined using a Bayesian 
approach with the multivariate regression model (4.7). To this purpose, a posterior predictive 
distribution for future responses must be obtained. 
Let 𝑓(𝐲|𝐱, 𝐁, 𝚺) be the probability density function for the new response 𝐲 under the set of 
inputs x, given the set of uncertain model parameters 𝐁 and the covariance of the residuals 𝚺. 
This pdf depends on the model adopted. The posterior predictive distribution for 𝐲, conditional 
on the historical data [𝐗; 𝐘], is given by: 
 
𝑔(𝐲|𝐱, 𝐗, 𝐘) = ∫ ∫ 𝑓(𝐲|𝐱, 𝐁, 𝚺)𝑝(𝐁, 𝚺|𝐗, 𝐘)𝑑𝐁𝑑𝚺 (4.8) 
 
where 𝑝(𝐁, 𝚺|𝐗, 𝐘) is the joint posterior distribution of the model parameters 𝐁 and the 
covariance of the residuals 𝚺. The probability Pr(𝐲 ∈ 𝐴R|𝐱, 𝐗, 𝐘) of (4.6) can then obtained 
from 𝑔(𝐲|𝐱, 𝐗, 𝐘) by simple integration within the entire AR: 
 
 
 
122 Chapter 4 
________________________________________________________ 
© 2018 Gabriele Bano, University of Padova (Italy) 
 
Pr(𝐲 ∈ 𝐴𝑅|𝐱, 𝐗, 𝐘) =  ∫  𝑔(𝐲|𝐱, 𝐗, 𝐘)𝑑𝐲
AR
. (4.9) 
 
Eq. (4.9), combined with (4.8), indicates that that the probability Pr(𝐲 ∈ AR|𝐱, 𝐗, 𝐘) can be 
determined once the joint posterior distribution of the model parameters 𝑝(𝐁, 𝚺|𝐗, 𝐘) is derived. 
This distribution can be obtained using Bayes’ theorem: 
 
𝑝(𝐁, 𝚺|𝐗, 𝐘) ℒ(𝐁, 𝚺|𝐘) 𝑝(𝐁, 𝚺) (4.10) 
 
where ℒ(𝐁, 𝚺|𝐘) is the likelihood function, given by (Tiao and Zellner, 1964): 
 
ℒ(𝐁, 𝚺|𝐘) |𝚺|−
𝑛
2 exp (−
1
2
𝑡𝑟 [𝚺−1(𝐘 − 𝐗𝐁)T(𝐘 − 𝐗𝐁)]) (4.11) 
 
and 𝑝(𝐁, 𝚺) is the joint prior distribution of the model parameters 𝐁 and 𝚺.  
MCMC sampling techniques can be used to draw samples from the joint posterior distribution 
of the model parameters 𝑝(𝐁, 𝚺|𝐗, 𝐘). The response posterior predictive distribution 
𝑔(𝐲|𝐱, 𝐗, 𝐘) can then be obtained from this distribution and finally Pr(𝐲 ∈ 𝐴𝑅|𝐱, 𝐗, 𝐘) can be 
computed. The sampling algorithm that has been used in this study is the Metropolis-Hastings 
algorithm (Hastings, 1960). 
The choice of the prior distributions for the model parameters and the covariance of the 
residuals is critical. Non-informative or informative priors can be used to this purpose. When 
informative priors are used, the amount of prior information available determines the choice of 
the parameters of these distributions. Strictly speaking, if no or very limited prior information 
is available, prior distributions that are considered informative from a structural point of view 
can be made uninformative by choosing uninformative prior parameters. Stated differently, 
when informative priors are used, the amount of prior information can be tuned by choosing 
the values of the parameters of these prior distributions. 
In this study, informative (from a structural point of view) prior distributions for the model 
parameters and the covariance of the residuals have been chosen. Namely, 𝑝(𝚩, 𝚺) =
𝑝(𝚩|𝚺)𝑝(𝚺) with 𝑝(𝚩|𝚺) matrix-variate normal distribution with mean 𝚩0 and covariances 𝚺 
and 𝚺0, i.e. 𝑝(𝚩|𝚺) N(𝚩0, 𝚺, 𝚺0), and 𝑝(𝚺) inverse Wishart distribution with scale matrix 𝛀 
and degrees of freedom 𝜈0, i.e. 𝑝(𝚺) 𝑊𝑖𝑠ℎ
−1(𝛀, 𝜈0). The choice of the prior parameters 
(𝐁0, 𝚺0, 𝜈0) determines the amount of prior information available. The values of these 
parameters have been set as uninformative as possible, since no prior information for the case 
studies considered was available. 
A graphical representation of the discussed Bayesian approach for the determination of the 
posterior predictive probability of a new response is shown in Fig. 4.1. 
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Figure 4.1. Diagram of the Bayesian approach to obtain the posterior predictive probability 
of a new response.  
 
4.4 Bayesian identification of the design space 
Identification of the DS according to the Bayesian definition (4.6) involves the following steps.  
1) Identification of the critical process parameters (CPPs) and critical quality attributes 
(CQAs) for the new product. 
2) Acquisition of an experimental dataset, by performing experiments according to a DoE-
based plan. 
3) Calibration of a model to relate the CPPs and raw material properties to the CQAs. In 
most situations, a statistical multivariate linear regression model is built at this stage. 
4) Identification of the multidimensional knowledge space (i.e., input domain). 
5) Discretization of the multidimensional KS. Different sampling algorithms can be used 
to this purpose. Space-filling algorithms are mostly used, which become 
computationally expensive as the number of input factors increases. 
6) Determination (by MCMC simulations) of the joint posterior probability of the CQAs 
to meet their specifications for every discretization point of the KS. 
7) Probabilistic reconstruction of the DS according to (4.6). 
8) Representation of the multidimensional DS with a tabular approach or a matrix of 2-
dimensional probability maps. 
Notice that the DoE inputs are the CPPs and the raw materials properties. Hence, they may be 
large in number and correlated, which has some notable drawbacks. Firstly, this complicates 
the DoE exercise, because independent factors should be singled out (step 2). Secondly, 
investigating the entire KS by experiments (step 2) may be hard or even impossible. Thirdly, 
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the discretization of the KS with space-filling algorithms (step 5) may be computationally very 
intensive . Finally, visualizing the DS  (step 8) may be complex. Two-dimensional posterior 
probability maps are often derived for each pair of model inputs, with the remaining inputs fixed 
at their nominal values. However, this approach does not account for the multivariate 
correlation structure of the model inputs, thus leading to results that are partial at best, but 
possibly even misleading.  
As discussed in Section 4.2, PLS can be used to project the input space onto a low-dimensional 
latent space, while simultaneously accounting for its correlation with the output space. 
Coupling PLS with the multivariate linear regression Bayesian approach discussed in Section 
4.3 can be a way to enhance the advantages of the latter (quantification of assurance of quality; 
handling of model parameter uncertainty and of the multivariate nature of the responses) with 
the ability of PLS to reduce the dimensionality of the multivariate input space. In this study, a 
systematic methodology is proposed to take full advantage of both techniques. In more detail, 
the ability of PLS to reduce the input space dimensionality is exploited to improve Step 5 and 
Step 8 of the above procedure. The methodology is discussed below. 
4.4.1 Proposed methodology 
Figure 4.2 provides an illustrative graphical representation of the methodology for a 2-LV 
space. 
The step-by-step procedure is as follows. 
a. Given the historical dataset [𝐗; 𝐘], a PLS model with 𝐴 LVs relating 𝐗 to 𝐘 is built. In 
this study, 𝐴 has been chosen according to the eigenvalue-greater-than-one rule (Kaiser, 
1970) in such a way as to explain a significant fraction of the variance of both 𝐘 and 𝐗. 
Once the PLS model has been calibrated, the KS is identified as the region defined by 
the 95% confidence limit of the Hotelling’s 𝑇2 statistic (Section 4.2). The boundary of 
the KS is identified by the ellipse of Fig. 4.2a for a two-dimensional latent space. 
b. The KS is discretized, e.g. by using the following approach:  
(i) a very large (e.g., 𝑁𝑎>1000) number of samples in the latent space is chosen 
inside a unit hyper-sphere centered in the origin; 
(ii) the samples are then scaled to the confidence hyper-ellipsoid size by 
multiplying their coordinates by the lengths of the ellipsoid axes. 
An example of KS discretization using this approach is shown in Fig. 4.2b for 𝑁𝑎 = 
2000. 
c. A representative number 𝑁𝑠 < 𝑁𝑎 of samples 𝐭𝑙 , 𝑙 = 1,2, …𝑁𝑠  is chosen. The 
corresponding values in the original input space 𝐱𝑙, 𝑙 = 1,2, …𝑁𝑠 are obtained 
according to Eq. (4.1) using the PLS loadings found in step #1. The choice of 𝑁𝑠 must 
be done so as to compromise between having a good coverage of the entire KS and 
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reducing the computational effort. The next subsection discusses how this can be 
achieved. Once 𝑁𝑠 has been determined, a space-filling algorithm is used to span the 
KS using the defined number of samples. In this study, the Kennard-Stone algorithm 
(Kennard and Stone, 1969) has been used. The Kennard-Stones algorithm is a sequential 
sampling algorithm that allows selecting a subset of 𝑁𝑠 samples given a set of 𝑁𝑎 
candidates. The rationale behind this algorithm is to select each new sample by choosing 
the farthest sample (in terms of Euclidean distance) from the previously selected ones, 
starting from the two farthest points in the KS. As other space filling algorithms, the 
Kennard-Stone algorithm suffers from dimensionality issues. Therefore, its 
implementation in the latent space is much less computationally expensive than in the 
true input space. 
An example of the selection of Ns = 100 samples using the Kennard-Stone algorithm is 
shown in Fig. 4.2c. 
d. For each of the 𝑁𝑠 selected samples, the joint posterior predictive distribution (PPD) of 
the quality responses is obtained by performing a Bayesian simulation in the true input 
space (Section 4.3). 
An example of posterior predictive distribution for a case study involving a single 
quality specification is shown in Fig. 4.2d. 
e. Given the desired quality target 𝐲𝑑𝑒𝑠 or the desired quality interval 𝐲𝑝 < 𝐲𝑑𝑒𝑠 (or 𝐲𝑙𝑜 <
𝐲𝑝 < 𝐲𝑢𝑝,, with 𝐲𝑙𝑜and 𝐲𝑢𝑝 lower and upper bounds for the quality variables 
respectively), if the condition expressed by (4.6) is satisfied, then the given sample is 
considered to belong to the probabilistic DS (green diamonds in Fig. 4.2e). If (4.6) is 
not satisfied, the given sample is rejected as it does not belong to the probabilistic DS 
(red diamonds of Fig. 4.2e). 
 
A schematic flowchart involving all the different steps  of the proposed methodology is shown 
in Fig. 4.3. 
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(a)                                                              (b) 
 
(c)                                                                      (d) 
 
   (e) 
 
Figure 4.2. Graphical representation of the proposed methodology for probabilistic DS 
determination in a two-dimensional latent space: (a) KS identification in the latent space; 
(b) discretization of the KS; (c) sampling of the selected point with KSA; (d) posterior 
predictive distribution for a single sample; (e) Bayesian DS. 
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Figure 4.3. Flowchart of the proposed methodology for the determination of the Bayesian 
design space of a new pharmaceutical product. 
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4.4.2 Selection of the optimal number of samples 
This section presents an automatic methodology to determine the optimal number 𝑁𝑠
𝑜𝑝𝑡
 of 
discretization samples of step 3 discussed in the previous section. 
Consider the PLS model (4.1)-(4.3). After calibration, the PLS model can be used to predict a 
new response 𝐲𝑝 given a new observation 𝐱𝑝 according to : 
 
𝐲𝑝 = 𝐭𝑝𝐐
T (4.12) 
 
where 𝐭𝑝 is the score vector of the new observation 𝐱𝑝. 
The score vector 𝐭𝑝 can be related to the input vector 𝐱𝑝 through the model weights 𝐖 according 
to: 
𝐭𝑝 = 𝐱𝑝𝐖
∗. (4.13) 
 
As shown elsewhere (Zhang and Garcia Munoz, 2009) both the score vector 𝐭𝑝 and the loadings 
matrix 𝐐T of (4.12) are affected by uncertainty, and accordingly weights , too. Eq. (4.13) can 
be seen as linear prediction model between the model “response” 𝐭𝑝 and the model “regressors” 
𝐱𝑝, through the model “parameters” 𝐖
∗. Therefore, the PPD of the score vector 𝐭𝑝 can be 
obtained by performing a Bayesian calibration of model (4.13) by feeding a new (fixed) set of 
model regressors 𝐱𝑝
∗ . 
The choice of the optimal number of discretization samples 𝑁𝑠 can therefore be done as follows. 
Let [𝑁1, 𝑁2, … , 𝑁𝑀] be a set of discrete values for 𝑁𝑠, with 𝑁𝑠 = 𝑁1 < 𝑁2 < ⋯ < 𝑁𝑀. The 
PPD of the score vector 𝐭𝑝 is obtained for each of these discrete values and for the given fixed 
value 𝐱𝑝
∗   adopting the Bayesian procedure presented in Section 4.3. The conditional posterior 
predictive distributions (CPPDs) of each component of 𝐭𝑝 can then be obtained by picking out 
the contributions of every single component to the PPD. 
An illustrative example of the two CPPDs obtained with a PLS model built on A = 2 LVs (i.e., 
𝐭𝑝 = [𝑡𝑝,1, 𝑡𝑝,2]) is shown in Fig. 4.4, where five discretization samples (𝑁𝑠 = 5) have been 
used. 
The 95% credible intervals for 𝑡𝑝,𝑎  ( 𝑎 =  1, … , 𝐴) can then be computed for each value of 𝑁𝑠. 
Mathematically, for 𝑁𝑠 = 𝑁1, 𝑁2, … , 𝑁𝑀, the 95 % credible intervals of 𝑡𝑝,𝑎, 𝑎 = 1,… , 𝐴  can 
be expressed as: 
 
                                      𝑡𝑝,1
𝑙𝑜 (𝑁𝑠) < 𝑡𝑝,1 < 𝑡𝑝,1
𝑢𝑝(𝑁𝑠)                                                            (4.14) 
                                                                                  … 
     
𝑡𝑝,a
𝑙𝑜 (𝑁𝑠) < 𝑡𝑝,a < 𝑡𝑝,a
𝑢𝑝(𝑁𝑠)                                                                      (4.15) 
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Figure 4.4. Illustrative example of the CPPDs of the two components of the score vector 𝒕𝑝 
with 5 discretization samples. 
 
where 𝑡𝑝,a
𝑙𝑜  and 𝑡𝑝,a
𝑢𝑝
 are the lower and upper bound of the credible interval for the 𝑎-th component 
of 𝐭𝑝. 
Let 𝑤𝑎(𝑁𝑠) = 𝑡𝑝,𝑎
𝑢𝑝 (𝑁𝑠) − 𝑡𝑝,𝑎
𝑙𝑜 (𝑁𝑠) , 𝑎 = 1,… , 𝐴  be the width of the credible intervals for the 
𝑎-th component of the score vector, and 𝑠𝑎 the semiaxis of the KS on the 𝑎-th LV as defined 
by Eq. (4.5).  The ratio: 
  
𝛼𝑎(𝑁𝑠) =
𝑤𝑎(𝑁𝑠)
𝑠𝑎
                               𝑎 = 1,… , 𝐴 (4.16) 
 
can be used as a measure of the amount of variability captured by the 𝑁𝑠 discretization samples 
for the a-th LV of the PLS model. For each value of 𝑁𝑠, the respective values of 𝛼𝑎 , 𝑎 = 1,… , 𝐴 
can then be computed. Simple regression models 𝑓𝑎, 𝑎 = 1,2, … , 𝐴 can then be built to relate 
the behavior of 𝛼𝑎, 𝑎 = 1, … , 𝐴 with respect to the number of discretization points 𝑁𝑠. 
Mathematically, the following regression models can be obtained: 
 
𝛼𝑎(𝑁𝑠) = 𝑓𝑎(𝑁𝑠)                                     𝑎 = 1, … , 𝐴 .        .    (4.17) 
 
Notice that regression models (4.17) can be built with a small set of values of 𝑁𝑠. Moreover, 
the maximum value assumed by 𝑁𝑠 (i.e. 𝑁𝑀) is relatively small (typically, less than 
25).Therefore, the derivation of the regression models (4.17) is computationally very fast and 
does not significantly contribute to the overall computational burden.  
We define the total amount of variability Ѱ (𝑁𝑠) captured by the 𝑁𝑠 discretization samples on 
the latent space as a weighted sum of the metrics 𝛼𝑎(𝑁𝑠) for all the 𝑎-th components, the 
weights being the amount of 𝐗-variability explained by the given LV. Mathematically: 
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Ѱ (𝑁𝑠) = ∑ 𝑅𝑋,𝑎
2𝐴
𝑎=1 𝛼𝑎(𝑁𝑠) .              (4.18) 
 
The optimal number 𝑁𝑠
𝑜𝑝𝑡
 of discretization points can be derived as the number of samples that 
maximizes Ѱ (𝑁𝑠) (i.e. that maximizes the total amount of variability captured by the 𝑁𝑠 
discretization samples) while keeping the total computational time to a minimum. For 
simplicity, the total computational time is considered as the product of the time  𝜏𝑠 required to 
perform a simulation for a single sample and the number of samples 𝑁𝑠: 
 
𝑇𝑠 = 𝑁𝑠 ⋅ 𝜏𝑠.              (4.19) 
 
𝑁𝑠
𝑜𝑝𝑡
 can then be computed as: 
 
𝑁𝑠
𝑜𝑝𝑡 = min
𝑁𝑠
[ − Ѱ (𝑁𝑠) + 𝑁𝑠 ⋅ 𝜏𝑠].              (4.20) 
 
The above strategy for the selection of the optimal number of discretization points has been 
implemented in MATLAB® and has been used for all the Bayesian simulations involved in this 
study. All the Bayesian Monte Carlo simulations for the multivariate linear regression model 
(4.7) have been implemented in MATLAB v. 2015b. Parallel computing (12 parallel threads) 
has been used to speed up the simulations on an InteL® Core™ I7-6700 CPU@3.40GHz 
processor with 16.0 GB RAM. 
4.5 Case studies 
4.5.1 Case study #1: dry granulation of a pharmaceutical blend by roller 
compaction 
The first case study concerns the dry granulation of a pharmaceutical blend by roller 
compaction. Historical data for this case study were generated by Facco et al. (2015) based on 
the model of Johanson (1965).The modeling environment of gSOLIDS® (Process Systems 
Enterprise, 2014)  was used to this purpose. 
The historical dataset is composed by eight input variables (compressibility factor, roller 
diameter, roller width, roller speed, pressure force, friction angle between solid granulate and 
roller compactor, effective friction angle and springback factor) and one response variable 
(intravoid fraction of the solids out of the compactor). A summary of the input/output variables 
and the characterization of the input dataset is reported in Table 4.1. Full details on the 
derivation of the historical dataset can be found in the cited reference. 
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Table 4.1.  Case study #1: list of the input and response variables (data from 
Facco et al. (2015), based on the model of Johanson (1965)) and 
characterization of the input dataset (columns 5 and 6). 
 ID Variable name Units Symbol Mean Std. 
Inputs      
1 Compressibility factor [-] 𝐾 9.85 2.53 
2 Roller width [m] 𝑠𝑟𝑜𝑙𝑙  0.13 0.02 
3 Roller diameter [m] 𝐷𝑟𝑜𝑙𝑙  0.40 0.07 
4 Roller speed [Hz] 𝜈𝑟𝑜𝑙𝑙  0.1707 0.1072 
5 Pressure force [kN] 𝐹𝑟𝑜𝑙𝑙  13866.67 6951.19 
6 Friction angle [rad] 𝛾𝐹𝑅 27.51 8.78 
7 Effective friction angle [rad] 𝛾𝐸𝐹𝐹  48.17 31.86 
8 Springback factor [-] 𝐹𝑠𝑏 0.11 0.03 
      
Response      
R1 Intravoid fraction of solids [𝑚3/𝑚3] 𝜙𝑠 [-] [-]  
 
The historical dataset presented in Facco et al. (2015) includes 80 calibration samples. In this 
study, 20 calibration samples have been randomly selected from the historical dataset. These 
data have been collected in the input calibration matrix 𝐗 [20 × 8], and in the response 
calibration vector 𝐲 [20 × 1]. 
4.5.2 Case study #2: high-shear wet granulation of a pharmaceutical 
blend 
This case study concerns the high-shear wet granulation of a pharmaceutical blend 
(API+excipient). Experimental data can be found in the study of Oka et al.(2015) and are based 
on a full factorial DoE (3 × 3 × 3). Three input variables are considered (impeller speed, liquid 
to solid ratio 𝐿/𝑆, wet massing time) and their effect on the particle size distribution (PSD) of 
the granulate has been studied. Twenty-seven samples are available.  
Three different scenarios of increasing complexity are considered: 
1. scenario 1 (univariate): only the median particle size 𝑑50 is considered to characterize 
the quality of the granulate; 
2. scenario 2 (bivariate): the quality of the granulate is characterized by the median 
particle size 𝑑50 and the 90-th percentile of the PSD (𝑑90); 
3. scenario 3 (trivariate): the quality of the granulate is characterized by 𝑑50, 𝑑90 and the 
10-th percentile of the PSD (𝑑10)). 
The respective calibration datasets have been collected in the input calibration matrix 𝐗 [27 ×
3] and the response matrices 𝐲𝟏 [27 × 1], 𝐲𝟐 [27 × 2]  and 𝐲𝟑 [27 × 3] for the three scenarios 
considered. 
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A summary of the input-output variables involved for the three scenarios is reported in Table 
4.2. In the same table, the target values of the CQAs that have been considered in the three 
scenarios are reported. 
Table 4.2. Case study #2: list of input and response variables for the three 
scenarios considered (data from Oka et al., 2015). 
ID Variable name Units Symbol Target value 
Inputs 
1 
 
Liquid to solid ratio 
 
[-] 
 
𝐿/𝑆 
 
2 Impeller speed [Hz] 𝑣𝑖𝑚𝑝 [-] 
3 Wet massing time [s] 𝑡𝑤𝑒𝑡 [-] 
Response     
Scenario 1     
R1 Median particle size [𝜇𝑚] 𝑑50 1129 
     
Scenario 2     
R1 Median particle size [𝜇𝑚] 𝑑50 1129 
R2 90-th percentile [𝜇𝑚] 𝑑90 1849 
     
Scenario 3     
R1 Median particle size [𝜇𝑚] 𝑑50 1129 
R2 90-th percentile [𝜇𝑚] 𝑑90 1849 
R3 10-th percentile [𝜇𝑚] 𝑑10 732 
     
 
The purpose of analyzing three different scenarios were: 
1)  to test the ability of the proposed methodology to identify the probabilistic DS when 
the number of quality specifications increases; 
2) to study the robustness of the methodology, namely to analyze how numerical issues 
(e.g., convergence of the Markov chain for every Bayesian simulation) may be affected 
when the problem dimensionality increases. 
4.5.3 Case study #3: roll compaction of an intermediate drug load 
formulation 
Experimental data for this case study are taken from the study of Souihi et al. (2015). Four input 
variables (roller force, roller width, roller diameter, dimensionless ratio of gap to roller diameter 
𝐺𝐷) and 3 product quality variables (ribbon envelope density, ribbon relative density and ribbon 
porosity) are considered. The historical dataset is composed by 34 calibration samples. A 
summary of the input-output variables for this case study is reported in Table 4.3. 
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Table 4.3. Case study #3: list of the input and response variables (data from Souihi et 
al.(2015)) 
ID Variable name Units Symbol Target values 
Inputs     
1 Roller force [kN/cm] 𝑝𝑟𝑜𝑙𝑙  [-] 
2 Roller width [mm] 𝑠𝑟𝑜𝑙𝑙  [-] 
3 Roller diameter [mm] 𝐷𝑟𝑜𝑙𝑙  [-] 
4 Ratio of the gap to roll diameter [-] 𝐺𝐷 [-] 
Response     
R1 Ribbon envelope density [g/cm3]  𝜌𝑒 1065 
R2 Ribbon relative density  [-] 𝜌𝑟 0.72 
R3 Ribbon porosity [%] 𝑃 28 
 
The target values for the CQAs that have been investigated are reported in the same table. 
4.6 Results  
4.6.1 Results for case study #1 
The problem addressed in this case study is the development of a granulate with an intravoid 
fraction of solids leaving the roller compactor equal to 0.6341 m3/m3. The ability of the 
proposed methodology is tested to identify a subspace of the historical knowledge space within 
which the probability that the product specification will be on target is equal to, or greater than, 
90%. First, a PLS model is calibrated using the historical dataset. Two LVs are used, explaining 
95.1 % of the variability of 𝐗 and 89.8 % of the variability of 𝐲. The PLS model allows 
identifying the KS onto the latent space (Fig. 4.5a). The KS is then discretized according to step 
2 of the proposed methodology, and the discretization is shown in Fig. 4.5b. A total of 𝑁𝑠
𝑜𝑝𝑡 =
242 representative samples are then chosen according to the procedure discussed in Section 
4.4.2. Fig. 4.5c shows the optimal sampling points (red diamonds). Once the sampling point 
have been chosen, an MCMC simulation is performed for each optimal sample and the posterior 
predictive probability is calculated. A summary of the computational specifications for this case 
study is shown in Table 4.4. A multivariate Gaussian distribution is chosen for the model 
parameters, and an inverse Wishart distribution for the covariance of the residuals. The values 
of the prior parameters have been set as uninformative, since no prior information on the system 
was available. 1e5 MCMC iterations are used for each selected input combination 
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(a)                                                                                   (b) 
 
  (c)                                                                                     (d) 
Figure 4.5. Case study #1. (a) KS boundary and calibration samples projected onto the latent space. (b) KS 
discretization. (c) Sampling within the KS. (d) Bayesian DS and rejected points. 
 
Of them, 1e3 are discarded (“burn-in” iterations). The optimal number of sampling points for 
the Kennard-Stone algorithm is 242. 
Table 4.3. Case study #1: problem specifications. 
 Specification Value 
No. of calibration samples 20 
No. of model parameters 8 
𝑁𝑠
𝑜𝑝𝑡
 242 
Priors of model parameters Non informative Gaussians 
No. of iterations per sample 1e5 
No. of burn-in iterations 1e3 
Total simulation time (parallel computing) 3h 35min 
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The probability of the given sampling points to give a granulate with the desired intravoid 
fraction of solids is then computed. Finally, the samples (i.e., combinations of raw material 
properties and process parameters) that allow obtaining the desired granulate with 90% 
probability are determined. These samples are represented by green diamonds in Fig. 4.5d.  
Being this a simulated case study, the first-principles model can be used to determine the set of 
input combinations that belong to the DS. A trial-and-error approach was used to determine a 
subset of them, and the result shown by the black circles in Fig. 4.5d was obtained. Note that 
we denote this subset as the actual DS, even though it more properly represents a subspace of 
it. It can be seen that the Bayesian DS returns a reliable estimation of the actual DS. The role 
of the threshold value for the probability can be understood from Fig. 4.6: the larger the 
probability required for the final product to be on target (i.e., the smaller the risk to manufacture 
a product not meeting its quality specifications), the narrower the subspace of input 
combinations that can be used. 
 
Figure 4.6. Case study #1: effect of the threshold value on the Bayesian DS. (a) Threshold = 
90% . (b) Threshold = 80%. 
 
The threshold value should be determined by engineering judgement. Too large values for the 
threshold may result in rejecting all the selected samples within the knowledge space, since the 
desired probability cannot be achieved at the given model accuracy (which is limited by 
definition, since different sources of uncertainty affect the model predictions). On the other 
hand, too small values for the threshold mean that the DS is identified with a larger uncertainty. 
In all the case studies considered in the following, a threshold value of 90% is used. 
4.6.2 Results for case study #2 
One of the 27 historical samples (namely, sample #17) is selected to validate the proposed 
methodology. The PLS model is then calibrated using the remaining 26 samples. Two LVs are 
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chosen, accounting for 97.2 % of the total variability of 𝐗 and 91.8 % of the total variability of 
𝐘. As discussed in Section 5.2, three scenarios are considered. The target values assigned to the 
CQAs for each scenario are reported in Table 4.2. 
Table 4.5 reports the problem specifications for the three scenarios. Non-informative Gaussian 
distributions are used for the model parameters, and inverse Wishart distribution for the 
covariance of the residuals.  
Table 4.5. Case study #2: problem specifications for the three scenarios 
considered. 
 Specification Scenario #1 Scenario#2 Scenario #3 
No. of calibration samples 26 26 26 
No. of model parameters 3 6 9 
𝑁𝑠
𝑜𝑝𝑡
 390 485 491 
Priors of model parameters Non informative 
Gaussians 
 
Non informative 
Gaussians 
Non informative 
Gaussians 
No. of iterations per sample 1e4 1e5 1e6 
No. of burn-in iterations 1e3 1e4 2e5 
Total simulation time (parallel 
computing) 
2h 05min 2h 15 min 2h 20min. 
 
The number of required iterations for each sampling point to obtain convergence of the Markov 
chain increases (from 1e4 to 1e6) with the number of quality specifications. Additionally, a 
larger number of iterations is required to build the joint PPD of the product quality attributes 
for the multivariate scenarios with respect to the univariate one. This is reasonable since the 
number of model parameters for the linear regression model increases with the number of model 
outputs, also resulting in a slower convergence of the Markov chain for each iteration. 
The probabilistic DS projections that can be obtained with the proposed methodology for the 
three scenarios are shown in Fig. 4.7. The green diamonds represent the sampling points (i.e., 
input combinations) that have a probability equal to, or higher than, 90% to give the desired 
granulate. For the univariate scenario (Fig. 4.7a), a narrow portion of the historical KS is 
determined as the probabilistic DS for the product. This subset of input combinations does 
include the actual input combination that allows obtaining the desired median particle size 
(circle in Fig. 4.7). It is worth noting that this circle is only one of the possible real input 
combinations that can lead to the desired product quality. When two quality specifications are 
assigned (Fig. 4.7b), a smaller portion of the historical KS is identified as a probabilistic DS. 
The subspace further shrinks in the trivariate scenario (Fig. 4.7c).  
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    (a) 
 
          (b)                                                                            (c) 
Figure 4.7. Case study #2: Bayesian DS at 90% probability (green diamonds) for: (a) a granulate with assigned 
𝑑50 = 1129 𝜇𝑚; (b) a granulate with assigned𝑑50 = 1129 𝜇𝑚 and 𝑑90 = 1849 𝜇𝑚; (c) a granulate with assigned 
𝑑50 = 1129 𝜇𝑚, 𝑑90 = 1849 𝜇𝑚 and  𝑑10 = 732 𝜇𝑚. 
 
The different shapes of the Bayesian DS obtained for the three scenarios can be explained by 
considering the reduction of dimensionality obtained with the PLS model. Since the number of 
LVs used in the PLS model is 2, when a single quality specification is assigned a 1-dimensional 
null space (Jaeckle and MacGregor, 1998) exists in the space of the model inputs, and the 
projection of the model inputs onto the latent space is therefore a straight line. This explains 
why, in the latent space, the probabilistic DS appears to bounded by straight lines. When the 
number of quality specifications is greater than 1, a null space does not exist in the latent space. 
In this case, if no uncertainty is accounted for, a PLS model would predict (after inversion) a 
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single point in the latent space for a given set of quality specifications. This is why no shape of 
the probabilistic DS is apparent in the latent space. Also note that even if a shape of the DS may 
be apparent in the latent space, this does not imply that the shape is maintained in the real input 
space. 
The results obtained for this case study confirm the ability of the proposed methodology to 
identify a set of input variables combinations for which the probability to meet the quality 
specifications is greater than the assigned thresholds, thus providing a quantification of the 
“assurance of quality” for the investigated product also for products characterized by 
multivariate quality targets. The computational effort increases as the number of quality 
specifications increases, but remains fully tractable 
4.6.3 Results for case study #3 
A historical dataset of 34 samples is available. One sample is chosen as a validation sample, 
and the other 33 are used as calibration samples for the PLS model. As for the other two case 
studies, 2 LVs are chosen, accounting for 96.1 % of the total variability of 𝐗, and 87.7 % of the 
total variability of 𝐲. The target values assigned to the CQAs are reported in Table 4.3. 
The problem specifications are summarized in Table 4.6. Note that the number of optimal 
samples for this case study is 234. 1e5 iterations are used for each iteration, and non informative 
Gaussians are set as prior distributions for the model parameters. 
Table 4.6. Case study #3: problem specifications. 
 Specification Value 
No. of calibration samples 33 
No. of model parameters 12 
𝑁𝑠
𝑜𝑝𝑡
 234 
Priors of model parameters Non informative Gaussians 
No. of iterations per sample 1e5 
No. of burn-in iterations 1e4 
Total simulation time (parallel computing) 1h 15min 
 
The projection onto the latent space of the input combinations that allow obtaining the desired 
quality with a probability equal to, or higher than, 90% is shown in Fig. 4.8 (green diamonds). 
The probabilistic DS captures the available true input combination leading to the desired quality 
target, and offers additional combinations of input materials properties and process operating 
conditions that can be used to manufacture the desired product, with a given probability to meet 
the desired quality targets. The probabilistic DS identification exercise is carried out in a 
reasonably short time (1.25 h). 
 
  
A Bayesian/latent variable approach for design space determination 139 
 
________________________________________________________ 
© 2018 Gabriele Bano, University of Padova (Italy) 
 
 
Figure 4.8. Case study #3: Bayesian DS at 90% probability (green diamonds) and actual 
input combination that gives the desired multivariate quality target (black circle). 
4.7 Discussion 
Two issues deserve further discussion at this point, namely i) the relation between Bayesian DS 
(as discussed in this study) and confidence region for the DS (as assumed by frequentist 
approaches), and ii) some limitations on the use of the proposed methodology. 
With respect to the first issue, it should be pointed out that the meaning of the Bayesian DS is 
intrinsically different from the concept of confidence region for the DS predicted with 
traditional frequentist approaches. For example, Facco et al. (2015) build a frequentist 
confidence region for the model prediction of the DS and name this restricted portion of the KS 
as the “experiment space”. This experiment space represents a subspace of the KS, which is 
deemed to include the DS at the given confidence level: the greater the confidence level, the 
wider the experiment space that must be investigated to determine the DS. On the other side, 
the Bayesian DS discussed in this study can be interpreted as the portion of the KS within which 
the probability for the product to be on target is greater than (or equal to) an assigned threshold: 
the greater the probability threshold, the narrower the Bayesian DS. 
The difference between the two approaches relies on the difference between the concepts of 
confidence region (in frequentist statistics) and credible region (in Bayesian statistics). The 
confidence region (i..e., the experiment space) determined by Facco and coworkers considers 
the model prediction of the DS as fixed, and the bounds of the experiment space as random 
variables. On the other side, the credible region (i.e., the Bayesian DS) as discussed in this study 
considers the bounds of the probabilistic DS as fixed, and the model prediction of the DS as a 
random variable. The practical outcome is that, whereas the experiment space proposed by 
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Facco and coworkers cannot be considered as a model-based representation of the DS, the 
Bayesian DS proposed in this study can be deemed as such, given that the intrinsic probabilistic 
nature of model predictions is recognized (Pantelides et al., 2012). 
With regard to the limitations of the proposed methodology, it must be noted that the amount 
of 𝐗-variability explained by the PLS model for the chosen number of LVs plays a key role for 
its successful implementation. Indeed, the smaller the amount of cumulative 𝐗-variability 
explained by the LVs, the greater the error on the projection of the KS onto the latent space, 
and the worse the representation of the original input space by the latent space. In practice, 
when the amount of explained 𝐗-variability is small, the risk of not considering portions of the 
KS that may belong to the DS of the process increases. As a rule of thumb, a limiting value for 
the amount of cumulative 𝐗-variability explained by the PLS model may be set as 90%, but this 
value can possibly be decreased according to the user’s risk adversity. The cumulative 𝐗-
variability may be increased by increasing the number of LVs of the PLS model (e.g., for A >
2), at the expense of a larger computational burden for the KS discretization as well as of a 
higher complexity of the graphical interpretation of the DS (possibly even losing the possibility 
to provide a graphical interpretation if A > 3). On the other side, a small amount of cumulative 
𝐲-variability explained by the PLS model does not preclude the use of the methodology, even 
though in certain situations it may be a warning that significant nonlinearity exists in the 
original dataset that is not captured adequately by the linear PLS model.  
4.8 Conclusions 
The aim of this Chapter was to propose a methodology that allows identifying the design space 
of a new pharmaceutical product with a risk-based Bayesian posterior predictive approach, 
while reducing the problem dimensionality by using PLS modeling. 
A methodology, based on PLS modeling, that allows automatic determination the optimal 
number of sampling points needed to cover the entire knowledge space has been developed. 
This methodology compromises between reduction of the computational effort and 
achievement of a satisfying coverage of the historical knowledge space. The joint posterior 
predictive probability of each sampling point was obtained with a multivariate Bayesian linear 
regression model, and the probability that product quality will meet its specifications for the 
given point was computed. By performing this analysis for each of the sampling points of the 
historical knowledge space, the probabilistic (or Bayesian) DS of the product under 
investigation was determined. The results were then expressed with a simple and intuitive 
graphical representation on the low-dimensional latent space. 
Three case studies were considered to illustrate the effectiveness of the proposed methodology. 
The obtained probabilistic DS represents a way to demonstrate (i.e., quantify) the level of 
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“assurance of quality” the manufacturer can guarantee for a given product, as advocated by the 
pharmaceutical regulatory agencies. 
Possible areas of further investigation can be pointed out. First, the methodology is completely 
general and can be applied not only to linear multivariate regression model, but also to nonlinear 
data-driven models or nonlinear mechanistic models. Therefore, the combined effect of a 
reduction of problem dimensionality given by PLS and the identification of the Bayesian DS 
using a detailed mechanistic model for the process can be investigated. Secondly, the effect of 
measurement uncertainty (e.g., noise) on the Bayesian DS can be studied (incorporation of 
measurement uncertainty in the Bayesian framework is straightforward). Finally, the effect of 
uncertainty propagation in manufacturing processes involving multiple units (thus with 
significant dimensionality issues) can be assessed with the proposed methodology.
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Chapter 5 
 
Feasibility analysis and latent variable 
modeling for design space 
determination* 
 
In this Chapter, a methodology that exploits first-principles (or semi-empirical) and latent 
variable modeling for the identification of the design space of a new pharmaceutical product is 
presented. Specifically, feasibility analysis is coupled with projection to latent structures (PLS) 
to obtain a computationally tractable identification of the DS of complex pharmaceutical 
processes. PLS is used to obtain a linear transformation between the original multidimensional 
input space and a lower dimensional latent space. Radial Basis Function (RBF) adaptive 
sampling feasibility analysis is then used on this lower dimensional space to identify the feasible 
region of the process. The accuracy and robustness of the results is assessed with three metrics, 
and the criteria that should be adopted for the choice of the number of latent variables are 
discussed. The performance of the methodology is tested on three simulated case studies, one 
of which involving the continuous direct compaction of a pharmaceutical powder. 
5.1 Introduction 
The design space (DS) of a pharmaceutical process is defined as the multidimensional 
combination and interaction of input variables (e.g. material attributes) and process parameters 
that have been demonstrated to provide assurance of quality (ICH, 2009). A modeling technique 
that can be used to assist a DS identification exercise is feasibility analysis (Boukouvala et al., 
2010; Wang and Ierapetritou, 2017). 
The aim of feasibility analysis (Halemane and Grossman, 1983) is to quantify the capability of 
a process design to be feasibly operated over the whole domain of input factors, thus including 
raw material properties and process parameters. The final objective is to determine the 
                                                          
* Bano G., Wang, Z., Facco, P., Bezzo, F., Barolo, M., Ierapetritou, M. (2018) A novel and systematic approach to identify 
the design space of pharmaceutical processes. Comput. Chem. Eng. 115, 309-322 
 
 
144 Chapter 5 
________________________________________________________ 
© 2018 Gabriele Bano, University of Padova (Italy) 
 
multivariate region of the input domain within which the process is considered to be feasible. 
Hence, the concept of feasible region is strictly related to the one of DS for pharmaceutical 
processes. 
Different mathematical approaches can be used to identify the feasible region. When the model 
of the process is computationally inexpensive, the feasible region can be directly determined 
from the model itself (Prpich et al, 2010; Close et al., 2014). When the original model is 
computationally expensive or the computation of its derivatives is cumbersome, surrogate-
based approaches can be used (Boukouvala et al., 2010; Grossmann et al.,2014; Wang and 
Ierapetritou, 2017; Wang et al., 2017). The underlying idea behind these methods is to build a 
surrogate as a computationally cheap and reliable approximation of the original model, and use 
this surrogate to identify the feasible region. In this regard, different types of surrogate models 
have been used (Goyal and Ierapetritou, 2002; Banerjee et al., 2010; Boukouvala et al., 2010; 
Rogers and Ierapetritou, 2015). Recently, Wang and Ierapetritou (2017) proposed a radial basis 
function (RBF) adaptive sampling approach that outperforms all the other surrogate-based 
approaches for low dimensional test problems. The adaptive sampling is a technique that was 
first proposed in the optimization literature (Jones et al., 1998). In surrogate-based feasibility 
analysis, it is used to maximize the potential of the sampling budget and to simultaneously 
explore regions of the original input domain that are close to the boundary of the feasible region 
and less explored regions. 
Although feasibility analysis can be a valuable tool to identify the feasible region of a 
manufacturing process, it suffers from one main limitation, namely the curse of dimensionality 
(Shan and Wang, 2010). When a large number of input factors is involved, as it is often the case 
with large and complex integrated flowsheet models, the computational cost of feasibility 
analysis has a potential to increase significantly. The solution of a feasibility analysis problem 
in this scenario can be extremely complicated if not impossible to solve. When the number of 
input factors is large, the computational burden could be so high or the results so inaccurate as 
to effectively preclude the application of this methodology. Moreover, a visualization problem 
of the feasible region in high dimensions arises, given the impossibility of graphically 
representing a 𝑁- dimensional space (𝑁 > 3). 
A recent work of Wang et al. (2017) tried to solve this problem by transforming a 
multidimensional feasibility analysis problem into a series of disjoint 2-dimensional problems, 
and presenting the results as a matrix of 2-dimensional feasibility contour plots. However, this 
approach does not account for the multivariate correlation between the original input factors 
and is thus incomplete.  
The input factors of a pharmaceutical process are often correlated to each other (Tomba et al., 
2013) and have a different impact on the process output (e.g. product quality; Saltelli et al., 
2010). In most common situations, not all the combinations of the original input factors have a 
strong effect on the output, i.e. some “driving forces” can be identified that predominantly affect 
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the responses (Jaeckle and McGregor, 2000). A class of statistical models that can identify these 
underlying driving forces are latent variable models (LVMs). In particular, partial least-squares 
(PLS) regression (Geladi and Kowalski, 1986; Wold et al., 1983) is a multivariate latent 
variable technique that can be used to capture the variability of the input and output spaces by 
means of few meaningful variables, called latent variables, thus reducing the problem 
dimensionality. The latent variables are chosen by performing a simultaneous decomposition 
of the input and output space, such that these variables explain as much as possible of the 
covariance between the two spaces. Stated differently, PLS identifies linear combinations of 
the original input factors that best describe the correlation between the input factors and their 
effect on the model responses. PLS can be used by itself as a black-box data-driven modelling 
technique to assist a DS identification exercise when a historical dataset of the process under 
investigation is available (Facco et al., 2015; Bano et al., 2017). However, when a historical 
dataset is not available or the process behavior cannot be captured by a linear regression model, 
the ability of PLS to “compress” the original multidimensional input and output spaces (Mevik, 
et al., 2004) can be coupled with more sophisticated modelling techniques to assist a DS 
identification exercise.  
The aim of this work is to overcome the curse of dimensionality of feasibility analysis 
identification by exploiting the ability of PLS to reduce the input space dimensionality. A PLS 
model is used to perform a linear transformation from the original multidimensional input space 
to a lower dimensional latent space. Based on the PLS diagnostics, different scenarios are 
identified in which the proposed methodology is deemed to be profitable.  
RBF-based adaptive sampling feasibility analysis is then performed on the latent space and the 
accuracy and robustness of the results are assessed with three appropriate metrics. The 
performance of the methodology is tested on three simulated case studies, two of them 
involving two-and three unit multidimensional test problems, and one involving a continuous 
direct compaction of a pharmaceutical powder. In all case studies, the ability of the 
methodology to give accurate and robust results by simultaneously reducing the computational 
burden for the feasibility analysis problem is shown. 
The rest of this Chapter is organized as follows. PLS and RBF-based adaptive sampling 
feasibility analysis are briefly reviewed in Section 5.2. The proposed methodology to couple 
PLS and feasibility analysis for the identification of the feasible region of a manufacturing 
process is then discussed in Section 5.3. Section 5.4 collects the case studies considered in this 
work and Section 5.5 shows the results obtained with the proposed methodology. 
5.2 Mathematical background 
In the following, we briefly review the mathematical techniques that we will use throughout 
this Chapter. 
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5.2.1 Partial Least Squares Regression (PLS) 
PLS (Geladi and Kowalski, 1986; Wold et al., 1983) is a multivariate regression technique that 
projects a historical dataset of input 𝐗 [𝐼 × 𝑄] and response variables 𝐘 [𝐼 × 𝑀] onto a common 
latent space of 𝐴 latent variables (LVs), according to the model structure: 
 
𝐗 = 𝐓𝐏T + 𝐄𝐗  (5.1) 
𝐘 = 𝐓𝐐T + 𝐄𝐘  (5.2) 
𝐓 = 𝐗𝐖∗  (5.3) 
where 𝐓 [𝐼 × 𝐴] is the score matrix, 𝐏 [𝑄 × 𝐴] and 𝐐 [𝑀 × 𝐴] are the 𝐗 and 𝐘 loading matrices, 
𝐄𝐗 and 𝐄𝐘 the residuals, 𝐖
∗[𝑄 × 𝐴] is the weight matrix. 
The new set of latent variables is determined by finding the multidimensional directions on the 
𝐗-space that explain the maximum multidimensional variance direction in the 𝐘-space. 𝐴 can 
be chosen in such a way as to explain a significant fraction of the variance of both the input and 
output data.  
The PLS model calibration described by Eqs. (5.1)-(5.3) can be interpreted as a linear 
transformation 𝐿𝑃𝐿𝑆 between the original set of input factors (𝑥1, 𝑥2, … , 𝑥𝑄) and the new set of 
𝐴 latent variables, identified by the model scores (𝑡1, 𝑡2, … , 𝑡𝐴), according to Eq. (5.1). 
Therefore, PLS can be used as a projection technique to express the original set of input factors 
(𝑥1, 𝑥2, … , 𝑥𝑄)  in terms of a reduced set of variables (𝑡1, 𝑡2, … , 𝑡𝐴).  
The latent representation of the original input space obtained with the PLS model captures most 
of the variability of the original input space that is correlated with the model outputs. This is a 
key advantage with respect to other decomposition techniques such as principal component 
analysis (PCA; Hotelling, 1933) or Singular Value Decomposition (SVD), in which the latent 
representation of the original input space only accounts for the variability of the original input 
dataset. In the presence of a strong input collinearity and/or in the presence of a strong 
sensitivity of the model outputs to a reduce set of input combinations, a significant reduction of 
the problem dimensionality can be obtained by exploiting the PLS model (5.1)-(5.3) (i.e. 𝐴 ≪
𝑄). The linearity of the transformation (5.1)-(5.3) allows expressing the original input factors 
as linear combinations of the latent variables, as opposed to other more sophisticated nonlinear 
methods such as Kernel PCA (Schölkopf et al., 1998). For the purpose of this study, this has 
the advantage of keeping the dimensionality reduction step as simple as possible, since process 
nonlinearity is tackled at a subsequent stage of the proposed methodology. 
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5.2.2 Feasibility analysis 
Feasibility analysis is a mathematical tool that allows investigating the portion of the input 
space within which the process under investigation is considered to be feasible. For 
pharmaceutical processes, this is equivalent to determining the design space of the process 
(ICH, 2009). A rigorous mathematical description of the feasibility of a process can be found 
in Wang and Ierapetritou (2017). In a nutshell, given a process with 𝐽 constraints 𝑓𝑗(𝐝, 𝐱), 𝑗 =
1, … , 𝐽, where 𝐝 is the vector of the design variables (which are constant since the process is 
determined) and 𝐱 is the vector collecting the input variables (raw material properties and 
process parameters), the process is considered to be feasible when all its constraints are met, 
i.e. when  𝑓𝑗(𝐝, 𝐱) ≤ 0 ∀𝑗 ∈ [1,… , 𝐽]. In order to verify if any of the process constraints is 
violated, it is enough to check the maximum value of all the constraint function values. The 
maximum value of the constraint function values is defined as a “feasibility function” 𝜓(𝐝, 𝐱) 
(Grossmann, 2014) according to 
 
𝜓(𝐝, 𝐱) = max
𝑗∈𝐽
𝑓𝑗(𝐝, 𝐱).                                                                                            (5.4) 
 
If 𝜓(𝐝, 𝐱) ≤ 0, it means that, for the given set of design variables and input variables, the 
process is feasible. If 𝜓(𝐝, 𝐱) > 0, it means that one or more of the constraints are violated, i.e. 
the process is not feasible. If 𝜓(𝐝, 𝐱) =  0, it means that we are at the boundary of the feasible 
region. The objective of feasibility analysis is to identify the subspace of input combinations of 
the original input domain within which the process is feasible, i.e. to identify the DS of the 
process under investigation.   
5.2.3 Surrogate-based feasibility analysis 
The feasibility analysis problem described in Section 5.2.2 is based upon the availability of a 
model to describe the single unit and/or the overall process under investigation. When the model 
complexity is high (e.g. in the case of an integrated flowsheet model) feasibility analysis can 
be rather difficult due to the computational burden required by the simulation. In this scenario, 
a surrogate-based method can be used to efficiently identify the feasible region. With this 
approach, a surrogate model is built as a computationally cheap approximation of the original 
model. The feasible region is then determined based on this surrogate. Adaptive sampling 
(Rogers and Ierapetritou, 2015) can then be used in order to improve the accuracy of the 
surrogate by making the best possible use of the sampling budget. New points are sampled near 
the boundary of the feasible region as well as in less explored regions of the historical input 
domain. In this work, the feasibility analysis problem is solved using a radial basis function 
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(RBF)-based adaptive sampling method proposed by Wang and Ierapetritou (2017). The main 
features of this approach are briefly discussed below; additional details can be found in the 
original reference. 
5.2.4 Radial basis function (RBF) surrogate model 
RBFs (Björkman and Holmström, 2000) can be used to predict the value of the original function 
at an unsampled point according to: 
 
𝑦𝑛(𝐱) =  ∑ 𝜆𝑖𝜉 (||𝐱 − 𝐱𝒊||𝟐) + 𝐛
T𝐱 + 𝑎𝒏𝑵𝒊=𝟏   (5.5) 
where 𝐱𝑖 ∈ 𝐑
𝑄 , 𝑖 = 1, … , 𝑁 are 𝑁 distinct sample points of known function values 𝑓(𝐱𝑖); ||∗||2 
is the Euclidean norm and 𝜉 is the basis function that in this study is chosen as the cubic basis 
function: 
 
𝜉(𝑟) = 𝑟3 . (5.6) 
The RBF surrogate model with cubic basis function has been proven to outperform other 
surrogate models by Wang and Ierapetritou (2017). 
The coefficients 𝜆𝑖, 𝐛 and 𝑎 of Eq. (5.5) can be determined by solving the following equation: 
 
(
𝚽 𝐒
𝐒𝑇 𝟎
) (
𝛌
𝐜
) = (
𝐅
𝟎
) . (5.7) 
where 𝚽 is the 𝑁 × 𝑁 matrix whose elements are defined by Φ𝑖𝑗 = 𝜉 (||𝐱 − 𝐱𝑖||2) and: 
 
𝐒 = (
𝐱1
𝑇
𝐱2
𝑇
⋮
𝐱𝑁
𝑇
 1
 1
 1
 1
) ; 𝝀 = (
𝜆1
𝜆2
⋮
𝜆𝑁
) ; 𝐜 =
(
 
 
𝐛1
𝐛2
⋮
𝐛𝑄
𝑎 )
 
 
 ; 𝐅 = (
𝑓(𝐱1)
𝑓(𝐱2)
⋮
𝑓(𝐱𝑁)
) .                                  (5.8) 
In order to describe how well the region near an unsampled point 𝐱∗ has been explored, an error 
indicator 1/𝜇𝑛(𝐱
∗) first introduced by Gutmann (2001) is used. The larger the value of 
1/𝜇𝑛(𝐱
∗), the less the nearby region of the unsampled point has been explored. Full details on 
the derivation of this estimator can be obtained in the cited reference and in Wang and 
Ierapetritou (2017). 
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5.2.5 Adaptive sampling 
Adaptive sampling is a technique that allows improving the accuracy of the surrogate without 
spanning the whole historical input domain of the original model (Boukouvala and Ierapetritou, 
2012; Rogers and Ierapetritou, 2015). Various adaptive sampling techniques have been 
developed for different purposes, such as enhancing the accuracy of a global surrogate model 
(Garud, et al. 2017), improving the approximation of distribution functions (Martino et al. 
2015), and facilitating surrogate-based global optimization (Huang et al. 2006; Picheny et al. 
2013; Boukouvala and Ierapetritou 2014).   
In this Chapter, the sampling strategy proposed by Boukouvala and Ierapetritou (2014) was 
used. With this technique, the search for new sample points is directed towards the boundary 
of the feasible region as well as less explored regions of the historical input domain. New 
sampling points are chosen by maximizing a modified expected improvement (EI) function: 
 
 max
𝐱
𝐸𝐼𝑓𝑒𝑎𝑠(𝐱) = 𝑠 × 𝜙 (
−?̂?
𝑠
) = 𝑠 × (
1
 √2𝜋
) 𝑒
−0.5(
?̂?2  
𝑠2
)
  (5.9) 
where 𝐸𝐼𝑓𝑒𝑎𝑠(𝐱) is the modified expected improvement function at 𝐱; 𝑠 is the standard error of 
the predictor; ?̂? is the surrogate model prediction; 𝜙(∗) is the standard normal density function.  
For RBF-based methods, the prediction error can be estimated with the error indicator 1/𝜇 
discussed in Section 5.2.4, by introducing a scale factor to balance the magnitude of 1/𝜇 with 
that of the surrogate value ?̂?. As shown by Wang and Ierapetritou (2017), 𝑠 can be estimated 
as: 
 
𝑠 = √
1/𝜇
𝑠𝑐𝑎𝑙𝑒
                                                                                                          (5.10) 
where: 
 
                   √
1/𝜇
𝑠𝑐𝑎𝑙𝑒
= √
(
1
𝜇
)
 (
1
𝜇0
)
max
×
RBF0
max
𝑉0
 .                                                                         (5.11) 
with  (
1
μ0
)
max
= max (
1
𝜇0
) maximum value of  
1
𝜇
 with the initial surrogate model; 
RBF0
max = max(𝑅𝐵𝐹0) is the maximum value of the initial cubic RBF prediction; 𝑉0 is the 
number of initial sample points. 
By taking the derivative of 𝐸𝐼𝑓𝑒𝑎𝑠(𝐱) with respect to ?̂?, it can be shown (Wang and Ierapetritou, 
2017) that its value is large when the surrogate prediction ?̂? is close to zero (i.e. near the 
boundary of the feasible region) and/or when prediction uncertainty 𝑠 is high. Therefore, the 
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adaptive sampling allows sampling new points near the boundary of the feasible region for the 
surrogate as well as in those regions of the historical input domain where prediction uncertainty 
is high (i.e. less explored regions).  
A schematic representation of the RBF-based adaptive sampling algorithm in shown in Figure 
5.1. This algorithm was first proposed by Wang and Ierapetritou (2017). Three steps are 
involved: in the first step, a space-filling sampling algorithm is used to span the historical input 
domain and build the initial surrogate according to a Design of Experiments (DoE) approach. 
The scale factor of Eq. (5.11) is computed at this step. In the second step, the surrogate accuracy 
is improved by sequentially adding new sampling points obtained with the adaptive sampling 
strategy discussed above. The adaptive sampling stops when the number of iterations exceeds 
a maximum defined by user. A typical value for the maximum number of iterations is 100. In 
the third and last step, the surrogate is used to predict the feasible region (i.e. the DS) of the 
process under investigation. 
 
Figure 5.1. RBF-based adaptive sampling for feasibility analysis. Originally presented by Wang and 
Ierapetritou (2017). 
 
5.2.6 Surrogate accuracy 
The results of the surrogate-based feasibility analysis can be deemed to be accurate if three 
conditions are simultaneously satisfied: 
1. The feasible region is correctly identified by the surrogate; 
2. The infeasible region is correctly identified; 
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3. The surrogate does not considerably overestimate the actual feasible region of the 
process. 
Different metrics have been proposed to quantify the surrogate accuracy, based on the 
computation of simple coverage probabilities (Rogers and Ierapetritou, 2015) or comparison 
between the predicted and theoretical hyper-volumes of the feasible region (Adi et al., 2016). 
However, while these techniques aim at quantifying the first two requirements listed above, 
they fail at addressing the third one. A set of simple metrics accounting for all three aspects is 
the one that has been recently proposed by Wang and Ierapetritou (2017). A graphical and 
analytical interpretation of these metrics can be found in the cited reference. 
The metrics are: 
1. CF (%): percentage of the feasible region for the original function which has been 
correctly discovered by the surrogate model; 
2. CIF (%): percentage of infeasible region for the original function which has been 
correctly discovered by the surrogate model; 
3. NC (%): percentage of feasible region that has been overestimated by the surrogate 
model. 
The first two metrics can be considered as “quality” metrics: they describe how well the input 
space has been explored and classified with respect to feasibility. The third metric can be 
considered as a measure of the “conservativeness” of the results, i.e. it describes how large is 
the portion of the input domain that has been wrongly classified as feasible by the surrogate 
with respect to the overall feasible region predicted by the surrogate itself. In summary, it can 
be said that the feasible region has been classified thoroughly and conservatively if CF(%) and 
CIF(%) are close to 100, and NC(%) is close to 0. 
5.3 Feasibility analysis and reduction of input space dimensionality 
In the following, a systematic methodology to couple PLS input space projection and feasibility 
analysis for the identification of the feasible region of a process involving a (possibly) large 
number of input factors is proposed.  
5.3.1 Proposed methodology 
The proposed methodology involves multiple steps. Although the discussion will be general, 
an illustrative case study shown in Figure 5.2 will be used to give a simple interpretation of the 
methodology. The example involves two units.  Let 𝑥1 and 𝑥2 being the input factors for the 
first unit. Let 𝜓1 be the feasibility function for the first unit, i.e the maximum values of all the 
constraints on the outputs of the first unit. Let 𝑢1 being an additional input for the second unit 
and 𝜓2 be the feasibility function for the second unit. The objective is to determine the set of 
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input combinations 𝐱 =  (𝑥1, 𝑥2, 𝑢1) that satisfy 𝜓2(𝐱) ≤ 0.  In the test problems, it is assumed 
that 𝜓2 monotonically increases with 𝜓1. It is worth noticing that this condition does not imply 
that 𝜓1 ≤ 0 if 𝜓2 ≤ 0; in practical terms, the outputs of the second unit may satisfy all their 
constraints, but the outputs of the first unit may violate some of their own constraints. This 
reflects a practical situation where a process may satisfy the quality constraints on the final 
product (output of unit #2), but not all the constraints on the outputs of all the units of the 
manufacturing line. 
In practical situations, the methodology assumes the availability of an integrated flowsheet 
model of the process (we will refer to this model as the “original” model), with quality 
constraints imposed on the final product. The maximum value of all these constraints will by 
denoted by the feasibility function 𝜓(𝐱). 
 
 
Figure 5.2. Illustrative example for the proposed methodology: block flow diagram. 
The flowchart of the methodology is shown in Figure 5.3. The steps are as follows. 
1. Step #1: collection of simulated data from the model. A dataset is generated using the 
original model (i.e., simulated data). First, the input space is spanned using the Kennard-
Stones’s sampling algorithm (KSA; Kennard and Stone, 1969). KSA is a space-filling 
sampling strategy that selects each new sample by choosing the farthest sample (in terms 
of Euclidean distance) from the previously selected ones, starting from the two farthest 
points on the historical input domain. Each selected sample corresponds to a selected 
input combination. Let 𝐱𝑖, 𝑖 = 1, . . , 𝑄 be the vector that collects all the selected values 
for the 𝑖-th input factor. The selected samples can then be collected in the input matrix 
= [𝐱1, 𝐱2, … , 𝐱𝑄] . The number of samples can be selected by the user and can be 
possibly increased to improve the PLS model accuracy. In all case studies, we generated 
a number of sample points equal to the number of sample points that we used to build 
the initial surrogate.  
Then, the values of the feasibility function 𝜓(𝐱) are collected according to the original 
process model. The vector that collects all these values is denoted by  𝛙. For the 
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illustrative example of Fig. 5.2,  𝐗 = [𝐱1, 𝐱2, 𝐮1], and the feasibility function for the 
overall process corresponds to the feasibility function for the second unit (i.e. 𝛙 = 𝛙2).  
 
2. Step #2: PLS model calibration. A PLS model (Eqs.(5.1)-(5.3)) is calibrated with the 
dataset generated in the previous step. A total number of 𝐴 latent variables are chosen 
according to the desired dimensionality reduction of the input space. In most situations, 
two or three LVs are able to capture most of the variability of the original input space.  
As explained in section 5.2.1, the PLS model is then used in the form of Eq. (5.1) to 
obtain a linear transformation 𝐿𝑃𝐿𝑆 between the original set of input factors 
(𝑥1, 𝑥2, … , 𝑥𝑄) and a new set of 𝐴 latent variables, identified by the PLS model scores 
(𝑡1, 𝑡2, … , 𝑡𝐴), according to Eq. (5.1). In the illustrative example considered, assuming 
𝐴 = 2 latent variables, the linear transformation 𝐿𝑃𝐿𝑆 ∶ (𝑥1, 𝑥2, 𝑢1) ↔ (𝑡1, 𝑡2) can be 
written as: 
 
            𝑥1 = 𝑡1𝑝11 + 𝑡2𝑝12 + 𝑒1   
                        𝑥2 = 𝑡1𝑝21 + 𝑡2𝑝22 + 𝑒2                                                                             (5.12) 
                        𝑢1 = 𝑡1𝑝31 + 𝑡2𝑝32 + 𝑒3  
 
           where 𝑒𝑖 is the residual (i.e. projection error) for the 𝑖-th input factor. 
3. Step #3: PLS model diagnostics. Some diagnostics on the representativeness of the PLS 
model are evaluated. To this purpose, the amount of 𝐗- and 𝐲-variability explained by 
the PLS model is used, which is quantified by the determination coefficients 𝑅𝑋
2 and 𝑅𝑦
2 
(together with their cumulative values 𝑅𝑋,𝑐𝑢𝑚
2  and 𝑅𝑦,𝑐𝑢𝑚
2 ): 
 
𝑅𝑋
2 = 1 −
∑ ∑ (𝑥𝑖,𝑞−?̂?𝑖,𝑞)
2𝑄
𝑞=1
𝐼
𝑖=1
∑ ∑ (𝑥𝑖,𝑞)
2𝑄
𝑞=1
𝐼
𝑖=1
 (5.13) 
𝑅𝑦
2 = 1 −
∑ ∑ (𝑦𝑖,𝑚−?̂?𝑖,𝑚)
2𝑀
𝑚=1
𝐼
𝑖=1
∑ ∑ (𝑦𝑖,𝑚)
2𝑀
𝑚=1
𝐼
𝑖=1
 (5.14) 
where ?̂?𝑖,𝑞 is the element of the 𝑖-th row and 𝑞-th column of the matrix  ?̂? = 𝐓𝐏
T 
reconstructed through the PLS model; ?̂?𝑖,𝑚 is the element of the 𝑖-th row and 𝑚-th 
column of the matrix ?̂? = 𝐓𝐐T. The two metrics (5.13)-(5.14) can be computed for 
every latent variable included in the model and their cumulative values can be reported. 
If the chosen number of latent variables is 𝐴, 𝑅𝑋,𝑐𝑢𝑚
2  and 𝑅𝑦,𝑐𝑢𝑚
2  represent the 
cumulative amount of input and output variability respectively captured by the PLS 
model with 𝐴 LVs. 
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Figure 3. Flow chart of the  proposed methodology. 
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Three possible levels for the metrics 𝑅𝑋,𝑐𝑢𝑚
2  and 𝑅𝑦,𝑐𝑢𝑚
2  are identified, namely “low” 
when they are smaller than 70%, “medium” when they are between 70% and 90%, and 
“high” when they are greater than 90%. These are indicative values dictated by 
experience and can be adjusted according to user’s risk adversity. 
According to the values of 𝑅𝑋,𝑐𝑢𝑚
2  and 𝑅𝑦,𝑐𝑢𝑚
2 , three different possible scenarios can be 
identified, namely Scenario #1 , Scenario #2 and Scenario #3 respectively. 
Scenario #1: the PLS model cannot explain a large portion of both the input and the 
output variability for the chosen number of LVs. In other words, the predictive ability 
of the PLS model is limited (low 𝑅𝑦,𝑐𝑢𝑚
2 ) and a large portion of the original input space 
is not captured by the PLS model (low 𝑅𝑋,𝑐𝑢𝑚
2 ). In order for the methodology to be 
effective, the number of latent variables 𝐴 must be increased to increase the cumulative 
𝐗-variability explained by the PLS model. The higher 𝑅𝑋,𝑐𝑢𝑚
2 , the better the description 
of the original input space by the latent space, the lower the projection error of the linear 
transformation of variables 𝐿𝑃𝐿𝑆. The value of 𝐴 should be increased to obtain a 𝑅𝑋,𝑐𝑢𝑚
2  
close to or higher than 90% (in order to switch to scenario #2). The greater the number 
of LVs chosen, the smaller the reduction of the dimensionality of the original input 
space, the higher the computational burden for the feasibility analysis. If feasibility 
analysis is computationally infeasible for the number of LVs required to satisfy the 
conditions above, the proposed methodology is not useful and should not be used. 
Scenario #2: for the chosen number of LVs, the amount of 𝐗-variability explained by 
the PLS model is high, while the amount of 𝐲-variability explained is low. In this 
scenario, the predictive ability of the PLS model is low (low 𝑅𝑦,𝑐𝑢𝑚
2 ), but the original 
input space is well described by the new latent space, i.e. the projection error of the 
linear transformation 𝐿𝑃𝐿𝑆 is low. This is an ideal scenario for the application of the 
methodology. In fact, recall from section 5.2.1 that, in this study, the PLS model is only 
used as a projection method and not for prediction. Therefore, a small value of 𝑅𝑦,𝑐𝑢𝑚
2  
indicates that PLS (i.e. a simple linear regression model) is not a suitable model for the 
description of the process under investigation. On the other hand, a high value of 𝑅𝑋,𝑐𝑢𝑚
2  
indicates that the original input space is well described by the latent space identified by 
the new set of latent variables (𝑡1, 𝑡2, … , 𝑡𝐴). Since feasibility analysis is performed on 
the original process model by applying the linear transformation of variables 𝐿𝑃𝐿𝑆, this 
scenario represents the ideal situation for the methodology to be effective. The 
feasibility analysis problem is transformed from a 𝑄-dimensional problem to an 𝐴-
dimensional problem, with 𝐴 ≪ 𝑄. 
Scenario #3: the amount of 𝐲-variability explained by the PLS model is high, 
independently of the amount of 𝐗-variability captured by the 𝐴 LVs. In this situation, 
the predictive ability of the PLS model is high, no matter how large is the projection 
error of the linear transformation 𝐿𝑃𝐿𝑆. This suggests that PLS (which is a linear 
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regression model) would be enough to describe the input-output correlation for the 
original process, and could be directly used to predict the feasible region. In this 
scenario, the use of a more sophisticated integrated model for the overall process is not 
necessary to determine the feasible region. Therefore, feasibility analysis is not required 
and the PLS model can be used by itself without going on with the next steps of the 
methodology. Details on the direct use of PLS modelling for the determination of the 
feasible region are reported elsewhere (e.g. Tomba et al., 2012; Facco et al, 2015; Bano 
et al., 2017). 
Figure 5.4 shows the possible combinations of the values of 𝑅𝑋,𝑐𝑢𝑚
2  and 𝑅𝑦,𝑐𝑢𝑚
2  and their 
corresponding scenarios. The cells with two indicated scenarios (e.g. Scenario 1/ 
Scenario 3) represent transitional situations where it is up to the user deciding which 
scenario to be chosen between the two, and therefore which corrective actions to be 
implemented as indicated in Figure 5.5. This gives the user a degree of freedom on the 
choice of the most suitable techniques/corrective actions to be implemented for the case 
study under investigation. 
 
4. Step #4: feasibility analysis. Once verified that the methodology can be effective 
(scenario #2), the surrogate-based feasibility analysis previously discussed is performed 
on the original process model, by applying the linear transformation of variables 𝐿𝑃𝐿𝑆. 
Going back to the illustrative example, the surrogate-based feasibility analysis is 
performed on the original model structure for units 1 and 2, but applying the linear 
transformation of the original input variables described by Eq. (5.14). The surrogate-
predicted feasible region is then identified on the new 𝐴-dimensional latent space, i.e. it 
is identified in terms of the new set of variables [𝑡1, 𝑡2, … , 𝑡𝐴]. 
 
5. Step #5: results validation on the latent space. The surrogate accuracy is validated on 
the latent space of the 𝐴 new variables. The three metrics CF(%), CIF(%),NC(%) are 
computed to test the accuracy and robustness of the results. It is worth noticing that 
these metrics, as computed at this step, simply quantify the agreement between the 
feasible region predicted by the surrogate and the projection of the actual feasible region 
of the process onto the latent space. If these metrics satisfy the threshold values specified 
by the user, the analysis of the surrogate accuracy with respect to the original input space 
can be performed (step #6). If the metrics do not satisfy the requirements, the accuracy 
of the results can be improved by increasing the maximum number of iterations of the 
feasibility analysis or by increasing the number of initial sample points to build the 
surrogate. As a rule of thumb, the following stopping criterion can be used for the 
accuracy metrics: CF(%) > 97, CIF(%) > 97, NC(%) < 3. 
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Figure 5.4. Application of the proposed methodology: possible PLS modeling scenarios. 
 
 
6. Step #6: PLS model inversion. The results of the feasibility analysis are expressed in 
terms of the original input variables by applying the inverse linear transformation 𝐿𝑃𝐿𝑆
−1 . 
In the illustrative example considered, the results of the feasibility of step #5 (expressed 
in terms of (𝑡1, 𝑡2)) are expressed in terms of (𝑥1, 𝑥2, 𝑢1). 
 
7. Step #7: results validation on the original input space. The accuracy and robustness of 
the results are evaluated by computing the metrics CF(%), CIF(%),NC(%) in terms of 
the original input factors (𝑥1, 𝑥2, … , 𝑥𝑄). To emphasize that these metrics are different 
from the ones of step #5, they have been defined as CF2(%), CIF2(%),NC2(%). It must 
be noticed that CF2(%) ≤ CF(%), CIF2(%) ≤ CIF(%) and NC2(%) ≥ NC(%) always 
result, due to the projection error of the linear transformation 𝐿𝑃𝐿𝑆. In the limiting case 
where there is no projection error with the PLS model, then CF2(%) =
CF(%), CIF2(%) = CIF(%) and NC2(%) = NC(%). If the metrics satisfy the 
requirements defined by the user, the results can be considered accurate and the 
algorithm stops. If these metrics do not satisfy the requirements, the projection error 
should be decreased by increasing the number of LVs of the PLS model (thus increasing 
the computational burden). A possible set of threshold values that can be imposed for 
the accuracy metrics at this step is CF2(%) > 90, CIF2(%) > 95, NC2(%) < 5. 
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Figure 5.5. Description and corrective actions for the different PLS modeling scenarios. 
 
 
The methodology presented above was implemented in MATLAB® 2015, and the simulations 
were performed on an InteL® Core™ I7-5600U CPU@2.60GHz processor with 16.0 GB 
RAM. A schematic of the different MATLAB® routines and their interactions are shown in 
Figure 6. Two main routines (PLS and feasibility routines) interact with each other to obtain 
the linear transformation of variables 𝐿𝑃𝐿𝑆. In the PLS routines, the dataset generation and the 
PLS diagnostics subroutines are sequentially called. In the main feasibility routine, the unit 
models and the results validation subroutines are involved. The feasibility routine interacts with 
the PLS routine to transform the reduce set of latent variables to the original input variables 
through the PLS loadings, thus computing the results validation on the original 
multidimensional input space.  
5.4 Case studies 
The proposed methodology was tested on three case studies of increasing complexity.  
In the first case study, a low dimensional two-unit mathematical test problem involving 3 input 
factors is considered. The second case study is a three-unit high dimensional test problem with 
7 input factors. The third case study involves a direct compaction manufacturing process of a 
pharmaceutical powder. Six units and six relevant input factors are considered with 40 
constraints on the model output. 
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Figure 6. Set of MATLAB® routines used to implement the methodology and their interaction 
5.4.1 Case study #1: low dimensional test problem 
The case study is a simplified 2-unit process, as schematically shown in Figure 5.7. The first 
unit is characterized by two input factors (𝑥1, 𝑥2), and the maximum constraint value for its 
output is denoted by 𝜓1. An additional input 𝑢1 enters the second unit, whose feasibility 
function is 𝜓2.  
 
 
Figure 5.7. Case study #1: block flow diagram. 
 
The models for the two units have been taken from Wang and Ierapetritou (2017), based on the 
previous work of Rogers and Ierapetritou (2015). Mathematically, the feasibility problem for 
the first unit (“ex3”) can be expressed as: 
 
−2𝑥1 + 𝑥2 − 15 ≤ 0                                                                                             (5.15) 
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𝑥1
2
2
+ 4𝑥1 − 𝑥2 − 5 ≤ 0                                                                                          (5.16) 
              −
(𝑥1−4)
2
5
−
𝑥2
2
0.5
+ 10 ≤ 0 .                                                                                     (5.17) 
10 ≤ 𝑥1 ≤ 5                                                                                                          (5.18) 
              −15 ≤ 𝑥2 ≤ 15                                                                                                     (5.19) 
 
while the feasibility problem for the second unit (“branincon”) can be expressed as: 
 
  𝑎(𝜓1 − 𝑏𝑢1
2 − 𝑐𝑢1 − 𝑑)
2 + ℎ(1 − 𝑓𝑓)cos(𝑢1) − 5ℎ ≤ 0                                (5.20)                      
-5 ≤ 𝜓1 ≤ 10                                                                                                        (5.21) 
0 ≤ 𝑢1 ≤ 15                                                                                                          (5.22) 
where  
 
𝑎 = 1; 𝑏 =
5.1
4𝜋2
; 𝑐 =
5
𝜋
; 𝑑 = 6; ℎ = 10; 𝑓𝑓 =
1
8𝜋
 .                                                (5.23) 
 
The overall process consists of three input factors (𝑥1, 𝑥2, 𝑢1), thus being a 3-dimensional 
problem. 
5.4.2 Case study #2: high dimensional test problem 
The case study is a high dimensional test problem involving three units and a total of 7 input 
factors for the overall process (Figure 5.8).  
 
 
Figure 5.8. Case study #2: block flow diagram. 
 
The model for the first unit (“g4con”) is taken from Koziel and Michalewicz (1999) and can be 
mathematically described as: 
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0 ≤ 85.334407 + 0.0056858𝑥2𝑥5 + 0.0006262𝑥1𝑥4 − 0.0022053𝑥3𝑥5 ≤ 92          (5.24) 
90 ≤ 80.51249 + 0.0071317𝑥2𝑥5 + 0.002955𝑥1𝑥2 + 0.0021813𝑥3
2 ≤ 110           (5.25) 
 20 ≤ 9.300961 + 0.0047026𝑥3𝑥5 + 0.0012547𝑥1𝑥3 + 0.0019085𝑥3 ≤ 25               (5.26) 
                 78 ≤ 𝑥1 ≤ 102, 33 ≤ 𝑥2 ≤ 45, 27 ≤ 𝑥𝑖 ≤ 45, 𝑖 = 3,4,5.                                 (5.27) 
 
The second unit is the “branincon” test model described for case study #1. The model for the 
third unit (“camelback”) is taken from Goel et al. (2007) and is given by: 
 
(4 − 2.1𝜓2
2 +
𝜓2
4
3
)𝜓2
2 + 𝜓2𝑢2 + (−4 + 4𝑢2
2)𝑢2
2 ≤ 0                                          (5.28) 
−3 ≤ 𝜓2 ≤ 3                                                                                                        (5.29) 
−2 ≤ 𝑢2 ≤ 2 .                                                                                                       (5.30) 
 
The feasibility function for the third unit is denoted as 𝜓3. The input factors for the overall 
process are (𝑥1, 𝑥2, 𝑥3, 𝑥4, 𝑥5, 𝑢1, 𝑢2). The case study is thus a 7-dimensional test problem. 
 
5.4.3 Case study #3: simulation of continuous direct compaction for 
pharmaceutical production 
This case study involves the continuous direct compaction (DC) for the production of powder 
based drugs and is based on the work recently presented by Wang et al. (2017). The flowsheet 
model of the manufacturing line is based on a continuous DC pilot plant situated at ERC-C-
SOPS Rutgers University and is shown in Figure 5.9. 
 
 
 
Figure 5.9: Case study #3: process flow diagram of the continuous direct compaction manufacturing line. 
Originally presented by Wang et al. (2017). 
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The integrated model was developed in gPROMS® (Process Systems Enterprise, 2014) and 
consists of 6 units (API, excipient and lubricant feeders, co-mill, blender and tablet press). The 
behavior of each unit is described by a semi-empirical model. Full details on the models of each 
unit can be found in the work of Wang et al. (2017).  
In this DC process, the API and the excipient are first fed to the co-mill. The lubricant is added 
after the co-mill to improve the flowability of the powder mixture. The API and the excipient, 
together with the lubricant, are then mixed in a continuous convective blender and then 
transported to a rotary feed frame, which feeds the mixture into dies where the press compacts 
the powder into tablets. 
The integrated flowsheet model consists of 22 input factors, including raw material properties, 
process parameters and tablet geometry, and 20 output variables, which include blends material 
properties, operation safety, mixing characterization and tablet product qualities. A detailed list 
of the input and output variables can be found in the cited reference. 
As shown by Wang et al. (2017), sensitivity analysis can be performed to determine the most 
influential input factors with respect to the desired output variables. Wang et al (2017) 
identified 10 influential input factors, 4 of them being raw material properties that are assumed 
to be fixed at their nominal values throughout the entire process operation. Therefore, only 6 
input factors are investigated by feasibility analysis, as reported in Table 5.1. 
Table 5.1. Case study #3: list of the influential input factors and the fixed raw 
material properties. Originally presented by Wang et al. (2017). 
Input # Variable name LB UB Nominal 
value 
Measure
ment unit 
Significant input factors      
1 API flow rate 2.85 3.15 [-] [kg/h] 
2 Excipient flow rate 25.365 28.035 [-] [kg/h] 
3 Co-mill blade speed 1064 1176 [-] [RPM] 
      
4 Blender blade speed 237.5 262.5 [-] [RPM] 
5 Tablet press fill 
depth 
0.0095 0.0105 [-] [m] 
6 Tablet press 
thickness 
0.002375 0.002625 [-] [m] 
Fixed material properties      
MP1 Excipient bulk 
density 
[-] [-] 400 [kg/m3] 
MP2 Excipient true 
density 
[-] [-] 2500 [kg/m3] 
MP3 Excipient 𝑑50 [-] [-] 120 [𝜇𝑚] 
MP4 Excipient 𝑑90 [-] [-] 250 [𝜇𝑚] 
 
A total of 20 double-sided inequality constraints (i.e. 40 single-sided inequality constraints) are 
assigned to the 20 output variables of the flowsheet model, thus making the feasibility problem 
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as a 6-dimensional problem with 40 inequality constraints. The maximum value of all these 
constraints is the feasibility function 𝜓(𝐱) of this case study. 
5.5 Results 
In the following, the results of the proposed methodology for the three case studies discussed 
above are presented and critically discussed. 
5.5.1 Results for case study #1 
The original feasibility problem for this case study was a 3-dimensional problem with quality 
constraints set for the output of the second unit. In other words, it has been imposed that the 
quality constraints must not be violated for the output of the second unit, while some of the 
constraints described by Eqs. (5.15)-(5.17) for the output of the first unit may possibly be 
violated.  
Mathematically, the feasible region on the 3-dimensional input domain identified by 
(𝑥1, 𝑥2, 𝑢1) was considered by accounting only for the feasibility function 𝜓2. The objective 
was to understand if the proposed methodology can reduce the original 3-dimensional problem 
to a lower-dimensional problem, without substantially affecting the accuracy of the prediction 
of the original feasible region. 
Following the procedure of Fig. 5.3, a simulated dataset was first built using the single unit 
models described in section 5.4.1. 49 = 72 KSA-selected calibration samples were used to build 
the PLS model. The obtained PLS diagnostics is reported in Table 5.2. 
Table 5.2. Case study #1. Diagnostics of the PLS model 
LV # 𝑅𝑋
2(%) 𝑅𝑋,𝑐𝑢𝑚
2 (%) 𝑅𝑦
2 (%) 𝑅𝑦,𝑐𝑢𝑚
2  (%)  
1 53.12 53.12 23.12 23.12  
2 42.01 95.13 28.08 51.20  
3 4.87 100.00 7.76 58.96  
 
 
From Table 5.2, it can be seen that with 𝐴 = 2 latent variables the PLS model explains 95.13 
% of the input variability and 51.20 % of the output variability. Recalling Figure 5.4, the case 
study falls into scenario #2 and the methodology can be effective to reduce the original 3-
dimensional problem to a 2-dimensional problem. The linear transformation 
𝐿𝑃𝐿𝑆: (𝑥1, 𝑥2, 𝑢1) ↔ (𝑡1, 𝑡2) was therefore applied and feasibility analysis was executed with 
this new set of latent variables. A rectangular-grid sampling with 49 initial samples (as we did 
to build the PLS model) was used to build the initial surrogate onto the 2-dimensional latent 
space. The contour plot of the original feasibility function 𝜓2 projected onto the 2-dimensional 
 
 
164 Chapter 5 
________________________________________________________ 
© 2018 Gabriele Bano, University of Padova (Italy) 
 
latent space is shown in Figure 5.10a. The grey-shaded areas represent the projection of the true 
feasible region of the process onto the latent space. It is important to notice that these areas, 
even if computed with the original feasibility function, do not correspond exactly to the 3-
dimensional feasible region of the process, due to the projection error of the linear 
transformation 𝐿𝑃𝐿𝑆. 
Adaptive sampling (section 5.2.5) was used to iteratively sample new points and improve the 
surrogate accuracy. A scale factor for the adaptive sampling 10 times larger than the default 
value identified by Eq. 5.11 was used, thus enhancing local search with respect to global search. 
In other words, it was preferred optimizing the sample budget without facing the risk to over 
explore the latent space. In all the case studies considered, it was verified a posteriori that all 
the disjoint feasible regions were correctly identified by the surrogate using the increased scale 
factor, thus confirming the validity of our choice. 100 iterations were fixed as the maximum 
number of iterations for the adaptive sampling. The surrogate accuracy after 100 iterations can 
be seen in Figure 5.10b, where the blue dots represent the initial sampling points and the red 
circles represent the adaptive sampling points after 100 iterations. From the same figure, it can 
be seen that the adaptive sampling points are correctly located near the boundaries of the 
disjoint feasible regions onto the latent space.  
 
 
                                              (a) 
 
  
                                       (b) 
Figure 5.10. Case study #1. (a) Projection of the original function onto the latent space. The 
grey-shaded area represents the projection of the feasible region. (b) RBF model after 100 
iterations. The blue dots represent the initial samples. The red circles represent the adaptive 
sampling points after 100 iterations. 
 
The three metrics 𝐶𝐹(%), 𝐶𝐼𝐹(%),𝑁𝐶(%), that quantify the accuracy and robustness of the 
results with respect to the projection of the actual feasible region onto the latent space, were 
then computed. After 100 iterations, the following values were obtained: 𝐶𝐹(%) =
99.1, 𝐶𝐼𝐹(%) = 99.9, 𝑁𝐶(%) = 1.20. These values confirmed that the surrogate can identify 
with high accuracy the projections of both the feasible and infeasible regions (over 99% of the 
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feasible regions were correctly discovered). They also confirmed that the percent of 
overestimated feasible regions is very low (1.20 %). 
As discussed in section 5.2.6, these metrics quantify the accuracy of the results on the 2-
dimensional latent space and are computed just as an intermediate step for the final assessment 
of the results. 
Since the values of these metrics resulted to be very satisfactory, the results in terms on the 
original input factors were computed, by applying the inverse linear transformation 𝐿𝑃𝐿𝑆
−1 . The 
values of the new metrics  CF2(%), CIF2(%),NC2(%), that describe the accuracy and 
robustness of the results with respect to the original input space, were: CF2(%) =
98.2, CIF2(%) = 99.90, NC2(%) = 1.32. As expected, the values of these metrics are worse 
than the previous ones, due to the projection error of 𝐿𝑃𝐿𝑆 . However, these values confirm that 
over 98% of the actual 3-dimensional feasible regions are correctly discovered, and that the 
methodology overestimates only 1.32% of them.  
In conclusion, the results are very satisfactory: the methodology was able to transform a 3-
dimensional problem into a 2-dimensional problem, reducing the computational burden for 
feasibility analysis, but at the same time guaranteeing the prediction of the actual feasible region 
with an accuracy higher than 98 %. Table 5.3 shows a summary of the results obtained for this 
case study. 
Table 5.3. Case study #1. Surrogate accuracy onto the latent and original 
input space after 100 iterations. 
   Metric 
 
Latent space (2-D) 
 
Original input space (3D) 
 
 
CF(%) 99.10 98.20  
CIF(%) 99.90 99.90  
NC(%) 1.20 1.32  
 
For this case study, the total simulation time for feasibility analysis was 11 min and 32 sec. 
5.5.2 Results for case study #2 
In the second case study, the original problem is 7-dimensional and it would make feasibility 
analysis computationally difficult if not impossible. Moreover, giving a compact representation 
(i.e. graphic) of a 7-dimensional feasible region is impossible and makes the interpretation of 
the results cumbersome.  
The PLS model was built with 49 KSA-selected calibration samples and the diagnostics of 
Table 5.4 were obtained. 
As can be seen in Table 5.4, even though the original number of input factors is 7, the “driving 
forces” that affect the process output are much less. In fact, with 2 latent variables, 88.14 % of 
the variability of the original input space can be captured, and 41.15 % of the variability of 
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output space is described. It is worth noticing that this represents an intermediate situation 
between scenario #1 and scenario #2, since the amount of 𝐗- variability explained is smaller 
than 90 %. 
Table 5.4. Case study #2. Diagnostics of the PLS model 
LV # 𝑅𝑋
2(%) 𝑅𝑋,𝑐𝑢𝑚
2 (%) 𝑅𝑦
2 (%) 𝑅𝑦,𝑐𝑢𝑚
2  (%)  
1 51.12 51.12 26.89 26.89  
2 37.02 88.14 14.26 41.15  
3 5.99 94.13 6.11 47.26  
4 1.09 95.22 1.12 48.38  
5 1.78 97.00 3.29 51.67  
6 0.15 97.15 1.01 52.68  
7 2.85 100.00 2.15 54.83  
 
Therefore, if the case study is treated as belonging to scenario #2, feasibility analysis can be 
applied to a reduced 2-dimensional problem and the accuracy of the results must be assessed. 
On the other hand, if we consider scenario #1, the number of latent variables should be increased 
to increase 𝑅𝑋,𝑐𝑢𝑚
2 . From Table 5.4, it can be noticed that if the number of latent variables is 
increased to 3, 𝑅𝑋,𝑐𝑢𝑚
2  becomes 94.13%, while 𝑅𝑦,𝑐𝑢𝑚
2  does not increase significantly. In this 
case, feasibility analysis must be performed on a 3-dimensional latent space thus increasing the 
computational burden. To compare the balance between the reduction of the projection error 
and the increase of the computational burden, the methodology was tested with both 2 and 3 
latent variables and compared the results. 
In the 2-dimensional case, the initial surrogate was built with 49 calibration samples selected 
according to a rectangular-grid sampling. The projection of the original function onto the latent 
space is shown in Figure 5.11a.  The surrogate accuracy after 100 iterations is shown in Figure 
5.11b.  
It can be noticed that the adaptive sampling points correctly identify the boundary of the feasible 
regions for the process. The metrics CF(%), CIF(%),NC(%) resulted to be 92.15, 98.87 and 
2.97 respectively. When computed on the original 7-dimensional input space, they become 
CF2(%) = 90.11, CIF2(%) = 98.15, NC2(%) = 3.26. These results show that, with 2 latent 
variables, over 90% of the feasible regions are correctly identified by the surrogate, and the 
percent of overestimated feasible regions is smaller than 4%. 
In the 3-dimensional case, a Latin hypercube sampling strategy with 64 samples was used to 
build the initial surrogate. We noticed that the accuracy and robustness of the results increases 
as expected. In fact, the surrogate accuracy after 100 iterations with respect to the original input 
space is CF2(%) = 94.13, CIF2(%) = 99.15, NC2(%) = 1.8. However, the total 
computational time for the feasibility analysis significantly increases from the 2-dimensional 
to the 3-dimensional problem (from 36 min. to 1h 26 min), as shown in Table 5.5. 
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This case study shows how the choice of the number of latent variables should be done as a 
compromise between the desired accuracy of the results and the reduction of the computational 
burden for the feasibility analysis. For most practical applications, an accuracy of around 90% 
 
 
(a) 
 
(b) 
 
Figure 5.11. Case study #2. (a) Projection of the original function onto the latent space. The 
grey-shaded area represents the projection of the feasible region. (b) RBF model after 100 
iterations. The dots represent the initial samples. The red circles represent the adaptive 
sampling points after 100 iterations. 
 
Table 5. Case study #2. Comparison of the surrogate accuracy and simulation 
time after 100 iterations with 2 and 3 latent variables respectively. 
Metric 
 
2 latent variables (2-D) 
 
3 latent variables (3-D) 
 
 
CF2(%) 90.11 94.13  
CIF2(%) 98.15 99.15  
NC2(%) 3.26 1.89  
Total computational time 32 min 1h 26 min  
 
in the identification of the feasible region is acceptable and therefore the original 7-dimensional 
problem can be reduced to a 2-dimensional problem. If more accuracy is required, this has to 
be done by increasing the computational burden for the feasibility analysis. 
5.5.3 Results for case study #3 
This case study is a comprehensive practical exercise of design space identification for a 
continuous manufacturing pharmaceutical process. The step-by-step methodology was applied 
to this 6-dimensional problem, involving 40 inequality constraints for the model output. The 
“historical” dataset was generated using the original integrated flowsheet model by selecting 
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25 KSA calibration samples. A PLS model was then built for the overall process. The PLS 
diagnostics are presented in Table 5.6. 
Table 5.6. Case study #3. Diagnostics of the PLS model. 
LV # 𝑅𝑋
2(%) 𝑅𝑋,𝑐𝑢𝑚
2 (%) 𝑅𝑦
2 (%) 𝑅𝑦,𝑐𝑢𝑚
2  (%)  
1 62.12 62.12 36.45 36.45  
2 29.60 91.72 12.13 48.58  
3 4.12 95.84 11.16 59.74  
4 3.16 99.00 4.21 63.95  
5 0.17 99.17 4.01 67.96  
6 0.83 100.00 1.04 69.00  
 
Table 5.6 results illustrate that the PLS model is able to capture 91.72% of the 𝐗-variability and 
48.58 % of the 𝐲-variability with only two latent variables, thus giving scenario #2. The 
explained 𝐗-variability would increase to 95.84% if 3 latent variables were chosen. Considering 
𝑅𝑋,𝑐𝑢𝑚
2 = 91.72% a good projection accuracy, only 2 latent variables were used for this case 
study. Feasibility analysis was then performed on the reduced 2-dimensional problem with the 
new set of latent variables. A total of 25 = 52 samples were used to build the initial surrogate 
according to a rectangular grid sampling scheme. The increased scale factor discussed for case 
study #1 was also used. The adaptive sampling routine was apoplied and the surrogate RBF 
model onto the latent space after 100 iterations is shown in Figure 5.12b. The projection of the 
original function onto the latent space is shown in Figure 5.12a. It can be noticed that the 
adaptive sampling points clearly identifies the boundary of the feasible region (i.e. the DS) of 
the process. The values of the three metrics CF(%), CIF(%),NC(%) after 100 iterations are 
95.22, 97.95 and 1.13 respectively.  
According to the ICH Q8(R2) guideline, the DS of the process can be described as a 
“combination of variables such as components of a multivariate model” (ICH, 2009).  
Moreover, the DS “can be explained mathematically through equations describing relationships 
between parameters for successful operation” (ICH, 2009). Being the original process 
parameters linear combinations of the PLS scores [𝑡1, 𝑡2] of Figures 5.12a and 5.12b according 
to Eq. (5.1), the representation of the DS of Figure 5.12b fully complies with the regulatory 
requirements. However, from a practitioner’s point of view, describing the DS in terms of latent 
variables may be difficult to translate into input materials properties and process operating 
conditions.  
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(a)  
(b) 
Figure 12. Case study #3. (a) Projection of the original function onto the latent space. The 
grey-shaded area represents the projection of the feasible region. (b) RBF model after 100 
iterations. The blue dots represent the initial samples. The red circles represent the adaptive 
sampling points after 100 iterations. 
 
It must be recalled that each point of Figure 5.12 corresponds to a combination of the six input 
factors of Table 5.1, and the resulting DS can be easily translated into practical information for 
the user by applying the inverse of the linear transformation 𝐿𝑃𝐿𝑆 (step 6 of Figure 6). For 
example, let 𝐭𝑓 = [𝑡1
𝑓 , 𝑡2
𝑓] be a point inside the feasible region identified the RBF model of 
Figure 12b. The corresponding 6-dimensional feasible operating condition 𝐱𝑓 can be obtained 
by applying the linear transformation (5.1) using the loadings of the PLS model (step 2 of Figure 
5.3). The procedure can be repeated for any desired number of points falling within, or at the 
boundary of, the feasible region identified by the RBF model (Figure 5.12b), thus translating 
the latent space results into practical operating conditions. As an example, let 𝐭𝑓 =
[−2.12, −3.18] be one of the points inside the feasible region of Figure 5.12b. The 
corresponding input combination that can be obtained by applying 𝐿𝑃𝐿𝑆
−1  is reported in Table 
5.7. The metrics CF2(%), CIF2(%) NC2(%) on the original 6-dimensional space were 
93.50, 97.20  and 2.30 respectively. These results show that more than 93% of the feasible 
region is correctly identified by the RBF model in the original input space, and the percent of 
overestimated feasible region is a little bit higher than 2%. A summary of the results is presented 
in Table 5.8. 
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Table 5.7. Case study #3. Example of feasible point expressed in terms of 
original input factors, given its coordinates on the latent space 𝑡𝑓 =
[−2.12, −3.18]. 
Original input factor 
combination 
Numerical value Measurement unit 
API flow rate 3.05 [kg/h] 
Excipient flow rate 26.925 [kg/h] 
Co-mill blade speed 1122 [RPM] 
Blender blade speed 253.2 [RPM] 
Tablet press fill depth 0.00998 [m] 
Tablet press thickness 0.002502 [m] 
 
Table 5.8. Case study #3. Surrogate accuracy onto the latent and original 
input space after 100 iterations. 
   Metric 
 
Latent space (2-D) 
 
Original input space (6-
D) 
 
 
CF(%) 95.22 93.50  
CIF(%) 97.95 97.20  
NC(%) 1.13 2.30  
 
The results are very satisfactory considering the dimensionality of the original problem. In a 
previous work, Wang et al. (2017) used a matrix of 2-dimensional feasibility plots to assess the 
accuracy of the results, without accounting for the multivariate correlation between the input 
factors. With the proposed methodology, a high accuracy in the prediction of the feasible region 
is obtained while fully taking into account the multivariate nature of the original problem.   
5.6 Conclusions 
In this work, a novel and systematic methodology to identify the feasible region of an integrated 
process by applying a linear transformation of the original input factors into a new set of PLS-
determined latent variables, and then applying feasibility analysis on this low dimensional 
problem was proposed. Given the original integrated flowsheet model, a PLS model was first 
built based on a simulated dataset obtained from the original flowsheet model. According to the 
amount of input and output variability explained by the PLS model for the chosen number of 
latent variables, three possible scenarios were identifed. In the first scenario, the methodology 
can be applied only if the number of latent variables can be increased while simultaneously 
maintaining the feasibility analysis computationally applicable. In the second scenario, the 
methodology can be directly used and can show its potential; in the latter scenario, feasibility 
analysis is not needed and the feasible region can be directly identified with the PLS model. 
The PLS model was used as a linear transformation between the original set of input variables 
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and the new set of latent variables, and RBF-based adaptive sampling feasibility analysis on the 
reduced latent space was performed. The quality and robustness of the results were assessed 
with three metrics, that describe how well the feasible and infeasible regions are identified by 
the RBF model, and how large is the portion of overestimated feasible region. The methodology 
was tested on three relevant case studies, the first two involving multiple unit test problems 
with 3 and 7 input factors respectively, and the last one involving a continuous manufacturing 
direct compaction process of a pharmaceutical powder. For all the case studies, the ability of 
the methodology to reduce the problem dimensionality while maintaining a good accuracy and 
robustness of the results was shown. It was also shown the ability of the methodology to give a 
simple and compact representation of the feasible regions for the process under investigation. 
For the second case study, it was proved how the choice of the number of latent variables must 
be done by finding a compromise between the desired accuracy and the reduction of the 
computational burden.
                     ________________________________________________________ 
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Chapter 6 
 
Design space maintenance by online 
model adaptation in pharmaceutical 
manufacturing* 
 
In this Chapter, a model adaptation strategy that allows obtaining an up-to-date representation 
of the design space in the presence of process/model mismatch is proposed. First, the motivation 
and the problem statement are presented. Then, the state-of-the art for design space 
determination using classical feasibility analysis is briefly discussed, together with a critical 
review of its main limitations. The proposed methodology is then presented and tested on two 
simulated case studies. Finally, the results of the proposed design space adaptation strategy are 
shown and critically analyzed. 
6.1 Introduction 
Although not compulsory, a detailed description of the design space (DS) of a pharmaceutical 
product is a key step of the Quality by Design (QbD) paradigm advocated by the pharmaceutical 
regulatory agencies. The design space is defined as the multidimensional combination and 
interaction of raw materials properties and critical process parameters that have been 
demonstrated to meet assigned specifications on the critical quality attributes of the final 
product (ICH, 2009). If the submitted design space is approved, the manufacturing process can 
be run anywhere within the design space without initiating a regulatory post approval change 
procedure. This increases process flexibility, since manufacturers can decide to change the 
process parameters and/or the raw material characteristics within the approved design space 
without the need to obtain a new regulatory endorsement.  
The use of mathematical models has been extensively exploited to assist design space 
description during the last decade, both in academia and in industry. In the following, we will 
                                                          
* Bano G., Facco, P., Ierapetritou, M., Bezzo, F., Barolo, M. (2018) Design space maintenance by online model adaptation in 
pharmaceutical manufacturing. Submitted to: Comput. Chem. Eng. 
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refer to the prediction of the design space that can be obtained using a process model as to the 
model-based DS, to distinguish it from the actual (and unknown) DS. In the context of data-
driven models, the use of response surface methodologies (Chatzizacharia and Hatziavramidis, 
2014; Kumar et al., 2014), multivariate experimental design (Charoo et al., 2012), high-
dimensional model representations (Li et al., 2001; Boukouvala et al., 2010), kriging 
methodologies (Jia et al., 2009; Boukouvala et al., 2010) and latent-variable model inversion 
(Tomba et al., 2012) have been reported to support DS description, with application to the 
manufacture of drug substances, intermediates and drug products. With reference to first-
principles models (or semi-empirical ones), techniques such as Monte-Carlo simulations (Burt 
et al., 2011; Brueggemeier et al., 2012; Garcia-Munoz et al., 2015; Garcia- Munoz et al., 2018), 
surrogate-based feasibility analysis (Banerjee et al., 2010; Rogers and Ierapetritou, 2015; Wang 
et al., 2017a; Wang et al., 2017b; Bano et al., 2018) and operability analysis (Vinson and 
Georgakis, 2000; Uztürk and Georgakis, 2002) have been used to assist DS determination. 
Steady-state systems (Lima et al., 2010; Boukouvala and Ierapetritou, 2012) as well as dynamic 
systems (Garcia-Munoz et al., 2015; Rogers and Ierapetritou, 2015) have been considered. 
Whether data-driven or first-principles, DS description using a mathematical model requires 
prior knowledge of the uncertainty affecting the model and of the disturbances that may affect 
plant operation. However, neither all sources of uncertainty nor all disturbances can be modeled 
a priori. Additionally, it should be reminded that the behavior of an industrial production plant 
is typically the outcome of a complex interaction of physical phenomena, and is affected by 
downstream and upstream units, as well by the external environment (Pantelides, 2009). 
Laboratory or pilot-scale measurements often do not embed enough information about these 
interactions, and this may result in deficiencies in the plant model. Finally, drifts may occur 
during actual operation of the plant due to (typically slow) physical phenomena, such as 
equipment fouling, leaks, catalyst deactivation and the like (Pantelides and Renfro, 2013). All 
of the above occurrences can result in process-model mismatch, which impacts on the accuracy 
of the critical quality attributes predicted by the model, thus in turn undermining the 
appropriateness of the design space described by means of the model as originally developed. 
Process-model mismatch can sometimes be mitigated or even removed by adjusting some of 
the original model parameters in real time. This continuous model adaptation methodology is 
long known in process engineering (Lainiotis,1971; Cheng et al., 1993; Ogunnaike, 1994; 
Pantelides, 2009) and, following the regulatory parlance, may also be defined as online model 
maintenance. Maintenance of a process model also affects the DS described using that model, 
an issue that is also addressed by the regulatory agencies in the ICH Q8(R2) guideline (ICH, 
2009), where it is noted that “…for certain design spaces using mathematical models, periodic 
maintenance could be useful to ensure the model’s performance…” and that “...expansion, 
reduction or redefinition of the design space could be desired upon gaining additional process 
knowledge…”. The fact that a DS should be adapted during the product lifecycle has started 
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being acknowledged by the academic community (Herwig et al., 2017). However, no 
indications have been provided so far on how DS maintenance should be carried out and 
reported. This study is intended to offer a contribution to the development of a DS maintenance 
strategy. A discussion on the regulatory implications of DS maintenance is beyond of the scope 
of the study, and therefore this issue will not be addressed in this paper. 
In this Chapter, a methodology that allows continuous maintenance of the model-based 
representation of the DS using online model adaptation is proposed. The main focus is on 
pharmaceutical processes described by first-principles models or semi-empirical models, and 
the availability of plant measurements from online sensors is assumed. Recent advances in 
online applications of first-principles models (commonly referred to as tracking simulators; 
Patwardhan et al., 2012; Pantelides et al., 2016) are coupled with advances in the area of 
feasibility analysis and surrogate-based feasibility analysis for DS determination (Grossmann 
et al., 2014; Bhosekar and Ierapetritou, 2017). Specifically, a dynamic state estimator suitable 
for differential-algebraic equation (DAE) systems (Cheng et al., 1997) is exploited for online 
model adaptation, and an online update of the model-based DS representation using feasibility 
analysis techniques is obtained. Situations where the impact of process-model mismatch can be 
removed online by adjusting some of the original model parameters are analyzed. 
The proposed methodology is tested on two simulated case studies: the former involves the 
roller compaction of microcrystalline cellulose based on the model of Hsu et al. (2010), and the 
latter the fermentation of penicillin in a fed-batch bioreactor based on the model of Riascos and 
Pinto (2004).  
 
6.2 Methods 
 
In the following, the two modelling techniques that will be jointly exploited in this study are 
briefly reviewed. It is assumed that a first-principles model or semi-empirical model of the 
pharmaceutical unit or process under investigation is available. 
 
6.2.1 State estimator for DAE systems 
Most of the models describing a pharmaceutical system are governed by index-1 or higher-
index system of nonlinear DAEs of the form: 
 
[?̇?1
(𝑡)
𝟎
] = [
𝐟1(𝐱1(𝑡), 𝐱2(𝑡), 𝐮(𝑡), 𝑡)
𝐟2(𝐱1(𝑡), 𝐱2(𝑡), 𝐮(𝑡), 𝑡)
] + [
𝐰1(𝑡)
𝐰2(𝑡)
]   (6.1) 
subject to the initial conditions: 
 
𝐱1(0) = 𝐱1,0 +𝐰1(0)   (6.2) 
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where the 𝑁-dimensional system state 𝐱(𝑡) is split into an 𝑁1-dimensional differential state 
𝐱1(𝑡) and an 𝑁2-dimensional algebraic state 𝐱2(𝑡). The model error 𝐰(𝑡) is a zero-mean 
random process with unknown statistics that, in accordance with 𝐱(𝑡), can be split into the 𝑁1-
vector 𝐰1(𝑡) and the 𝑁2-vector 𝐰2(𝑡). The 𝐼-dimensional vector 𝐮(𝑡) is the control vector. 
Online measurements are assumed to be available at discrete sampling instants 𝑡𝑘 and are 
collected in the 𝑀-dimensional vector 𝐲(𝑡𝑘). The online observations are related to the state 
vector at time 𝑡𝑘 according to: 
 
 𝐲(𝑡𝑘) = 𝐡(𝐱1(𝑡𝑘), 𝐱2(𝑡𝑘), 𝑡𝑘) + 𝐯(𝑡𝑘); 𝑘 = 1,2, … , 𝐾    (6.3) 
where 𝐯(𝑡𝑘) is the 𝑀-dimensional vector of unknown measurement noise. Eq. (6.1) is the state-
space model of the system, while Eq. (3) is the observation model. 
In principle, index-1 DAE systems can always be reformulated in standard ODE form, and 
higher index DAEs can be reduced to 1-DAE systems e.g. using Pantelides’ algorithm 
(Pantelides, 1988) or dummy derivative index reduction (Mattsson and Söderlind, 1993). 
Therefore, standard state estimators based on pure ODE state-space models may be used for 
these systems. However, in practical applications, obtaining consistent initial conditions for the 
system state and the initial model error covariance for index-1 DAE systems can be very 
cumbersome. In this case, derivation of state estimators based on the original DAE form can be 
beneficial to overcome this issue. In this study we use the sequential state estimator proposed 
by Cheng et al. (1997), which is directly obtained from the original DAE formulation of the 
system.  
Given the discrete time measurements 𝐲(𝑡𝑘) in the time interval 0 ≤ 𝑡𝑘 ≤ 𝑇, it is required to 
estimate 𝐱1(𝑡) and 𝐱2(𝑡) at a given time 𝑡. The estimation criterion is the minimization of the 
least-squares error functional (Cheng et al., 1997): 
 
𝐼 =   
1
2
 [𝐱1(0) − 𝐱1,0]
T
 𝐏11
−1(0)[𝐱1(0) − 𝐱1,0] + 
+
1
2
∫ { [
?̇?1(𝑡)
0
] − [
𝐟1(𝐱1(𝑡), 𝐱2(𝑡), 𝐮(𝑡), 𝑡)
𝐟2(𝐱1(𝑡), 𝐱2(𝑡), 𝐮(𝑡), 𝑡)
]}
T
𝐐−1(𝑡) {[
?̇?1(𝑡)
0
]
𝑇
0
− [
𝐟1(𝐱1(𝑡), 𝐱2(𝑡), 𝐮(𝑡), 𝑡)
𝐟2(𝐱1(𝑡), 𝐱2(𝑡), 𝐮(𝑡), 𝑡)
]} d𝑡 + 
      +
1
2
∫ [𝐲(𝑡) − 𝐡(𝐱1(𝑡), 𝐱2(𝑡), 𝑡)]
T
𝑇
0
𝐑𝑑
−1(𝑡)[𝐲(𝑡) − 𝐡(𝐱1(𝑡), 𝐱2(𝑡), 𝑡)]d𝑡 (6.4) 
where the first term minimizes the square error of the initial estimate of 𝐱1(0), the second term 
minimizes the integral square model error and the third term minimizes the integral square 
measurement error. Although the three matrices 𝐏11
−1(0), 𝐐−1(𝑡), 𝐑−1(𝑡) do not have statistical 
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meaning, they can be tuned by the user to reflect the errors on the initial estimate of the 
differential state, the process model and the measurement device, respectively. Their meaning 
is analogous to the covariances of the initial state errors, the process noise and the measurement 
noise respectively of the linear Kalman filter (Kalman, 1960). Matrix 𝐑𝑑
−1(𝑡) can be computed 
according to: 
 
 𝐑𝑑
−1(𝑡) = ∑ 𝐑−1(𝑡𝑘)𝛿(𝑡 − 𝑡𝑘)Δ𝑘
𝐾
𝑘=1  (6.5) 
where  Δ𝑘 is the sampling interval at sample 𝑘 and 𝛿(𝑡 − 𝑡𝑘) is the Dirac delta function.  
Application of the calculus of variations to (6.4) allows obtaining a sequential solution to the 
estimation problem. The relevant equations that can be obtained are reported in Appendix A. 
The sequential estimator that can be obtained simplifies to the standard extended Kalman filter 
(EKF) (Ray, 1981) equations when the system is described by ordinary differential equations 
(ODEs). Therefore, the approach considered in this study can be considered as an extension of 
the standard EKF estimation to DAE systems. The robustness of this estimator has been recently 
proved to be satisfactory even with large (227 differential variables plus 14268 algebraic 
variables) high-order nonlinear DAE systems (Pantelides et al., 2016). 
 
6.2.2 Feasibility analysis for dynamical systems 
Feasibility analysis (Halemane and Grossman, 1983) is a mathematical technique that can be 
used to identify the subset of combinations of uncertain parameters that guarantee to satisfy all 
the relevant process constraints (e.g. quality constraints, production constraints, environmental 
constraints). These combinations represent the feasible region of the process. According to the 
standard terminology of feasibility analysis, the uncertain parameters collect three different 
sources of uncertainty (Dimidiatris and Pistikopulos, 1995): 
a) variability on external variables such as raw material properties (e.g., composition of 
available feedstock); 
b) variability on internal variables such as critical process parameters ( e.g., fluctuations 
of the flowrate of the inlet streams); 
c) uncertainty on  model parameters (e.g., heat/mass transfer coefficients, kinetic 
constants). 
These sources of uncertainty can potentially affect the key performance indicators (KPIs) of the 
process. 
From a general perspective, the physical behavior of a dynamic system can be described by the 
systems of DAEs of Eq. (1). This set of equations can be written in the implicit form: 
 
𝐅(𝐝, ?̇?(𝑡), 𝐱(𝑡), 𝐮(𝑡), 𝛉(𝑡), 𝑡)= 0;     𝐱(0) = 𝐱0  (6.6) 
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where the vector collecting the design variables 𝐝 (which is fixed, since we assume that the 
process design is fixed) and the vector collecting the uncertain parameters 𝛉(𝑡) are shown 
explicitly. 
The key performance indicators of the process are subject to a set of constraints (e.g. quality 
constraints). These constraints can be path constraints, i.e. of the form: 
 
𝐠(𝐝, ?̇?(𝑡), 𝐱(𝑡), 𝐮(𝑡), 𝛉(𝑡), 𝑡) ≤ 𝟎 (6.7) 
or a set of 𝑝 = 1,2, … , 𝑃 point constraints, i.e.: 
 
𝐠𝐩(𝐝, 𝐱(𝑡𝑝), 𝐮(𝑡𝑝), 𝛉(𝑡𝑝), 𝑡𝑝) ≤ 𝟎;    𝑝 = 1,…𝑃. (6.8) 
A common type of point constraints is the end-time point constraint: 
 
 𝐠end(𝐝, 𝐱(𝑡𝑒𝑛𝑑), 𝐮(𝑡𝑒𝑛𝑑), 𝛉(𝑡𝑒𝑛𝑑), 𝑡𝑒𝑛𝑑) ≤ 𝟎. (6.9) 
where 𝑡𝑒𝑛𝑑 may be, for example, the total duration of a batch or the total duration of a 
production campaign. The characterization the feasible region of the process can be obtained 
by solving a flexibility test problem (Halemane and Grossmann, 1983). The conventional 
formulation of the flexibility test problem, under the assumption that no control variables are 
manipulated (open-loop scenario), is as follows: 
 
                              𝜒(𝐝) = max
𝛉(𝑡)∈𝐓(𝑡)
Ψ(𝐝, 𝛉(𝑡)) 
      subject to:       Ψ(𝐝, 𝛉(𝑡)) = max
𝑖∈𝐼
(𝑔𝒊(𝐝, 𝐱(𝑡), 𝛉(𝑡), 𝑡)) , 𝑖 = 1,2, … , 𝐼.     
                              𝐅(𝐝, ?̇?(𝑡), 𝐱(𝑡), 𝛉(𝑡), 𝑡) =  𝟎;   
                               𝐱(0) = 𝐱0 
                              𝐓(𝑡) = {𝛉(𝑡)|𝛉𝐿(𝑡) ≤ 𝛉(𝑡) ≤ 𝛉𝑈(𝑡)                                                     (6.10) 
where Ψ(𝐝, 𝛉(𝑡)) is the feasibility function, i.e. the maximum value of all the 𝐼 constraints on 
the process KPIs. The practical meaning of the feasibility function is straightforward: if 
Ψ(𝐝, 𝛉(𝑡)) > 0, there is at least one constraint that is being violated for the given design and 
the process is not feasible at the point in time considered. If Ψ(𝐝, 𝛉(𝑡)) < 0, the process is 
feasible at time 𝑡. If Ψ(𝐝, 𝛉(𝑡)) = 0, vector 𝛉(𝑡) identifies the boundary of the feasible region 
at the given point in time. We will refer to the feasible region of the process as to the set of 
uncertain parameter values that satisfies: 
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                            𝑅(𝑡) = {𝛉(𝑡)| Ψ(𝐝, 𝛉(𝑡)) ≤ 0}   ,                                                          (6.11) 
namely, the combinations of uncertain parameters 𝛉(𝑡) that satisfy all the constraints on the 
key performance indicators. 
The solution of the bi-level optimization problem (6.10) can be deterministic, i.e. by directly 
using the model equations (6.6), or can be obtained exploiting surrogate-based methods 
(Boukouvala and Ierapetritou, 2012).  
In the former case, the solution can be obtained by embedding a differential solver into the 
optimization algorithm or by converting the differential equations into algebraic equations, e.g. 
by means of the direct quadrature (DC) method (Adi and Chang, 2013). In both cases, the 
solution can be computationally very demanding if the process model is expensive to evaluate 
or in the presence of black-box constraints. In the latter case, a surrogate is used as a cheap 
approximation of the original process model, and the optimization problem (6.10) is solved 
using this surrogate. This clearly results in a lower computational cost at the expense of 
introducing an approximation error. A detailed surrogate-based approach for dynamical 
systems based on kriging regression was developed by Rogers and Ierapetritou (Rogers and 
Ierapetritou, 2015). 
 
6.3 Feasibility analysis for design space determination  
 
In the following, a systematic description of the application of feasibility analysis for design 
space determination is given. First, the terminology used in classical feasibility analysis 
formulation is adapted to the one used by the regulatory documents for design space 
determination. Secondly, the application of feasibility analysis for offline model-based DS 
identification is described. Thirdly, the typical procedure adopted for offline model-based DS 
identification is presented and the motivation that leads to an adaptive online model-based DS 
determination is discussed.  
6.3.1 Feasible region and design space  
The definition of feasible region as described by Eq. (6.11) is closely related to the definition 
of design space of a pharmaceutical product. To make the terminology adopted by the 
pharmaceutical regulatory documents consistent with the one adopted in the classical feasibility 
analysis formulation, it must be observed that: 
i) when applied to a design space identification, the constraints on the key performance 
indicators that need to be satisfied are the constraints on the critical quality attributes of 
the pharmaceutical product considered (e.g., mean particle size of a pharmaceutical 
granulate, ribbon density etc.). These constraints reflect the quality specifications that 
are imposed on the final product. 
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ii) The regulatory definition of design space strictly refers to the multidimensional 
combinations of critical process parameters and raw material properties (uncertainty 
sources of the types a) and b) of the previous section) that have been demonstrated to 
meet the specifications on the critical quality attributes of the product.. On the other 
hand, in the classical formulation of the feasibility region (6.11), the uncertainty vector 
𝛉(𝑡) also collects the uncertain parameters of the model that is used to describe the 
process behavior. This source of uncertainty is unrelated to the concept of design space 
and should therefore be considered separately from the other two sources. 
 In view of the above, the uncertainty vector 𝛉(𝑡) in two parts can be split according to: 
 
𝛉(𝑡) = [𝐪(𝑡); ?̃?]                                                                                          (6.12) 
where 𝐪(𝑡) collects the raw material properties and critical process parameters that directly 
affect the product critical quality attribute (i.e. the input variables), whereas ?̃? collects the subset 
of uncertain model parameters of the first-principles model describing the pharmaceutical 
process considered. The model-based DS (𝐷?̂?) can then be defined from a feasibility analysis 
perspective as: 
 
𝐷?̂? = {𝐳(𝑡)  |   Ψ(𝐝, 𝐪(𝑡), ?̃?) ≤ 0}                                                                           (6.13)                                                               
where the feasibility function Ψ(𝐝, 𝐪(𝑡)) is, in this context, the maximum value of all the 
constraints imposed on the productcritical quality attributes.. The definition of design space as 
described by the feasibility analysis formulation (6.13) is now fully consistent with the 
regulatory definition. 
6.3.2 Limitations of existing model-based design space description 
methodologies 
Design space description using a mathematical model is typically performed as an offline 
activity following four sequential steps, namely: 
1) Parameter estimation and model validation. 
2) Design space determination. 
3) Uncertainty quantification on the estimated model parameters and uncertainty 
propagation to the predicted product critical quality attributes. 
4) Uncertainty back-propagation from the product critical quality attributes to the design 
space  obtained at step #2.  
During the parameter estimation and model validation step, the information available from 
designed laboratory or pilot-scale experiments is exploited to obtain an accurate estimate of the 
model parameters (Pantelides et al., 2012). Well-established techniques are available to 
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perform this activity for data-driven models as well as for first-principles models (Asprey and 
Macchietto, 2000). In the design space determination stage, a representation of the design space 
is obtained using one selected modeling strategy. In the uncertainty quantification step, a 
determination of the different sources of uncertainty (i.e., uncertainty on the model parameters, 
measurement error on the calibration dataset, external disturbances) that may affect the model-
based design space representation obtained at the previous step is obtained. Uncertainty can be 
quantified with frequentist (Zhang and Garcia-Munoz, 2009; Garcia-Munoz et al., 2010), or 
Bayesian (Peterson and Yahyah, 2009; Stockdale and Cheng, 2009; Bano et al., 2018a) 
methodologies. During the uncertainty back-propagation step, uncertainty is propagated from 
the output space (i.e. the space spanned by the product critical quality attributes) to the design 
space using suitable uncertainty back-propagation strategies (Facco et al., 2015; Bano et al, 
2017).  
If feasibility analysis is used, steps 2-4 are merged together and the uncertainty on the model 
parameters and modeled disturbances is expressed in terms of expected deviations from their 
nominal values (Pistikopoulos and Mazzucchi, 1990; Straub and Grossmann, 1990; Dimitriadis 
and Pistikopoulos, 1995; Pistikopoulos and Ierapetritou, 1995). The model-based DS is then 
computed accounting for these expected uncertainty ranges (Wang and Ierapetritou, 2017b). 
Despite uncertainty quantification, process-model mismatch may still exist due to the following 
reasons: 
1. Not all of the disturbances that may affect plant operation can be known and modeled a 
priori; 
2. Model calibration and validation (step #1) is typically performed on laboratory or pilot-
scale data. During a production campaign, the plant behavior is affected by the 
interaction of downstream and upstream units as well as of external environmental 
factors. Laboratory-scale (or pilot-scale) data typically do not include enough 
information to capture these phenomena and therefore affect the model-based 
representation of the design space obtained with the calibrated model of step#1. This 
source of uncertainty may, in principle, be included in the uncertainty quantification 
analysis (step #3) and therefore back-propagated to the model-based DS (step #4). 
However, this would require at least a qualitative understanding of these phenomena 
(Pantelides and Renfro, 2013) and how they can affect the model prediction of the 
product critical quality attributes. This is usually a very difficult task to implement in 
practice and requires a strong empirical reasoning. 
3. Some of the model parameters may drift during plant operation due to (typically slow) 
physical phenomena (e.g., catalyst deactivation, fouling, etc.). 
Since process-model mismatch can potentially affect the appropriateness of the design space 
described using the original model, maintenance of the model-based DS would be useful 
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whenever process-model mismatch is encountered. In the next section, we propose a 
methodology to tackle this problem. 
6.4 Design space maintenance by online model adaptation  
An extension to the offline model-based DS identification described in section 6.3.2 is here 
proposed. A 4-step systematic methodology is derived that performs sequentially: i) an offline 
model-based DS identification using feasibility analysis; ii) an online maintenance of the 
model-based DS by jointly exploiting the state estimator described in section 6.2.1 and 
feasibility analysis. 
Let us consider the production of a pharmaceutical product with a process with a fixed design 
and assume that a first-principles model (or semi-empirical model) describing the dynamic 
process is available. Mathematically, the model can be described by the DAE system (6.15) in 
its fully-implicit form, or by Eq. (6.1) (without the error terms) in its semi-explicit form. It is 
assumed that the raw material properties and critical process parameters (collected in the vector 
𝐪(𝑡)) and the product critical quality attributes have already been identified at a previous stage 
of the product development. Quality specifications are imposed on the product critical quality 
attributes in the form of single- and/or double-sided path inequality constraints or single- and/or 
double-sided point inequality constraints. In the former case, the quality constraints can be 
expressed in the implicit form of Eq. (6.7), whereas in the latter case they can be expressed in 
the implicit form of Eq. (6.8). Notice that double-sided inequality constraints can be decoupled 
into a system of two single-sided inequality constraints. The analysis will be focused only to 
end-time specifications imposed on the product critical quality attributes, but the methodology 
is general and can be applied to any type of quality specifications. In this scenario, quality 
specifications are expressed by Eq. (6.9).  
It is assumed that the first-principles model has been validated with laboratory experimental 
data and the nominal values of the model parameters have been estimated and/or taken from 
the literature accordingly. It is also assumed that a set of measurements 𝐲(𝑡𝑘), 𝑘 = 1,…𝐾  will 
be available online from the plant unit at each time instant 𝑡𝑘. In most situations, the product 
critical quality attributes are not measured online and therefore do not belong to 𝐲(𝑡𝑘). The 
methodology can be summarized in 4 steps, as schematically shown in Fig. 6.1. 
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Figure 6.1. Schematic representation of the online design space maintenance methodology. 
6.4.1. Proposed methodology 
The step-by-step methodology is summarized as follows. 
1. Step #1: offline model-based DS identification. Feasibility analysis is used to identify 
the design space of the process with the model whose parameters are set at their nominal 
values. The design space is determined as per the regulatory definition (6.13) by solving 
the optimization problem (6.10) and replacing 𝛉(𝑡) with 𝐳(𝑡). The model-based DS is 
predicted in a deterministic way directly from the first-principles model and does not 
account for the uncertainty on model parameters. 
2. Step #2: determination of the uncertain model parameters ?̃? to be calibrated online. As 
discussed in section 3, the underlying assumption that we make is that the process-model 
mismatch can be removed online by simultaneously updating the system state and 
recalibrating some of the model parameters. If severe structural deficiencies are detected 
in the model, the methodology is not useful: the model should be corrected and the 
methodology re-started from step#1.  
The choice of the parameters to be calibrated online can be made following two criteria: 
a. if prior knowledge of the un-modeled physical phenomena or disturbances that 
may cause the process-model mismatch in the actual plant is available, the model 
parameters that are mostly affected by these disturbances can be determined by 
a qualitative preliminary diagnosis of the model;  
b. if case a) does not hold true, a preliminary sensitivity analysis can be performed 
offline in order to determine the model parameters that most affect the prediction 
of the product critical quality attributes. Since the main target is to remove the 
process-model mismatch affecting the prediction of the critical quality 
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attributes, only the most influential parameters will be calibrated during plant 
operation. 
3. Step #3: state estimation and online parameter recalibration. Given the online 
measurements 𝐲(𝑡𝑘), the state estimator described in section 6.2.1 is used to obtain, at 
each time 𝑡𝑘, both the current state vector of the system ,un up-to-date and an updated 
(recalibrated) model providing an accurate prediction of the product critical quality 
attributes. 
The online model recalibration is obtained through a state augmentation procedure 
(Ricker and Lee, 1995; Smith et al., 2013). The differential subset 𝐱1(𝑡) of the state 
vector is augmented with a new set of time-dependent parameters ?̃?(𝑡), leading to the 
overall state vector: 
 
𝐱(𝑡) = [
𝐱1(𝑡)
?̃?(𝑡)
𝐱2(𝑡)
].                                                                                              (6.14) 
The system of equations (6.1) can then be re-written as: 
 
[
?̇?1(𝑡)
?̇̃?(𝑡)
𝟎
] = [
𝐟1(𝐱1(𝑡), ?̃?(𝑡) , 𝐱2(𝑡), 𝐮(𝑡), 𝑡)
𝟎
𝐟2(𝐱1(𝑡), ?̃?(𝑡), 𝐱2(𝑡), 𝐮(𝑡), 𝑡)
] + [
𝐰1(𝑡)
𝐰?̃?(𝑡)
𝐰2(𝑡)
]   (6.15) 
with initial conditions: 
 
𝐱1(0) = 𝐱1,0 +𝐰1(0)   (6.16) 
  ?̃?(0) = ?̅? + 𝐰?̃?(0)   (6.17) 
where ?̅? is the vector collecting the nominal values of the parameters to be recalibrated 
(i.e., the ones obtained during the offline model calibration procedure); 𝐰?̃?(𝑡) is a 
random process with mean 0 representing the uncertainty on the parameters ?̃?. Based on 
the augmented state (6.14), the estimation criterion and the sequential estimator 
equations are the same as in section 6.2.1 and Appendix A. It is important to notice that, 
with the above state augmentation procedure, the number of parameters that can be 
calibrated online cannot exceed the number of online measurements. The model can be 
updated with the same frequency of online measurements or at a user-defined time step 
Δ𝑡𝑘. 
4. Step #4: online model-based DS maintenance. Feasibility analysis is used to 
periodically update the design space prediction with the up-to-date model returned by 
the state estimator. The design space maintenance frequency Δ𝑡𝑚 must be compatible 
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with the computational time required to solve the optimization problem (6.10). In this 
regard, surrogate-based feasibility analysis provides a competitive advantage in terms 
of the total computational time (typically few seconds) required when complex models 
are used. The condition Δ𝑡𝑚 ≥ Δ𝑡𝑘 must hold true in any event. 
In order to quantify the accuracy of the model-based DS identification with respect to the actual 
DS (which is however unknown in practical applications), the three metrics proposed by Wang 
and Ierapetritou (2017b) are exploited, namely: 
(i) 𝐶𝐹(%) = percentage of the design space of the process that has been correctly 
estimated by the model; 
(ii) 𝐶𝐼𝐹 (%) = percentage of  the infeasible region (i.e. portion of the input domain that 
does not belong to the design space) that has been correctly estimated by the model; 
(iii) 𝑁𝐶(%) = percentage of design space predicted by the model that does not belong 
to the actual DS of the process. 
The closer 𝐶𝐹(%), 𝐶𝐼𝐹 (%) are to 100 and 𝑁𝐶(%) to 0, the better the accuracy in the design 
space identification. Details on the derivation of these metrics can be found in the cited 
reference. 
The feasibility analysis step can be solved using the classical formulation (i.e., by using 
deterministic NLP techniques) or surrogate-based approaches (e.g., by using kriging, or radial-
basis function, or other surrogates), based on the computational requirements for the online 
implementation. Notice that the methodology can be first tested offline once a set of 
measurements are collected in the plant and then implemented online once its robustness is 
assessed. 
The above methodology was implemented in MATLAB® and all simulations discussed in this 
study were performed on an Intel® Core™ I7-5600U CPU@2.60GHz processor with 16.0 GB 
RAM. A sequential quadratic programing (SQP) optimizer was used in all simulations. 
6.5 Case studies 
In the following, two simulated case studies are discussed to test the proposed methodology. 
The following notation will be used: 
1. the “process” denotes the set of equations used to generate synthetic measurements to 
be fed to the state estimator (i.e., the set of equations representing the actual plant 
behavior); 
2. the “model” denotes the set of equations used to simulate the plant behavior. 
Process-model mismatch was enforced as a parametric mismatch in Case study #1 and as a 
structural mismatch in Case study #2. 
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6.5.1 Case study #1: roller compaction of microcrystalline cellulose 
The first case study involves the roll compaction of microcrystalline cellulose grade Avicel 
PH102 and is based on the model proposed by Hsu et al. (2010a), which combines Johanson’s 
rolling theory (Johanson, 1965) with a dynamic material balance. The set of model equations is 
as follows: 
 
d
d𝑡
(
ℎ0
𝑅
) =
𝜔[𝜌𝑖𝑛 cos(𝜃𝑖𝑛) (1 +
ℎ0
𝑅 − cos(𝜃𝑖𝑛)) (
𝑢𝑖𝑛
𝜔𝑅) − 𝜌𝑒𝑥𝑖𝑡 (
ℎ0
𝑅 )]  
∫ 𝜌(𝜃)
𝜃𝑖𝑛
0
cos(𝜃) d𝜃
 (6.18) 
𝑃ℎ =
𝑊
𝐴
𝜎𝑒𝑥𝑖𝑡𝑅
(1 + sin(𝛿))
∫ [
ℎ0
𝑅
(1 +
ℎ0
𝑅 − cos(𝜃)) cos (𝜃) 
]
𝐾
cos(𝜃) d𝜃
𝛼
0
 (6.19) 
𝜎𝑒𝑥𝑖𝑡 = 𝐶1𝜌𝑒𝑥𝑖𝑡
𝐾 . (6.20) 
The product critical qualiy attributes are the ribbon density at the outlet 𝜌𝑒𝑥𝑖𝑡 and the ribbon 
thickness ℎ0. The roll pressure 𝑃ℎ, the roll speed 𝜔 and inlet feed speed 𝑢𝑖𝑛 are process 
parameters that affect the critical quality attributes. However, as proved by Hsu et al. (2010a), 
the roll pressure has a significantly stronger influence on the product quality than the other two 
factors. Therefore, the roll pressure was considered as a critical process parameter and the other 
two variables as control variables that can be manipulated in order to guarantee the product 
specifications. In this regard, Hsu et al. (2010a) proposed to simulate the actuator dynamics for 
the two control variables with a first-order dynamics: 
 
𝜏𝜔
d𝜔
d𝑡
+ 𝜔 =  𝜔𝑑 (6.21) 
𝜏𝑢
d𝑢𝑖𝑛
d𝑡
+ 𝑢𝑖𝑛 = 𝑢𝑑 (6.22) 
where 𝜏𝜔 and 𝜏𝑢 are the time constants, and 𝜔𝑑 and 𝑢𝑑 are the set-points for the roll speed and 
feed speed respectively. The inlet density of the bulk material 𝜌𝑖𝑛 is a raw material property 
that directly affects the critical quality attributes. The meaning and nominal values of all the 
variables and parameters of the model are reported in Table 6.1. An approximated analytical 
expression for the denominator of Eq. (19) can be found in the cited reference.  
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Table 6.1. Case study #1: list of model parameters for roll compaction process 
(taken from Hsu et al., 2010a). 
Parameter Definition Units Value 
𝛿 Effective angle of friction [rad] 0.7068 
𝑅 Roll radius [m] 0.125 
𝐴 Compact surface area [m2] 0.01 
𝑊 Roll width [m] 0.05 
𝐶1 Compression parameter [Pa/(kg m
3)4.97] 7.5×10-8 
𝐾 Compression parameter #2 [-] 4.97 
𝛼 Nip angle [rad] 0.173 
𝜏𝜔 Time constant for 𝜔 [s] 6 
𝜏𝑢 Time constant for 𝑢𝑖𝑛 [s] 6 
𝜔𝑑 Set-point for 𝜔 [rad/s] 0.5236 
𝑢𝑑 Set-point for 𝑢𝑖𝑛 [m/s] 3.27×10
-2 
 
The design space for this system can be defined as the multidimensional combinations of roll 
pressure (critical process parameter) and inlet bulk density (raw material property) that 
guarantee to meet the desired constraints on the product critical quality attributes (ribbon 
density and ribbon thickness). With reference to the dynamic model (18)-(22), the following 
issues deserve attention. 
 It has been pointed out (Hsu et al., 2010a; Hsu et al., 2010b) that the estimate of the inlet 
angle 𝜃𝑖𝑛 is affected by a high degree of uncertainty. Rogers and Ierapetritou (2015) 
showed that 𝜃𝑖𝑛 has a strong effect on the critical quality attributes and consequently on 
the prediction of the design space. For instance, a ±5° (0.09 rad) error on the inlet angle 
can result in a ±50% error in the inlet mass flow rate, thus causing a significant process-
model mismatch on the critical quality attributes. 
 The ribbon density 𝜌𝑒𝑥𝑖𝑡 can be measured online with near-infrared (NIR) spectroscopy 
at a minimum time frequency of 0.1s (Hsu et al., 2010b). 
 Since the roll compactor is meant to operate at steady state (continuous manufacturing), 
the dynamic model (6.18)-(6.22) describes transitions (e.g. start-up, set-point changes) 
between different steady-state operations of the unit. Fast process dynamics coupled 
with model computational complexity act as severe challenges towards online model 
applications (Hsu et al., 2010b). 
In view of the above, the “process” is denoted as the set of equations (6.18)-(6.22) where 
nominal values for 𝜃𝑖𝑛 and initial state vector are used. On the other hand, the “model” is given 
by the set of equations (6.18)-(6.22) with a wrong initial estimate of the system state and a 
wrong initial estimate of 𝜃𝑖𝑛 (parametric mismatch). Namely, a scenario is considered where 
the value of 𝜃𝑖𝑛 obtained during the offline validation procedure is wrongly estimated by 
± 30%, and the initial steady-state values of state variables 𝜌𝑒𝑥𝑖𝑡 and ℎ0 are wrongly estimated 
(by +5% with respect to the nominal values). The error in the initial estimate of 𝜃𝑖𝑛 is consistent 
with the uncertainty on the value of 𝜃𝑖𝑛 that is reported in the literature (Rogers and Ierapetritou, 
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2015). Note that this scenario represents a conservative worst-case one for the estimation of 
𝜃𝑖𝑛.  
6.5.2 Case study #2: penicillin fermentation 
In this case study, the fermentation of penicillin in a fed-batch bioreactor is considered. The 
simplified mechanistic model used by Riascos and Pinto (2004) complemented with the CO2 
production equation proposed by Birol et al., (2002) was used as the reference “model”. The 
model consists of 5 differential equations on the following differential states: volume 𝑉(𝑡), 
biomass concentration 𝐵(𝑡), substrate concentration 𝑆(𝑡), penicillin concentration 𝑃(𝑡), moles 
of CO2 produced per liter of broth [CO2]. The model equations are: 
 
d𝐵(𝑡)
d𝑡
= 𝜇(𝑡)𝐵(𝑡) − (
𝐵(𝑡)
𝑆𝐹𝑉(𝑡)
)𝑈 (6.23) 
d𝑃(𝑡)
d𝑡
= 𝜌(𝑡)𝐵(𝑡) − 𝐾deg𝑃(𝑡) − (
𝑃(𝑡)
𝑆𝐹𝑉(𝑡)
)𝑈 (6.24) 
d𝑆(𝑡)
d𝑡
= −𝜇(𝑡) (
𝐵(𝑡)
𝑌𝐵/𝑆
) − 𝜌(𝑡) (
𝐵(𝑡)
𝑌𝑃/𝑆
) − (
𝑚𝑆𝑆(𝑡)
𝐾𝑚 + 𝑆(𝑡)
)𝐵(𝑡) +
(1 −
𝑆(𝑡)
𝑆𝐹
)𝑈
𝑉(𝑡)
 (6.25) 
d𝑉(𝑡)
d𝑡
=
𝑈
𝑆𝐹
 (6.26) 
d[CO2](𝑡)
d𝑡
= 𝛼1
d𝐵(𝑡)
d𝑡
+ 𝛼2𝐵(𝑡) + 𝛼3 (6.27) 
with: 
𝜇(𝑡) = 𝜇𝑚𝑎𝑥 (
𝑆(t)
𝐾𝑋𝐵(𝑡) + 𝑆(𝑡)
) (6.28) 
𝜌(𝑡) = 𝜌𝑚𝑎𝑥 (
𝑆(𝑡)
𝐾𝑃 + 𝑆(𝑡) (1 +
𝑆(𝑡)
𝐾in
)
). (6.29) 
The nominal values of the model parameters and the initial conditions for the state variables are 
reported in Table 6.2.  
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Table 6.2. Case study #2: list of model parameters for the penicillin 
fermentation model (data from Riascos and Pinto (2004) and Birol et al. 
(2002)). 
 Parameter Definition Units Value 
𝜇max Maximum specific biomass growth rate  [h
−1] 0.11 
𝜌max Maximum specific production rate [g𝑃/(g𝐵ℎ)] 0.0055 
𝐾𝑋 Saturation parameter for biomass growth [g𝑆/g𝐵] 0.006 
𝐾𝑃 Saturation parameter for production [g𝑆/L] 0.0001 
𝐾in Inhibition parameter for production [g𝑆/L] 0.1 
𝐾deg Product degradation rate [h
−1] 0.01 
𝐾𝑚 Saturation parameter for maintenance consumption [g𝑆/L] 0.0001 
𝑚𝑆 Maintenance consumption rate [g𝑆/(g𝐵h)] 0.029 
𝑌𝐵/𝑆 Yield factor for substrate to biomass [g𝐵/g𝑆] 0.47 
𝑌𝑃/𝑆 Yield factor for substrate to product [g𝑃/g𝑆] 1.2 
𝛼1 Constant relating CO2to growth [mmol CO2/g𝐵] 0.143 
𝛼2 Constant relating CO2 to maintenance energy [mmol CO2/(g𝐵 h)] 4× 10
−7 
𝛼3 Constant relating CO2 to penicillin production [mmol CO2/(Lh)] 10
−4 
 
By plugging Eqs. (6.28)-(6.29) into Eqs (6.23)-(6.27), the original DAE system can be 
converted into a pure ODE system whose state vector is given by 𝐱1(𝑡) =
[𝐵(𝑡); 𝑃(𝑡); 𝑆(𝑡); 𝑉(𝑡); [CO2](𝑡)]. Note that in this scenario, the estimator of section 6.2.1 
simplifies to the standard EKF observer.  
The model described by Eqs. (6.23)-(6.27) is based on some assumptions and simplifications 
that do not hold true in industrial penicillin fermenters (structural mismatch). These 
assumptions and simplifications can be summarized as follows. 
 The effects of environmental factors, such as pH and temperature in the bioreactor, are 
not modeled. These variables actually play a key role in penicillin fermentation, having 
a direct impact primarily on the biomass growth rate and penicillin production rate. 
 The model assumes saturation conditions for the oxygen dissolved in the broth. 
However, in industrial applications, oxygen limitation is a key issue that directly affects 
the biomass growth rate and the penicillin production rate. 
 In industrial fermenters, a significant amount of the broth inside the reactor (up to ~10–
20 % in one week of operation, as observed by Birol et al., 2002) is lost due to 
evaporation. In addition, the volume inside the reactor is affected by addition of 
acid/base solutions to control the broth pH. The model does not account for any of these 
phenomena. 
A detailed set of equations that take into account all the phenomena described above in 
penicillin fermentation is the one proposed by Birol et al (2002), based on a previous work of  
Bajpai and Reuss (1980). A description of these equations is reported in the supplementary 
material. This set of equations was used as the reference “process”, from which synthetic 
measurements to be fed to the state estimator were generated. Summarizing: 
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1. the “process” is the set of equations proposed by Birol et al (2002) that can be found in 
the supplementary material. These equations account for all the relevant physical 
phenomena described above; 
2. the “model” is the set of equations (6.23)-(6.29), in which the phenomena described 
above are not explicitly considered in the model structure. 
 
 
6.6 Results and discussion 
6.6.1 Results and discussion for Case study #1 
6.6.1.1 Simulation set-up  
By plugging Eq. (6.20) into Eq. (6.19), and solving Eq. (6.19) with respect to the ribbon density 
𝜌𝑒𝑥𝑖𝑡, the dynamic model of the granulator is in the general DAE form of Eq. (6.1), where the 
only differential state is given by the ribbon thickness ℎ0(𝑡), the only algebraic state is 𝜌𝑒𝑥𝑖𝑡(𝑡), 
and the control vector is given by the inlet feed speed 𝐮(𝑡) = [𝜔(𝑡); 𝑢𝑖𝑛(𝑡)]. As remarked in 
section 6.5.1, the inlet angle 𝜃𝑖𝑛(𝑡) is the uncertain parameter that needs online recalibration. 
During normal operation of the roller compactor, measurements of the ribbon density can be 
obtained online through NIR spectroscopy. To the purpose of testing the proposed 
methodology, synthetic process measurements of  𝜌𝑒𝑥𝑖𝑡(𝑡𝑘) ( 𝑘 = 1,…𝐾) were generated at a 
frequency of 1 Hz and a nominal value ?̅?𝑖𝑛 = 0.4 rad. White Gaussian noise (𝑡𝑘)~(0,0.9
2) , 
corresponding to a standard deviation of 0.1% of the nominal value ?̅?𝑒𝑥𝑖𝑡 = 900 kg/m
3, was 
added to the 𝜌𝑒𝑥𝑖𝑡 measurements. 
6.6.1.2. Offline model-based DS identification (step #1) 
Wrong identification of 𝜃𝑖𝑛 and of the initial state of the system causes a process-model 
mismatch that strongly impacts on the prediction of the product critical quality attributes, as 
shown in Fig. 6.2. 
In order to identify offline the model-based DS, the following upper (superscript up) and lower 
(superscript lo) specifications were assigned to the product critical quality attributes (𝜌𝑒𝑥𝑖𝑡 and 
ℎ0) for a new steady-state reached at time 𝑡𝑆𝑆: 
 
𝜌𝑒𝑥𝑖𝑡(𝑡𝑆𝑆) − 𝜌𝑒𝑥𝑖𝑡
𝑢𝑝 ≤ 0                                                      (6.30) 
  𝜌𝑒𝑥𝑖𝑡
𝑙𝑜 − 𝜌𝑒𝑥𝑖𝑡(𝑡𝑆𝑆)  ≤ 0                                                      (6.31) 
ℎ0
𝑙𝑜 − ℎ0(𝑡𝑆𝑆) ≤ 0                                                            (6.32) 
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ℎ0(𝑡𝑆𝑆) − ℎ0
𝑢𝑝 ≤ 0.                                                          (6.33) 
 
                                               (a)                                                                     (b) 
      
Figure 6.2. Case study #1: effect of process-model mismatch on (a) prediction of the ribbon thickness and 
(b) prediction of the ribbon density.                    
 
According to the feasibility analysis formulation (6.10), the model-based DS can be formulated 
as follows: 
 
𝜒(𝐝) = max
𝑃ℎ, 𝜌𝑖𝑛
Ψ(𝐝, 𝑃ℎ, 𝜌𝑖𝑛)                                                       (6.34) 
                                    s.t.       Ψ(𝐝, 𝑃ℎ, 𝜌𝑖𝑛) = max { 𝜌𝑒𝑥𝑖𝑡(𝑡𝑆𝑆) − 𝜌𝑒𝑥𝑖𝑡
𝑢𝑝 ≤ 0; 
                                                        𝜌𝑒𝑥𝑖𝑡
𝑙𝑜 − 𝜌𝑒𝑥𝑖𝑡(𝑡𝑆𝑆) ≤ 0; 
                                                              ℎ0
𝑙𝑜 − ℎ0(𝑡𝑆𝑆) ≤ 0; 
ℎ0(𝑡𝑆𝑆) − ℎ0
𝑢𝑝 ≤ 0};                                                                (6.35) 
d
d𝑡
(
ℎ0
𝑅
) −
𝜔[𝜌𝑖𝑛 cos(𝜃𝑖𝑛)(1+
ℎ0
𝑅
−cos(𝜃𝑖𝑛))(
𝑢𝑖𝑛
𝜔𝑅
)−𝜌𝑒𝑥𝑖𝑡(
ℎ0
𝑅
)]  
∫ 𝜌(𝜃)
𝜃𝑖𝑛
0 cos(𝜃)d𝜃
= 0                              (6.36) 
𝑃ℎ −
𝑊
𝐴
𝜎𝑒𝑥𝑖𝑡𝑅
(1+sin(𝛿))
∫ [
ℎ0
𝑅
(1+
ℎ0
𝑅
−cos(𝜃)) cos (𝜃) 
]
𝐾
cos(𝜃) d𝜃
𝛼
0
= 0                             (6.37) 
𝜎𝑒𝑥𝑖𝑡 − 𝐶1𝜌𝑒𝑥𝑖𝑡
𝐾 = 0                                                              (6.38) 
ℎ0(0) = ℎ0
𝑖𝑛                                                                     (6.39) 
𝜌𝑖𝑛 ∈ [𝜌𝑖𝑛
min; 𝜌𝑖𝑛
𝑚𝑎𝑥]                                                              (6.40) 
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𝑃ℎ ∈ [𝑃ℎ
𝑚𝑖𝑛; 𝑃ℎ
𝑚𝑎𝑥].                                                             (6.41) 
All the numerical values (initial conditions; product quality specifications; input variables 
domain) are reported in Table 6.3. In problem formulation (6.34)-(6.41), we assumed time-
invariant input variables 𝑃ℎ   and  𝜌𝑖𝑛; the control variables 𝜔(𝑡) and 𝑢𝑖𝑛(𝑡) do not appear 
because their trajectories are explicit functions of (𝑃ℎ,  𝜌𝑖𝑛). Notice that, although we steady-
state quality constraints were assigned and time-invariant input variables were considered, 
formulation (34)-(41) is inherently dynamic since it requires integration until the new steady-
state is reached. 
Table 6.3. Case study #1: values of the parameters appearing in problem 
formulation (34)-(41). 
 Parameter Units Value 
ℎ0
𝑖𝑛 [cm] 0.183 
ℎ0
𝑢𝑝
 [cm] 0.190 
ℎ0
𝑙𝑜 [cm] 0.170 
𝜌𝑒𝑥𝑖𝑡
𝑢𝑝
 [kg/m3] 950 
𝜌𝑒𝑥𝑖𝑡
𝑙𝑜  [kg/m3] 850 
𝜌𝑖𝑛
𝑚𝑎𝑥 [kg/m3] 550 
𝜌𝑖𝑛
𝑚𝑖𝑛 [kg/m3] 150 
𝑃ℎ
𝑚𝑎𝑥 [MPa] 1.1 
𝑃ℎ
𝑚𝑖𝑛  [MPa] 0.9 
 
The model was updated every Δ𝑡𝑘 = 1 𝑠, whereas the design space was updated every Δ𝑡𝑚 =
5 𝑠. Accordingly, a solution to the optimization problem (6.34)-(6.41) must be obtained within 
5 s. However, the optimization problem in its classical formulation can only be solved in a time 
frame 10 times larger than required, and classical feasibility analysis would therefore make the 
proposed methodology ineffective. As discussed in section 6.2.2, the approach proposed by 
Rogers and Ierapetritou (2015) was implemented, which builds a kriging surrogate as a cheap 
approximation of model (6.18)-(6.22).  
The ability of the surrogate approach to give a reliable representation of the actual DS with 
respect to the classical formulation approach was first tested offline. The boundary of the 
model-based DS obtained with the classical and kriging-based feasibility analysis are shown in 
Fig. 6.3. It can be noticed that the boundary of the model-based DS obtained with the kriging 
approach (obtained after 10 iterations) are in perfect agreement with the ones obtained with the 
classical formulation. However, the computational time with the kriging surrogate is 30 times 
faster than with the original model, thus making online implementation of the proposed 
methodology possible. 
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Figure 6.3. Case study #1: boundary of the model-based DS of the process obtained with the classical 
formulation (42) and with the kriging surrogate approach. 
 
Fig. 6.3 also shows that there is a direct relationship between the effect of the roll pressure and 
inlet bulk density with respect to the product critical quality attributes. The higher the roll 
pressure, the greater the inlet bulk density the process can tolerate to guarantee the final product 
specifications. This is in agreement with the experimental work of Hsu et al. (2010a). 
6.6.1.3 State estimation for online model adaptation (steps #2 and #3) 
The case study represents a situation where the model parameter that needs online re-calibration 
(i.e. 𝜃𝑖𝑛) is known a priori. Implementation of step #2 of the proposed methodology is therefore 
straightforward. 
With respect to step #3, the following conditions were set for the state estimator: 
 
 𝐏11(0) = (
0.012 0
0 12
);  𝐐 = (0.01
2 0
0 12
) ;   𝐑 = 0.92 ;   Δ𝑡𝑘 = 1s .                        (6.42) 
The value of the initial error covariance, model error covariance and measurement covariance 
were treated as tuning parameters. An alternative systematic procedure that can be used to set 
the values of these matrices is the one proposed by Schneider and Geoargakis (2012). Note that 
we used a model error for 𝜌𝑒𝑥𝑖𝑡 (= 1
2) slightly greater than its measurement error (= 0.92), in 
order to reflect the greater confidence that we have on the measured values of 𝜌𝑒𝑥𝑖𝑡 rather than 
their model prediction. 
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The results obtained with the state estimator for the two scenarios considered (± 30% 
estimation error on 𝜃𝑖𝑛, +5% error on initial state) are shown in Fig. 6.4. Note that this figure 
refers to a situation where 𝑃ℎ and 𝜌𝑖𝑛 are set at their nominal values and simply illustrates the 
estimator performance. 
It can be noticed that the state estimator quickly removes the effect of process-model mismatch 
from both 𝜌𝑒𝑥𝑖𝑡 (measured variable) and ℎ0 (inferred state variable, not available to measure). 
Additionally, the alignment of 𝜃𝑖𝑛 to its actual value occurs quickly.  
 
 
(a)                                                              (b) 
 
                                                                            (c)                               
Figure 6.4. Case study #1: state estimator predictions, process states and measurements. (a) Ribbon 
thickness. (b) Ribbon density. (c) Inlet angle. 
6.6.1.4 Online model-based DS maintenance (step #4) 
The online model-based DS maintenance can be formulated at each time-step 𝑡𝑚 using the 
kriging-based feasibility analysis as: 
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𝜒(𝐝) = min
𝑃ℎ,𝜌𝑖𝑛
𝑈𝑝,𝑚(𝑃ℎ, 𝜌𝑖𝑛, 𝜃𝑖𝑛(𝑡𝑚))                                                       (6.51) 
                                 s.t.       𝜌𝑖𝑛 ∈ [𝜌𝑖𝑛
min; 𝜌𝑖𝑛
𝑚𝑎𝑥]                                                              (6.52) 
𝑃ℎ ∈ [𝑃ℎ
𝑚𝑖𝑛; 𝑃ℎ
𝑚𝑎𝑥].                                                             (6.53) 
where 𝑈𝑝𝑚(⋅) is the surrogate (kriging) feasibility function with initial conditions for the state 
variables given by the up-to date state vector 𝐱(𝑡𝑚). The design space identification with 
formulation (6.51)-(6.53) is accurate (as proved in Fig. 6.3) and requires a short computational 
time (1.67 s in less than 10 iterations).  
The offline model-based DS that would be obtained with the –30% and +30% error on the 
estimate of 𝜃𝑖𝑛 are compared with the actual DS of the process in Fig. 6.5. The figure shows 
that a wrong estimate of 𝜃𝑖𝑛 strongly affects the model-based DS identification. Namely, 𝜃𝑖𝑛 
strongly influences the prediction of the variability of the inlet bulk density that the process can 
tolerate to guarantee the final product quality. 
 
Figure 6.5. Case study #1: comparison between the actual DS and the offline model-based DS with +30% 
and –30% estimate on the bulk inlet angle 𝜃𝑖𝑛 and 5% error on the initial state. 
 
The evolution of the model-based DS that can be obtained with the proposed online DS 
maintenance procedure is shown in Fig. 6.6. The figure refers to the scenario with a –30% 
wrong estimate on 𝜃𝑖𝑛 and +5% error on the initial state of the system. The results for the case 
with +30% error on 𝜃𝑖𝑛 are analogous and can be found in the supplementary material. The 
online model-based DS is shown after 0 (i.e., initial offline model-based DS), 5, 10, 15 and 35 
s (i.e., the time the process takes to reach its new steady-state) seconds. Consistently with Fig. 
6.6, it can be noticed that it takes less than 20 s for the model-based DS to be in complete 
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agreement with the actual DS. For this lab-scale roller compactor, the methodology is able to 
restore the correct model-based DS identification in less than half of the time the process needs 
to reach its new steady state. The values of the metrics 𝐶𝐹(%). 𝐶𝐼𝐹(%) and 𝑁𝐶(%) are 99.95, 
99.97 and 0.03 respectively, thus confirming the perfect agreement between the model-based 
DS and the actual DS. The total computational time required for the sequential state estimation 
step is 0.44 s, whereas the kriging-based feasibility step requires 1.67 s.  
 
 
(a)                                                                             (b) 
 
(c)                                                                                (d) 
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                                                                                        (e) 
 
Figure 6. Case study #1: up-to date model-based DS obtained after (a) 0 s, (b) 5 s, (c) 10 s, (d) 15 s  
and (e) 35 s. (= 𝑡𝑆𝑆) for a –30% deviation in the inlet angle estimate and +5% error in the initial state 
 
6.6.2 Results and discussion for Case study #2 
6.6.2.1 Simulation set-up 
A scenario was considered where a first principles model developed and calibrated at the 
laboratory scale (Eqs (6.23- 29)) fails to account for some physical phenomena that occur at a 
different scale and/or that were not observed during the offline model validation procedure 
(type 2 uncertainty as described in section 6.4). In industrial applications, two variables that can 
be measured online with little effort are the moles of CO2 in the outlet gas per liter of broth the 
volume (𝑦1), and the volume 𝑉(𝑡) (𝑦2). Therefore, synthetic process measurements were 
generated for these two variables with a measurement interval of Δ𝑡𝑘 = 10 min. These 
measurements were corrupted with white Gaussian noise 𝐯𝑘~𝑁(𝟎, 𝐑) with: 
 
𝐑 = (0.1
2 0
0 0.52
) .                                                                    (6.43) 
The concentration of penicillin 𝑃(𝑡) was considered as a product critical quality attribute , and 
the concentration of substrate 𝑠𝐹 in the feed as a raw material property. The critical process 
parameter that was taken into account was the inlet feed flowrate 𝑈. As in the previous case 
study, both variables were considered as time-invariant, but the analysis can be easily extended 
to time-varying inputs. 
A single end-point specification was set on the penicillin concentration for a batch duration of 
𝑡𝑒𝑛𝑑 = 200 h: 
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𝑃𝑙𝑜 − 𝑃(𝑡𝑒𝑛𝑑) ≤ 0 .                                                                  (6.44) 
6.6.2.2 Offline model-based DS identification (step #1) 
The model-based DS of this process can be described in terms of a feasibility analysis problem 
as: 
 
𝜒(𝐝) = max
𝑈,𝑠𝐹
Ψ(𝐝, 𝑈, 𝑠𝐹)                                                               (6.45) 
                                    s.t.       Ψ(𝐝, 𝑈, 𝑠𝐹) = 𝑃
𝑙𝑜 − 𝑃(𝑡𝑒𝑛𝑑) ≤ 0  ; 
                                                           eqs. (6.23) − (6.29)  
𝑈 ∈ [ 𝑈𝑙𝑜; 𝑈𝑢𝑝 ]                                                                    (6.46) 
𝑠𝐹 ∈ [𝑠𝐹
𝑙𝑜; 𝑠𝐹
𝑢𝑝 ] .                                                                   (6.47) 
The values of the parameters that appear in the formulation (6.45) are reported in Table 6.4. 
Table 6.4. Case study #2: values of the parameters appearing in the 
formulation (6.45). 
 Parameter Units Value 
𝑃𝑙𝑜 [g𝑆/L] 1.25 
𝑈𝑙𝑜 [L/h] 5 
𝑈𝑢𝑝 [L/h] 80 
𝑠𝐹
𝑙𝑜 [g𝑆/L] 300 
𝑠𝐹
𝑢𝑝
 [g𝑆/L] 900 
 
Fig. 6.7 shows that the un-modeled phenomena cause a strong process-model mismatch that 
impacts on the penicillin concentration (Fig 6.7c) as well as all other state variables. The plots 
of Fig. 6.7 refer to the initial conditions (assumed to be estimated correctly in the first principles 
model) and nominal values 𝑈 and 𝑠𝐹 reported in Table 6.4. Note that the model significantly 
overestimates the final concentration of penicillin of the actual process (Fig. 6.7c). 
The solution of the feasibility problem (6.45)-(6.47) requires the integration of the model 
equations (6.23)-(6.27) embedded in the optimization algorithm, and it takes 2.6 min to get a 
solution. However, since the process dynamics is very slow and the design space is updated 
every 24 h, the computational time for the solution of the feasibility problem (6.45)-(6.47) is 
consistent with online implementation. Therefore, surrogate-based approaches are not needed 
for this case study.  
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Table 6.5. Case study #2:initial conditions for the state variables and 
nominal values of the substrate feed concentration and feed flowrate. ). 
Variable Symbol Units Initial value Nominal value 
Biomass concentration 𝐵 [g𝐵/L] 0.1 [-] 
Substrate concentration 𝑆 [g𝑆/L] 15 [-] 
Penicillin concentration 𝑃 [g𝑃/L] 0 [-] 
Volume 𝑉 [L] 100 [-] 
CO2 concentration [CO2] [mmol/L] 0.5 [-] 
Feed flowrate 𝑈 [gS/h] [-] 27 
Substrate feed concentration 𝑠𝐹 [gS/L] [-] 600 
 
 
(a)                                                             (b) 
 
(c)                                                             (d) 
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     (e) 
Figure 6.7. Case study #2: impact of process-model mismatch for the penicillin fermenter on the (a) 
concentration of biomass, (b) concentration of substrate, (c) concentration of penicillin, (d) volume and 
(e) concentration of CO2. 
 
6.6.2.3 Identification of uncertain model parameters (step #2) 
According to step #2 of the proposed methodology, the parameters that need online 
recalibration should be identified in order to remove the process-model mismatch. Note that no 
more than two parameters can be recalibrated, since we assumed that only two online 
measurements are collected in the plant.  
Qualitatively, it is expected that the environmental factors (pH, temperature) and the dissolved 
oxygen concentration will have a remarkable effect on the biomass growth rate as well as on 
the penicillin production rate (Birol et al., 2002). Since these are not included explicitly in the 
model formulation, an adjustment parameter 𝜙𝜌(𝑡) was introduced in the expression of the 
penicillin production rate (i.e., the relevant critical quality attribute in this case) in order to 
account for this lack of the “model”: 
 
𝜌(𝑡) = 𝜌𝑚𝑎𝑥𝜙𝑝(𝑡) (
𝑆(𝑡)
𝐾𝑃+𝑆(𝑡)(1+
𝑆(𝑡)
𝐾in
)
)  .                                                      (6.48) 
𝜙𝑝(𝑡) is treated as an additional state that is used with the purpose of increasing the adaptive 
capability of the state estimator. Note that 𝜙𝑝(𝑡) was introduced without directly adjusting 𝜌𝑚𝑎𝑥 
in order to preserve its physical meaning. No claim is made on the physical meaning of 𝜙𝑝(𝑡). 
To account for broth evaporation, a second adjustment parameter 𝜙𝑉(𝑡) was introduced in the 
volume balance equation: 
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d𝑉(𝑡)
d𝑡
= (
𝑈
𝑆𝐹
) (1 − 𝜙𝑉(𝑡)).                                                                (6.49) 
The same considerations made for 𝜙𝑝(𝑡) hold true for 𝜙𝑉(𝑡). The initial (i.e., nominal) values 
of 𝜙𝑝 and 𝜙𝑉 are 1 and 0, respectively. 
6.6.2.4 State estimation for online model adaptation (step #3) 
State estimation techniques and control applications have been extensively studied for this 
process (Birol et al., 2002; Georgakis, 2013; Kager et al., 2018). The initial model error 
covariance and the model error covariance were tuned with a trial-and-error approach in order 
to obtain the best performance of the estimator. The following values were chosen (1=𝐵; 2=𝑃; 
3=𝑆; 4=𝑉, 5=[CO2], 6=𝜙𝑝, 7=𝜙𝑉): 
 
𝐏11(0) =
(
 
 
 
 
0.12 0 0 0 0 0 0
0 0.12 0 0 0 0 0
0 0 0.12 0 0 0 0
0 0 0 0.52 0 0 0
0 0 0 0 0.12 0 0
0 0 0 0 0 12 0
0 0 0 0 0 0 12)
 
 
 
 
; 𝐐 =
(
 
 
 
 
0.12 0 0 0 0 0 0
0 0.12 0 0 0 0 0
0 0 0.12 0 0 0 0
0 0 0 12 0 0 0
0 0 0 0 0.12 0 0
0 0 0 0 0 0.52 0
0 0 0 0 0 0 0.52)
 
 
 
 
. 
(6.50)  
The ability of the state estimator to remove the process-model mismatch is shown in Fig. 6.8 
for all the state variables considered (𝑈 and 𝑠𝐹 are set at their nominal values in these plots). 
Very good agreement between the estimator predictions and the simulated process profiles for 
the state variables is obtained. 
 
 
(a)                                                 (b)                                                    (c) 
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                                 (d)                                                      (e)                                                    (f)  
 
(g) 
Figure 6.8. Case study #2: state estimator predictions and process states and measurements. (a) CO2 
concentration. (b) Volume. (c) Concentration of biomass. (d) Concentration of substrate. (e) 
Concentration of penicillin. (f) Growth adjustment parameter. (g) Volume adjustment parameter. 
6.6.2.5 Online model-based DS maintenance (step #4) 
As discussed earlier, the update interval for the design space was set to Δ𝑡𝑚 = 24 h. The online 
model-based DS can be obtained by solving the feasibility problem (6.45)-(6.47) with the initial 
conditions given by the up-to-date state vector 𝐱1(𝑡𝑚) returned by the state estimator at time 
𝑡𝑚.The solution of the feasibility problem requires integration from time 𝑡𝑚 till the end of the 
batch (200 h). 
Fig. 6.9 shows the actual DS of the process and the evolution of the model-based DS after 0, 
48, 72, 96 and 120 h. 
The values of the three metrics 𝐶𝐹(%), 𝐶𝐼𝐹(%),𝑁𝐶(%) for all the time steps involved during 
the fermenter operation is reported in Table 6.6. Fig. 6.9a shows that the offline model-based 
DS (i.e., 𝑡 = 0 h) is significantly wider than the actual DS of the process. This is in agreement 
with Fig. 6.7c, which shows that the original model significantly overestimates the 
concentration of penicillin at the end of the batch, and it is confirmed by the value of the metric 
𝑁𝐶%), which is significantly greater than 0. The model-based DS keeps being significantly 
wider than the actual DS till the time step 𝑡𝑚 = 48 ℎ: this can be easily understood (Fig. 6.8c) 
with the fact that there is not a process-model mismatch impact on the concentration of 
penicillin during the first 48 h (penicillin is still not being produced). 
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(a)                                                             (b) 
 
      (c)                                                             (d) 
 
 
(e) 
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Consistently, the adjustment parameter 𝜙𝑝(𝑡) is not adjusted by the state estimator during this 
time frame. The accuracy of the model-based DS identification significantly increases after 72 
h, since a substantial adjustment of the system state and 𝜙𝑝(𝑡) is performed (Fig. 6.8f).  
 
Figure 6.9. Case study #2: actual DS of the process (red wavy region) and model-based DS (light gray 
regions) obtained after (a)0 h.,(b) 48 h., (c)72 h., (d) 96 h and (e) 120 h.  
Table 6.6. Case study #2: accuracy metrics for the DS maintenance tool. 
Time[h]  𝑪𝑭 (%) 𝑪𝑰𝑭 (%) 𝑵𝑪(%) 
0 100.0 15.3 81.25 
24 100.0 17.4 77.23 
48 100.0 21.2 72.5 
72 100.0 71.2 25.0 
96 100.0 99.1 0.22 
120 100.0 99.0 0.23 
144 100.0 99.1 0.21 
168 100.0 99.2 0.22 
192 100.0 99.0 0.21 
 
The DS identification accuracy stabilizes at satisfactory values (𝐶𝐹(%) ≅ 100.0, 𝐶𝐼𝐹(%) ≅
99.0, 𝑁𝐶(%) ≅ 0.2 ) after 96 h, and this accuracy is maintained throughout the entire fermenter 
operation. It is worth noticing the model-based DS obtained with the online maintenance tool 
is slightly conservative (𝑁𝐶(%) > 0), which is desirable in terms of operational flexibility.  
Summarizing, after the first 50 h (where penicillin is still not being produced and therefore the 
adaptive ability of the state estimator is still not exploited in terms of critical quality attributes 
prediction), the design space maintenance methodology quickly recovers the correct DS. Note 
that the DS updating frequency can be increased after the first 50 h of operation to obtain an 
even prompter DS adaptation.  
6.7. Conclusions 
In this study, a methodology was proposed for the maintenance of the design space of a 
pharmaceutical product using online model adaptation. By combining the predictions of a first-
principles model with measurements made available by plant sensors, the methodology exploits 
dynamic state estimation for online model adaptation and feasibility analysis to obtain an up-
to-date representation of the design space during plant operation.  
The effectiveness of the proposed methodology was proved on two simulated case studies, 
involving the roller compaction of microcrystalline cellulose and the fermentation of penicillin 
in a bioreactor. For both the case studies considered, the ability of the proposed approach to 
timely track the design space was proved. 
Applications of this up-to date design space include, but are not limited to:  
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(i) management of real-time raw materials variability;  
(ii) search of the optimum operation point within the design space by real-time dynamic 
optimization based on the up-to-date first-principles model;  
(iii) open-loop decision support within the boundary of the design space (e.g., manual 
intervention on critical process parameters’ set-points); 
(iv) closed-loop decision support within the boundary of the design space (e.g., definition 
of optimal set-points or set-point trajectories).  
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© 2018 Gabriele Bano, University of Padova (Italy) 
 
 
 
Chapter 7 
 
Model-based design of experiments in 
pharmaceutical freeze drying 
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In this Chapter, model-based design of experiments (MBDoE) techniques are exploited to 
design optimal experiments for the correct identification of the most critical parameters in a 
pharmaceutical freeze drying first-principles model. A preliminary analysis is carried out in 
order to identify the structural consistency and the most influential parameters of the model, 
and MBDoE is subsequently used to design an optimal experiment based on the results of the 
preliminary analysis. The designed experiment is first simulated in silico, then performed on a 
real small-scale equipment, and finally the model parameters are identified based on the 
experimentation. 
The Chapter is organized into six sections. In the first section, a brief description of the freeze 
drying process is given, with a specific focus on pharmaceutical applications. Section 7.1 
collects a detailed description of the primary drying step of the process, which is the focus of 
this Chapter. In section 7.2, a brief overview of the mathematical formulation of MBDoE 
techniques is presented. Section 7.3 thoroughly describes the mathematical model used for the 
description of the primary drying stage. In section 7.4, a preliminary assessment of the 
performance of this model is presented. Section 7.5 collects the results obtained with the 
MBDoE activity. Finally, in section 7.6 the final remarks and the future areas of research are 
discussed.   
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7.1 Freeze drying: process description  
Freeze drying (or lyophilization) is a process that is used to remove a solvent (typically water) 
from a frozen product, in order to (Pikal, 1980): 
1. guarantee product stability both in terms of its physicochemical properties and 
microbiological quality attributes; 
2. allow an easy reconstitution of the dried product by water addition (the dried product 
has a high surface area and can be easily re-hydrated). 
It is extensively used in pharmaceutical manufacturing to recover the active pharmaceutical 
ingredient (API) and the excipients from an aqueous solution, in all those situations where other 
simpler drying technologies cannot be applied. In pharmaceutical applications, the frozen 
product is typically processed in vials, placed over shelves in a drying chamber. A schematic 
representation of a typical freeze-dryer, with a short description of all its components, is shown 
in Fig. 7.1. 
 
 
 
Figure 7.1. Schematics of a freeze dryer and its components (Adapted from: http://www.gmpua.com). 
 
The process involves low temperatures and high vacuum, and can thus be considered an energy-
intensive one. A full drying cycle typically consists of seven steps, as schematically shown in 
Fig. 7.2: 
1. Loading. The vials are loaded on the shelves of the drying chamber. The loading can be 
full (i.e. all the shelves are loaded with vials) or partial (only one or more of the shelves 
are loaded). The loading level (i.e. partial or full) can affect the subsequent stages of the 
drying cycle. 
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2. Freezing. The product temperature is lowered below the solution freezing point at 
atmospheric pressure and the solvent freezes, forming ice crystals. The main physical 
mechanisms of this step are crystal nucleation and growth: in most situations, stochastic 
nucleation (i.e. non-controlled nucleation) is obtained. In this scenario, the freezing 
protocol strongly affects the crystal size (i.e., the product morphology), hence all the 
subsequent drying stages. Some freeze dryers allow keeping under control the 
nucleation of crystal sites (i.e., nucleation is not stochastic anymore). In this scenario, 
product morphology can be controlled and therefore the subsequent drying stages can 
be sped up. In both scenarios, part of the solvent can remain bounded to the product and 
must therefore be desorbed. The freezing stage typical involves 5-10% of the total 
duration of the drying cycle. 
3. Condenser cooling and evacuation. The condenser temperature is cooled down and 
vacuum is introduced in the drying chamber. This in intermediate step that is performed 
to prepare the system to the subsequent stage. 
4. Primary drying. In this step, ice sublimation occurs at low temperatures and high 
vacuum. The energy supply for ice sublimation is given by the heating fluid (typically 
a silicone oil) flowing through the coils inserted in the shelves of the drying chamber. 
Typical temperatures are in the range (–40)-(–10) °C, and typical operating pressures in 
the drying chamber are between 50-150 mT (milli Torr, where 1 Torr corresponds to 
133.322 Pa or 1/760 atm). This step is the most energy-intensive stage and involves 60-
80% of the total duration of the drying cycle. 
5. Secondary drying. After ice sublimation, the residuals particles of solvent that are 
bounded to the dried product are desorbed in order to lower the residual solvent content 
(defined as residual moisture content if the solvent is water) of the final product. This is 
achieved by increasing the temperature of the shelves (typical temperatures range 
between 20-40 °C) and (possibly) decreasing the chamber pressure. The desorption time 
strongly depends on the product morphology obtained after freezing, and typically 
involves 10-20% of the total duration of the drying cycle. 
6. Backfilling. The vacuum pump is stopped, and the drying chamber and the condenser 
are filled with an inert gas at an assigned pressure. A typical backfill operation is 
performed between 500-900 mbar of dry nitrogen. The advantage of backfilling is that 
oxidation of the dried product during storage is avoided. 
7. Stoppering. The shelves are closed by hydraulic means and the partially inserted 
stoppers are fully inserted in the vials.  
The most critical steps of a drying cycle are step # 2 (freezing), step #4 (primary drying) and 
step #5 (secondary drying). 
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Freezing is crucial since the freezing rate directly affects the morphology of the ice crystals and 
therefore all the subsequent drying steps. Primary drying involves the largest portion of the 
entire drying duration, and its optimization is therefore pivotal to reduce the overall cycle time.  
As regard secondary drying, a satisfactory removal of the residual moisture in the product is 
critical to guarantee its stability over its entire life cycle duration, thus making this step crucial 
for the entire drying operation. 
The focus of this Chapter is to parametrically identify a mathematical model to be subsequently 
used to optimize the behavior of the system during the primary drying operation, given its strong 
impact on the entire drying duration. A thorough description of the other two steps and the 
mathematical models that can be used to describe them can be found in Pikal, 1985 and Fissore 
et al., 2012. 
 
 
Figure 7.2. Schematics of the different steps of a freeze-drying cycle. 
7.1.1 Primary drying 
As described in Section 7.1, during primary drying the frozen product is subject to low 
temperature and high vacuum, and ice sublimation occurs at the interface between the frozen 
layer and the dried layer. The sublimation front progresses inwards as long as primary drying 
proceeds, leaving a layer of dried material behind. A schematic representation of the evolution 
of the dried layer with time is shown in Fig.7.3.  
 
 
 
Figure 7.3. Evolution of ice sublimation during primary drying. 
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In order to avoid product melting (i.e., solid/liquid transition), the partial pressure of water in 
the drying chamber (but not the total pressure in the chamber) is kept below the triple point of 
the solvent (6.63 mbar in case of water). Energy supply for ice sublimation at the sublimation 
interface is provided by the silicone oil flowing inside the shelves and involves different 
mechanisms of heat transfer, namely (Scutellà et al., 2017a):  
1. heat conduction through the gas in the drying chamber; 
2. heat conduction between “solids”; 
3. radiation. 
The first mechanism involves heat conduction through low-pressure water vapor in the gap 
between the vials and the metallic rails that are used to load the vials in the chamber. Recent 
studies (Pikal et al., 2016; Scutellà et al., 2018) have shown that this mechanism plays a key 
role in the overall heat transfer mechanism to the sublimation interface. 
The second mechanism involves heat transfer by conduction through solids, namely (i) heat 
transfer between the silicone oil and the shelf surface, (ii) heat transfer between the shelf surface 
and the vial bottom through direct contact points, and (iii) heat transfer between the vial bottom 
and the sublimation interface through the frozen layer. 
The third mechanism involves all the radiant effects that occur in the drying chamber. These 
effects are responsible for the drying heterogeneity between vials of the same shelf and between 
different shelves, and involve different phenomena such as: 
(a) radiation from top and bottom shelves with respect to the vial considered; 
(b) radiation from the chamber walls to the vials facing the walls or to the rails; 
(c) radiation from the top shelf to the rails; 
(d) radiation from the internal walls of the vials and the sublimation interface. 
The above considerations suggest that the description of the heat transfer mechanisms inside 
the drying chamber can be very complex and some simplifying assumptions are often 
considered to capture the overall behavior of the freeze dryer. These mechanisms are not the 
same for all the vials within a single shelf and within the vials of different shelves, and this 
results in a strong heterogeneity of the drying behavior between vials. As an example, vials that 
are close to the chamber walls are subject to higher sublimation rates than vials that are placed 
in internal positions within the shelf, due to heat radiation through the chamber walls and 
conduction through the gas in the drying chamber.  
Besides the issue of drying heterogeneity, the dryer operation during primary drying is affected 
by two constraints (related both to the equipment and to the product) that must be fulfilled.  
1. The product temperature must be kept below the glass transition temperature (for 
amorphous materials) or eutectic temperature (for crystalline materials) in order to avoid 
the “collapse”/”melting” of the product (i.e., irreversible alteration of the product 
morphology). Within a vial, the fraction of the product that is subject to a higher 
temperature is located at the vial bottom, since it is in contact with the heated shelf. 
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Monitoring of the vial bottom temperature is therefore critical to avoid the collapse of 
the cake. Moreover, vials that are close to the chamber walls or to the window (if 
present) of the freeze dryer, i.e. the so-called “edge” vials, are subject to higher 
temperatures and slower freezing rates than the internal vials, thus being potentially 
critical for product collapse. 
2. The sublimation rate must be compatible with the condenser capacity and choked flow 
must be avoided in the duct that connects the drying chamber to the condenser (Searles, 
2004). This prevents loss of pressure control inside the drying chamber, with related 
effects on both the product and the safety of the equipment operation. 
The presence of operational and quality constraints on the dried product, coupled with the 
complexity of heat transfer mechanisms occurring inside the drying chamber, make the 
mathematical description of primary drying very complex. Moreover, other factors such as 
equipment geometry, vials geometry, as well as duct, valve and condenser design can affect the 
drying operation and the final product quality (Pikal, 1985). Several modeling approaches have 
been proposed to describe the behavior of the system during primary drying. A short 
classification of these models, with focus on mono-dimensional lumped parameter models, is 
reported in the next section. 
7.2 Mathematical modeling of primary drying 
Several mathematical models have been proposed to describe the primary drying stage of 
freeze-drying. These models aim at predicting the key performance indicators of the system 
(e.g., vial bottom temperature, amount of water sublimated, etc…) and at describing how 
primary drying progresses with time. Model classification can be performed using different 
criteria, e.g. based on the modeling assumptions adopted (pseudo steady-state / dynamic 
models), based on the ways the system geometry is described (mono- and bi-dimensional 
models), or based on the type of model parameters involved (lumped/distributed parameter 
models). 
A rough classification of freeze-drying models involves the following categories: 
1. Mathematical models based on a detailed description of the multi-physics phenomena 
of the system, typically (but not necessarily) implemented on computationally fluid 
dynamics (CFD) software; 
2. Mathematical models involving distributed parameters, i.e. parameters that depend on 
the spatial position within the drying chamber; 
3. Mathematical models involving lumped parameters, i.e. parameters that do not depend 
on the spatial position within the drying chamber. 
The first class of models (Liapis and Bruttini, 1995; Mascarenhas et al., 1997; Sheehan and 
Liapis, 1998; Pisano et al., 2011; Ramšak et al., 2017) involves detailed CFD simulations and 
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high model complexity (i.e. large number of model equations and model parameters). This 
model complexity results in two notable drawbacks: 
 large computational time, that partially or totally prevents online use of these models 
for real-time parameter estimation or real-time process optimization; 
 large number of model parameters to be estimated. In most cases, the values of these 
parameters are taken from the literature and may have been obtained under different 
equipment configuration and/or different product formulation. 
The second class of models collects mono- and bi-dimensional models that aim at capturing the 
heterogeneous behavior within the drying chamber by introducing a spatial dependence on 
some of the model parameters. The model complexity is kept relatively low and the models can 
be used, under certain circumstances, for process simulation and control. However, their online 
use is still limited by identifiability issues (Brülls and Rasmuson, 2002; Tsinontides et al., 2004; 
Zhai et al., 2005 ; Hottot et al., 2006; Gieseler et al., 2007; Trelea et al., 2007; Duralliu et al., 
2018).  
The third class of models collects several mono-dimensional lumped-parameter models (e.g., 
Pikal, 1985; Millman et al., 1985; Sadikoglu and Liapis, 1997; Velardi and Barresi, 2008). 
involving few parameters and requiring small computational times. This is obtained at the 
expense of neglecting such phenomena as radial gradients of temperature and composition and 
heat transfer between the product and the side wall of the vial, as well as other radiation 
phenomena. Despite these limiting assumptions, it has been shown (Fissore et. al, 2010; Fissore 
et al., 2011a; Fissore et al., 2011b; Bosca et al., 2013; Bosca et al., 2015) that these models can 
capture the key performance indicators (KPIs) of the system during primary drying with 
reasonable accuracy, and therefore they represent a good starting point towards a macroscopic 
mechanistic description of the process. Moreover, the complexity of these models can be 
modulated by introducing and/or neglecting some (heat-transfer) phenomena that are 
considered to be relevant/irrelevant for the end purpose, thus providing some flexibility to the 
modeling framework. 
A simplified mono-dimensional lumped parameter model that has gained increasing attention 
is the one proposed by Velardi and Barresi (2008), based on a previous study (Pikal, 1985). 
This model is one-dimensional and collects the mass balance for the frozen layer and the 
macroscopic heat- and mass-transfer equations for the frozen product. The relevant model 
equations are as follows. 
The frozen product is heated by the silicone oil flowing through the shelf, and the driving force 
for heat transfer is given by the difference between the temperature 𝑇𝑓𝑙𝑢𝑖𝑑(𝑡) of the heating 
fluid and the temperature 𝑇𝐵(𝑡) at the bottom of the frozen layer. The heat flux 𝐽𝑞(𝑡)[W/m
2] 
between the silicone oil and the vial bottom can therefore be expressed as: 
 
𝐽𝑞 = 𝐾𝑣(𝑇𝑓𝑙𝑢𝑖𝑑 − 𝑇𝐵)    , (7.1) 
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where 𝐾𝑣[W/(m
2K)] is the heat transfer coefficient. It is worth noticing that Eq. (7.1) only 
accounts for the heat transfer between the silicone oil and the vial bottom. However, as 
explained in section 7.1.1., other heat transfer mechanisms affect the overall energy supply to 
the frozen layer, but they are not taken into account explicitly in the heat flux formulation (7.1).  
The heat transfer coefficient of Eq. (7.1) strongly depends on the pressure 𝑝𝑐 [Pa] in the 
chamber. The dependence of 𝐾𝑣 with respect to 𝑝𝑐 is expressed as: 
 
𝐾𝑣 = 𝐶1 +
𝐶2𝑝𝑐
1 + 𝐶3𝑝𝑐
      , 
(7.2) 
 
where 𝐶1, 𝐶2, 𝐶3 are parameters to be estimated.  
Given the heat supply expressed by Eq. (7.1), the frozen product sublimates at the sublimation 
front and the sublimation flux 𝐽𝑤(𝑡)[kg/(m
2s)] can be expressed as: 
 
𝐽𝑤 =
1
𝑅𝑝
(𝑝𝑤,𝑖 − 𝑝𝑤,𝑐)     , 
(7.3) 
 
where 𝑝𝑤,𝑖[Pa] is the partial pressure of water at the sublimation front, 𝑝𝑤,𝑐[Pa] is the partial 
pressure of water in the chamber (which is typically assumed equal to the total pressure 𝑝𝑐 of 
the chamber ), and 𝑅𝑝[m/s] is the resistance to the mass transfer. 
The interpretation of Eq. (7.3) is straightforward: the driving force for the sublimation flux is 
the difference between the vapor partial pressure at the sublimation interface and the vapor 
partial pressure in the chamber, and the proportionality factor is the inverse of the mass transfer 
resistance to the vapor flow. The mass transfer resistance 𝑅𝑝 is a function of the thickness 
𝐿𝑓𝑟𝑜𝑧𝑒𝑛 of the frozen layer according to the expression: 
 
𝑅𝑝 = 𝑅0 +
𝑅1𝐿𝑓𝑟𝑜𝑧𝑒𝑛
1 + 𝑅2𝐿𝑓𝑟𝑜𝑧𝑒𝑛
   , 
(7.4) 
 
where 𝑅0, 𝑅1 and 𝑅 are parameters to be estimated. 
The partial pressure 𝑝𝑤,𝑖 of water at the sublimation interface is a function of the temperature 
𝑇𝑖[K] at the interface. This dependence can be expressed with the Goff-Gratch equation (Goff, 
1946); a simplified expression for the values of pressure and temperature that are typically 
involved during primary drying has been proposed by Fissore and Barresi (2011): 
 
𝑝𝑤,𝑖 = exp (−
6150.6
𝑇𝑖
+ 28.932)   . 
(7.5) 
 
  
Model-based design of experiments in pharmaceutical freeze-drying 215 
 
________________________________________________________ 
© 2018 Gabriele Bano, University of Padova (Italy) 
 
The heat that is exchanged between the oil flowing in the shelves and the product is assumed 
to be entirely used for ice sublimation. The energy balance at the sublimation interface can be 
written as: 
 
𝐽𝑤 =
1
Δ𝐻𝑠
 𝐽𝑞 =
1
Δ𝐻𝑠
 𝐾𝑣(𝑇𝑓𝑙𝑢𝑖𝑑 − 𝑇𝐵)    , 
(7.6) 
 
where Δ𝐻𝑠[J/kg] is the heat of sublimation, which is dependent on the partial pressure of water 
in the chamber (the pressure dependency can often be neglected). Since no heat accumulation 
is assumed in the frozen layer, the energy balance for the frozen product can be written as: 
 
𝐾𝑣(𝑇𝑓𝑙𝑢𝑖𝑑 − 𝑇𝐵) =
𝑇𝑓𝑙𝑢𝑖𝑑 − 𝑇𝑖
(
1
𝐾𝑣
+
𝐿𝑓𝑟𝑜𝑧𝑒𝑛
𝜆𝑓𝑟𝑜𝑧𝑒𝑛
)
   , 
(7.7) 
 
where 𝜆𝑓𝑟𝑜𝑧𝑒𝑛 [W/(mK)] is the thermal conductivity of the frozen layer. Eq. (7.7) can be 
rewritten as: 
 
𝑇𝐵 = 𝑇𝑓𝑙𝑢𝑖𝑑 −
1
𝐾𝑣
(
1
𝐾𝑣
+
𝐿𝑓𝑟𝑜𝑧𝑒𝑛
𝜆𝑓𝑟𝑜𝑧𝑒𝑛
)
−1
(𝑇𝑓𝑙𝑢𝑖𝑑 − 𝑇𝑖)  , 
(7.8) 
 
which allows relating the temperature 𝑇𝐵 at the bottom of the vial (measurable variable) to the 
temperature 𝑇𝑖 at the sublimation interface (unmeasurable variable). 
The time evolution of the frozen layer thickness can be obtained by solving the material 
balance: 
 
d𝐿𝑓𝑟𝑜𝑧𝑒𝑛
d𝑡
=  −
1
𝜌𝑓𝑟𝑜𝑧𝑒𝑛 − 𝜌𝑑𝑟𝑖𝑒𝑑
 𝐽𝑤   , 
 (7.9) 
 
where 𝜌𝑓𝑟𝑜𝑧𝑒𝑛[kg/m
3] is the density of the frozen product, and 𝜌𝑑𝑟𝑖𝑒𝑑[kg/m
3] is the density of 
the dried product. 
The total amount 𝑀[kg] of water sublimated during primary drying can be computed from the 
sublimation flux 𝐽𝑤 according to the equation: 
 
 𝑀 = 𝐴𝑣∫ 𝐽𝑤(𝑡)
𝑡𝑑
0
d𝑡   , 
(7.10) 
 
where 𝑡𝑑 is the total duration of primary drying, and 𝐴𝑣 is the internal cross-sectional area of 
the vial.  
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The mono-dimensional model consists of Eq. (7.1)-(7.10). From a structural point of view, the 
model is a system of one differential equation (Eq. (7.9)), one integral equation and seven 
algebraic equations. The model inputs, outputs and parameters are listed in Table 1. 
Table 7.1. Input variables, output variables and model parameters for the 
mono-dimensional model (7.1)-(7.10). 
 ID Variable name Units Symbol Type 
Inputs     
1 Chamber pressure [Pa] 𝑝𝑐 Algebraic 
2 Heating fluid temperature [K] 𝑇𝑓𝑙𝑢𝑖𝑑  Algebraic 
     
Outputs     
1 Length of the frozen layer [m] 𝐿𝑓𝑟𝑜𝑧𝑒𝑛  Differential 
2 Cumulative amount of water sublimated [kg] 𝑀 Algebraic 
3 Heat flux [W/m2] 𝐽𝑞 Algebraic 
4 Sublimation flux [kg/(m2s)] 𝐽𝑤 Algebraic 
5 Vial bottom temperature [K] 𝑇𝐵 Algebraic 
6 Sublimation interface temperature [K] 𝑇𝑖  Algebraic 
7 Water partial pressure at the sublimation interface [Pa] 𝑝𝑤,𝑖 Algebraic 
     
Parameters     
1 Heat transfer coefficient - parameter #1 [W/(m2K)] 𝐶1 [-] 
2 Heat transfer coefficient - parameter #2 [W/(m2KPa)] 𝐶2 [-] 
3 Heat transfer coefficient - parameter #3 [W/(m2KPa)] 𝐶3 [-] 
4 Mass transfer resistance - parameter #1 [m/s] 𝑅0 [-] 
5 Mass transfer resistance - parameter #2 [1/s] 𝑅1 [-] 
6 Mass transfer resistance - parameter #3 [1/m] 𝑅2 [-] 
 
With reference to Table 7.1, some comments are in order. 
1. The two variables that can be manipulated during the dryer operation are the pressure 
in the chamber and the heating fluid temperature. These variables can be manipulated 
according to a time-invariant, piecewise constant or (only the heating fluid temperature) 
piecewise linear behavior. Additional details will be given in section 7.5. 
2. Among the output variables, one of the variables that can typically be measured during 
a drying cycle is the vial bottom temperature. This is done by placing a thermocouple 
inside the vial, and measurements can be obtained online with relatively low frequency 
Thermocouples are typically placed inside different vials located at selected positions 
within the dryer in order to account for their different thermal behaviors within the same 
shelf.  
3. The dryer operation is subject to both product constraints and equipment constraints. 
From a modeling perspective, the product constraints are imposed on the vial bottom 
temperature 𝑇𝐵, which must be kept below the critical temperature (glass transition or 
eutectic temperature) of the product for the entire drying operation. The equipment 
constraints are imposed on the sublimation flux 𝐽𝑤, that must be kept below a limiting 
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value to avoid choked flow through the duct linking the drying chamber to the 
condenser.  
In view of the above, obtaining good predicitions for the vial bottom temperature and 
sublimation flux from the model is crucial to guarantee product quality and safe 
operation. Therefore, 𝑇𝐵 and 𝐽𝑤 are considered as KPIs for the model. Moreover, the 
amount of water sublimated during primary drying can be considered as an additional 
KPI, since its value is directly related to the overall duration of the primary drying stage: 
obtaining a good predicition of M is therefore essential for process optimization. 
4. The model involves 6 parameters, that describe the dependency of the global heat 
transfer coefficient 𝐾𝑣 and the mass transfer resistance 𝑅𝑝 with respect to the chamber 
pressure and length of the frozen layer respectively. A good estimation of the values of 
these parameters is required in order to obtain reliable predictions for the KPIs described 
above. 
The step-by-step methodology that has been used to calibrate and validate the above model is 
reported in the next section. 
7.3 Model-based design of experiments (MBDoE): brief overview 
In the following, a short description of the mathematical background of model-based design of 
experiments (MBDoE) techniques is reported. A thorough mathematical formulation can be 
found in the work of Franceschini and Macchietto (2008) and Galvanin (2013). 
7.3.1 Design of an optimal experiment 
The goal of MBDoE is to find the optimal initial conditions, the optimal profile of manipulated 
inputs, the optimal sampling instants for the measured variables, and the optimal duration of a 
new experiment in order to maximize the information that can be extracted from the experiment 
for the purpose of model identification. 
Mathematically, given a dynamic system described by a system of differential and algebraic 
equations (DAEs) of the form: 
 
𝐟(?̇?(𝑡), 𝐱(𝑡), 𝐮(𝑡),𝐰, 𝛉, 𝑡) = 0 
𝐲(𝑡) = 𝐡(𝐱(𝑡)) 
(7.11) 
 
where 𝛉 [1 × Nθ] is the set of parameters to be estimated, 𝐱(𝑡) is the state vector, 𝐮(𝑡) and 𝐰 
are the time-dependent and time-invariant control variables respectively, 𝐲(𝑡) is the output 
vector, the target is to find the optimal value of the design vector: 
 
𝛗 = [𝐲0, 𝐮(𝑡), 𝐰, 𝐭
𝑠𝑝, 𝜏] (7.12) 
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that maximizes the information for the identification of 𝛉. Eq. (7.12) uses the following 
notation: 
 𝐲0 is the set of initial conditions for the measured variables; 
 𝐭𝑠𝑝 = [𝑡1, 𝑡2, … , 𝑡𝑠𝑝] is the vector collecting the different sampling times in which 
measurements are collected; 
 𝜏 is the total duration of the experiment. 
The time-dependent input variables 𝐮(𝑡) are typically approximated as piecewise constant or 
piecewise linear variables for a given set of intervals splitting the entire experiment duration. 
The optimal value of the design vector is found as the value that minimizes a given metric 𝛼 of 
the variance-covariance matrix of the model parameters 𝐕𝜃(𝛉,𝛗) according to: 
 
𝛗𝑜𝑝𝑡 = argmin {𝛼[𝐕𝜃(𝛉,𝛗)]}    . (7.13) 
 
The variance-covariance matrix 𝐕𝜃(𝛉,𝛗) is defined as: 
 
𝐕𝜃(𝛉,𝛗) = [𝐇𝜃
𝟎 + 𝐇𝜃(𝛉,𝛗)]
−1
   ,  (7.14) 
 
where 𝐇𝜃(𝛉,𝛗), defined as the dynamic information matrix, is a measure of the information 
that can be exploited from the experiment for the identification of 𝛉, while 𝐇𝜃
𝟎  is the initial 
(i.e., preliminary) value of this matrix. For a set of 𝑁exp experiments, 𝐇𝜃(𝛉,𝛗) is expressed as: 
 
𝐇𝜃(𝛉,𝛗) = ∑ ∑ ∑  𝑠𝑖𝑗|𝑘𝐐𝑖|𝑘
𝑇𝑁𝑦
𝑗=1 𝐐𝑗|𝑘
𝑁𝑦
𝑖=1 + 𝐇𝜃
0  
𝑁𝑒𝑥𝑝
𝑘=1      , 
(7.15) 
 
where 𝐐𝑖|𝑘 is the dynamic sensitivity matrix of the 𝑖-th measured response in the 𝑘-th 
experiment, whose elements for the 𝑘-th experiment are given by: 
 
𝐐𝑖  = [
𝜕𝑦𝑖𝑙
𝜕𝜃𝑚
]      𝑙 = 1, 2, … , 𝑛𝑠𝑝 ; 𝑚 = 1, 2, … ,𝑁𝜃     ,     
(7.16) 
 
and 𝑠𝑖𝑗|𝑘 is the 𝑖𝑗-th element of the inverse matrix of the measurement errors in the 𝑘-th 
experiment. According to the metric 𝛼 that is optimized in Eq. (7.13), different design criteria 
can be identified: 
 A-optimal: 𝛼 is defined as the trace of the variance-covariance matrix; 
 E-optimal: 𝛼 is defined as the largest eigenvalue of the variance-covariance matrix; 
 D-optimal: 𝛼 is defined as the determinant of the variance-covariance matrix. 
Based on the design criterion adopted, the solution of optimization problem (7.13) allows 
obtaining all the information needed to perform a new optimal experiment for the system under 
investigation. 
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7.3.2 Additional MBDoE activities 
The design of a new experiment according to the formulation described in the previous section 
is followed by two sequential activities: 
1. Execution of the designed experiment on the experimental equipment; 
2. Estimation of parameters based on the data collected from the experiment. 
If the parameter estimation is statistically satisfactory, the MBDoE activity can be considered 
as concluded. On the other hand, if the parameter estimation is not satisfactory, a new 
experiment must be designed based on the updated estimates of the model parameters, and the 
overall procedure must be iterated. A schematic representation of the iterative procedure is 
shown in Fig. 7.4.  
 
 
 
Figure 7.4. Simplified flowsheet for a standard MBDoE activity. 
 
The stopping criterion for the MBDoE activity can be dictated by different (and often case-
dependent) occurrences, including: 
 attainment of a desired level of precision on the estimated values of the model 
parameters; 
 attainment of a desired level of model accuracy, to be intended as goodness of fit for 
the desired responses; 
 attainment of the maximum experimental budget, typically dictated by both operational 
and cost-dependent constraints. 
Once one or more of the above conditions is reached, the MBDoE activity is stopped. The final 
target is the attainment of a well-calibrated model to be used for decision-support scenarios. 
7.4 Preliminary assessment of freeze-drying model performance  
In order to facilitate a successful application of MBDoE techniques with the mono-dimensional 
model described in Section 7.2, two preliminary activities are required, namely: 
1. assessment of the adequacy of the model structure with respect to the experimental 
observations on the real equipment. In other words, it must be assessed if the (potential) 
mismatch between the model predictions and the experimental observations can be 
removed by adjusting (i.e., calibrating) the model parameters. Alternatively, structural 
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deficiencies (e.g., due to a lack of fundamental knowledge or to simplifying assumptions 
introduced during model development) may be identified in the original model. In the 
latter case, the model needs structural adjustments before using it for MBDoE purposes 
(yet, MBDoE can potentially be used also to discriminate among rival model structures). 
2. identification of reasonable preliminary values for the model parameters, in order to 
speed up the MBDoE activity (Fig. 7.4) and reduce the total number of experiments to 
be performed for model calibration. These values may be taken (if available) from the 
literature or estimated from historical data. 
For the case study reported in this Chapter, historical data of primary drying were available. A 
detailed description of each step, together with the organization of the available historical data, 
is reported in the next sections. 
7.4.1 Description of the historical datasets 
Five historical experimental datasets have been used to preliminarily calibrate and validate the 
model parameters. The datasets differ from each other for the product considered, the type of 
vials used during drying, the loading of the shelves in the freeze dryer, the number of 
measurements available, and the experimental protocol adopted. All experiments the datasets 
refer to were carried out in the same equipment, and this equipment is the same to be used 
within the current MBDoE activity. 
Three historical datasets (namely, datasets A, B and C) were used for model calibration. The 
remaining two datasets (D, E) were used to validate the model. A detailed description of each 
dataset is reported in the following. 
7.4.1.1 Calibration datasets 
The following three datasets were used to calibrate the model. 
 Dataset A: data refer to three incomplete primary drying experiments (i.e., the primary 
drying was stopped before reaching its completion) at three different values of chamber 
pressure, namely at 67%, 100% and 133% of its nominal value. Siliconized vials were 
used in each experiment. The vials were filled with 0.6 mL of microfiltered water and 
only one shelf out of five (i.e., 20% partial loading) was loaded. Two different vial 
frames were loaded for each shelf, as schematically shown in Fig. 7.6. From the same 
figure, it can be seen that the vial arrangement in each shelf has been partitioned in 12 
different zones, each of which with expected similar thermal behavior. Measurements 
of vial bottom temperature were collected by placing one thermocouple in one single 
vial for each zone (light blue-shaded vials in Fig. 7.6). In other words, the behavior of 
the vial inside which a thermocouple was placed is considered as representative of the 
behavior of all the vials within the same zone. This is a simplification dictated by 
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operational limits, and some studies (Pikal, 2000; Pikal et al., 2016) have also shown 
that the very presence of a thermocouple alters the thermal behavior of the vial with 
respect to the adjacent ones. 
 
 
 
Figure 7.6. Arrangement of the vials on the shelves. Vials tagged with a number were 
weighted before and after drying. Thermocouples were placed inside the vials shaded 
in light blue. The rectangular boxes indicate the logic partitioning of vials considered 
in each shelf. 
 
Measurements of chamber pressure (obtained with both a Pirani gauge and a capacitance 
manometer), heating fluid temperature at the inlet of the shelf and vial bottom 
temperature at the 12 locations described above were collected with a measurement 
interval of 30 s for the first two experiments, and of 20 s for the third experiment.  
Moreover, the vials tagged with a number in Fig. 7.6 were weighted at the beginning 
and at the end of the experiment, thus giving an additional measurement of the total 
amount of water sublimated during primary drying. The time profiles for the input 
variables (chamber pressure and heating fluid temperature) that were set during the 
experiments are reported in Table 7.2 
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Table 7.2.  Time profiles of the input variables for dataset A. 
Step # Interval duration [min] 𝒑𝐜 ?̅?𝒄⁄ [−] 𝑻𝒇𝒍𝒖𝒊𝒅 ?̅?𝒇𝒍𝒖𝒊𝒅⁄ [−] 
Experiment 1    
1 15 0.667 0.898 (constant) 
2 30 0.667 0.898-1.000 (linear) 
3 327 0.667 1.000 (constant) 
Experiment 2    
1 15 1 0.898 (constant) 
2 30 1 0.898-1.000 (linear) 
3 186 1 1.000 (constant) 
Experiment 3    
1 15 1.333 0.898 (constant) 
2 30 1.333 0.898-1.000 (linear) 
3 100 1.333 1.000 (constant) 
 
 Dataset B: the structure of this dataset is the same as for dataset A (with three 
experiments at three different pressures). The formulate is a 5% sucrose-based placebo 
and the vials used were non-siliconized. The same measurements collected for dataset 
A were collected also for this dataset. The time profiles of the input variables set during 
the three experiments are reported in Table 7.3. 
Table 7.3. Time profile of the input variables for dataset B. 
Step # Interval duration [min] 𝒑𝐜 ?̅?𝒄⁄ [−] 𝑻𝒇𝒍𝒖𝒊𝒅 ?̅?𝒇𝒍𝒖𝒊𝒅⁄ [−] 
Experiment 1    
 1 15 0.667 0.898 (constant) 
2 30 0.667 0.898-1.000 (linear) 
3 331 0.667 1.000 (constant) 
Experiment 2    
1 15 1 0.898 (constant) 
2 30 1 0.898-1.000 (linear) 
3 180 1 1.000 (constant) 
Experiment 3    
1 15 1.333 0.898 (constant) 
2 30 1.333 0.898-1.000 (linear) 
3 120 1.333 1.000 (constant) 
 
 Dataset C: as for the previous datasets, data refer to an incomplete drying cycle, but 
were obtained with a 5% sucrose-based formulation placebo at only one value for the 
chamber pressure (equal to its nominal value). The same vials format and the same 
thermocouple arrangement as in the previous datasets experiments were used, but vials 
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were in this case siliconized. As for the previous case, measurements of chamber 
pressure (Pirani and capacitance manometers), heating fluid temperature and vial 
bottom temperature were collected every 30 s. The tagged vials were weighted before 
and after drying in order to measure the total amount of water sublimated during primary 
drying. The recipe used for this experiment is reported in Table 7.4.  
Table 7.4. Time profiles of the input variables for dataset C. 
Step # Interval duration [min] 𝒑𝐜 ?̅?𝒄⁄ [−] 𝑻𝒇𝒍𝒖𝒊𝒅 ?̅?𝒇𝒍𝒖𝒊𝒅⁄ [−] 
 1 15 1 (constant) 0.898 (constant) 
2 30 1 (constant) 0.898-1.000 (linear) 
3 175 1 (constant) 1.000 (constant) 
 
7.4.1.2 Validation datasets 
The following two datasets have been used to validate the model. 
 Dataset D: data have been extracted from a dataset of a complete drying cycle (involving 
all the seven steps described in section 7.1.2) and refer to the primary drying step of this 
cycle. The dataset was obtained with a 5% sucrose-based formulation placebo using 
non-siliconized vials. Only one shelf (the central one) out of five was loaded with 238 
vials. Each vial was filled with 0.6 mL of placebo. Two thermocouples were placed to 
monitor the bottom temperature of two vials placed in the middle of the first row and 
last row of the first half of the central shelf, according to the schematic representation 
of Fig. 7.7. The time profile for the input variables (chamber pressure and heating fluid 
temperature) during primary drying is the one reported in Table 7.5. The dataset collects 
measurements of chamber pressure (obtained with a Pirani gauge and a capacitance 
manometer), heating fluid temperature at the inlet of the shelf and vial bottom 
temperature at the two locations described above with a measurement interval of 30 s. 
 
 
Figure 7.7. Arrangement of the thermocouples (numbered as 5 and 6) on the central 
shelf for dataset D. 
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Table 7.5.  Times profile of the input variables for dataset D. 
Step # Interval duration [min] 𝒑𝐜 ?̅?𝒄⁄ [−] 𝑻𝒇𝒍𝒖𝒊𝒅 ?̅?𝒇𝒍𝒖𝒊𝒅⁄ [−] 
 1 15 1 (constant) 0.910 (constant) 
2 30 1 (constant) 0.910-1.000 (linear) 
3 990 1 (constant) 1.000 (constant) 
4 180         1 (constant) 1.237 (constant) 
 
 Dataset E: as for the previous dataset, data of primary drying have been extracted from 
a complete freeze-drying cycle of a 5% sucrose-based placebo. The dataset was obtained 
by loading 2380 siliconized vials (full loading) on all the five shelves placed in the 
drying chamber. Eleven thermocouples were inserted in 11 vials placed according to the 
schematic representation of Fig. 7.8. The filling volume was set to 0.6 mL as for the 
previous datasets. The recipe for the primary drying is reported in Table 7.6. The time 
profiles for the input variables are the same as for the previous dataset, with a significant 
increase in the duration of the third time interval. Measurements of chamber pressure 
(Pirani and capacitive), heating fluid temperature and vial bottom temperature for the 
11 locations described above were collected every 30 s. 
 
 
Figure 7.8.  Arrangement of the eleven thermocouples (numbers) on the five shelves 
for dataset E. 
Table 7.6.  Time profile of the input variables (i.e. “recipe”) for dataset E. 
Step # Interval duration [min] 𝒑𝐜 ?̅?𝒄⁄ [−] 𝑻𝒇𝒍𝒖𝒊𝒅 ?̅?𝒇𝒍𝒖𝒊𝒅⁄ [−] 
 1 15 1 (constant) 0.910 (constant) 
2 30 1 (constant) 0.910-1.000 (linear) 
3 2430 1 (constant) 1.000 (constant) 
4 180         1 (constant) 1.237 (constant) 
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The step-by-step methodology used for this preliminary analysis in shown in Fig. 7.5. 
 
 
Figure 7.5. Schematic of the different steps for the preliminary assessment of model 
performance. 
7.4.2 Step #1: gravimetric estimation of 𝐾𝑣 
In the first step of the proposed methodology, an estimation of the parameters 𝐶1, 𝐶2 and 𝐶3 for 
the heat transfer coefficient 𝐾𝑣 has been obtained through a standard gravimetric method 
(Fissore and Barresi, 2010). The purpose of this gravimetric estimation for the scope of this 
work is to facilitate the numerical solution of the maximum likelihood estimation of these 
parameters (step # 4), by assigning reasonable initial guesses to the estimator. In fact, it has 
been verified that bad initial guesses of 𝐶1, 𝐶2 and 𝐶3 may lead the estimator to diverge.  
The gravimetric method is a standard procedure adopted in the characterization of freeze drying 
equipment to estimate the heat transfer coefficient 𝐾𝑣. This coefficient is estimated from 
incomplete drying experiments (such as the ones collected for datasets A and B), given the 
availability of measurements of vial bottom temperature 𝑇𝐵(𝑡) and total amount of water 
sublimated 𝑀 for a given drying time 𝑡𝑑, according to: 
 
𝐾𝑣 =
𝑀 ΔHs
𝐴𝑣 ∫ (𝑇𝑓𝑙𝑢𝑖𝑑
𝑡𝑑
0
(𝑡) − 𝑇𝐵(𝑡))
    . (7.17) 
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As discussed in section 7.2, the 𝑇𝐵(𝑡) profile, as measured by a themocouple located inside a 
given zone, is typically assumed to be the same for all the vials within that zone. Therefore, Eq. 
(7.17) allows obtaining a different value of 𝐾𝑣 for each vial characterized by a measurement of 
M. This allows one to obtain a distribution of values of 𝐾𝑣 both within the same zone and 
between different zones of a given shelf. This in turn allows a quantitative characterization of 
the thermal behavior of each zone.  
If the experiment is repeated for at least three different values of chamber pressure, the values 
of 𝐶1, 𝐶2 and 𝐶3 of Eq. (7.2) can be obtained by simple fitting. It is worth noticing that the 
values of 𝐾𝑣 do not depend (in principle) on the product considered, but are affected by the type 
of vials (i.e. siliconized or non-siliconized in this study). In fact, the presence of a thin layer of 
silicone on the internal surface of a vial affects the overall heat transfer to the frozen product. 
Based on the previous considerations, a preliminary estimation of the heat transfer coefficient 
𝐾𝑣, as well as of the parameters 𝐶1, 𝐶2 and 𝐶3, have been obtained from the historical datasets 
A (siliconized vials) and C (non-siliconized vials). The results are presented in the next sections. 
7.4.2.1 Results for dataset A 
The distribution of the values of 𝐾𝑣 for each zone and between different zones is shown in Fig. 
7.9  for the three different values of chamber pressures described in section 7.4.1. The values 
of 𝐾𝑣 have been normalized with the value obtained for a vial placed at the same location (zone 
7) at 𝑝𝑐/?̅?𝑐 = 0.667. 
 
 
    (a)                                                                                   (b)                                                   
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      (c) 
 
Figure 7.9. Values of the heat transfer coefficient for the different vials on a shelf at three 
different chamber pressures. 
 
The mean values of (normalized) 𝐾𝑣 are reported in Tables 7.7-7.9 together with their standard 
deviations, for each zone and at the three pressures at which the experiments were carried out. 
Note that standard deviations are computed with respect to the normalized values of 𝐾𝑣, and 
that the mean values have been normalized with the same nominal values used for Fig 7.9. The 
vials have been divided into two categories, namely “edge” (the ones belonging to zones 1, 2, 
3, 5, 8, 10, 11) and “central” (the ones belonging to zones 4, 6, 7, 9), in order to reflect the 
geometric arrangement shown in Fig. 7.6. 
Table 7.7. Mean values of the heat transfer coefficient and standard deviations 
for dataset A at  𝑝𝑐/?̅?𝑐  = 0.667. 
Zone # Normalized mean value of 𝑲𝒗 [-] Standard deviation Vial type 
1 1.420 0.121 Edge 
2 1.089 0.090 Edge 
3 1.279 0.113 Edge 
4 1.036 0.154 Central 
5 1.192 0.138 Edge 
6 0.977 0.128 Central 
7 1.015 0.171 Central 
8 1.396 0.131 Edge 
9 0.888 0.142 Central 
10 1.627 0.242 Edge 
11 1.343 0.192 Edge 
12 2.286 0.299 Edge (window) 
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Table 7.8. Mean values of the heat transfer coefficient and standard deviations 
for dataset A at  𝑝𝑐/?̅?𝑐  = 1. 
Zone # Normalized mean value of 𝑲𝒗 [-] Standard deviation Vial type 
1 1.747 0.098 Edge 
2 1.255 0.066 Edge 
3 1.495 0.125 Edge 
4 1.134 0.097 Central 
5 1.390 0.087 Edge 
6 1.168 0.082 Central 
7 1.202 0.085 Central 
8 1.572 0.121 Edge 
9 1.052 0.113 Central 
10 1.765 0.204 Edge 
11 1.430 0.095 Edge 
12 2.988 0.164 Edge (window) 
 
Table 7.9. Mean values of the heat transfer coefficient and standard deviations 
for dataset A at  𝑝𝑐/?̅?𝑐  = 1.333. 
Zone # Normalized mean value of 𝑲𝒗 [-] Standard deviation Vial type 
1 1.690 0.122 Edge 
2 1.321 0.131 Edge 
3 1.563 0.139 Edge 
4 1.069 0.062 Central 
5 1.460 0.157 Edge 
6 1.211 0.141 Central 
7 1.338 0.185 Central 
8 1.810 0.359 Edge 
9 1.149 0.369 Central 
10 1.700 0.180 Edge 
11 1.697 0.133 Edge 
12 2.476 0.158 Edge (window) 
 
The numerical values of 𝐾𝑣 obtained with the gravimetric method suggest some considerations. 
1. As expected, the vial thermal behavior across different zones changes remarkably . 
Namely, vials at the edge of a shelf are characterized by greater values of 𝐾𝑣 with respect 
to the central ones. This results in larger sublimation rates (hence smaller drying times), 
but also in greater product temperatures. Product temperature control for these vials is 
therefore crucial to avoid irreversible alteration of the product morphology. 
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2. Vials directly exposed to the equipment window (zone 12) show considerable greater 
values of 𝐾𝑣 with respect to other vials. This is clearly related to the heat exchange 
through the window, which speeds up the sublimation process. Following the reasoning 
of the previous remark, this means that these vials are significantly exposed to the risk 
of product collapse/melting. 
3. The variability of 𝐾𝑣 across vials belonging to the same zone is not neglible, as the 
standard deviations of Tables 7.7-7.9 suggest. However, this variability is significantly 
smaller than the one that would be obtained by considering a single value of 𝐾𝑣 for all 
the vials placed on the shelf, as can be easily inferred from Table 7.10. In other words, 
whereas assuming a uniform thermal behavior for the vials belonging to a given zone is 
reasonable, the same cannot be said for all the vials located on the same shelf. This 
means that the mono-dimensional model (7.1)-(7.10) must be calibrated for each 
thermal zone, since significantly different values of 𝐾𝑣 are expected across zones. 
Table 7.10. Mean values and standard deviations of the “global” (i.e. 
computed  for all the 12 zones) heat transfer coefficient at the three different 
values of chamber pressure considered. 
Normalized chamber pressure [-] Normalized mean value of 𝑲𝒗 [-] Standard deviation 
0.667 1.347 0.765 
1 1.577 0.854 
1.333 1.614 0.895 
 
In view of the above considerations, the values of parameters 𝐶1, 𝐶2 and 𝐶3 of Eq. (7.2) can be 
computed for each zone. Although the numerical values of these parameters cannot be reported 
for confidentiality reasons, it was noted that: 
 the value of 𝐶1 significantly differs between the different zones. This is justified by the 
fact that, as proved by Pikal and coworkers (Pikal, 2000), this parameter primarily 
accounts for the radiation contributions from the top and bottom shelves, as well as from 
the chamber walls. These contributions change with the location in the freeze dryer 
(Tables 7.7-7.9). 
 The values of 𝐶2 and 𝐶3 do not significantly vary between zones. This is in agreement 
with the work of Pikal (Pikal, 2000), who justifies this behavior by noting that 𝐶3 mainly 
depends on the distance between the bottom of the vial and the shelf (that is constant in 
the equipment considered), whereas 𝐶2 mainly accounts for conductive effects through 
the sidewall of the vial (which are constant within the shelf) and through the gas 
entrapped between the vial bottom and the shelves. 
Based on the above observations, the twelve different values of 𝐶1 obtained with the gravimetric 
method have been used as initial guesses for the twelve different parameter (preliminary) 
 
 
230 Chapter 7 
________________________________________________________ 
© 2018 Gabriele Bano, University of Padova (Italy) 
 
estimation exercises required at step #4 of the proposed methodology. On the other hand, 𝐶2 
and 𝐶3 have been used as fixed values. 
The procedure described above for dataset A was repeated for dataset C, in order to account for 
the different type of vials considered (siliconized vs. non-siliconized). The numerical results 
can be found in Appendix A. The results show that, surprisingly, the presence of the silicone 
layer does not significantly affect the values of the heat transfer coefficient, even though they 
significantly affect the values of the mass transfer resistance, as will be discussed in more detail 
in section 7.4.5. 
7.4.3. Step #2: sensitivity analysis for 𝐾𝑣 
As discussed in the previous section, due to the variability of the heat transfer coefficient 
between the different zones of a shelf, twelve different model calibrations are required in order 
to capture the relevant behavior of each zone of the shelf. It is worth noticing that, in principle, 
whereas parameter 𝐶1 requires to be estimated with the maximum likelihood estimator on each 
zone, parameters 𝐶2 and 𝐶3 need to be estimated for one zone only, since their values are 
expected to be the same for all zones.  
Notwithstanding this aspect, there would be at least one model calibration activity that would 
require the joint maximum likelihood estimation of parameters 𝐶1, 𝐶2 and 𝐶3, as well as of mass 
transfer resistance parameters 𝑅0, 𝑅1, 𝑅2. As discussed in section 7.4, it was verified that the 
joint estimation of these six parameters is affected by convergence issues due to the limited 
number of measured response variables (vial bottom temperature and end-point cumulative 
amount of water sublimated). This prevented the possibility of jointly estimating all parameters 
together. Therefore, the possibility to reduce the total number of parameters to be estimated 
was considered in order to facilitate the estimator convergence. 
Sensitivity analysis (Cruz and Perkins, 1964) can be used to understand the influence of model 
parameters with respect to the KPIs of the system. The greater the sensitivity of a given 
parameter with respect to a given KPI, the greater the impact of a wrong calibration of that 
parameter on the model prediction of the KPI. In other words, it is always desirable to obtain 
accurate estimations of the parameters with highest sensitivities with respect to the outputs of 
interest, since small variations on their values can significantly affect the model predictions. On 
the other hand, parameters with smaller sensitivities can be set to their nominal (e.g., literature) 
values without significantly impacting on the model performance. 
During primary drying, the KPIs of interest are the temperature 𝑇𝐵 at the bottom of the vials, 
the sublimation flux 𝐽𝑤, and the cumulative amount M of water sublimated during the drying 
stage. The first two KPIs are dynamic variables, while the third one is an end-point variable. 
Therefore, the sensitivities of 𝐶1, 𝐶2, 𝐶3 with respect to the first two KPIs are time-dependent 
(i.e., they are defined as dynamic sensitivities) and are given by: 
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𝑠𝑇,𝑖(𝑡) =
𝜕𝑇𝐵(𝑡)
𝜕𝐶𝑖
 ;   𝑠𝐽𝑤,𝑖(𝑡) =
𝜕𝐽𝑤(𝑡)
𝜕𝐶𝑖
    𝑖 = 1,2,3   , 
(7.18) 
 
while the sensitivities with respect to 𝑀 do not depend on time: 
  
𝑠𝑀,𝑖 =
𝜕𝑀
𝜕𝐶𝑖
;    𝑖 = 1,2,3    . 
(7.19) 
 
As regard the dynamic sensitivities, the maximum absolute values of their time profiles have 
been considered 
Table 7.11. Sensitivities of vial bottom temperature, sublimation flux and 
cumulative amount of water sublimated with respect to the three parameters 
𝐶1, 𝐶2, 𝐶3. The values refer to a +1% deviation on the nominal value of the Ci 
parameters and sensitivities are expressed as % of the nominal value of the 
KPI considered. Values in boldface indicate the strongest sensitivities. 
Parameter  |𝑠𝑇,𝑖
𝑚𝑎𝑥|[%] |𝑠𝐽𝑤,𝑖
𝑚𝑎𝑥|[%] |𝑠𝑀,𝑖|[%] Parameter |𝑠𝑇,𝑖
𝑚𝑎𝑥|[%] |𝑠𝐽𝑤,𝑖
𝑚𝑎𝑥|[%] |𝑠𝑀,𝑖|[%] 
 Zone 1    Zone 7    
𝐶1 0.752 5.789 26.96 𝐶1 0.512 4.874 24.12 
𝐶2 0.186 1.012 0.312 𝐶2 0.182 0.945 0.289 
𝐶3 0.163 0.198 0.059 𝐶3 0.158 0.164 0.045 
Zone 2    Zone 8     
𝐶1 0.645 5.124 26.12 𝐶1 0.647 5.478 27.56 
𝐶2 0.178 1.123 0.365 𝐶2 0.187 1.058 0.395 
𝐶3 0.166 0.201 0.062 𝐶3 0.159 0.241 0.056 
Zone 3    Zone 9    
𝐶1 0.654 5.212 26.54 𝐶1 0.403 3.215 23.11 
𝐶2 0.183 1.056 0.251 𝐶2 0.184 0.665 0.221 
𝐶3 0.169 0.195 0.069 𝐶3 0.163 0.121 0.039 
Zone 4    Zone 10     
𝐶1 0.478 4.786 25.13 𝐶1 0.785 5.632 27.89 
𝐶2 0.184 0.996 0.354 𝐶2 0.184 1.026 0.397 
𝐶3 0.157 0.164 0.044 𝐶3 0.161 0.226 0.055 
Zone 5     Zone 11    
𝐶1 0.612 5.478 27.14 𝐶1 0.635 5.124 27.56 
𝐶2 0.179 1.047 0.321 𝐶2 0.183 1.023 0.378 
𝐶3 0.164 0.212 0.065 𝐶3 0.162 0.225 0.074 
Zone 6     Zone 12    
𝐶1 0.496 4.324 25.56 𝐶1 1.245 6.451 29.23 
𝐶2 0.180 0.987 0.276 𝐶2 0.201 1.451 0.452 
𝐶3 0.168 0.156 0.048 𝐶3 0.189 0.321 0.087 
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. The results obtained with a +1% deviation on nominal values (obtained by the gravimetric 
method) of the parameters are reported in Table 7.11 for all the twelve groups of vials19 
considered. The values reported in Table 7.11 have been computed with the model inputs set at 
their nominal values, i.e. 𝑝𝑐/?̅?𝑐 =1 and 𝑇𝑓𝑙𝑢𝑖𝑑/?̅?𝑓𝑙𝑢𝑖𝑑 = 1. The general trend of the sensitivities 
is the same independently of the values set for these inputs. 
The results of Table 7.11 show that parameter 𝐶1 has the strongest influence on all the three 
KPIs of interest. In particular, the total amount of water sublimated show a very strong 
sensitivity with respect to 𝐶1 (values are highlighted in bold), whereas very limited sensitivities 
with respect to 𝐶2 and 𝐶3.  
Based on these results, it was decided to set the values of 𝐶2 and 𝐶3 at their nominal 
(gravimetric) values, and to perform a maximum likelihood estimation of 𝐶1 for each zone. The 
estimation results are discussed in detail in section 7.4.6. 
7.5.4 Step #3: sensitivity analysis for 𝑅𝑝 
Once 𝐶1 has been identified as the most relevant parameter to be estimated for an accurate 
description of the heat transfer coefficient, an estimation of the mass transfer resistance 𝑅𝑝 must 
be obtained in order to complete the preliminary model calibration activity.  
The resistance to the vapor flow during ice sublimation is the sum of three main contributions, 
namely: 
1. the resistance to the vapor flow due to the dried layer, whose thickness increases as the 
ice sublimation progresses; 
2. the resistance to the vapor flow exerted by the elastomeric stoppers that are partially 
inserted in the neck of the vials during the drying process. These stoppers can have 
different opening configurations to allow the vapor flow during drying operation and 
are fully inserted at the end of the overall drying cycle to guarantee product sterility; 
3. the resistance to the vapor flow due to path from the drying chamber to the condenser.  
Several experimental studies (Pikal, 2000; Rambhatla et al., 2004; Pikal et al., 2016) have 
shown that the first contribution accounts for more than 80% of the total mass transfer 
resistance, whereas the stoppers and chamber-to-condenser contributions account for no more 
than 3-6% each. Therefore, the latter contributions are typically neglected and the mass transfer 
resistance reported in Eq. (7.3) only accounts for the contribution of the growing dried layer. 
The dependence of 𝑅𝑝 with respect to the thickness 𝐿𝑓𝑟𝑜𝑧𝑒𝑛 of the dried layer is typically 
expressed by Eq. (7.4), and the three parameters appearing in this equation, which need to be 
estimated, are 𝑅0, 𝑅1 and 𝑅2. 
                                                          
19 Note that the fact that 𝐶2 and 𝐶3 are the same for each zone does not mean that their sensitivities are the same, since their 
values are affected by the nominal value of 𝐶1 (which is different for each zone).  
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𝑅0 is the mass transfer resistance at the beginning of the ice sublimation process and depends 
on the product formulation. The interpretation of this parameter has been attributed to the mass 
transfer resistance of the top layer of the frozen product, but a rigorous physical explanation is 
still missing (Rambhatla et al., 2004). 𝑅1 describes the “speed” at which the mass transfer 
resistance increases with the dried layer thickness. The contribution of 𝑅2 is sometimes 
neglected (Pikal, 2000), and the dependence of 𝑅𝑝 with respect to 𝐿𝑓𝑟𝑜𝑧𝑒𝑛 is expressed as a 
linear relationship. 
Some experimental studies (Pikal, 2000; Rambhatla et al., 2004) have shown that the evolution 
of the mass transfer resistance during ice sublimation strongly depends on the product 
morphology, which is in turn affected by the freezing protocol adopted. In fact, the greater the 
nucleation temperature and degree of supercooling during the freezing step, the greater the size 
of ice crystals and dried pores inside the product, the smaller the mass transfer resistance to the 
vapor flow during ice sublimation. Different techniques (e.g., controlled ice nucleation and 
introduction of an annealing step during freezing) can be used to increase the dimensions of the 
ice crystals and therefore to reduce the value of 𝑅𝑝 during primary drying. 
The estimation of the parameters 𝑅0, 𝑅1 and 𝑅2 is typically performed with ad-hoc experimental 
techniques that all suffer from several limitations. The typical procedure consists of two 
sequential steps. 
1. First, the mass transfer resistance 𝑅𝑝 is determined experimentally using the 
relationship: 
 
𝑅𝑝 =
𝐴𝑣(𝑝𝑖 − 𝑝𝑐)
𝐽𝑤
    . 
(7.20) 
 
The sublimation flux 𝐽𝑤 can be obtained experimentally by inserting a weighing device 
inside the drying chamber (Fissore et al., 2010), by performing a pressure rise test 
(Fissore et al., 2010), or by using a non-invasive spectroscopic method called tunable 
diode laser absorption spectroscopy (Cassidy and Reid, 1982). However, the 
experimental values of 𝐽𝑤 (hence of 𝑅𝑝) obtained with these methods are only “local” 
values (i.e., valid for a single vial in the case of the weighing device) or “global” values 
(i.e., a single value of the mass transfer resistance is obtained for all the vials inside the 
drying chamber, in the case of pressure rise test and tunable diode laser absorption 
spectroscopy ). Additionally, these values do not account for the different mass transfer 
behavior of the vials inside the drying chamber. Note also that the application of Eq. 
(7.20) also requires measurements of the temperature at the bottom of the vials, since 
temperature 𝑇𝑖 at the sublimation interface can be inferred from them according to Eq. 
(7.8); after that, also 𝑝𝑖 can be inferred, according to Eq. (7.5). As will be shown in 
section 7.6, this is a serious (and still not resolved) limitation of these methods, since 
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the estimation of the mass transfer resistance depend on the estimation of the heat 
transfer coefficient. A wrong estimation of 𝐾𝑣 (which is typically obtained with the 
gravimetric method described in section 7.4.1) would result in a wrong estimation of 
𝑅𝑝, and, most importantly, the (possible) presence of a high correlation between those 
two parameters would completely invalidate the ability of these experimental methods 
(gravimetric for 𝐾𝑣 together with experimental identification of 𝑅𝑝) to correctly identify 
the model parameters. 
2. Parameters 𝑅0, 𝑅1 and 𝑅2 are then estimated by looking for the best fit between a 
reference curve and the experimental values of 𝑅𝑝 vs. the dried layer thickness 𝐿𝑑𝑟𝑖𝑒𝑑 
that can be obtained with one of the experimental strategies described above. 
Despite the aforementioned experimental techniques, which all suffer from some limitations, 
the parameters of the mass transfer resistance 𝑅𝑝 equation can also be estimated directly with 
the maximum likelihood estimator once measurements of vial bottom temperature and total 
amount of water sublimated are available. In other words, 𝑅0, 𝑅1 and 𝑅2 can be estimated 
together with the heat transfer parameter 𝐶1 at step #4 (Fig. 7.5) of the proposed methodology. 
For the same reasons discussed in the previous section, it is always desirable to study if some 
of these parameters can be set to their nominal values without affecting the overall model 
performance, so as to facilitate the estimation. To this purpose, a sensitivity analysis for the 
system KPIs with respect to 𝑅0, 𝑅1 and 𝑅2 was performed. 
The nominal values of these parameters are reported in the literature for the same formulation 
(5% sucrose-based placebo) that was used in the historical experiments. In this study, the values 
reported by Mortier et al. (2016) were used as nominal values for 𝑅0, 𝑅1 and 𝑅2. Note that these 
values are assumed to be the same for all the vials, and therefore sensitivity analysis can only 
be performed by assuming a “global” behavior of the mass transfer resistance (i.e., “global” 
nominal values are available for 𝑅𝑝, whereas “local” nominal values were available for 𝐾𝑣 
thanks to the gravimetric measurements). However, in this work, 𝑅𝑝 was not assumed to have 
the same values for all zones: instead, a value of 𝑅𝑝 was determined for each zone through the 
maximum likelihood estimator. As a consequence, since the results of the sensitivity analysis 
are only available on a “global” level, it is implicitly assumed that the sensitivities of the KPIs 
with respect to the three mass transfer parameters are not significantly affected by their “local” 
nominal values. 
The results of the sensitivity analysis are shown in Table 7.12. These values refer to the same 
drying recipe used for the sensitivity analysis on 𝐾𝑣 and were obtained by keeping 𝐾𝑣  constant 
and equal to the gravimetric value. 
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Table 7.12. Sensitivities for the vial bottom temperature, sublimation flux and 
cumulative amount of water sublimated with respect to the three parameters 
𝑅0, 𝑅1, 𝑅2. The values refer to a +1% deviation on the nominal value of the 
parameters and sensitivities are expressed as % of the nominal value of the 
KPI considered. The strongest sensitivity value is shown in boldface. 
Parameter  |𝑠𝑇,𝑖
𝑚𝑎𝑥|[%] |𝑠𝐽𝑤,𝑖
𝑚𝑎𝑥|[%] |𝑠𝑀,𝑖|[%] 
𝑅0 0.020 0.009 0.000 
𝑅1 0.076 1.321 0.199 
𝑅2 0.024 0.000 0.000 
 
From the results shown in Table 7.12, it can be concluded that: 
 𝑅2 has a negligible impact on all the KPIs of interest and can therefore be neglected (as 
confirmed by several experimental studies); 
 𝑅1 has a stronger influence on the KPIs of interest than 𝑅0, especially on the sublimation 
flux and the total amount of water sublimated (as one would expect). Therefore, accurate 
estimation of this parameter is crucial to obtain a reliable prediction of the sublimation 
flux and duration of the ice sublimation. 
In view of the above, parameter 𝑅0 was set to its nominal value, and 𝑅1 was treated as an 
additional model parameter to be preliminarily estimated. Note that the nominal value of 𝑅0 
depends on the product formulation; therefore, if its value cannot be found in the literature for 
the product under investigation, this parameter needs to be calibrated together with 𝐶1 and 𝑅1 
at the next step of the proposed methodology. 
7.4.5 Step #4: parameter estimation 
Based on the analyses performed in the previous steps, the  maximum likelihood estimation of 
the parameters of model (7.1)-(7.10) is reduced to a joint estimation of: 
 the heat transfer parameter 𝐶1, with initial guess set as the corresponding gravimetric 
value determined during step #1; 
 the mass transfer parameter 𝑅1, with initial guess set as the corresponding literature 
value. 
The two parameters 𝐶1, 𝑅1 must be estimated for each one of the 12 zones, with the other 
parameters 𝐶2, 𝐶3, 𝑅0, 𝑅2 set at their nominal values.  
The estimation activity has to be repeated for dataset B (non-siliconized vials) as well as dataset 
C (siliconized vials). The results of the parameter estimation activity for all the 12 zones 
considered is reported in Table 7.13 for dataset B. The results for dataset C can be found in 
appendix A. Note that the values of the parameters are reported as % of their nominal (i.e. initial 
guess) values.  
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Table 7.13. Maximum likelihood parameter estimation for the 12 zones 
considered. Dataset B (non-siliconized vials). 
Parameter 
% 
nominal 
value 
95% 
 t-value 
Reference 
t-value 
Parameter 
% 
nominal 
value 
95% 
t-value 
Reference 
 t-value 
 Zone 1    Zone 7    
𝐶1 103.65 74.41 1.65 𝐶1 103.12 78.12 1.65 
𝑅1 104.13 63.58 1.65 𝑅1 103.89 66.32 1.65 
Zone 2    Zone 8     
𝐶1 109.14 75.87 1.65 𝐶1 106.82 77.52 1.65 
𝑅1 102.12 66.41 1.65 𝑅1 104.82 65.56 1.65 
Zone 3    Zone 9    
𝐶1 102.45 77.89 1.65 𝐶1 107.74 74.52 1.65 
𝑅1 105.69 69.45 1.65 𝑅1 106.16 63.56 1.65 
Zone 4    Zone 10     
𝐶1 106.23 67.89 1.65 𝐶1 104.56 78.98 1.65 
𝑅1 109.12 62.12 1.65 𝑅1 102.12 67.85 1.65 
Zone 5     Zone 11    
𝐶1 112.25 70.25 1.65 𝐶1 102.31 75.65 1.65 
𝑅1 103.64 64.12 1.65 𝑅1 106.14 66.32 1.65 
Zone 6     Zone 12    
𝐶1 121.53 72.14 1.65 𝐶1 108.12 71.21 1.65 
𝑅1 114.73 65.9 1.65 𝑅1 114.56 59.87 1.65 
 
Table 7.13 shows that the two parameters can be identified by the maximum-likelihood 
estimator with high precision20, since their 95% t-values are significantly greater than the 
reference t-value. The good agreement between the experimental data and the model prediction 
is shown in Fig. 7.10 for 𝑝𝑐/?̅?𝑐 = 0.667. Similar results have been obtained for the other values 
of chamber pressure. Although these plots refer to the model calibrated for  zone # 6 of the 
batch of vials, similar results have been obtained for all the other 11 zones.  
 
                                                          
20 Note that a high precision on the parameter estimation does not necessarily mean a high accuracy on the estimated values. 
  
Model-based design of experiments in pharmaceutical freeze-drying 237 
 
________________________________________________________ 
© 2018 Gabriele Bano, University of Padova (Italy) 
 
 
 
Figure 7.10. Comparison between experimental observations (light blue markers) and model 
predictions (red lines) for zone 6 and 
𝑝
?̅?𝑐
= 0.667. 
 
A good fit of the historical experimental data is obtained with the available model. Particularly, 
the prediction of the end-point value of the cumulative amount of water sublimated is in good 
agreement with the experimental value (the model prediction is 0.87% smaller than the 
averaged experimental value). Moreover, the model is slightly underestimating this variable, 
which provides a conservative prediction of the total time needed to complete the ice 
sublimation. The state variables profiles predicted by the calibrated model in the zone 6 of the 
shelf are shown in Fig. 7.11. 
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Figure 7.11. Time profiles of the (a) length of the frozen layer, (b) sublimation flux, and (c) 
heat flux as predicted by the calibrated model for zone #6. 
 
7.4.6 Step #5: model validation 
Once the model has been preliminarily calibrated, the model performance can be assessed using 
a dataset that was not used for model calibration. Two validation datasets have been used to 
this purpose, namely dataset D for non-siliconized vials, and dataset E for siliconized vials.  
The ability of the model to give a reliable estimation of the KPIs of interest has been 
investigated. A slight complication to this model validation activity is due to a difference in the 
location of the thermocouples between the calibration and validation datasets, as well as the 
different loading between the calibration and validation datasets that could impact on the 
temperature dynamics. 
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For example, for non-siliconized vials, the validation dataset D collects measurements of 
product temperature for two vials placed in the middle of the first and last row of the first half 
of the shelf. According to Fig. 7.7, these locations should correspond, in principle, to zone 12 
and zone 7 (respectively) of the calibration dataset. Therefore, the model calibrated for these 
two zones should be used to challenge the model predictions against the experimental 
observations. However, since the position of the thermocouple itself is different between the 
two datasets, the models calibrated for zones adjacent to zones 12 and 7 have also been used to 
test the performance. Note that the only measurement available in the validation datasets is the 
vial bottom temperature, and the accuracy of the model prediction can therefore be assessed 
only for this variable. 
The comparison between the experimental values for the two temperature measurements of 
dataset D and the relevant model predictions is shown in Fig. 7.12. 
 
 
(a)                                                                              (b) 
 
Figure 7.12. Model validation for (a) thermocouple #5 and (b) thermocouple #6 of the 
validation dataset D. 
 
The first important remark to be made is on the experimental profile of the vial bottom 
temperature. This profile (black dots) is characterized by an abrupt inflection at around half of 
the total duration of primary drying, due to the transition of the frozen layer through the bottom 
of the vial. In principle, if the thermocouple touches the bottom of the vial, the inflection should 
correspond to the end of the ice sublimation process. Starting from this instant, the heating flow 
from the shelf is used to significantly increase the product temperature, but it is still not large 
enough to promote a significant water desorption (Pikal, 2000). From a practical point of view, 
it is difficult to guarantee a complete adherence between the thermocouple and the vial bottom, 
and the very presence of the thermocouple affects the vial behavior during ice sublimation. For 
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these reasons, the inflection on the product temperature profile can only be considered as a 
qualitative indication that the sublimation process is close to the end. 
The mono-dimensional model (7.1)-(7.10) only accounts for the ice sublimation process, and 
is therefore not suitable to describe the vial behavior when ice sublimation ends. Therefore, the 
behavior of the product temperature after the inflection cannot be captured by the available 
model. This behavior can be described by introducing a desorption model in the original 
formulation (Fissore et al., 2012). 
Due to the different geometry configurations between the calibration and validation datasets, it 
is not possible to describe the experimental profile with the model calibrated for a specific zone. 
However, Fig 7.12 shows that the model predictions of zones adjacent to the one where a 
temperature measurement is available are able to bracket the relevant behavior of the system 
during ice sublimation21. A better representation of the system could be obtained by developing 
an integrated multi-vial model accounting for the different thermal behaviors between the vials. 
Such a model is still an open research area that will be investigated in the future. 
Summarizing, the following conclusions to this preliminary analysis can be drawn: 
1. the model (7.1)-(7.10) is structurally consistent with the experimental observations as 
ice sublimation progresses. However, the different behaviors of the vials placed at 
different locations on the shelf cannot be captured by this model. The model can only 
be used to capture the behavior of each zone (assuming that all the vials of the same 
zone behave in the same way), and therefore its applicability to different configurations 
is limited. 
2. In the experimental conditions used for this study, the number of parameters that need 
to be identified by MBDoE is only two: one involving the heat transfer coefficient (𝐶1), 
the other involving the mass transfer resistance (𝑅1). These parameters can be identified 
from historical data with high precision (high t-values), but their accuracy is not 
guaranteed. However, if a different freeze-dryer geometry configuration, different vial,  
different formulation or different loading system (e.g., in frames or not) is used, 
optimally designed experiments are still needed to maximize their information in order 
to assist the parameter estimation activity. 
The latter issue is thoroughly discussed in the next section. 
7.5 Model-based design of experiments for primary drying 
The preliminary analysis described above showed that the two most influential model 
parameters 𝐶1 and 𝑅1 can be estimated from historical data with good precision. However, their 
values are affected by factors (such as system geometry and type of formulation) that are not 
                                                          
21 In absolute values, the prediction of the vial bottom temperature is bracketed within a ± 2°C accuracy by the model 
predictions. 
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taken into account explicitly in the model structure. Therefore, a new estimation of these 
parameters is required whenever the system configuration changes or a different formulate is 
used. In order to maximize the information that can be obtained from a new identification 
experiment, MBDoE techniques can be used to design optimal experiments based on the mono-
dimensional model (7.1)-(7.10). 
The objective of this section is to design a new experiment in order to maximize the precision 
that can be obtained for the estimation of 𝐶1 and 𝑅1. The same system configuration as the 
previous preliminary analysis will be kept, and a comparison between the precision on the 
estimated values of 𝐶1 and 𝑅1 that can be obtained with or without the new designed experiment 
will be discussed. Note that, in practical applications where both the system configuration and 
the type of formulation change, a reasonable estimate of the other model parameters 
(𝐶2, 𝐶3, 𝑅0, 𝑅2) is required. These estimates can be obtained with the same considerations 
described in the previous section, with the only difference that the value of 𝑅0 may not be 
available in the literature. In this scenario, 𝑅0 should be taken into account in the MBDoE 
activity as an additional parameter that must be estimated. 
7.5.1 Problem statement 
The design of a new optimal experiment, based on the model (7.1)-(7.10), requires the following 
information: 
1. initial conditions of the system, namely initial thickness of the frozen layer; 
2. assignment of the control variables whose profile need to be optimized, namely total 
chamber pressure and heating fluid temperature; 
3. time profile of the control (i.e., manipulated) inputs, which can be assumed to be time-
invariant, piecewise constant or piecewise linear. If a time-varying profile is chosen, the 
number of intervals and the upper and lower bounds of the control variables for each 
interval must be specified. For the system considered, a piecewise linear behavior for 
𝑇𝑓𝑙𝑢𝑖𝑑 and a piecewise constant behavior for 𝑝𝑐 have been chosen; 
4. assignment of the measurements that have to be collected and sampling frequency. For 
the system under investigation, the only variable that can be measured is the vial bottom 
temperature TB at specific locations within the freeze dryer, and a sampling interval of 
30 s was set; 
5. constraints on the state variables that need to be satisfied over the entire experiment or 
at the end of the experiment. As discussed in section 7.1.2, the two constraints that need 
to be satisfied during primary drying are (i) product temperature below the glass 
transition/eutectic temperature of the product, and (ii) sublimation flux lower than the 
maximum allowable flux to avoid choked flow. Both constraints were assumed to be 
time-invariant interior-point constraints to be satisfied over the entire drying operation; 
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6. model parameters that need to be estimated from the designed experiment, namely 𝐶1 
and 𝐴.  
The results of the MBDoE activity are: 
1. total duration of the experiment. Note that this variable can also be set to a fixed value 
depending on the type of experiment desired; 
2. length of the switching intervals for the manipulated inputs; 
3. profile (for 𝑇𝑓𝑙𝑢𝑖𝑑) or value (for 𝑝𝑐) of the control inputs within each switching interval. 
The MBDoE activity was performed based on the following assumptions and operational 
constraints for the experimental equipment: 
a. the model originally calibrated for zone #6 (central vials) was used as the reference 
model for the MBDoE. This is because central vials represent the majority of the vials 
within the freeze dryer, and therefore the experiment is optimized based on the behavior 
of the majority of the vials within the system. Note that this may cause the edge vials to 
not fulfill the constraint on the maximum allowable product temperature; 
b. a maximum normalized product temperature ?̅?𝐵
𝑚𝑎𝑥 = 1.32 and a maximum normalized 
sublimation flux 𝐽?̅?
𝑚𝑎𝑥 = 1.26 were set based on the type of formulation and machine 
considered. 
c. the maximum allowable number of intervals was set equal to 13 due to limitations in 
the recipe implementation on the machine. 
The results of the MBDoE activity are reported in the next section. 
7.5.2 Designed experiment: “in silico” results 
The experiment was designed using the D-optimal criterion (section 7.3) and the total duration 
of the experiment was set to 990 min (16.5 h). The optimal profiles of the control inputs are 
shown graphically in Fig. 7.13 and numerically in Table 7.14. 
 
 
 
Figure 7.13. Control input profiles for the optimal experiment designed using MBDoE. 
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Notice that, although a piecewise linear profile was looked for, the heating fluid temperature is 
kept constant in each interval, and is characterized by an initial decrease followed by a slight 
increase of temperature towards the end of the experiment. With respect to the chamber 
pressure, only one meaningful switch is required from ∼ 50 mT to 75 mT after ~380 min. 
The designed experiment can be simulated in silico in order to study how the precision in the 
estimation of parameters 𝐶1 and 𝐴 improves with respect to the historical (non-designed) 
experiments.  
The results of the parameter estimation activity using the in-silico designed experiment are 
summarized in Table 7.15. For the designed experiment, two scenarios are analyzed, namely 
one where both the designed experiment and the historical datasets are used to estimate the 
parameters, and one where only the designed experiment is used to this purpose. It is worth 
noticing that whereas the designed experiment collects measurements of vial bottom 
temperature only, the historical data collect measurements of vial bottom temperature and 
cumulative amount of water sublimated. As can be seen, in both designed scenarios the 
precision of the estimation increases (much larger t-values are obtained) than when only 
historical experiments are used. 
Table 7.14. Numerical values of the control inputs for each interval of the 
optimally designed experiment of Figure 7.13. 
Interval # 
Interval duration 
[min] 
Normalized heating 
fluid temperature [-] 
Normalized chamber 
pressure [-] 
1 61.0 1.025 0.667 
2 61.0 1.019 0.667 
3 79.8 1.011 0.667 
4 83.5 1.005 0.667 
5 84.5 1.001 0.667 
6 84.6 1 0.667 
7 84.3 1.001 0.667 
8 83.5 1.002 1 
9 82.0 1.004 1 
10 79.5 1.007 1 
11 74.3 1.009 1 
12 60.9 1.011 1 
13 70.7 1.014 1 
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Table 7.15. Final values and estimate precision for parameters C1 and A 
using historical and optimal (in silico) experiments 
Parameter 
95% t-value (only 
historical data) 
95% t-value 
(historical data + 
designed experiment) 
95% t-value 
(only designed 
experiment) 
Reference t- 
value 
𝐶1 73.62 111.7 81.12 1.645 
𝐴 59.6 72.6 63.21 1.645 
 
It is worth noticing, however, that the two parameters are strongly correlated between, as 
confirmed by the following correlation matrices (index 1 = 𝐶1, index 2 = 𝑅1): 
 
          Only historical data:                   (
1 −0.932
−0.932 1
),    (7.21) 
 
Historical data+ designed exp. : (
1 −0.993
−0.993 1
), (7.22) 
 
Only designed exp.:                     (
1 −0.974
−0.974 1
). (7.23) 
 
This may have a potential effect on the accuracy of the estimates of the two parameters, since 
their values are jointly dependent on each other. This issue is still under investigation and is not 
covered in this Dissertation 
 
7.6 Final remarks and future work 
In this Chapter, a methodology to design a new experiment for the primary drying stage of a 
pharmaceutical freeze dryer has been proposed.  
First, a step-by-step approach has been developed in order to assess the structural consistency 
and the most influential parameters of a mono-dimensional model available in the literature. 
The methodology allowed to reduce the number of parameters to be estimated to only two 
parameters, related to heat and mass transfer. Moreover, a systematic approach to identify the 
nominal values of the other parameters has been proposed. 
Secondly, a new optimal experiment has been designed using MBDoE according to a D-optimal 
criterion. The designed experiment has been simulated in silico and promising results have been 
obtained for the parameter estimation activity, with a significant increase of the precision of the 
parameter estimates over the one that could be achieved using historical (non-designed) 
experiments. A significant correlation between the two parameters has also been identified at 
this stage. 
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Future work involves the implementation of the designed experiment on the real equipment. 
Moreover, the issue related to the high correlation of the two parameters will be tackled by 
considering re-parameterization techniques and different parameter estimation activities. 
Finally, further improvements to the available model will be implemented in order to capture 
the behavior of the partial pressure of water in the chamber in a more detailed fashion.
 ________________________________________________________ 
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Conclusions and future perspectives 
 
The description of the design space (DS) of a new pharmaceutical product is one of the most 
important activities that has been introduced within the Quality by Design (QbD) framework. 
An approved DS can represent a competitive advantage for the applicant company, since the 
process can be run anywhere within the DS without requiring any additional regulatory 
approvals. This translates into an enhanced process flexibility, which in turn translates into an 
increase of profitability.  
Different activities related to DS description are involved during the lifecycle of a 
pharmaceutical product. In pharmaceutical development, design space determination and 
uncertainty quantification (i.e., quantification of “assurance” of quality for the final product) 
represent two fundamental steps that companies should implement in order to prepare a 
submission for a new drug approval to the relevant regulatory bodies (e.g. Food and Drug 
Administration, FDA). During the technology transfer phase, design space scale-up and design 
space scale-out allows transferring the DS obtained at the laboratory scale to the commercial 
plant scale, or across different manufacturing sites. Finally, during commercial manufacturing, 
design space maintenance allows obtaining a continuous update of the DS as more information 
about the manufacturing process is gained through plant operation. 
Model-based approaches play a key role to tackle all the aforementioned activities related to 
DS description. Models can be used to link the raw material properties and critical process 
parameters of the manufacturing process to the critical quality attributes of the final product, 
thus allowing determination of the DS of the product. Moreover, models can be used to assist 
technology transfer activities related to DS description, as well as to assist DS maintenance 
during plant operation. 
 
In this Dissertation, advanced modeling strategies for the description and maintenance of the 
design space of new (or existing) pharmaceutical products have been developed. The proposed 
approaches aim at utterly fulfilling the definitions and requirements defined by the regulatory 
documents, in terms of both demonstration of the DS (i.e., rigorous scientific explanation of 
the methodology adopted for DS determination) and of quantification of assurance of quality 
(i.e., probability that the product will meet its quality specifications). Specifically, the following 
four different research areas were investigated: 
1. development of rigorous methodologies and metrics for the quantification of the 
assurance of quality for the final product; 
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2. development of computationally feasible and user-friendly (to be intended as ease of 
interpreting the results) methodologies for design space description; 
3. development of a methodology to adapt and maintain the model-based representation 
of a DS as process operation progresses; 
4. exploitation of model-based design of experiments (MBDoE) techniques for the 
identification of first-principles models to be used for DS description. 
Table C.1 summarizes the main achievements of this Dissertation, with indication of example 
applications, type of data used, and references where the results have been discussed. 
In Chapter 1, a thorough review of the methodologies that have been proposed in the literature 
to assist the description of a design space during product/process development, technology 
transfer and commercial manufacturing has been given. 
With reference to the issue of the quantification of “assurance” of quality, in Chapter 3 and 
Chapter 4 two methodologies have been proposed. The methodology presented in Chapter 3 is 
derived with concepts of frequentist statistics and suited for situations where a projection onto 
latent structures (PLS) model is to be used for DS description. The methodology presented in 
Chapter 4 is built upon concepts of Bayesian statistics and jointly exploits PLS modeling and 
Bayesian multivariate linear regression model to obtain a probabilistic representation of the 
design space. 
In more detail, in Chapter 3 two frequentist models were developed to back-propagate the 
uncertainty from the space of product quality (output space from a modeling perspective) to the 
space of raw material properties and process parameters (input space) of a pharmaceutical 
process. The backpropagation models were obtained for situations where a PLS model (built 
on historical manufacturing data of products “similar” to the one under development) is used 
to relate the raw material properties and process parameters to the product quality 
characteristics. It was shown how PLS model inversion, together with uncertainty back-
propagation, allows identifying a restricted portion of the original input domain (called 
experiment space) where the design space of the new product is expected to lie with a given 
degree of confidence. The experiment space can then be used to tailor an experimental 
campaign within this restricted set of input combinations, with advantages in terms of reduction 
of the duration and cost of the experimental campaign. The effectiveness of the methodology 
was tested on five case studies involving typical unit operations of the pharmaceutical industry, 
such as dry/wet granulation and roll compaction, involving both simulated and real 
experimental data. For all the case studies considered, the predicted experiment space 
effectively bracketed the actual design space of the pharmaceutical product under investigation. 
In Chapter 4, a methodology was proposed to exploit Bayesian multivariate regression together 
with PLS modeling in order to quantify the assurance of quality for the final product. The metric 
used to this purpose is the probability (to be intended according to its Bayesian interpretation) 
that the product will meet its quality specification, given the historical data available. The 
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proposed methodology combines: (i) a PLS model to reduce the dimensionality of the original 
input space for an easier discretization and interpretation; (ii) Markov-chain Monte-Carlo 
techniques to reconstruct the posterior probability distribution (PPD) of the product quality 
attributes for each input combination considered. The PPD obtained for all the combinations of 
the input domain allows identifying a probabilistic (or Bayesian) design space, defined as the 
set of input combinations for which the probability that the product will meet its specifications 
is greater than an assigned threshold. The DS obtained according to this approach is fully 
consistent with the regulatory requirements, since it contains a quantitative metric of the risk 
that the product may not reach its quality targets. The final outcome is a step-by-step 
methodology that companies may decide to use in design space submission to the regulatory 
agencies. The effectiveness of the proposed approach was tested on three case studies involving 
real experimental data (taken from the literature) of pharmaceutical unit operations. 
 
With respect to the issue of design space determination, a methodology was proposed in 
Chapter 5 to obtain a computationally feasible and user-friendly representation of the DS. The 
methodology was obtained by combining two different modeling strategies: (i) a PLS model to 
reduce the dimensionality of the input space; (ii) surrogate-based feasibility analysis to identify 
the DS on the latent representation of the input space obtained with the PLS model. It was 
shown how a cubic radial-basis function surrogate can be used to obtain a computationally 
cheap approximation of the original process model, and how an adaptive sampling strategy can 
be used to determine the DS boundary on the latent space identified by the PLS model. The 
methodology effectiveness was tested on a continuous line for pharmaceutical tablet 
manufacturing, and the computational benefits (~80% reduction of the overall computational 
time) were presented together with the improvements in terms of ease of DS representation (a 
single two-dimensional latent plot can be used to represent a six-dimensional design space). 
Moreover, the robustness of the methodology was tested with other strongly nonlinear 
mathematical examples. 
 
The problem of design space maintenance during plant operation was discussed in Chapter 6, 
where a methodology was proposed to obtain a continuous adaptive refinement of the 
representation of the DS that can be obtained using a first-principles model. Given the available 
measurements coming from plant sensors, the methodology jointly exploits (i) a dynamic state 
estimator and (ii) surrogate-based feasibility analysis to perform continuous adaption of the DS 
as process operation progresses. It was shown how the state estimator can be used to adjust in 
real time a small subset of the model parameters in order to compensate for process/model 
mismatch, and obtain an up-to-date representation of the state of the system. Feasibility analysis 
were then used to identify the DS boundary based on the up-to-date model returned by the state 
estimator
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Table C.1. Summary of the main achievements of this Dissertation, with indication of their relevant applications, the original of the 
data used and the related references. 
Chapter Main achievement       Application Data origin Reference 
Chapter 1 Review on methodologies 
for design space 
description 
             (-) (-) Bano, G., Facco, P., Bezzo, F., Barolo M. (2018) Design space 
description in pharmaceutical development and manufacturing: a review. 
In preparation.  
               (-)   
Chapter 3 Development of two 
uncertainty back-
propagation models for 
PLS model inversion in 
pharmaceutical product 
development  
 Roll compaction 
 High-shear wet     
   granulation 
 Dry granulation 
Simulated and 
laboratory 
Bano, G., Meneghetti, N., Facco, P., Bezzo, F., Barolo M. (2017) 
Uncertainty back-propagation in PLS model inversion for design space 
determination in pharmaceutical product development. Comput. Chem. 
Eng. 101, 110-124.  
 
Facco, P., Bano, G., Bezzo, F., Barolo M. (2017) Multivariate statistical 
approaches to aid pharmaceutical processes: product development and 
process monitoring in a Quality-by-design perspective. EuroPACT 2017. 
May 10-12, Potsdam (Germany).  
 
 
Bano, G., Meneghetti, N., Facco, P., Bezzo, F., Barolo, M. (2017) 
Determinazione dello spazio di progetto di un nuovo prodotto 
farmaceutico: caratterizzazione dell’incertezza. Convegno GRICU 2017: 
gli orizzonti dell’ingegneria chimica. September 24-29, Anacapri (NA; 
Italy). 
 
 
Chapter 4 Joint Bayesian/latent 
variable approach for the 
quantification of the 
“assurance” of quality of a 
new pharmaceutical 
product 
 Roll compaction 
 High-shear wet     
   granulation 
 Dry granulation 
 
Simulated and 
laboratory 
Bano, G., Facco, P., Bezzo, F., Barolo, M. (2018) Probabilistic design 
space determination in pharmaceutical development: a Bayesian/latent 
variable approach. AIChE J. 64, 2438-2449. 
 
Bano, G., Facco, P., Bezzo, F., Barolo, M (2017) Handling parametric 
and measurement uncertainty for design space determination in 
pharmaceutical product development: a Bayesian approach. Presented 
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at: World Congress of Chemical Engineering WCCE10. October 1-5, 
Barcelona (Spain). 
 
Chapter 5 General methodology to 
describe the design space 
of a pharmaceutical 
product through a joint 
PLS/feasibility analysis 
approach 
 Continuous direct  
   compaction  
          manufacturing line 
Simulated Bano, G., Wang, Z., Facco, P., Bezzo, F., Barolo, M., Ierapetritou, M. 
(2018) A novel and systematic approach to identify the design space of 
pharmaceutical processes. Comput. Chem. Eng. 115, 309-322. 
 
Bano, G., Z. Wang, P. Facco, F. Bezzo, M. Barolo, M. Ierapetritou 
(2018). Dimensionality reduction in feasibility analysis by latent variable 
modeling. In: Computer-Aided Chemical Engineering 44, Proc. of the 
13th International Symposium on Process Systems Engineering – PSE 
2018, July 1-5 2018 (M.R. Eden, M.G. Ierapetritou, G.P. Towler, Eds.), 
Elsevier, Amsterdam (The Netherlands), 1477-1482. 
 
 
Chapter 6  Systematic methodology 
for online maintenance of 
the design space 
 Dry granulation 
 Penicillin       
   fermentation 
Simulated Bano, G., Facco, P., Ierapetritou, M., Bezzo, F., Barolo, M. (2018) 
Design space maintenance by online model adaptation in pharmaceutical 
manufacturing. Submitted to: Comput. Chem. Eng.  
 
Chapter 7  Design of optimal 
experiments for 
pharmaceutical freeze 
drying 
 Pharmaceutical  
   freeze drying 
Industrial (-) 
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The methodology was tested with two case studies, the former involving the granulation of a 
pharmaceutical formulate, the latter involving the fermentation of penicillin in pilot scale 
bioreactor. In both situations, the ability of the proposed approach to timely track the DS was 
proven. The methodology was tested on two case studies, the former involving the granulation 
of a pharmaceutical formulate, the latter involving the fermentation of penicillin in pilot scale 
bioreactor. In both situations, the ability of the proposed approach to continuously track the DS 
was proven. 
 
With respect to the issue of the design of optimal experiments for the identification of first-
principles models to be used for DS description, in Chapter 7 it was shown how model-based 
design of experiments (MBDoE) techniques can be exploited to reach this target. MBDoE was 
used to design a new experiment in order to extract the maximum amount of information for 
the identification of the most influential parameters of a mechanistic model of an experimental 
pharmaceutical freeze dryer. A preliminary analysis was first performed based on historical 
data in order to assess the structural consistency of the model and to determine its most 
influential parameters (with respect to the key performance indicators of the system). A new 
experiment was then designed using MBDoE in order to extract the maximum amount of 
information for the identification of the two most influential model parameters. Significant 
improvements were obtained in terms of precision in the parameter estimates, both in silico and 
in the experiment performed on the real equipment.  
 
Some areas of further investigation can be discussed at this point.  
 Validation of the methodologies presented in Chapter 3 through Chapter 6 was carried 
out using laboratory or simulated data. It would be very useful if industrial data could 
be used instead. Chapter 7 has started considering the use of industrial datasets, but more 
work needs to be done in this direction. 
 The methodology proposed in Chapter 3 could be extended to situations where 
multivariate quality specifications are imposed on the product quality. The current 
methodology can only handle univariate quality specifications, due to a lack of proper 
prediction uncertainty models for PLS. The identification of such models is still an open 
research area that could be investigated and integrated with the uncertainty back-
propagation approach presented in Chapter 3. 
 The methodology presented in Chapter 4 could be extended to nonlinear models (data-
driven or mechanistic) in order to handle strong process nonlinearities, where the 
proposed linear approach is deemed to fail in most practical situations. The application 
of Bayesian methodologies on complex nonlinear models poses some (still unresolved) 
issues in terms of both computational demand and choice of the prior distributions of  
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the parameters. The solution to these problems could be beneficial in terms of 
probabilistic DS description for complex process models. 
 The methodology presented in Chapter 5 could be extended to surrogates other than the 
cubic radial basis function one, and a comparison between the performance of the 
different surrogates could be performed. Moreover, there is still a need to develop new 
metrics to link the projection error of the PLS model to the accuracy metrics of the 
surrogate-based feasibility analysis step. 
 Areas of future research for the methodology presented in Chapter 6 could be the 
extension to other state estimation algorithms (e.g., particle filters), as well as the 
development of more sophisticated methodologies to identify the parameters to be 
adjusted in real time during plant operation. Moreover, a validation with real plant data 
could be beneficial to test the robustness of the methodology. 
 The work presented in Chapter 7 is still ongoing and different areas of investigation are 
currently being considered. First, the possibility of performing some improvements 
(from a structural point of view) to the mechanistic model are being studied. These 
improvements include a better representation of the dynamics of water partial pressure 
within the drying chamber, as well as a better representation of the drying heterogeneity 
within the vials. With respect to the MBDoE activity, other experiments considering 
different types of operational constraints and different experimental settings are 
currently being designed.  
.
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Appendix A 
 
Penicillin fermentation model 
 
 
 
This Appendix collects a detailed description of the penicillin fermentation model proposed by 
Birol et al. (2002) that has been used in Chapter 6 to simulate the pilot plant behavior. The 
relevant model equations, as well as all the relevant model parameters, are reported. 
A.1 Model equations 
The model equations are reported below. These equations were implemented in MATLAB™ 
2017b. 
 
Biomass growth: 
d𝐵
d𝑡
= 𝜇𝐵 − (
𝐵
𝑆𝐹𝑉
)𝑈                                                                      (A.1) 
with:  
𝜇 = [
𝜇𝑥
1+
𝐾1
[H+]
+
[H+]
𝐾2
]
𝑆
𝐾𝑏𝐵+𝑆
𝐶𝐿
𝐾𝑜𝑥𝐵+𝐶𝐿
{[𝑘𝑔 exp (−
𝐸𝑔
𝑅𝑇
)] − [𝑘𝑑 exp (−
𝐸𝑑
𝑅𝑇
)]}.                  (A.2) 
Substrate utilization: 
d𝑆
d𝑡
= −𝜇 (
𝐵
𝑌𝐵/𝑆
) − 𝜇𝑝𝑝 (
𝐵
𝑌𝑃/𝑆
) − 𝑚𝐵𝐵 +
𝑈𝑆𝐹
𝑉
−
𝑆
𝑉
d𝑉
d𝑡
                                         (A.3) 
Effect of pH: 
d[H+]
d𝑡
= 𝛾 (𝜇𝐵 −
𝑈𝐵
𝑉
) + [
 
 
 −𝛿+√(𝛿2+4⋅10−14)
2
−[𝐻+]
]
 
 
 
Δ𝑡
                                           (A.4) 
with: 
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 𝛿 = [
10−14
[𝐻+]
− [𝐻+]] 𝑉 −
𝐶𝑎/𝑏(𝐹𝑎+𝐹𝑏)Δ𝑡
𝑉+(𝐹𝑎+𝐹𝑏)Δ𝑡
.                                                 (A.5) 
Dissolved oxygen material balance: 
d𝐶𝐿
d𝑡
=
𝜇
𝑌𝐵/𝑜
𝐵 −
𝜇𝑝𝑝
𝑌𝑃/𝑜
𝐵 −𝑚𝑜𝐵 + 𝐾𝑙𝑎(𝐶𝐿
∗ − 𝐶𝐿) −
𝐶𝐿
𝑉
d𝑉
d𝑡
                                 (A.6) 
with 
𝐾𝑙𝑎 = 𝛼√𝑓𝑔 (
𝑃𝑤
𝑉
)
𝛽
.                                                                    (A.7)  
Penicillin production: 
d𝑃
d𝑡
= 𝜇𝑝𝑝𝐵 − 𝐾𝑃 −
𝑃
𝑉
 
d𝑉
d𝑡
                                                                (A.8) 
with 
𝜇𝑝𝑝 = 𝜇𝑝𝑝
𝑚𝑎𝑥 𝑆
𝐾𝑝+𝑆+
𝑆2
𝐾1
 
𝐶𝐿
𝐾𝑜𝑝𝐵+𝐶𝐿
 .                                                          (A.9) 
Volume change: 
d𝑉
d𝑡
=
𝑈
𝑠𝐹
+ 𝐹𝑎/𝑏 − 𝐹𝑙𝑜𝑠𝑠                                                                 (A.10) 
with  
𝐹𝑙𝑜𝑠𝑠 = 𝑉𝜆(𝑒
5(𝑇−𝑇0)
𝑇𝑣−𝑇0 −1) .                                                             (A.11) 
Heat generation: 
d𝑄𝑟
d𝑡
= 𝑟𝑞1
d𝐵
d𝑡
𝑉 + 𝑟𝑞2𝐵𝑉.                                                             (A.12) 
Energy balance: 
d𝑇
d𝑡
=
𝑈
𝑠𝐹
(𝑇𝑓 − 𝑇) +
1
𝑉𝜌𝑐𝑝
 [𝑄𝑟 −
𝑎𝐹𝑐
𝑏+1
𝐹𝑐+(
𝑎𝐹𝑐
𝑏
2𝜌𝑐𝑝𝑐
)
].                                          (A.13) 
CO2 evolution: 
d[CO2]
d𝑡
= 𝛼1
d𝐵
d𝑡
+ 𝛼2𝐵 + 𝛼3.                                                     (A.14) 
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The state variables involved in the model (A.1)-(A.14) are collected in Table A.1. A full list of 
the initial conditions that have been used for the simulations presented in Chapter 6, as well as 
a full list of all the model parameters with their respective values are reported in Table A.2 and 
Table A.3 respectively. 
Table A.1.  List of state variables involved in the process of Birol 
 Symbol Definition 
𝐵 Biomass concentration  
𝑆 Substrate concentration 
𝑃 Penicillin concentration 
𝐶𝐿 Dissolved oxygen concentration 
[H+] Concentration of hydrogen ions 
𝑉 Volume 
𝑄𝑟  Heat generation power 
𝑇 Temperature 
[CO2] Concentration of CO2 produced 
 
Table A.2.  List of initial conditions for the state variables 
State variable Initial value Units 
Biomass concentration  0.1 [gB/L] 
Substrate concentration 15 [gS/L] 
Penicillin concentration 0 [gP/L] 
Dissolved oxygen concentration 1.16 [go/L] 
Volume 100 [L] 
CO2 concentration 0.5 [mmol/L] 
Hydrogen ion concentration 10−5.1 [mol/L] 
Temperature 297 [K] 
Heat generation 0 [cal] 
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Table A.3. List of parameters for the penicillin fermentation model of Birol et 
al. (2002). 
Parameter Definition Units Value 
𝜇x Maximum specific biomass growth rate  [h
−1] 0.092 
𝐾𝑥 Contois saturation constant  [g/L] 0.15 
𝑌𝐵/𝑆 Yield constant [gB/gS] 0.45 
𝑌𝐵/𝑜 Yield constant [gB/go] 0.04 
𝑌𝑃/𝑆 Yield constant [gP/gS] 0.90 
𝑌𝑃/𝑜 Yield constant [gP/go] 0.20 
𝐾1 Constant for 𝜇 [mol/L] 10
−10 
𝐾2 Constant for 𝜇 #2 [mol/L] 7 × 10
−5 
𝑚𝑥 Maintenance coefficient on substrate [h
-1] 0.014 
𝑚𝑜 Maintenance coefficient on oxygen [h
-1] 0.467 
𝛼1 Constant relating CO2 to growth [mmol CO2/𝑔𝐵] 0.143 
𝛼2 Constant relating CO2 to maintenance energy [mmol CO2/(𝑔𝐵h)] 4 × 10
−7 
𝛼3 Constant relating CO2 to penicillin production [mmol CO2/(L h)] 10
−4 
𝐾𝑜𝑥 , 𝐾𝑜𝑝 Oxygen limitations constants (no limitation) [-] 0 
𝐾𝑜𝑥 , 𝐾𝑜𝑝 Oxygen limitations constants (with limitation) [-] 2 × 10
−2, 5 × 10−4 
𝜇𝑝𝑝
𝑚𝑎𝑥 Specific rate of penicillin production [h
-1] 0.005 
𝐾𝑝 Inhibition constant [g/L] 0.0002 
𝐾𝐼  Inhibition constant for product formation [g/L] 0.10 
𝑝 Constant [-] 3 
𝐾 Penicillin hydrolysis rate constant [h-1] 0.04 
𝑘𝑔 Arrhenius constant for growth [-] 7 × 10
−3 
𝐸𝑔 Activation constant for growth [cal/mol] 5100 
𝑘𝑑 Arrhenius constant for cell death [-] 10
33 
𝐸𝑑 Activation energy for cell death [cal/mol] 50000 
𝜌𝑐𝑝 Density × heat capacity of the medium [cal/(°C L)] 1/1500 
𝜌𝑐𝑝𝑐 Density × heat capacity of the cooling liquid [cal/(°C L)] 1/2000 
𝑟𝑞1 Yield of heat generation [cal/𝑔𝐵] 60 
𝑟𝑞2 Constant in heat generation [cal/𝑔𝐵  ℎ] 1.6783× 10
−4 
𝑎 Heat transfer coefficient [cal/h °C] 1000 
𝑏 Constant [-] 0.60 
𝛼 Constant for 𝐾𝑙𝑎 [-] 70 
𝛽 Constant for 𝐾𝑙𝑎 [-] 0.4 
𝜆 Constant in 𝐹𝑙𝑜𝑠𝑠 [h
-1] 2.5 × 10−4 
𝛾  Proportionality constant [mol [H+]/𝑔𝐵] 10
−5 
𝑇𝑓 Feed temperature of substrate [K] 298 
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Appendix B 
 
Additional numerical results for the 
freeze-drying process 
 
In this Appendix, the results that have been obtained for dataset C (siliconized vials) of the 
process described in Chapter 7 are presented. The results are shown following the same 
structure that has been used for dataset A (non-siliconized vials) in Chapter 7. 
B.1 Gravimetric estimation of 𝑲𝒗 for dataset C 
Table B.1 – B-3 collect the esimates of the heat transfer coefficient obtained with the 
gravimetric method. Similar results to the ones for dataset A have been obtained, thus 
suggesting that the heat transfer coefficient is not sensibly affected by the presence of the 
silicone layer on the internal surface of the vials. 
Table B.1.  Mean values of the heat transfer coefficient and standard 
deviations for dataset C at  𝑝𝑐/?̅?𝑐   = 0.667. 
Zone # Normalized mean value of 𝑲𝒗 [-] Standard deviation Vial type 
 1 1.413 0.129 Edge 
2 1.081 0.082 Edge 
3 1.225 0.121 Edge 
4 1.041 0.133 Central 
5 1.187 0.145 Edge 
6 0.972 0.122 Central 
7 1.019 0.154 Central 
8 1.346 0.124 Edge 
9 0.868 0.122 Central 
10 1.611 0.296 Edge 
11 1.299 0.201 Edge 
12 2.212 0.287 Edge (window) 
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Table B.2.  Mean values of the heat transfer coefficient and standard 
deviations for dataset A at  𝑝𝑐/?̅?𝑐   = 1. 
Zone # Normalized mean value of 𝑲𝒗 [-] Standard deviation Vial type 
 1 1.715 0.094 Edge 
2 1.213 0.086 Edge 
3 1.455 0.135 Edge 
4 1.124 0.095 Central 
5 1.341 0.083 Edge 
6 1.119 0.087 Central 
7 1.201 0.085 Central 
8 1.513 0.112 Edge 
9 1.050 0.122 Central 
10 1.746 0.264 Edge 
11 1.422 0.101 Edge 
12 2.974 0.196 Edge (window) 
 
Table B.3.  Mean values of the heat transfer coefficient and standard 
deviations for dataset A at  𝑝𝑐/?̅?𝑐   = 1.333. 
Zone #0 Normalized mean value of 𝑲𝒗 [-] Standard deviation Vial type 
 1 1.642 0.113 Edge 
2 1.310 0.125 Edge 
3 1.542 0.145 Edge 
4 1.055 0.055 Central 
5 1.412 0.142 Edge 
6 1.200 0.133 Central 
7 1.322 0.194 Central 
8 1.848 0.368 Edge 
9 1.136 0.341 Central 
10 1.697 0.145 Edge 
11 1.655 0.193 Edge 
12 2.412 0.166 Edge (window) 
 
The “global” heat transfer coefficient that would be obtained by averaging all the values within 
the drying chamber is reported in Table B.4, together with its standard deviation. 
 
 
 
 
 
 
Additional numerical results for the freeze-drying process 261 
 
________________________________________________________ 
© 2018 Gabriele Bano, University of Padova (Italy) 
Table B.4.  Mean values and standard deviations of the “global” (i.e. 
computed  for all the 12 zones) heat transfer coefficient at the three different 
values of chamber pressure considered. 
Normalized chamber pressure [-] Normalized mean value of 𝑲𝒗 [-] Standard deviation 
 0.667 1.341 0.793 
1 1.552 0.892 
1.333 1.601 0.889 
 
B.2 Maximum likelihood parameter estimation for dataset C 
Table B.5 collects the resulta of the MLE activity for dataset C. The results suggest a strong 
effect of the silicone layer on the mass transfer resistance, while only a slight effect on the heat 
transfer coefficient (as already suggested by the gravimetric estimates). 
Table B.5.  Maximum likelihood parameter estimation for the 12 zones 
considered. Dataset C (siliconized vials). 
Parameter 
% 
nominal 
value 
95% 
 t-value 
Reference 
t-value 
Parameter 
% 
nominal 
value 
95% 
t-value 
Reference 
 t-value 
 Zone 1    Zone 7    
𝐶1 103.44 74.41 1.65 𝐶1 103.10 68.11 1.65 
𝑅1 112.11 69.18 1.65 𝑅1 121.79 46.22 1.65 
Zone 2    Zone 8     
𝐶1 109.00 72.11 1.65 𝐶1 108.40 65.41 1.65 
𝑅1 109.12 57.14. 1.65 𝑅1 107.92 50.12 1.65 
Zone 3    Zone 9    
𝐶1 101.16 75.82 1.65 𝐶1 111.61 71.46 1.65 
𝑅1 118.32 62.12 1.65 𝑅1 101.12 48.57 1.65 
Zone 4    Zone 10     
𝐶1 106.21 64.59 1.65 𝐶1 103.12 68.92 1.65 
𝑅1 107.56 52.13 1.65 𝑅1 107.11 65.16 1.65 
Zone 5     Zone 11    
𝐶1 112.14 68.26 1.65 𝐶1 112.30 71.25 1.65 
𝑅1 113.12 60.12 1.65 𝑅1 108.19 56.25 1.65 
Zone 6     Zone 12    
𝐶1 121.41 68.59 1.65 𝐶1 109.10 61.12 1.65 
𝑅1 119.71 61.92 1.65 𝑅1 119.51 44.32 1.65 
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